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1 Introduction 
 
Around 200 billion tons of carbohydrates are accumulated by photosynthesis every year, which 
makes them the most abundant group of natural products.[1] Carbohydrates possess multiple 
functional groups, including one carbonyl and several hydroxyl groups per saccharide unit and 
various stereocenters.[2] One or more of these groups can participate in oligomerization or 
polymerization reactions, which result in linear as well as in branched structures.[3] The large 
structural diversity of (poly)carbohydrates covalently bound to non-sugar natural products results 
in a tremendous pool of functions in living organisms. Even though they do not carry information 
within the meaning of a biological code as in oligonucleotides, they are able to store biological 
information due to their three-dimensional structure.[2] This is of great importance in recognition 
processes on the molecular level, such as cell-cell adhesion or cell-cell communication.[4] 
Glycosylated proteins and lipids are major constituents of mammalian cells. The carbohydrates 
decorate the outer surface of cells as a kind of a carbohydrate coat, which is distinctive for a 
particular species, the type of cell and its status of development.[2, 5] Additionally, they can mediate 
the interaction between multiple organisms, for instance between a host and a symbiont or a 
parasite. The glycan N-acetylneuraminic acid on the outer cell surface mediates the attachment of 
human influenza virus by interaction with the hemagglutinin trimers on the surface of the virus.[6] 
The human AB0 and Lewis blood group system is based on the presence or the lack of fucose, 
N-acetylgalactosamine and galactose residues as glycoconjugate oligosaccharides.[7] However, 
there are more biomolecules which interact non-covalently with carbohydrate residues. These 
include carbohydrate-specific enzymes, antibodies, lectins and transport proteins. Lectins are 
highly selective for specific carbohydrate structures and can interact with multiple glyco-
conjugates at the same time. The concept of multivalency in nature is predominantly used to 
transmit signals and to trigger various biological events.[5, 8]  
Most of the eukaryotic cells need a continuous supply with various carbohydrates, which are used 
to produce adenosine-5’-triphosphate (ATP). The transport of carbohydrates into cells ensues either 
by Na+ coupled carrier systems (SGLTs) or by glucose transporters, so-called GLUTs.[9] The 
GLUTs are encoded by the SLC2 genes and facilitate the energy-independent transport through the 
lipid bilayers of cells along the concentration gradient.[10] Up to now, 14 members of the GLUT 
Introduction 
6 
family are identified and basically, one or more of different GLUTs are embedded in every cell of 
the human body.[11] The different membrane proteins can be divided into three classes according 
to characteristics such as specific sequences of amino acids.[9] Eleven of the 14 members are 
capable for the transport of D-glucose, which can be explained by the predominant use of D-glucose 
as energy source in comparison to all other sugars and the need of multiple transporter systems.[11] 
Whereas most of GLUTs accept multiple sugars (for instance GLUT1 is tolerating glucose, 
galactose, mannose and glucosamine), GLUT5 reveals exclusive binding for D-fructose and is 
expressed in the membranes of cells of the small intestine, testis and kidney. Since the selectivity 
of GLUT5 for D-fructose was clearly shown in 1992,[12] many studies were performed on this topic. 
The structure of the GLUT5 transporter was confirmed recently[13] and studies showed the 
interaction of GLUT5 with other molecules than D-fructose, such as 2,5-anhydro-D-mannitol.[14] 
However, the GLUT5 membrane transporter is also investigated regarding its connection to various 
pathological structures.[15-16] Patients suffering from diabetes type II exhibit significantly increased 
level of GLUT5 in tissues of the skeletal muscle[17] and small intestine.[18] Additionally, linkages 
between other diseases, such as cardiomyopathy[19] and obesity,[20] are proposed, but need to be 
further investigated. The connection between cancer and D-fructose intake, GLUT5 expression and 
D-fructose levels in the blood is well investigated and showed direct correlations with various types 
of cancers.[21-22]  
An overexpression of the GLUT5 transporter in breast cancer cells is heavily discussed by the 
scientific community. Whereas one group claimed that there is no overexpression of GLUT5 in 
breast cancer tissues,[23] the results of various other groups supported the overexpression. When 
incubated with D-fructose, breast cancer cells revealed altered glycan structures on the cell 
membrane and enhanced proliferative activity.[24] GLUT5 was also shown to be overexpressed in 
breast carcinoma cell lines MDA-468 and MCF-7 and poorly expressed in mammary epithelial 
cells.[25] A large study about the existence of GLUTs in various types of cancer further revealed 
the overexpression of GLUT5 in about 21% of all tested cell lines and in more than 85% of 33 
tested breast cancer cell lines.[22] Furthermore, the knockdown of the GLUT5 transporter by anti-
sense oligonucleotides resulted in inhibited cell proliferation of breast cancer cell lines MDA-MB-
231 and MCF-7.[26] Recent investigations might point to a correlation between cells of acute 
myeloid leukemia (AML) and overexpressed levels of GLUT5.[27] 
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In the light of these findings, the GLUT5 transporter represents a potential target for the treatment 
of the mentioned diseases, including various types of cancers with a focus on breast cancer. As a 
consequence, the conjugation with D-fructose could result in novel pharmaceuticals with increased 
GLUT5 affinity. In general, the considered compounds should be crudely divided into low molar 
mass (A) and macromolecular ones (B). The underlying mechanisms for the uptake of these classes 
into breast cancer cells are completely different (Figure 1.1).  
Figure 1.1. Uptake mechanisms of D-fructose conjugated compounds. A. Low molar mass 
molecules with D-fructose residue(s) are taken up by the GLUT5 transporter. B. Macromolecular 
assemblies bearing D-fructose unit(s) are accumulated outside of the cell due to binding to the 
GLUT5 and are internalized by endocytosis.  
 
 
Small molecules, conjugated with D-fructose, are recognized by the GLUT5 transporter due to their 
targeting moiety and are taken up energy-independently through the lipid bilayer. Literature reports 
prove the GLUT5 targeting ability of low molar mass compounds functionalized with D-fructose 
in comparison to their sugar-free analogues. Labeling of D-fructose with e+ emitting 18F at various 
positions resulted in radiotracers, which could be easily detected by positron emission tomography 
(PET) and which revealed selectivity for GLUT5 overexpressing cells in vitro.[28-29] 7-Nitro-1,2,3-
benzadiazole as fluorescent dye was used to label D-fructose and the resulting substances show the 
selective accumulation in breast cancer tissue quantified by flow cytometry.[30] Due to the unique 
properties of metal ions, a strong effort in the synthesis of D-fructose conjugated metal complexes 
was undertaken. A phosphorescent Re(I) complex bearing D-fructose exhibited selective 
accumulation in breast carcinoma cells MCF-7 and MDA-MB-231.[31] An Ir(III) complex 
functionalized with D-fructose displayed a 3.7 times increased uptake in MCF-7 cells compared to 
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non-cancerous cells, whereas the non-functionalized complex did not show any selective 
accumulation.[32] It is further mentionable that except for very few examples, D-fructose was 
connected via the C1 position of the sugar. A systematic study revealed the synthesis of various 
mono-allylated derivatives of D-fructose present in various ring forms, which allow to formulate 
some major tendencies about the position of choice in terms of chemical modification and the 
tolerance by the GLUT5 transporter.[33] The configuration of the C2, C3, C4 and C5 position are 
of crucial importance for the recognition and, therefore, epimers of D-fructose have low affinity for 
GLUT5. Also the 5-thio derivative of D-fructose showed poor binding affinity, indicating the 
involvement of the ring oxygen in the recognition by the GLUT5 protein.[34] All mono-allylated 
compounds exhibited poor tolerance except for the C6 derivative. In particular, the high Ki value 
for the C1 derivative indicated a reduced interaction with the GLUT5 transporter and, therefore, 
the need of substitution at other positions. In contrast to these findings, another study showed the 
substitution of the C1-OH by an allylamine group.[35] This derivative revealed a moderate Ki value, 
indicating a good affinity to GLUT5 even with substitution at the C1 position. Therefore, binding 
modes as depicted in Figure 1.2 are likely to occur. The red marked positions are not included in 
the interaction with the GLUT5 protein, whereas the C3, C4 and C5 positions always occupy 
binding sites of the receptor. As a consequence, C6 as well as C1 can be chemically modified and 
based on these structures also bulky substituents might be tolerated by the GLUT5 protein.  
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Figure 1.2: Schematic representation of various forms of D-fructose and the proposed orientation 
to the GLUT5 receptor in breast cancer cells. β-D-Fructofuranose occupies binding sites of the 
receptor with anomeric center trailing (A) or leading (B). β-D-Fructopyranose is limited with 
trailing of the anomeric center by occupation of the GLUT5 binding sites (C).   
 
However, some central aspects for the design of D-fructose conjugated low molar mass compounds 
are not clarified yet. 1. With the aforementioned knowledge about the different positions of 
D-fructose at hand, the link between size of the substituents at varying positions and the recognition 
of the D-fructose unit by the GLUT5 transporter is still missing, even if C3, C4 and C5 could be 
excluded from this question. 2. What is the critical size of the substituents, which is tolerated by 
the transport protein? 3. How does the chosen linker affect the uptake of the D-fructose conjugated 
compound into breast cancer cells? Is there a beneficial functionality for the recognition? 4. Does 
D-fructose keep the targeting properties for GLUT5 even when a large biomolecule is attached to 
it? The present thesis tries to address these questions. For this purpose, the second chapter focuses 
on the synthesis of sugar bearing metal complexes. This includes a short overview about metal 
complexes of the bifunctional chelator curcumin (Chapter 2.1), the attachment of D-fructose to a 
derivative of curcumin by using “click” chemistry and the formation of the corresponding 
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[Ru(bpy)2(L)]Cl complex (Chapter 2.2). A strategy to address the C6 position of D-fructose 
selectively without tedious protection steps is also presented (Chapter 2.3). 
However, due to their size, macromolecular assemblies are not capable of passing the lipid bilayer 
by a GLUT5 mediated transport. This fact changes the role of D-fructose to a mere targeting 
functionality, which causes the accumulation of the particles outside of the cells of interest by 
binding to GLUT5 in a multivalent fashion. The main process of particle internalization represents 
three different forms of endocytosis, in particular phagocytosis, fluid phase pinocytosis or receptor-
mediated endocytosis.[36] The uptake mechanisms are highly complex events, which are dependent 
of plenty of variables, such as the concentration of the particles in- and outside of the cell, 
competition processes like exocytosis, the time after the first uptake and more. The underlying 
mechanisms could not be completely clarified up to now, but recent examples of polymer-
D-fructose conjugates proofed their favorable properties in terms of selective uptake into breast 
cancer cells. D-Fructose conjugated methacrylate block copolymers were self-assembled to 
micelles in water. The micelles showed selective uptake into breast cancer cells, but only a very 
low uptake into macrophages.[37] The same group also investigated the influence of the attached 
sugar residues. Methacrylate-based block copolymers with different attached carbohydrates, in 
particular D-glucose, D-galactose and twice D-fructose via different positions were conjugated to a 
platinum-based anticancer agent and formulated micelles in water. The tested breast cancer cells 
showed a high preference for the D-fructose coated nanoparticles.[38] D-Fructose based 
nanoparticles revealed an increased uptake into breast carcinoma cells MDA-MB-231 in 
comparison to the polymers conjugated with other sugars in this study.[39] When the hydrophilic 
block of poly(ε-caprolactone)-b-poly(ethylene glycol) (PCL-PEG) was linked to D-fructose, the 
resulting mixed micelles exhibited breast cancer selectivity in vitro as well as in vivo in MCF-7 
tumor bearing mice xenografts.[40] 
In the last decade, many excellent studies on the uptake of D-fructose conjugated macromolecules 
into breast cancer cells were performed. But there are still important questions, which need to be 
addressed. 1. What are suitable sizes of the polymers? 2. Which polymeric backbone has the best 
properties, in terms of hydrophobicity, potential charges, flexibility and other parameters? 3. How 
many D-fructose units are required to target GLUT5 overexpressing cells and which distance 
between the D-fructose residues is favorable? 4. Does the implied multivalency affect the uptake 
of D-fructose conjugated polymers? These questions are discussed in the third chapter. The 
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functionalization of linear poly(ethyleneimine) (L-PEI) with D-fructose and the extensive 
biological evaluation of the glycopolymers is subject of Chapter 3.1. The last Chapter 3.2 discusses 
the attachment of various aldoses (D-glucose, D-galactose, D-mannose) to an acrylate backbone by 
SN2 reaction, which could be transferred to D-fructose. As a model for multivalent binding, the 
affinity of these polymers to the binding protein concanavalin A (Con A) is also investigated. 
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2 Sugar conjugated metal complexes 
 
The attachment of sugar molecules to metal ions to form metal complexes can be achieved with 
two different approaches. First, the carbohydrate is attached directly to the metal ion after the 
introduction of suitable donor atoms or chelating units.[41] The second approach aims to attach the 
sugar molecule via a linking unit to a bifunctional molecule that is able to chelate the metal ion 
(Figure 2.1).  
 
Figure 2.1: Schematic representation of the structure of a molecule following the bifunctional 
chelator concept containing a targeting unit (1), a linker unit (2), a bifunctional chelator (3) and 
the metal ion (4). 
 
Due to the wide range of properties, various metal ions have gained increased attention in medical 
inorganic chemistry. Next to Pt-based agents, which are utilized for the treatment of solid tumors 
(e.g. colorectal and non-small cell lung cancers),[42] other metal complexes for different 
applications are used in hospital routines. Complexes of emitting metal ions, such as 99mTc (γ) and 
64Cu (e+), were used for imaging. Metal complexes with different modes of actions to these of Pt-
based drugs are investigated for their potential in the treatment of various diseases. To diminish 
side effects of the applied metal-based pharmaceuticals, an increase in selectivity is a key challenge 
in recent approaches.[43] 
This can be achieved by suitable targeting moieties, such as monoclonal antibodies, small peptides 
or carbohydrates, which carry the metal complex to the tissue with an increased concentration of 
the corresponding receptor.[44] As mentioned before, D-fructose represents a suitable biomolecule 
for targeting the GLUT5 protein. But also other sugars are of interest. For instance, D-galactose 
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can be used to target asialglycoprotein receptors associated with various diseases of the liver[45] or 
D-glucose, which interacts with the GLUT1 transporter that was shown to be overexpressed in 
various types of cancer.[46-47] 
The carbohydrates have to be coupled to the bifunctional chelator (BFC) via a linker unit. There 
are multiple linkers available, such as cationic, anionic or neutral ones, and all of them result in 
altered pharmacokinetic properties. For instance, the use of an alkyl chain will enhance the 
lipophilicity, whereas a peptide sequence will increase the hydrophilicity.[44]  
For the design of BFCs, some major requirements should be considered. The BFC should form 
thermodynamically and kinetically stable complexes with the metal ion of interest in an efficient 
and rapid synthesis suitable for biomolecules. The skeleton of the BFC can be cyclic, such as in 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), or acyclic, like in 
diethylenetriaminepentaacetic acid (DTPA).[48] But also molecules besides the classical structures 
are under investigation by the scientific community. Amino acids were modified manifold to attach 
a biomolecule at the one and to chelate a metal ion on the other site.[49-50] Another highly active 
molecule is curcumin, which derives from the root of turmeric (Curcuma longa) and which can 
complex metal ions due to its β-diketone functionality.[51] 
The first sub-chapter will address the variety of the metal complexes of curcumin. The second sub-
chapter will focus on the synthesis of carbohydrate conjugated curcumin ligands and their 
corresponding ruthenium complexes. The third sub-chapter will emphasize sucrose as a starting 
molecule for the synthesis of D-fructose compounds conjugated via the C6 position of D-fructose. 
2.1 Curcumin metal complexes 
 
Parts of this chapter have been published in: P1) M. Pröhl, U. S. Schubert, W. Weigand, M. 
Gottschaldt, Coord. Chem. Rev. 2016, 307, Part 1, 32-41. 
Among a large variety of naturally occurring polyphenols curcumin (1,7-bis(4-hydroxy-3-
methoxyphenyl)-1,6-heptadiene 3,5-dione) has been identified as a highly biologically active 
compound. Curcumin interacts with a large number of molecular targets by various mechanisms 
linked to the most prevalently diseases of modern societies. It shows not only anti-cancer, anti-
inflammatory, anti-oxidant, anti-diabetic and anti-arthritic properties and protective effects against 
various cardiovascular diseases, but also against neurodegenerative afflictions such as Alzheimer 
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disease (AD), multiple sclerosis and others.[52] Curcumin is non-toxic in high doses up to 12 g·d-1, 
when administered orally.[53] However, curcuminoids in general show some major limitations in 
contrast to their miraculous biological activities. Curcumin is sensitive to light, the presence of 
solvents and oxygen.[54] Additionally, it is poorly stable in aqueous media with pH൑5.0 and it 
degrades rapidly (after 10 min at pH 7.4, only 10% of the initial amount of curcumin are left).[55] 
In the last decades, many attempts have been performed to overcome these limitations to improve 
the bioavailability of curcumin and its derivatives. Adjuvant molecules, such as piperine,[56] as well 
as delivery-systems based on liposomes,[57] micelles,[58] or nanoparticles[59] were studied. From a 
chemical point of view, curcumin is a bis-α,β-unsaturated β-diketone, where two oxy-substituted 
aryl groups are connected by a seven carbon chain.[60] Modification of this curcumin-skeleton is 
one strategy to improve the pharmacological properties. For instance, the stability in cultured cells 
was increased after the phenol groups were substituted with methoxy groups.[55, 61] Also the 
introduction of biomolecules can result in enhanced properties of the resulting compound in 
comparison to curcumin itself.[62] However, complexation reactions of curcumin and its derivatives 
with various metal ions yield not only in increased stability of the formed complexes, but also 
offering the synthesis of metal complexes with distinct properties. The potential applications of the 
novel formed metal complexes are strongly dependent on the structure of the curcumin skeleton, 
the complexed metal ion, ancillary ligand(s), the counterion and other parameters. From a 
perspective of medical applications of curcumin-based metal complexes, they can be crudely 
divided into 1. metal complexes for molecular imaging and 2. for the use as anti-cancer agents 
(Figure 2.2). 
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Figure 2.2: Schematic representation of the structure of the curcuminoid skeleton bound to a 
metal ion (top, anions, ancillary ligands and positions of modifications were omitted for clarity). 
The use of selected metal ions as potential imaging agents (left, including the visualization 
method) and anti-cancer therapy agents (right) is presented.  
 
The coordination of curcumin and its derivatives to emitting metal ions led to a variety of novel 
complexes suitable for imaging of several diseases. Complexes of the general formula [68Ga(L)2]+ 
provided a high affinity for amyloid-β,[63] a peptide that can be correlated to AD.[64] Due to the 
positron emission of 68Ga, the formed complexes are suitable for PET imaging and additionally, 
when incubated with A549 lung cancer cells, the localization of them inside the cells differ from 
the parent ligands mediated by the hydrophobicity differences (Figure 2.3 A).  
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Figure 2.3: Schematic representation of selected curcumin conjugated metal complexes (anions 
are omitted for clarity). 
 
An non-toxic Eu3+ based complex of the formula [Eu(py)2(L)3] (py = pyridine) revealed 
luminescence in the near infrared (NIR) region, which is mediated by the ancillary py-ligands and, 
therefore, by the extension of the π-conjugated system (Figure 2.3 B).[65] Curcumin was also linked 
to the known contrast agent Gd3+-DTPA (Figure 2.3 C).[66] The novel formed complex possesses 
binding to amyloid-β and an about four times higher longitudinal relaxivity than Gd3+-DTPA, 
which represents a strong benefit for MRI imaging.  
Planar molecules or compounds with planar elements can directly interact with the 
deoxyribonucleic acid (DNA) in multiple ways. For instance, two connected base pairs form a 
binding pocket for an intercalating molecule, which causes damage of the DNA by single strand 
breaks.[67-68] A curcumin conjugated Zn2+ complex revealed the strongest growth inhibition in all 
tested cell lines and a lower half maximal inhibitory concentration (IC50) in LAN-5 neuroblastoma 
cells than curcumin alone, caused by an intercalative binding mode (Figure 2.3 D).[69] Another class 
of curcumin conjugated Cu2+ complexes showed the use of ferrocenyl bearing amino acids as 
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ancillary ligands (Figure 2.3 D).[70] After irradiation at Ȝ = 454 nm the complexes revealed a 
complete cleavage of the DNA mediated by a radical pathway. The complexes were taken up and 
localized in the cytosol after incubation and showed an enhanced cytotoxicity in comparison to 
curcumin alone or the corresponding pentane-2,4-dione (acac) complex.  
Curcumin is a highly biological active molecule that suffers from some major drawbacks, such as 
poor aqueous solubility and bioavailability. To overcome these limitations, the complexation with 
a wide variety of metals results in novel compounds with improved properties in comparison to 
curcumin alone. The reaction with emitting metal ions, such as 99mTc+ or 68Ga3+, yields curcumin 
conjugated metal complexes, which can be used for imaging of multiple diseases. But also Cu2+ or 
Zn2+ as metal ions can be used to synthesize novel complexes suitable for the treatment of cancer 
by various mechanism, including intercalation and photodynamic approach. 
 
2.2 Synthesis of D-fructose conjugated curcumin and its corresponding ruthenium complex 
 
Parts of this chapter have been published in: P2) M. Pröhl, T. Bus, J. A. Czaplewska, A. Traeger, 
M. Deicke, H. Weiss, W. Weigand, U. S. Schubert, M. Gottschaldt, Eur. J. Inorg. Chem. 2016, 
5197-5204. P6) H. Weiss, J. Reichel, H. Görls, K. R. A. Schneider, M. Micheel, M. Pröhl, 
M. Gottschaldt, B. Dietzek, W. Weigand, Beilstein J. Org. Chem. 2017, 13, 2264-2272. 
 
It was shown that the complexation of curcumin can result in novel complexes with advanced 
properties regarding their use as medical agents. The use of sugar molecules to modify curcumin 
is rarely described. Solely, the attachment of D-galactose by Cu(I) catalyzed Huisgen 1,3-dipolar 
cycloaddition (CuAAC), so called “click” reaction, between propargyl-modified curcumin and 
azide bearing D-galactose with subsequent deprotection of the sugar moiety resulted in a water 
soluble, non-toxic curcumin derivative with increased inhibition properties of amyloid-β and 
τ-peptide aggregation.[62] To the best of our knowledge the combination of the modification of 
curcumin with carbohydrates and the subsequent complexation with a suitable metal ion was 
demonstrated only once. A curcumin ligand bearing D-glucose and its corresponding oxovanadium 
complex revealed an increased solubility in water and enhanced uptake in the nucleus and 
cytoplasm of HaCaT (human adult low calcium high temperature keratinocytes) and HeLa (cervical 
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cancer cell line, which derived from Henrietta Lacks) cells in contrast to sugar-free complexes.[71] 
Vanadium was selected because it represents a biocompatible metal[72] and oxovanadium(IV) 
complexes are reported to be suitable for PDT (photodynamic therapy) due to their low energy d-
d absorption band.[73] Ru2+ represents another alternative metal ion. Ru-based complexes could 
overcome resistance problems, which are often linked to the application of Pt-containing drugs.[74] 
Additionally, Ru complexes reveal the interaction with N- or O-donor ligands comparable to that 
of Pt-based agents, the oxidation states +2 and +3 are easily available and they can be incorporated 
by transferrin into tumor cells.[75]  
Our study aimed to combine the potential of D-fructose and its derivatives to interact with GLUT5 
overexpressing cells, the biological activity of curcumin and its derivatives and metal complexes 
based on Ru2+. For this purpose, the synthesis of sugar conjugated bisdemethoxycurcumin ligands 
was carried out as depicted in Scheme 2.1.  
 
Scheme 2.1: Schematic representation of the syntheses of the ligands. 
 
The synthesis of propargyl bearing bisdemethoxycurcumin derivative was conducted according a 
modified literature procedure.[76] Propargyl-modified bisdemethoxycurcumin 1 was obtained in a 
one-pot synthesis by double-times aldol condensation between BF2-protected acetylacetone and 
p-(propargyloxy)-benzaldehyde in excellent yield (96%). The sugar-free ligand 2 was used for 
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comparison and was obtained in a similar reaction to that of ligand 1. The BF2-group was cleaved 
under basic conditions with NaOH. Cu(I) catalyzed cycloaddition between azido-modified sugars 
and ligand 1 with CuSO4·5H2O and sodium ascorbate as catalyst forming pair yielded the sugar 
conjugated ligands (3a and 3b) in moderate yields. During the “click” reaction, the BF2 group of 
the curcumin skeleton was cleaved. In this context, the cleavage of the BF2 group was reached by 
heating a mixture of THF (or another organic solvent) and water (or a base), whereas heating only 
in dry THF did not result in the formation of the free ligand. The proposed mechanism includes the 
formation of a difluoroboric acid ester, a hydroxydifluoro borate after nucleophilic attack and 
hydrolysis to create boric acid, HF and the corresponding curcumin in the anionic form. Copper 
complexes of curcumin and its derivatives were shown to be more stable than curcumin itself.[77] 
Competing ligands, such as ethylenediaminetetraacetic acid (EDTA) or NH3, could not be applied 
successfully to remove all Cu2+ ions completely, which were bound in a stable fashion to the 
curcumin ligands, what also explains the relatively low yields. Additionally, due to their structural 
similarities curcuminoids are challenging to purify via chromatographic techniques.[78]  
To use the ligands in aqueous media, the protection groups of the carbohydrates have to be cleaved 
off. Acetyl-groups of 3a were cleaved off under basic conditions using sodium methoxide. When 
analyzing 4a with nuclear magnetic resonance (NMR) spectroscopy, the signals remain sharp and 
well separated. Due to the glycosidic linkage at the C1 position of D-glucose, the sugar units are 
not able to undergo ring-opening reactions and, therefore, no stereoisomers are detectable. 
Isopropylidene-groups, which were used to protect the D-fructose units of 3b, are usually cleaved 
in aqueous, acidic solvents. Due to the lability of curcumin towards acids,[55] neither standard 
deprotection conditions nor acidic exchange resins could be applied successfully. Stirring in 85% 
formic acid resulted in the replacement of the isopropylidene groups by formic acid esters, which 
were easily cleaved under basic conditions afterwards.[79] Cleavage of the protection groups 
resulted in an equilibrium between open-chained, furanose und pyranose forms of D-fructoses. This 
was clearly observable by the existence of more than one signal for the triazole group of the 
different forms of the ligand in the aromatic region in 1H as well as in 13C NMR. All of these forms 
result and in a single signal of the [M+Na]+ ion in the ESI-MS spectrum.  
To form the corresponding complexes, the β-diketone moieties of the ligands 2, 4a and 4b were 
deprotonated with sodium methoxide and reacted with Ru(bpy)2Cl2 (Scheme 2.2). 
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Scheme 2.2: Schematic representation of the syntheses of the complexes. 
 
Due to the lack of carbohydrates in the structure of complex 5c, the hydrophilicity of this compound 
was decreased and, therefore, dialysis vs. H2O could not be successfully applied for purification. 
A size exclusion column (Sephadex® LH-20) was used instead to isolate the Ru complex in high 
purity. The structure of 5b was challenging to validate due to instability during mass spectrometry 
measurements. LC-MS-Measurements with an orbitrap mass analyzer and gentle measurement 
conditions identified the desired complex additionally to a set of fragments, which derived from 
the parent [M-Cl]+ ion (Figure 2.4). For instance, tandem MS experiments revealed fragments with 
cleaved sugar unit(s) (F1 and F3) or triazole unit(s) (F4 and F6).  
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Figure 2.4: Schematic representation of fragments F1 to F6 resulting from the parent ion 
[M-Cl]+ obtained by ESI-Orbitrap-MS investigations of 5b. 
 
The ligands 2, 4a and 4b as well as the complexes 5a to 5c were investigated for their cytotoxicity 
against various cell lines. Due to fluorescence quenching of [Ru(bpy)2(L)]Cl2 complexes in 
aqueous solvents,[80] no uptake could be detected by standard methods, such as flow cytometry or 
confocal laser scanning microscopy (CLSM). However, inhibition of cellular metabolic activity in 
non-cancerous L929 cells, in liver cancer HepG2 cells and in breast cancer cells MDA-MB-231 
was investigated, using a resazurin-based assay (alamarBlue). Since there is no significant 
concentration-dependent cytotoxicity, only one concentration for all compounds (100 ȝM) in each 
cell line is depicted in Figure 2.5.  
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Figure 2.5: Relative viability of L929, MDA-MB-231 and HepG2 cells after 24 h incubation 
with the compounds 2 and 4a to 5c at 100 ȝM. Values represent the mean ± S.D. (n=3).  
 
None of the tested compounds caused a reduction of the cell viability in non-cancerous cell line 
L929. Sugar-complexes 5a and 5b showed a slight inhibition effect of cellular metabolic activity 
in breast cancer MDA-MB-231 cells in comparison to their ligands. This might be induced by the 
2,2‘-bipyridine (bpy) groups of the complexes, which increase the lipophilicity and, therefore, 
facilitate the diffusion through the cell membrane contrary to the more polar ligands 4a and 4b. 
D-Fructose conjugated complex 5b did not show cytotoxicity for MDA-MB-231 cells. The sugar-
free compounds 2 and 5c induced an inhibitory effect on cellular metabolic activity of relative 
viability of 70% for 2 and of 45% for 5c. This might be attributed by the enhanced hydrophobicity 
of these compounds due to the missing sugar moieties. Liver cancer HepG2 cells did not reveal 
sensitivity against sugar-free complex 5c and only a slight decrease of cell viability of 73% for 
ligand 2 was encountered. Sugar conjugated ligands 4a and 4b did not reveal any inhibitory effect 
as well. In contrast to that, HepG2 cells were strongly affected by sugar conjugated complexes 5a 
(41%) and 5b (50%). It has been reported that D-galactose inhibits the growth of HepG2 cells and 
that drug-induced mitochondrial toxicity is increased for HepG2 cells grown in D-galactose 
containing media instead of D-glucose.[81-82] HepG2 cells revealed also a significant decrease in 
cell viability after exposition to high D-glucose levels, which might be caused by an apoptotic 
mode.[83] Therefore, the decrease of cell viability of HepG2 cells, when incubated with sugar 
conjugated complexes 5a and 5b could be attributed to the interaction with the attached sugar units. 
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Additionally, another D-glucose conjugated [Ru(L)3]Cl2 complex showed an enhanced uptake into 
HepG2 cells in comparison to the D-galactosyl- respectively D-mannosylated complexes[84] and 
curcumin itself is reported to inhibit the cellular metabolic activity of HepG2 cells.[85-86]  
The performed investigations show the synthesis and characterization of a D-fructose conjugated 
curcumin derivative as well as the corresponding Ru complex. To obtain this complex, multistep 
syntheses of a sensitive biomolecule were required, including challenging protection group 
chemistry and the purification from multiple side-products. In the light of these findings, some 
changes in the synthesis regarding linking structures and the use of other curcumin derivatives 
would elevate the synthesis of D-fructose conjugated curcumin metal complexes. A novel curcumin 
derivative, which is modified with carboxylic acid functionalities at the benzyl rings, was reported 
recently.[87] Amino-functionalized D-fructose can be readily synthesized, starting from D-glucose, 
which undergoes an Amadori rearrangement when reacted with N,N-dibenzylamine.[88] The formed 
1-amino-dibenzyl D-fructose derivative can be hydrogenated to obtain amino-functionalized D-
fructose, which could react in a very efficient manner with the activated carboxylic acid of the 
curcumin derivative to form a carboxamide linker. Using this approach, no protection groups of 
the D-fructose would be required and, therefore, introduction of formic acid esters instead of 
isopropylidene groups with subsequent basic deprotection procedures could be avoided. It was also 
shown that D-fructose bound to a Re complex via a carboxamide linker revealed an increased 
uptake into MCF-7 cells mediated by GLUT5 in comparison to the D-fructose free compounds 
tested in this study.[31] However, the step with the lowest yield was the “click” reaction between 
the sugar-azides and the propargyl-modified curcumin derivative 1 with mono-functionalized 
product and Cu-curcumin complexes as side-products. Removal of the excessive Cu ions with 
EDTA or ammonia solution was not satisfying. Copper-free reactions between azides and alkynes 
are of strong interest for the conjugation of biomolecules and could also offer an alternative 
approach to the Cu(I) catalyzed reaction.[89-90] The biological evaluation of the novel compounds 
revealed sensitivity of the liver cancer cell line HepG2 against sugar-conjugated [Ru(bpy)2(L)]Cl2 
complexes. Quenched fluorescence of these compounds in aqueous media hampered uptake studies 
by fluorescence-based methods. Further investigations by other methods, such as ICP-MS 
(inductively coupled plasma mass spectrometry), could provide new insights in the uptake of sugar 
conjugated curcumin Ru complexes. 
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2.3 Sucrose as precursor for D-fructose derivatives functionalized at the C6 position 
 
Parts of this chapter have been published in: P4) M. Pröhl, P. D. Moser, J. A. Czaplewska, 
P. Hoffmann, T. Bus, A. Traeger, H. Görls, U. S. Schubert, M. Gottschaldt, Carbohydr. Res. 2017, 
446–447, 19-27. 
As described above, the GLUT5 transporter might be a target in the design of novel 
pharmaceuticals for GLUT5 overexpressing cells related to various diseases such as different types 
of breast cancer and AML. As a consequence, the interest in derivatives of D-fructose is 
continuously increasing. Derivatives include modification and / or substitutions of hydroxyl groups 
to form ethers, carboxylic acids, epoxides and halides, but also N-derivatives, such as amines and 
S-derivatives, such as thiols or thioethers. However, almost all of the up to now synthesized 
compounds are derivatized only at the C1 or C3 position of D-fructose due to commercially 
available starting materials with suitable protective groups (1,2;4,5-di-O-isopropylidene-β-D-
fructopyranose and 2,3;4,5-di-O-isopropylidene-β-D-fructo-pyranose). But also other positions of 
D-fructose are of interest for the design of novel derivatives, e.g. for complexation reactions. As 
aforementioned, C6 as well as C1 can be chemically modified without losing the affinity for the 
GLUT5 protein. The synthesis of C6-modified D-fructose derivatives is challenging. Starting from 
D-fructose, the equilibrium between the furanose and pyranose forms result in three primary 
hydroxyl groups (C1 in pyranose and C1 and C6 in furanose form), which impedes the selective 
protection of the C6 position. Hence, the synthesis of C6 derivatives usually includes the glycosidic 
linkage of the anomeric C2 position. Although, the C6 position of D-fructose might be interesting 
for the synthesis of GLUT5 targeting molecules, the increased number of steps for the synthesis 
plus the lack of commercially available starting materials effectively diminishes the available 
derivatives. As a starting point for the synthesis of C6 derivatives of D-fructose, sucrose is a suitable 
candidate (Figure 2.6). Sucrose contains one unit D-glucopyranose α-(1→2)-glycosidically linked 
to one unit of D-fructofuranose, which prevents ring-opening reactions until this bond is cleaved 
under acidic conditions. 
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Figure 2.6: Schematic representation of the structure of sucrose with one unit of D-glucose 
(black) and one unit of D-fructose (red). 
 
Our study aimed to modify the C6 position of D-fructose selectively. In a seven-step synthesis, 
pyridyl triazole group (pyta) as a two-dentate ligand was introduced to the C6 position of D-fructose 
in the sucrose molecule. Additionally, this group was also attached to the C1 position of D-fructose 
(Scheme 2.3). 
Scheme 2.3: Schematic representation of the synthesis of the ligands. 
 
Compound 6 was synthesized according to literature procedures. Starting from commercially 
available sucrose, the C6 position of the D-fructose unit was blocked with TBDPSCl and separated 
by column chromatography from di- and trisilylated derivatives. The purified product was 
acetylated with acetic acid anhydride in pyridine to obtain compound 6.[91-92] Literature procedure 
for the deprotection of compound 6 includes the use of pyridinium fluoride as fluoride source for 
the cleavage of the silylether.[91] To avoid the formation of highly toxic HF, TBAF was used instead 
to cleave off the silyl group at the C6 position of the D-fructose unit. Due to the basic character of 
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TBAF in aqueous solutions, one equivalent acetic acid was added to prevent migration of acetyl 
groups within the molecule. To introduce the azide functionality, a suitable leaving group for SN2 
conditions had to be installed at the C6 position before. A literature procedure reported the 
synthesis of mesylated sucrose, which was subsequently substituted using NaN3.[91] This procedure 
could not be reproduced. The formation of compound 9 was hampered, which might be attributed 
to the stability of mesylated sucrose. Increasing the temperature did not result in a higher yield for 
compound 9, but rather led to a cleavage of acetyl groups. Therefore, tosyl chloride was used to 
prepare tosylated sucrose 8 in high yield (96%). Crystallographic data for compounds 7 and 8 
revealed the structure and the purity of these compounds (Figure 2.7).  
 
Figure 2.7: Schematic representation of the molecular structure of compounds 8 (left) and 9 
(right). Crystals were obtained by diffusion of n-hexane into a solution of 8, respectively 9 in 
CHCl3. Thermal ellipsoids are drawn at 50% probability and hydrogen atoms and atom labels 
are omitted for clarity. Blue-colored carbons represent the oxygen at the C6’ positions of the 
sucrose derivatives. 
 
Azido-modified sucrose derivative 9 was obtained in quantitative yield after stirring tosylated 
sucrose 8 at 120 °C in DMF in the presence of NaN3 in the microwave. Microwave irradiation of 
9 dissolved in a mixture of t-BuOH and H2O with CuSO4·5H2O and sodium ascorbate as catalyst 
forming pair as well as 2-ethynyl-pyridine resulted in the pyta-modified derivative 10 in high yield 
(83%).[91] Zemplén transesterfication conditions using NaOMe in dry CH3OH resulted in water-
soluble sucrose derivative 11 bearing the pyta-group at the C6 of D-fructose unit in excellent yield 
(98%). Pyta-bearing D-fructose itself was not possible to synthesize by using 2 M HCl. ESI-MS 
investigations as well as thin layer chromatography (TLC) with RP18 coated on glass slides 
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revealed the formation of multiple side-products. Therefore, 11 was used as ligand for 
complexation to ruthenium and the D-glucose unit was cleaved off after the complexation reaction. 
For comparison, the pyta-functionality was also introduced to the C1 position of D-fructose. 
Isopropylidene-protected azido-fructose derivative 12 was used and reacted in a Cu(I) catalyzed 
cycloaddition with 2-ethynyl-pyridine to obtain pyta-modified D-fructose derivative 13 in high 
yield. Acidic cleavage of acetal groups could be successfully applied by stirring in 2M HCl in H2O 
at 40 °C to yield water-soluble D-fructose derivative 14. Also for comparison, ligand 15 was 
synthesized according to a literature procedure.[93] 
Subsequently, the ligands were reacted with Ru(bpy)2Cl2 to form complexes of the general formula 
[Ru(bpy)2(L)]Cl2 (Scheme 2.4). 
Scheme 2.4: Schematic representation of the syntheses of the complexes 16 to 19. 
 
The complexation reaction of compound 11 was carried out in the presence of Et3N to avoid the 
partial cleavage of the D-glucose unit of sucrose. Cleavage of the glycosidic linkage to form 
complex 17 was conducted with 2 M HCl in H2O. The reaction time was relatively long (> 1 week) 
and side-products were formed, when ligand 14 was stirred at 60 °C in methanol with the 
Ru(bpy)2Cl2 precursor. Therefore, the synthesis was performed using a microwave for 2 h at higher 
temperatures (120 °C). Since the Re(I) tricarbonyl complex of compound 15 revealed high 
cytotoxicity in HepG2 cells,[93] the corresponding ruthenium complex was synthesized in a similar 
manner to that of ligand 11 and was used for comparison. All complexes were purified by size 
exclusion chromatography using Sephadex LH-20® in H2O (for 16 to 18) or CH3OH (for 19). 1H 
NMR spectra of complex 18 revealed a set of signals (δ = 9.3 to 9.8 ppm) attributed to the triazole 
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proton of various stereoisomers of compound 18, when dissolved in deuterated DMSO (Figure 
2.8). 
 
Figure 2.8: Zoom into the 1H NMR spectrum of 18 dissolved in deuterated DMSO and 
assignment of different forms of D-fructose to the signals. 
 
An approximate amount of 37.5% of β-D-fructopyranose, 27% of β-D-fructofuranose, 27% of α-D-
fructopyranose and 8.5% of the open-chained form was detected by 1H NMR measurement. The 
ratio of the isomers in solution is strongly dependent from various factors such as pH value, 
temperature, solvent and others.[94-96] Additionally, each signal for the different stereoisomers of 
the complexes appeared twice and, therefore, indicates the existence of λ- and Δ-diastereoisomers 
at the octahedral coordination spheres of the central Ru complexes. This double set of signals in 
1H as well as in 13C NMR spectra was also observable for the other complexes, except for sugar-
free complex 19. Due to three two-dentate ligands in an octahedral coordination sphere, 
enantiomers should exist for this complex as well. However, the mixture shows a specific rotation 
of complex 19 ([α]20D = -7.2 °; c = 0.1 mg·mL-1; CH3OH), which indicates the dominance of one 
enantiomer and the lack of a racemic mixture. Absorption and emission spectra of all compounds 
were measured in aerated CH3OH. The absorption bands of the ligands at Ȝmax = 280 nm were 
associated with π→π* transitions. An additional band at Ȝmax = 440 nm for the metal complexes 
derives from metal to ligand charge transfer (MLCT) transition. Excitation by about Ȝex = 440 nm 
resulted in fluorescence in the visible region at around Ȝmax = 600 nm for all complexes. 
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To evaluate the complexes regarding their biological properties, cytotoxicity and uptake studies 
with non-cancerous cell line L929 and breast cancer cell lines MDA-MB-231 and MCF-7 were 
conducted. As expected, none of the compounds revealed significant inhibition of the metabolic 
activity of the tested cell lines. Also for this complexes (like observed for the complexes in 
chapter 2.1), the fluorescence is quenched when measured in aqueous media and, therefore, the 
uptake studies by fluorescence-based methods are hampered.[80] Instead, ICP-MS studies with the 
Ru complexes were conducted (Figure 2.9). 
 
Figure 2.9: Uptake of complexes 16 to 19 (Ru in fg per cell). L929, MDA-MB-231 and MCF-7 
cells were incubated at 50 ȝM for 1 h. As a control, more cells were not incubated with Ru 
complexes and no Ru content was determined (Ru < 0.03 fg / cell) by applying the same 
measurements. 
 
In contrast to the “soft” MS techniques, such as ESI- and MALDI-MS, elemental MS uses high 
temperature plasma (up to 7000 K) to form completely fragmented metal ions, which can be 
quantified out of solid, liquid or gaseous samples.[97] High sensitivity, accuracy and precision of 
the analytical data obtained by this method enlarges its application in the life science field.[98] Using 
ICP-MS, the data shows that the sugar-free complex 19 revealed an enhanced, unspecific uptake 
into all tested cell lines in comparison to the other compounds. This might be attributed to its 
increased hydrophobicity due to the missing sugar-units, which elevates the diffusion through the 
non-polar cell membrane. D-Fructose conjugated complexes 17 and 18 did not show any selectivity 
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for breast cancer cell lines. The results indicate that for this kind of metal complexes no enhanced 
uptake, independently of the substitution position of D-fructose, is observable. 
In summary, in the performed study two D-fructose conjugated Ru complexes of the general 
formula [Ru(bpy)2(L)]Cl2 could be synthesized and characterized. Sucrose was used as starting 
material since D-glucopyranose is α-(1→2)-glycosidically linked to D-fructofuranose and, 
therefore, the anomeric centers are blocked, holding both carbohydrates in a full-acetal form. Using 
this approach, C6-derivatives of D-fructose are accessible in high yields, which might enlarge the 
availability of various D-fructose conjugated metal complexes in future investigations. 
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3 Carbohydrate conjugated polymers 
 
Due to their important role in numerous biological events, saccharides gained also interest of 
polymer chemists. This chapter will focus on the synthesis of different glycopolymers by post-
polymerization functionalization procedures. In detail, the first sub-chapter emphasizes the 
synthesis of D-fructose conjugated linear poly(ethylenimine) and its selectivity for MDA-MB-231 
breast cancer cells. The synthesis of saccharide conjugated poly(acrylates) with varying the 
saccharides and block lengths as well as their lectin-binding ability is subject of the second sub-
chapter. 
 
3.1 D-Fructose conjugated linear poly(ethylenimine) 
 
Parts of this chapter have been published in: P3) C. Englert, M. Pröhl, J. A. Czaplewska, 
C. Fritzsche, E. Preußger, U. S. Schubert, A. Traeger, M. Gottschaldt, Macromol. Biosci. 2017, 17, 
1600502. 
 
Since the fundamental importance of the DNA in the control of cellular processes was recognized 
and the first clinical trial of gene therapy was authorized in the USA in 1990, remarkable progress 
over the last almost three decades was reached. Various kinds of genetic material, such as DNA, 
anti-sense oligodeoxynucleotides or small interfering ribonucleic acid (siRNA), were delivered 
into cells to treat hereditary as well as acquired diseases.[99] However, genetic materials have to 
struggle with some major barriers in vivo, which limit their use in clinical applications. Due to their 
high density of negative charges, the strong hydrophilic genetic materials are not capable to pass 
the lipophilic cell membrane by diffusion. When administrated systematically, they have to detract 
macrophages, renal filtration and endogenous nucleases. Once they passed the cell membrane by 
the endocytic pathway, their efficiency is further restricted by endosomal entrapment, lysosomal 
degradation and cytosolic viscosity.[99-102] Therefore, the stability and efficiency of “naked” genetic 
material has to be increased by specific gene delivery vectors. Viral vectors offer beneficial 
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properties, such as intrinsic mechanisms for endosomal escape and high transduction efficiency. 
They are derived from adeno-, retro- and herpes simplex virus and are the most widely used 
systems. Unfortunately, their use is restricted by the size of the carried gene and by strong immune 
responses.[99] As an alternative, non-viral vectors are extensively investigated to deliver genes of 
interest into cells. Those naturally occurring or synthetic materials should be relatively easy to 
synthesize in large amounts and can be functionalized to enhance their specificity. Many systems, 
such as cell penetrating peptides,[103] antibodies[104] and lipid-based carriers[105] are used. But also 
cationic polymers represent a class of candidates forming polyplexes with genetic material due to 
the positive charges of the polymers. Among the cationic polymers, PEI is used as the gold standard 
because of its high buffering ability facilitating the endosomal escape of the attached genetic 
material by the known “proton sponge effect”.[106] However, its use is also restricted by various 
factors. PEI is non-degradable, its polyplexes aggregate during blood circulation in vivo and its 
cytotoxicity depends on the molar mass, structure and concentration of the polymer.[107] To 
overcome these limits the PEI backbone and / or the side-chains can be modified. For instance, 
PEGylation (poly(ethylene glycol)) is used to form PEI-PEG-copolymers, but non-degradable 
bonds between PEI and PEG, such as urea and thiourea, require the additional use of a 
biodegradable linker.[108] Also targeting moieties were successfully attached to PEI. Folates,[109] 
RGD peptides[110] and antibodies[111] were used to target various structures. Another approach 
represents the attachment of carbohydrates to the PEI backbone to form glycopolymers by post-
polymerization functionalization procedures. For instance, D-mannose conjugated PEI was used to 
deliver DNA into dendritic cells and D-galactose was attached to target hepatocytes.[112]  
We synthesized a D-fructose conjugated high molar mass linear poly(ethyleneimine) (L-PEI) by a 
post-polymerization modification procedure using the versatile thiol-ene photo-addition. 
Furthermore, its biological properties in terms of polyplex formation, breast cancer selectivity and 
toxicity were evaluated. For this purpose, a thiol-modified D-fructose derivative was synthesized 
and tested for reaction with double-bond modified L-PEI. First attempts showed a low reactivity 
between 1-deoxy-1-mercapto-β-D-fructopyranose and the double-bond bearing copolymer, which 
might be attributed to sterical hindrance. Therefore, the introduction of a spacer unit between the 
sugar-ring and the thiol functionality was necessary (Scheme 3.1). 
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Scheme 3.1: Schematic representation of the synthesis of thiol-bearing D-fructose derivative 24. 
 
Commercially available, protected D-fructose derivative 20 was reacted in a Williamson ether 
synthesis with benzyl-2-bromoethyl ether to form (2-benzyloxy)-ethyl derivative 21 after 
purification by column chromatography. The benzyl group was cleaved under reductive conditions 
with hydrogen and Pd on activated charcoal to obtain 1-(2-hydroxy)-ethyl modified D-fructose 22 
in high yield (95%). The novel hydroxyl group was transformed into a leaving group by reaction 
with mesyl chloride in CH2Cl2 under an Ar atmosphere and with 4-DMAP as nucleophilic catalyst 
in accordance to literature procedures.[113] SN2 reaction with thiourea resulted in the formation of 
an isothioronium salt, which was hydrolyzed in the presence of K2S2O5 to avoid oxidation of the 
formed thiol group. 
Subsequently, D-fructose conjugated L-PEI was synthesized as depicted in Scheme 3.2. 
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Scheme 3.2: Schematic representation of the synthesis of the D-fructose conjugated L-PEI 28. 
 
Poly(2-ethyl-2-oxazoline) (PEtOx, 25) was synthesized by microwave supported cationic ring-
opening polymerization according to literature procedures.[114] The tosylate signals in the 1H NMR 
were used to calculate the degree of polymerization (DP) of the homopolymer 25. To obtain L-PEI 
26 the amides were hydrolyzed by refluxing with aqueous 6 M HCl for 16 h. The amidation 
reaction of 26 with the activated acid N-succinimidyl-4-pentenate resulted in copolymer 27 with 
23% of all ethylenimin units functionalized with terminal ene-group via amide linkage.[115] The 
previously synthesized thiol-bearing D-fructose derivative 24 was attached by thiol-ene photo-
addition using 2,2-dimethoxy-1,2-diphenylethan-1-one (DMPA) as photo-catalyst. To verify the 
composition of the copolymer, the integral of the signals of the remained double bonds 
(δ = 5.9 ppm) was compared to the integral of the signal of the PEI backbone (δ = 2.5 to 2.9 ppm). 
Roughly 60% of all double bonds respectively 14% of all repeating units were functionalized with 
D-fructose. This is also in accordance to the amount of sulfur determined by elemental analysis of 
the polymers 27 (S: 0%) and 28 (4.66%). A higher degree of functionalization (DF) was not 
reachable, also not by increasing the irradiation time, amount of catalyst or thiol. This is mainly 
attributed to the sterical hindrance of the bulky side-chains and by the protection groups of the D-
fructose units.[79] But a higher content of saccharides attached to PEI does not result inevitably in 
improved properties. As shown for a library of D-galactose conjugated PEIs with varying DFs, the 
increase of D-galactose units resulted in a lower transfection efficiency in mouse fibroblasts.[116] 
However, acidic cleavage of isopropylidene groups resulted in copolymer 28, which represents the 
first literature-known D-fructose conjugated, cationic polymer. The success of the deprotection was 
shown by various NMR techniques. The disappearance of signals attributed to isopropylidene 
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groups and the appearance of signals of various forms of D-fructose in the 1H as well as in the 13C 
NMR spectra as a result of the formation of hemiketal structures proves the cleavage of the 
protection groups. Furthermore, diffusion-ordered NMR (DOSY NMR) showed a decrease in the 
hydrodynamic radius of polymer 28 in comparison to the polymer bearing the protected D-fructose 
units.  
The polymers 26 to 28 were extensively studied in terms of cytotoxicity, hemocompatibility, 
polyplex formation, cell-type dependent uptake and transfection efficiency.  
Cytotoxicity of non-viral vectors represents a major drawback for potential applications. Hence, 
the polymers were investigated regarding their inhibition effect of the cellular metabolic activities 
of L929, MDA-MB-231 and a primary human endothelial cells (HUVEC) using the AlamarBlue 
assay (Figure 3.1). 
 
Figure 3.1: Relative viability of L929, HUVEC and MDA-MB-231 cells after 24 h incubation 
with the polymers 26 to 28 at varying concentrations. Values represent the mean ± S.D. (n=3).  
 
The cell viability of all tested cell lines was reduced to below 3% for L-PEI 26 at 100 ȝg·mL-1, 
which is in accordance to literature results.[117] Compound 27 showed moderate biocompatibility 
for L929 (c ൑ 400 ȝg·mL-1; viability ൒ 80%) and HUVEC cells (c ൑ 150 ȝg·mL-1; 
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viability ൒ 80%). In contrast to that, it inhibited the metabolic activity of MDA-MB-231 cells 
entirely at 50 ȝg·mL-1. D-Fructose bearing polymer 28 revealed a significant reduction of the cell 
viability of MDA-MB-231 cells to 3% at 150 ȝg·mL-1 with no significant cytotoxicity over the full 
concentration range in L929 (~100%) and HUVEC cells (~80%). 
Cationic polymers interact with various components of the blood. Due to the formation of bridges 
between the membranes of red blood cells and the polymer, irreversible erythrocyte aggregation 
can occur. As a result of this interaction, the viscosity of the blood is increased, which can be 
harmful for vital organs.[118] Furthermore, cationic polymers disrupt the membranes of 
erythrocytes. This hemolytic effect can be measured by the detection of hemoglobin with 
spectroscopic methods. Therefore, polymers 26 to 28 were investigated for their erythrocyte 
aggregation and hemolytic potential (Figure 3.2). 
Figure 3.2: Investigations of the hemocompatibility. A. Erythrocyte aggregation assay of 
polymers at indicated concentrations. Branched PEI served as positive control and PBS as 
negative control; B. Hemolysis assay of erythrocytes after incubation with polymers at indicated 
concentrations. Triton X-100 served as positive control (100% hemolysis) and PBS as negative 
control (1.99%). A value less than 2% hemolysis rate is classified as non-hemolytic, 2 to 5% as 
slightly hemolytic and >5% as hemolytic. Values represent the mean ± SD (n = 3). 
 
None of the tested polymers (26 to 28) showed erythrocyte aggregation up to 100 ȝg mL−1. 
Compounds 26 and 27 were slightly hemolytic over the full concentration range, whereas the 
D-fructose conjugated polymer 28 is non-hemolytic until 50 ȝg mL−1 and only revealed very low 
hemolytic activity at 100 ȝg mL−1.  
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Plasmid deoxyribonucleic acid (pDNA) was used to investigate the binding properties of the 
polymers with genetic material by using the ethidium bromide assay (EBA). Therefore, the pDNA 
was pre-incubated with the intercalator ethidium bromide, which results in a fluorescent adduct. 
When adding a competitor for the negative binding sites of the pDNA, a decrease of the 
fluorescence is caused due to the displacement of the ethidium bromide by the cationic polymer. 
Various ratios of polymer (N from nitrogen of the PEI backbone) to DNA (P from phosphate of 
the DNA backbone) were investigated (Figure 3.3A).  
Figure 3.3: Investigation of the polyplex formation and stability with plasmid DNA. A. Decrease 
in relative fluorescence (RFU) at indicated N/P ratios; B. Dissociation assay of polyplexes 
formed at N/P 20 using heparin (0-60 U mL−1). Values represent the mean ± SD (n = 3). 
 
Polymer 26 showed a formation of stable polyplexes for N/P ratios between 10 and 40 (~25% 
RFU). Compounds 27 and 28 showed a fairly constant RFU of around 60% from N/P 20 to 40 for 
various reasons. The amidation of 26 resulted in the decrease of 23% of available nitrogen atoms 
for the polyplex formation for compound 27 and 28. Additionally, sterically demanding side-chains 
and the attached D-fructose units lower effectively the binding of the polymers to pDNA and, 
therefore, increasing the RFU. The obtained data is in accordance to comparable polymers.[119]  
For the evaluation of the stability of the polyplexes and the release of the genetic material, the 
heparin assay was used. Heparin is a highly negatively charged glycosaminoglycan, which 
competes with the pDNA in the polyplex.[120] If added together with ethidium bromide, the 
increasing RFU is proportional to the displacement of the nucleic acid out of the polyplex and the 
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subsequent formation of the fluorescent DNA adduct (Figure 3.3B). The pDNA of polyplexes of 
27 and 28 was rapidly released (~100%) after adding only 10 U·mL-1 heparin, whereas the full 
pDNA release of the polyplexes of L-PEI (26) required higher amounts of heparin (40 U·mL-1). 
Also the size of the polyplexes is of great importance for their properties, since the size of 
nanocarriers is recommended to be below 200 nm for an effective uptake into cells.[121] All 
polyplexes of the polymers with pDNA revealed favorable sizes, when their dispersions in HBG 
buffer were analyzed by DLS (Table 3.1). 
Table 3.1: Size and zeta potential of pDNA polyplexes of 26 to 28 at N/P = 20 in HBG buffer, 
measured by dynamic and electrophoretic light scattering. 
 
Abbrev. z-Average (d·nm-1) PDI Number-weighted size (d·nm-1) Zeta potential 
(mV) 
26 217±8 0.47 71±13 24.0±0.4 
27 264±11 0.35 109±33 ʹͶ.͵ ±1.1 
28 165±1 0.26 83±29 ͳ͹.͸ ±0.4 
 
Another crucial parameter for the design of non-viral gene delivery vectors represents the effective 
uptake of the functionalized polyplexes into cells. Non-functionalized polyplexes are shown to be 
internalized by an endocytic pathway with subsequent release of the pDNA in the cytosol into 
many cells in an unspecific fashion.[122] The functionalization with D-fructose was aimed to target 
the GLUT5 transporter. As a consequence, GLUT5 overexpressing cell lines, such as MDA-MB-
231, should reveal a higher uptake of the polyplexes of 28 relative to these of 26 and 27. This was 
investigated using flow cytometry and CLSM. Therefore, the used pDNA was pre-incubated with 
YOYO-1, a DNA specific dye with a high fluorescence intensity once intercalated and with no 
displacement during the polyplex formation. 
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Figure 3.4: Polyplexes of 26 to 28 with YOYO-1 labeled pDNA were incubated with L929, 
HUVEC, and MDA-MB-231 cells for 1 h at indicated N/P ratios. The percentages of cells 
(columns), which have taken up pDNA polyplexes as well as the mean fluorescence intensity 
(MFI) of all viable cells compared to pDNA control without polymers were depicted. Values 
represent the mean ± SD (n ≥ 3). 
 
As expected, the non-functionalized polymer 26 showed an unspecific, strong uptake into all cell 
lines for all N/P ratios. Polyplexes of 27 revealed no uptake in any cell line for N/P = 10, a slight 
uptake into HUVEC and MDA-MB-231 cells for N/P = 20 and an enhanced unspecific uptake into 
all cell lines for N/P = 50. In contrast to that, polyplexes of D-fructose bearing polymer 28 were 
exclusively incorporated by breast-cancer MDA-MB-231 cells at N/P = 20. At N/P = 50 
polyplexes of 28 were taken up more into MDA-MB-231 cells and to a lower extent into all other 
cell lines relative to the polyplexes of 26 and 27, emphasizing the selectivity of 28 towards GLUT5 
overexpressing cells. To further investigate the uptake mechanism and to rule out distortive effects, 
such as sticking of the polyplexes at the cell membranes, CLSM studies of labeled polyplexes were 
performed. Before the polymers were stirred in an appropriate solvent and adding the reactive 
derivative cyanine-5-NHS-ester for 26 or rhodamin B isothiocyanate for 27 and 28. Free dyes were 
removed by precipitating the labeled polymers, re-dissolving the precipitated solid and dialyis 
against H2O. Under consideration of the distinct labeling efficiencies, the labeled polymers were 
mixed with different amounts of their unlabeled counterparts and were incubated with MDA-MB-
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231, L929 and HUVEC cells. The CLSM data is in accordance with the results obtained by flow 
cytometry and revealed the uptake of the polyplexes into the cells with location in the cytosol. 
After formation of the polyplexes and uptake into the cells of interest, the ultimate aim of non-viral 
vectors is the release of the cargo into the cell. This can, e.g., be monitored by the expression of 
the enhanced green fluorescent protein (EGFP), which is coded on a pDNA applying a standard 
procedure. For the polymers 26 to 28 the genetic material was released up to 30% from the 
polyplexes for 26 and up to 40% for 27, whereas 28 revealed only transfection efficiencies lower 
than 1% for all investigated N/P ratios. This is most probably attributed to the complex interaction 
between polyplexes and cell components. Usually, polyplexes release their cargo after the 
endosomal escape mediated by the proton sponge effect. The accumulation of weak basic groups 
inside the endosome increases its osmolarity and, as a consequence, the endosomes swell and 
release their content into the cytosol.[123] Due to the modification of the PEI backbone by amidation 
reaction, only 77% of all amines are available for protonation, which effectively reduces the 
swelling behavior. 
In summary, a D-fructose conjugated L-PEI could be synthesized and evaluated for its biological 
properties. A novel, thiolated D-fructose derivative was reacted with modified L-PEI via photo-
catalyzed thiol-ene addition in high yield. The deprotected polymer 28 showed a pool of beneficial 
properties in terms of its use as non-viral vector. Surprisingly, just the polymer 28 revealed already 
a cell-specific toxicity in breast cancer cell line MDA-MB-231 without affecting the viability of 
the other cell lines on a significant level in comparison to polymers 26 and 27. Furthermore, it 
shows an enhanced hemocompatibility relative to the other tested materials. Polymer 28 forms with 
pDNA stable polyplexes of advantageous size regarding efficient delivery for N/P ratios above 20 
and it requires only small amounts of the competitor molecule heparin to release the pDNA. The 
uptake of the dye-labeled polyplexes was quantified by flow cytometry and CLSM. The polyplexes 
containing D-fructose bearing polymer 28 exhibited specific uptake into MDA-MB-231 cells at 
N/P = 20 in comparison to the other polyplexes. Unfortunately, the transfection efficiency was 
strongly decreased even when compared to the already low transfection efficiencies of compounds 
26 and 27. This might be attributed to the decreased amount of secondary amines in the backbone 
and, therefore, to the reduced proton sponge effect. Increased transfection efficiencies, in particular 
for the use of around 250 times smaller and more rigid siRNA, might be reachable by using B-PEI 
instead of L-PEI.[124] But also the molar mass of the polymers matters. The properties of polyplexes 
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containing siRNA and B-PEI of different molar masses were shown to be strongly dependent of 
the molar mass of the polymer: The polyplexes of high molar mass B-PEI showed an enhanced 
stability and uptake.[125] Also, the decrease of the sugar-content might result in higher transfection 
efficiencies due to the higher amounts of secondary amines available for protonation. However, by 
changing parameters to reach higher transfection efficiencies, it should be also noted that this might 
influences other properties, such as polyplex formation, toxicity and stability. Therefore, further 
systematic studies are required. 
 
3.2 Carbohydrate conjugated polyacrylates 
 
Parts of this chapter have been published in: P5) M. Pröhl, C. Englert, M. Gottschaldt, U. S. 
Schubert, J. C. Brendel, J. Polym. Sci., Part A: Polym. Chem. 2017, 55, 3617-3626. 
 
The interactions between saccharides and proteins play central roles on a cellular level in cell 
adhesion and differentiation, viral replication, inflammation, parasitic infection as well as other 
processes.[3, 126] Lectins represent a group of important proteins, responsible for selective binding 
of carbohydrates with high stereo-specificity. Whereas a single saccharide reveals only low binding 
affinity to its natural ligand, multivalency, caused by the interaction between multiple 
carbohydrates with one lectin molecule and / or the formation of higher-order clusters of multiple 
lectins, is of fundamental importance in nature.[5, 8] In light of this, the so-called “cluster effect”[127] 
strongly emphasizes the need of well-defined polymers bearing carbohydrate residues 
(glycopolymers) to address the multivalency in cell-cell communications by artificial entities 
bearing multiple sugar residues. 
Glycopolymer architectures can be obtained in two different ways: Polymerization of 
carbohydrates functionalized with polymerizable groups (glycomonomers) or the functionalization 
with carbohydrates after polymerization of reactive monomers (post-polymerization 
functionalization). Glycopolymers were obtained by polymerizing various glycomonomers using 
free radical,[128] controlled radical,[129-130] anionic,[131] cationic,[132] ring-opening[133] and other 
polymerization techniques.[134] However, the use of glycomonomers also reveals disadvantages, 
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such as multi-step synthesis of the glycomonomers, incompatibility of unprotected carbohydrates 
with various polymerization techniques and challenging synthesis of polymers with high molar 
masses as well as narrow distributions.[135] Alternative post-polymerization functionalization 
procedures include the uses of various reactive groups, such as para-fluoro-phenyl,[136] alkinyl-
,
[137]
 alkenyl-groups[138] and others.[135] 
The SN2 substitution of halide-containing polymers with suitable nucleophiles represents a 
relatively unexplored reaction in the design of glycopolymers. This might be attributed to the 
sensitivity of halides against abstraction by radicals and, therefore, to the limited use of reversible 
deactivation radical polymerization (RDRP) techniques. However, alkyl halides offer great 
reactivity in terms of post-modification by substitution reactions with suitable nucleophiles. 
Poly(epichlorhydrin) (PECH) was reacted with a SH-bearing derivative of D-glucose to form 
bristle-like polymers.[4] Stenzel and coworkers showed the synthesis of poly(vinyl benzylchlorid) 
(PVBC) via reversible addition-fragmentation chain transfer polymerization (RAFT). Equimolar 
amounts of the sodium salt of 1-SH-D-glucose were used to substitute the chloride in the polymer 
and to form glycopolymers with moderate dispersities.[139] Furthermore, the Perrier group showed 
the synthesis of poly(bromoethyl acrylate) (PBEA) and the post-substitution with various 
nucleophiles, including P- (e.g. trimethylphosphine), N- (e.g. sodium azide) and S-nucleophiles 
(e.g. thiophenol) emphasizing the versatility of this polymer scaffold.[140]  
The study aimed to synthesize glyco-homopolymers by controlled radical polymerization 
techniques with low dispersities and DPs exceeding 100 units. The DP of the obtained polymers 
ranges from 45 to 115 and various saccharides were attached, in detail D-glucose, D-galactose as 
well as D-mannose, by post-polymerization functionalization. Additionally, the affinity of the 
synthesized polymers for the lectin concanavalin A (Con A) was investigated using turbidimetry 
experiments. 
The polymers were synthesized as depicted in Scheme 3.3. 
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Scheme 3.3: Schematic representation of the polymer syntheses. 
 
Monomer 29 was obtained in higher purity than in reported procedures[140] due to the removal of 
side-products by stirring with 0.1 M NaOH(aq) with subsequent vacuum destillation. Therefore, it 
could be used to form PBEA via RAFT without loss of control with (4-cyanopentanoic acid)ylethyl 
trithiocarbonate (CPAETC) as chain transfer agent (CTA) and AIBN (azobisisobutyronitrile) as 
radical initiator. By varying the ratio [monomer]·[CTA]-1, various DPs were obtained with good 
conversions (>55%), low dispersities (Ð ൑ 1.2) and narrow distributions (Table 3.2).  
Table 3.2: List of polymers obtained by polymerization of BEA. 
Abbrev. [M]0/CTA [CTA]/I0 conv.a) (%) Mn,thb) Mn,NMRc) Mn,SECd) Ð 
    g·mol-1  
30 60 10 75 7,600 8,300 8,800 1.10 
31 100 10 78 15,700 14,200 11,200 1.21 
32 200 10 58 22,700 20,800 18,000 1.11 
a) Determined from 1H NMR of the polymerization mixture before precipitation. b) Calculated 
from monomer conversion. c) Determined from 1H NMR end-group analysis (calculated from 
signal intensity of the proton of the tertiary C-atom next to trithiocarbonate (δ = 4.93 ppm) in 
comparison to the proton signal of the C1 atom of the acryl ester (δ = 4.43 ppm) before post-
polymerization modification). d) SEC: DMAc + 0.21 wt.% LiCl, polystyrene calibration. 
 
Post-polymerization functionalization was carried out using thiol(ate) modified carbohydrates 
D-glucose, D-galactose and D-mannose (Table 3.3).  
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Table 3.3: List of glycopolymers synthesized in this study. 
 
Abbrev. DPa) Attached sugar (R1) Mn,thb) Mn,SECc) Ð 
    g·mol-1  
33 45 Glc 13,500 10,000 1.19 
34 45 Gal 13,500 9,900 1.22 
35 45 Man 13,500 3,300 1.44 
36 78 Glc 23,200 17,400 1.25 
37 78 Gal 23,200 16,400 1.28 
38 78 Man 23,200 9,400 1.34 
39 115 Glc 34,100 23,300 1.26 
40 115 Gal 34,100 23,300 1.28 
41 115 Man 34,100 15,900 1.33 
a)
 DP was assumed from precursor polymers 30 to 32. b) The theoretical Mn was calculated 
assuming 100% substitution of the Br. c) SEC: H2O, 0.1 M NaNO3, 0.05% NaN3, Pullulan 
calibration. 
 
D-Glucose and D-galactose were attached using 1.1 equivalents of their deprotected 1-SH-
derivatives by stirring them together with the respective polymer in DMSO in the presence of Et3N 
for 24 h. D-Mannose was conjugated using 1.1 equiv. of 1-deoxy-1-mercaptothiolate-α-
D-mannopyranose in a DMSO-H2O mixture without any base. All low molar mass impurities were 
separated by dialysis vs. H2O (molecular weight cut-off [MWCO] 3.5 kDa). The polymers were 
analyzed by various techniques, including 1H and DOSY NMR as well as by elemental analysis 
(Table 3.4) and SEC (Figure 3.5).  
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Figure 3.5: SEC traces of polymers 33 to 41 (H2O, 0.1 M NaNO3, 0.05% NaN3, Pullulan 
standard). 
 
The attachment of sugar residues resulted in the increase of the hydrodynamic volume relative to 
the polymers 30 to 32 and the SEC traces appeared mono-modal with narrow dispersities 
(Ð ൑ 1.50). Using only a slight excess of the sugar resulted in the lack of side-reactions, such as 
cleavage of the CTA with subsequent disulfide formation, in comparison to previous studies.[140] 
The increased dispersities are caused by the use of different SEC systems for polymers 30 to 32 
and for 33 to 41. The interaction of the glycopolymers with the column material was also 
responsible for the decreased Mn of the D-mannolysated polymers relative to all other 
glycopolymers, although the hydrodynamic radius should be comparable. One difference between 
the attached aldoses represents the axial alignment of the OH group at the C2 atom in D-mannose, 
whereas the other aldoses possess equatorial orientation at this position. Therefore, as the reason 
for the later elution the interaction between the hydroxyl group at the C2 of D-mannose and the 
column material and / or the polymeric backbone is proposed. 
The DF was calculated to further evaluate the substitution reactions and some tendencies are 
mentionable (Table 3.4).  
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Table 3.4: Elemental compositions of polymers 30 to 41. 
 
Abbrev. DP Saccharide Elemental compositiona) (%) DFb) (%) 
   C H S Br  
 
  
     
30 45 - 33.74 4.00 1.16 43.35 - 
33 45 Glc 43.87 6.17 10.81 0.89 97.9 
34 45 Gal 41.88 6.13 11.99 1.99 95.4 
35 45 Man 43.76 6.27 10.36 0 100 
 
  
    
 
31 78 - 33.66 3.97 0.68 43.89 - 
36 78 Glc 44.15 6.18 9.48 2.14 95.1 
37 78 Gal 43.28 6.18 9.31 3.09 93 
38 78 Man 43.80 6.14 10.45 0 100 
 
  
    
 
32 115 - 33.63 3.96 0.46 44.12 - 
39 115 Glc 43.53 6.20 10.20 1.54 96.5 
40 115 Gal 41.73 6.05 10.58 2.52 94.3 
41 115 Man 43.83 6.16 10.42 0.36 99.2 
a)
 Elemental composition of starting polymers 30 to 32 was calculated assuming one polymer species 
with the depicted DP. b) Calculated DFs are based on theoretical Br content of polymers 30 to 32.  
 
The DFs range from 93 to 100%, indicating high efficiency. The D-mannosylated polymers 35, 38 
and 41 showed a remaining Br content between 0% and 0.36%, which represents also the lower 
detection limit of the determination of the elemental composition. This effect might be attributed 
to the use of sodium thiolate instead of the thiol and a suitable base.  
An important variable for potential applications represents the ability to bind to lectins, which are 
specific for the respective sugars. Con A is a binding protein which is specific for α-D-mannose 
and α-D-glucose. It consists of aggregates of 25 kDa units and is predominantly existing as 
tetramers above pH = 7.[141] By adding glycopolymers with suitable carbohydrate residues to a 
solution of Con A, various aggregates are precipitating time-dependently.[142] The change in the 
turbidity can be monitored in real-time by measuring the absorbance at Ȝ = 420 nm over the time 
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immediately after mixing the solutions. The slope of the steepest portion of the initial curve was 
determined and represents the clustering rate kc expressed in arbitrary units per second (a.u.·s-1).[143] 
The initial increase of the turbidity is caused by isolated Con A polymer clusters, whereas the 
formation of cross-linked clusters of higher order is attributed to later points.[144] The results are 
summarized in Figure 3.6. 
Figure 3.6: Results of the turbidimetry assays. A. Absorbance (Ȝ = 420 nm) curves after adding 
1 mL solutions of polymers 33 to 41 (50 ȝM per sugar unit) to 1 ȝM solutions of Con A in HBS 
buffer; B. Calculated rates of clustering between Con A tetramers and D-glucosyl- or 
D-mannosylated polymers obtained by a linear fit of the steepest portions of the curves, kc values 
represent the average of three replicates. 
 
As previously reported,[136] D-galactosylated polymers did not form measurable amounts of Con A 
clusters, whereas D-glucosylated and D-mannosylated polymers aggregated in the presence of 
Con A with varying clustering rates kc. Due to the higher binding affinity of Con A towards 
α-D-mannose in comparison to α-D-glucose and the use of β-D-glucose in polymers 33, 36 and 39, 
the kc values for the polymers grafted with D-mannose are higher than for the corresponding 
D-glucosylated compounds. The high clustering rates, obtained for 35, 38 and 41, indicate the rapid 
precipitation of most of the Con A tetramers, whereas D-glucose bearing polymers revealed a 
slower, but continuous increase in turbidity, which indicates to secondary interactions, such as the 
formation of higher-order clusters. Also the comparison of polymers with the same sugar residues, 
but with different DP values, revealed general tendencies. The clustering rates increase with 
increasing DP for both kinds of saccharide bearing polymers, which is also in accordance with 
literature reports.[144-145] The clustering rates of the investigated D-mannosylated polymers seem to 
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approximate to a constant level with higher DPs. Therefore, no large increase for kc is expected for 
D-mannosylated polymers of this structure with DPs higher than 115. 
To investigate the strength of the previously formed clusters, competition experiments were 
conducted. Hence, the precipitate was allowed to rest for additional 2 h to ensure that all secondary 
interactions are past and a large excess of α-D-methyl-mannopyranose (αMeMan) was added. 
αMeMan represents a competitor for the binding sites of the Con A and as a result, the clusters 
were dissolved again and the change in the turbidity is monitored by the absorbance at Ȝ = 420 nm 
over the time immediately after adding the competitor (Figure 3.7). 
Figure 3.7: Results of the competition assays. A. Absorbance (Ȝ = 420 nm) curves after adding 
0.2 mL solution of αMeMan (54 mM) to the polymer solutions (50 ȝM per sugar unit) in HBS 
buffer. B. Calculated rates of the reverse interaction between Con A aggregates and the 
competitor αMeMan obtained by a linear fit of the steepest portions of the curves. 
 
The dissolution rates kd of the polymers grafted with D-glucose are strongly enhanced in 
comparison to the D-mannosylated polymers, indicating a rather weak interaction between Con A 
and the D-glucosylated polymers. Additionally, the turbidity caused by clusters of D-glucosylated 
polymers was decreasing faster to a constant level with increasing DP. In contrast to that, 
aggregates of polymers bearing D-mannose revealed very slow kd values. The decrease of the 
turbidity was slow, but continuous to a constant level, which indicates the formation of stable 
clusters and which might hint to an incomplete dissolution of the precipitated aggregates. This can 
be shown by comparing the difference between the highest and lowest absorption after adding 
Con A to the polymer solutions with the difference obtained after adding αMeMan (Figure 3.8). 
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Figure 3.8: Ratio of the dissolved Con A polymer clusters after adding αMeMan relative to the 
DP. The values were calculated by the ratio of the moduli of the difference between the highest 
and lowest absorbance after adding αMeMan or Con A to the polymer solutions, respectively. 
 
Previously reported examples commonly showed the full dissolution of clusters of D-glucosylated 
polymers and Con A.[143] In contrast to that, the presented D-glucosylated polymers 36 and 39 (69% 
or 62% re-dissolved clusters, respectively) revealed an incomplete dissolution despite the addition 
of the competitor αMeMan in around 1000 fold excess. For the D-mannosylated polymers 35, 38 
and 41 an even higher stability of the clusters was observable, which is attributed to the flexibility 
of the polymeric backbone and therefore, to the increased interaction with the Con A tetramers.  
In summary, a library of new glycopolymers was synthesized by RAFT polymerization of BEA 
monomer with subsequent SN2 reaction using various thiol(ate) aldoses, in detail D-glucose, 
D-galactose and D-mannose. Precursor polymers 30 to 32 were obtained with good conversions and 
different DPs. A DP of up to 115 could be achieved by changing the ratio [monomer]·[CTA]-1. In 
contrast to literature examples, this approach can be used to synthesize linear and reactive 
homopolymers with large DPs (> 100) and high control during the polymerization. The DF of the 
SN2 reactions ranges from 93 to 100% and showed the efficiency of this approach. The 
carbohydrates were attached using only slight excesses of the deprotected thiol(ate) derivatives. 
Only non-toxic side-products were produced, which could be easily removed by dialysis in water. 
By the use of protected carbohydrates to functionalize the polymers, the backbones of the different 
blocks should not contain functionalities which have the same lability than the protection groups 
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of the sugar residues. This thought is obsolete by using the presented approach for the synthesis of 
co-polymeric architectures containing base- or acid-labile groups. The turbidity measurements of 
the synthesized polymers with Con A revealed an incomplete dissolution of the Con A cluster of 
the D-mannosylated polymers, which was not reported yet. It could be also possible to address 
higher DP values and to synthesize larger polymers, to vary the epitope density of one or more 
residues of different saccharides. Also the use as hydrophilic block in various block copolymers 
and their assemblies in water are worth to investigate. The attachment of D-fructose by using the 
sodium salt of the thiol derivative and the precursor polymer(s) would represent an interesting 
strategy for the synthesis of D-fructosylated (co-)polymers. All structural modifications could also 
be investigated regarding their affinity to suitable binding proteins to gain deeper insights into the 
multivalency as a central concept in nature.  
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4 Summary and outlook 
 
The present thesis describes the synthesis, characterization and biological evaluation of D-fructose 
conjugated molecules. The work focused on two different classes of compounds: On one hand low 
molar mass metal complexes and on the other hand polymers with complete different types of 
interaction with GLUT5 transporters (Figure 4.1). 
 
Figure 4.1: Schematic representation of the uptake of D-fructose conjugated molecules. Left: 
D-Fructose conjugated low molar mass metal complexes were taken up through the GLUT5 
transporter, which is strongly dependent on the molecular structure. Right: D-Fructose 
conjugated polymers were taken up by an endocytotic pathway, which is mediated by the GLUT5 
protein acting as receptor and which is observed for multiple polymer classes.  
 
Before this work, only two literature examples about D-fructose conjugated metal complexes were 
available. They revealed an increased uptake of the D-fructose conjugated metal complexes into 
breast cancer cells mediated by the facilitative glucose transporter 5 (GLUT5) when compared to 
the D-fructose free analogues, which showed no selective accumulation. To further evaluate this 
hypothesis, a derivative of the highly biological active molecule curcumin was used and conjugated 
to two units of D-fructose by using the Cu(I) catalyzed alkine azide cycladdition (CuAAC). The β-
diketo moiety of the curcumin derivative was used afterwards to form ruthenium complexes of the 
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general formula [Ru(bpy)2(L)]Cl. Due to the quenching of their fluorescence in aqueous media, the 
uptake of these complexes into breast cancer cells could not be evaluated. The mentioned studies 
were limited to D-fructose derivatives bound to the ligand scaffold via the C1 of the D-fructose 
molecule. One major questions of the present thesis represented the influence of the substitution 
position in the D-fructose molecule. For this purpose, two novel D-fructose conjugated ruthenium 
complexes starting from sucrose or a commercially available D-fructose derivative, respectively, 
were synthesized. The D-fructose units were attached via the C1 and C6 position by maintaining 
the rest of the molecules without chemical modifications. Inductively coupled plasma mass 
spectrometry measurements (ICP-MS) were conducted to investigate the influence of the 
substitution position on the cellular uptake after the complexes were incubated with breast cancer 
cells. Unfortunately, ruthenium complexes of the general formula [Ru(bpy)2(L)]Cl2 with pyridyl 
triazole functionalized D-fructose as ancillary ligand did not show selective accumulation in breast 
cancer cells, independently from the position of modification. This is not transferable to other metal 
complexes with D-fructose conjugated ligands and has to be evaluated for every new complex again 
in detail. 
Literature examples for D-fructose conjugated macromolecules and their use for the selective 
uptake into breast cancer cells were rare as well, when the present thesis was started. But in the last 
four years, numerous studies were published and show the possibility to target GLUT5 by 
D-fructose conjugated macromolecules. In this work, results for the first literature-known, cationic 
polymer with covalently attached D-fructose molecules could be contributed to this field. A 
D-fructose conjugated high-molar mass linear poly(ethylenimine) (L-PEI) was synthesized and 
showed an excellent biocompatibility paired with selective toxicity. The hemolytic potential was 
clearly decreased in comparison to the parent polymers while the ability to form stable polyplexes 
with plasmid deoxyribonucleic acid (pDNA) was maintained. The formed polyplexes of this 
polymer were shown to be taken up exclusively in significant levels into breast cancer cells. It can 
be stated that high-molar mass L-PEI with a degree of functionalization (DF) of 14% with 
D-fructose offers a large pool of beneficial biological properties, but the influence of many other 
parameters, such as DF, length of the polymer or degree of branching, have to be studied in future 
investigations.  
Besides the interaction of D-fructose with GLUT5, the interaction of sugar molecules with receptors 
and other binding proteins is of major interest for the synthesis of potential D-fructose bearing 
Summary and outlook 
53 
polymers. The binding affinity of these receptors is strongly dependent from multiple variables 
including the epitope density and the polymer flexibility. The last chapter of the present thesis 
focused on these interactions. Therefore, bromide bearing acrylates with large degree of 
polymerization values (DP) obtained by RAFT polymerization were post-functionalized with 
various aldoses with high DF values and without tedious protection steps. The glycopolymers were 
tested for their affinity to the binding protein concanavalin A (Con A) using turbidity 
measurements. A length- and sugar-dependent behavior for the clustering as well as for the 
dissolution constants was shown. The clusters of the most of the glycopolymers and Con A were 
not fully dissolved despite a 1000-fold excess of the competitor α-D-methyl-mannopyranose 
(αMeMan). This indicates a high affinity of these polymers towards Con A, which is attributed to 
the flexibility of the acrylate backbone and therefore, to the increased interaction with the Con A 
tetramers. The precursor polymer can be used to readily attach D-fructose and to investigate its 
affinity for the transport protein GLUT5.  
Several changes can be performed to further clarify the uptake mechanisms of the two classes of 
D-fructose conjugated molecules. The uptake of the curcumin metal complexes can be investigated 
with ICP-MS to gain deeper insights into the interaction of these compounds with GLUT5 
overexpressing cells. All presented ligand can be applied to other metal ions with compatible 
coordination spheres, such as Pt2+ or Ir3+. The presented strategy to address the C6 position of 
D-fructose by using sucrose offers the possibility to readily install functionalities, such as SH-, N3- 
or NH2-, at the C6 position and to create an entire set of novel D-fructose derivatives. The 
transfection efficiency of the D-fructose conjugated L-PEI was very low, which is mainly attributed 
to the decreased proton sponge effect mediated by the conjugated D-fructose units. Future studies 
have to systematically evaluate how much the DF can be lowered to increase the transfection 
efficiency while maintaining the beneficial properties at the same time. The size of the used cationic 
polymer can also be varied to find the intersection of optimal DF and best size for polyplex 
formation. Branched poly(ethylenimine)s (B-PEIs) of different sizes are of interest as well due to 
their advanced complexation abilities for genetic material and other labeling strategies for 
D-fructose, e.g. by using new C6 derivatives, can be evaluated as well. The presented 
poly(bromoethyl acrylate)s (PBEAs) can be readily functionalized by using the thiolate via C1 and 
C6 of D-fructose to form novel polyacrylates in an effective approach and to evaluate their affinity 
for the GLUT5 transporter. 
Summary and outlook 
54 
In summary, the conjugation of metal complexes and polymers with D-fructose represents a 
strategy to address the GLUT5 transporter, which is overexpressed in most of the breast cancer 
cells. But not in all cases selectivity can be achieved. In particular, for the low molar mass metal 
complexes the selectivity seems to be very much depending on the molecular structure and the 
resulting properties, such as hydrophobicity and stability. There are different positions in the 
D-fructose molecule available and it should be considered, that the affinity of GLUT5 for 
derivatives of D-fructose is strongly dependent on the conformation of all positions, the sterical 
demand of the substituents and on the non-functionalized groups in terms of recognition. In the 
case of polymeric D-fructose conjugates other parameters have to be considered. The length of the 
used polymer, the flexibility of the backbone, the size of the macromolecular assemblies, the uptake 
mechanism by endocytosis and others have a major influence on the effective targeting of the 
GLUT5 protein and the selective uptake into GLUT5 overexpressing cells. 
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5 Zusammenfassung 
 
Die vorliegende Arbeit fokussierte die Synthese, Charakterisierung und biologische Bewertung 
von verschiedenen D-Fructose-konjugierten Molekülen. Die Verbindungen können grob in zwei 
Klassen unterschieden werden: Niedermolekulare Metallkomplexe und Polymere (Figure 4.1). 
 
Figure 5.1: Schematische Darstellung der Aufnahme von D-Fructose konjugierten 
Verbindungen. Links: D-Fructose konjugierte niedermolekulare Metallkomplexe werden direkt 
vom GLUT5-Transporter aufgenommen, was jedoch stark von der molekularen Struktur 
beschränkt wird. Rechts: D-Fructose konjugierte Polymere werden, vermittelt durch das GLUT5-
Protein als Rezeptor, endozytotisch aufgenommen. Das konnte bereits bei mehreren Polymeren 
gezeigt werden. 
 
Als die vorliegende Dissertation begonnen wurde, waren nur zwei Beispiele über D-Fructose-
konjugierte Metallkomplexe in der wissenschaftlichen Literatur verfügbar. Im Gegensatz zu den 
D-Fructose-freien Verbindungen konnte bei den betreffenden D-Fructose-konjugierten 
Metallkomplexen eine erhöhte Aufnahme in Brustkrebszellen durch einen Glucosetransporter 5 
(GLUT5) abhängigen Weg gezeigt werden. Um diese Hypothese zu evaluieren, wurden zwei 
Einheiten D-Fructose mittels Cu(I) katalysierter Azid-Alkin-Cycloaddition (CuAAC) an das stark 
biologisch aktive Molekül Curcumin geklickt. Das β-Diketonat des Curcumin-Derivats wurde 
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anschließend zur Komplexierung von Ruthenium genutzt, um Komplexe der allgemeinen Formel 
[Ru(bpy)2(L)]Cl herzustellen. Durch Fluoreszenzauslöschung dieser Komplexe in wässrigen 
Medien konnte die Zellaufnahme in Brustkrebszellen durch spektroskopische Methoden nicht 
näher untersucht werden. Die anfangs erwähnten Studien nutzten ausschließlich Liganden, die über 
die C1-Position der D-Fructose verknüpft waren. Ein zentraler Schwerpunkt der vorliegenden 
Arbeit beschäftigte sich daher mit dem Einfluss der Substitutionsposition im D-Fructose-Molekül. 
Dafür wurden zwei neuartige D-Fructose-konjugierte Ruthenium-Komplexe hergestellt, deren 
Synthesen auf Saccharose bzw. einem kommerziell erwerblichen D-Fructose-Derivat als 
Startmaterial basieren. Die D-Fructose-Einheiten wurden über die C1- bzw. C6-Position verknüpft, 
während der Rest des Moleküls identisch war. Nachdem die Komplexe mit Brustkrebszellen 
inkubiert wurden, wurde Massenspektrometrie mit induktiv gekoppeltem Plasma (ICP-MS) 
durchgeführt, um den Einfluss der Substitutionsposition auf die Zellaufnahme zu untersuchen. 
Leider zeigten die hergestellten Komplexe mit der allgemeinen Formel [Ru(bpy)2(L)]Cl, die über 
einen Pyridyltriazol-Linker mit den D-Fructose-Einheiten verknüpft sind, unabhängig von der 
gewählten Position keine selektive Akkumulation in Brustkrebszellen. Diese Erkenntnisse sind 
allerdings nicht übertragbar auf andere D-Fructose-konjugierte Metallkomplexe und müssen für 
jede Verbindung neu evaluiert werden. 
Die Literatur über D-Fructose-konjugierte Polymere war zum Beginn der vorliegenden Arbeit 
ebenso rar, allerdings konnten in den letzten vier Jahren mehrere Studien die Möglichkeit zeigen, 
den GLUT5-Rezeptor durch D-Fructose-konjugierte Makromoleküle anzusteuern. Die vorliegende 
Arbeit konnte zu diesem Feld das erste kationische Polymer beitragen, welches kovalent 
gebundene D-Fructose-Einheiten trägt. Das hergestellte D-Fructose-konjugierte lineare 
Polyethylenimin (L-PEI) zeigt hervorragende Biokompatibilität gepaart mit selektiver Toxizität. 
Die hämolytische Verträglichkeit im Vergleich zu den anderen getesteten Polymeren war deutlich 
erhöht, während weiterhin stabile Polyplexe mit Plasmid-Desoxyribonucleinsäure (pDNA) 
gebildet werden konnten. Die Polyplexe des Polymers wurden in signifikant höheren Mengen und 
exklusiv in Brustkrebszellen aufgenommen. Mit diesen Erkenntnissen eröffnet ein 
Funktionalisierungsgrad des L-PEIs von 14% mit D-Fructose eine Vielzahl von positiven 
biologischen Eigenschaften, während in zukünftigen Studien der systematische Einfluss von 
anderen Parametern, wie z.B. Länge des Polymers, Verzweigungsgrad etc., untersucht werden 
muss.  
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Für die potentielle Synthese von D-Fructose-konjugierten Polymeren spielt die Interaktion von 
Zuckermolekülen mit Rezeptoren und Bindungsproteinen eine wesentliche Rolle. Die Affinität 
dieser Rezeptoren ist von mehreren Parametern, wie z.B. der Menge der angebrachten Zucker und 
der Flexibilität des Polymer-Rückgrats, abhängig. Das letzte Kapitel der vorliegenden Arbeit 
beschäftigte sich daher mit diesen Wechselwirkungen. Durch kontrollierte Radikalik hergestellte 
bromierte Polyacrylate mit hohem Polymerisationsgrad wurden mit verschiedenen Aldosen und 
ohne aufwändige Schutzgruppen-Chemie post-funktionalisiert. Durchgeführte Affinitätsstudien 
der Glycopolymere mit dem Bindungsprotein Concanavalin A (Con A) zeigten längen- und 
zuckerabhängige Clusterbildungs bzw. –auflösungsraten. Trotz eines tausendfachen Überschusses 
des Bindungskonkurrenten α-D-Methylmannopyranose (αMeMan), haben sich die meisten 
gebildeten Glycopolymer-Con A-Cluster nicht aufgelöst, was auf die erhöhte Interaktion der 
flexiblen Acrylate mit den Con A-Tetrameren zurückzuführen sein könnte.  
Sowohl für die nieder- als auch für die makromolekularen Verbindungen sind Veränderungen 
denkbar. Die Aufnahme der Curcumin-Metall-Komplexe kann beispielsweise ebenso mit ICP-MS-
Messungen untersucht werden um die Wechselwirkung dieser Verbindungen mit GLUT5-
überexprimierenden Zellen besser verstehen zu können. Metallionen mit kompatiblen 
Koordinationssphären, wie z.B. Pt2+ oder Ir3+, können mit den gezeigten Liganden komplexiert 
werden. Die präsentierte Strategie zur Synthese von D-Fructose-Derivaten an der C6-Position 
ausgehend von Saccharose kann ebenso genutzt werden, um verschiedenste Funktionalitäten, wie 
z.B. SH-, N3- oder NH2-, einzuführen und somit eine Vielzahl neuartiger Derivate herzustellen. 
Die verringerte Transfektionseffizienz des gezeigten D-Fructose-konjugierten L-PEIs kann durch 
eine Veränderung des Funktionalisierungsgrads behoben werden. Dabei muss allerdings 
systematisch untersucht werden, wie stark der Funktionalisierungsgrad verringert werden kann, 
ohne die anderen positiven Eigenschaften zu beeinflussen. Weiterhin kann die Größe des 
kationischen Polymers variiert werden, um die beste Größe für die Bildung von Polyplexen 
herauszukristallisieren. Durch die verbesserte Komplexierung von genetischem Material sind 
verzweigte Polyethylenimine (B-PEIs) ebenso von großem Interesse wie verbesserte 
Markierungsstrategien für D-Fructose an Polymere. Die verwendeten Vorläufer-Polymere auf 
Polybromoethylacrylat-Basis (PBEA) können außerdem für das einfache Anhängen von 
D-Fructose-Einheiten genutzt werden, um deren Affinität zum GLUT5-Transporter zu untersuchen 
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Zusammenfassend kann gesagt werden, dass die Konjugation von D-Fructose an Metallkomplexe 
und Polymere eine geeignete Strategie darstellt, um den in den meisten Brustkrebszellen 
überexprimierten GLUT5-Rezeptor anzusteuern. Das Anhängen von D-Fructose führt allerdings 
nicht zwangsläufig zu Selektivität. Besonders die Selektivität niedermolekularer Metallkomplexe 
ist nicht nur abhängig von der Molekülstruktur, sondern auch von den daraus resultierenden 
Eigenschaften, wie z.B. der Hydrophobizität und der Stabilität. Da verschiedene Positionen im 
D-Fructose-Molekül verfügbar sind, sollte insbesondere bedacht werden, dass die Affinität des 
GLUT5-Rezeptors für D-Fructose-Derivate stark abhängig von der Konformation aller Positionen, 
dem sterischen Bedarf der Substituenten und den nicht-funktionalisierten Positionen ist. Für 
D-Fructose-konjugierte Makromoleküle müssen weitere Parameter bedacht werden. Hier spielen 
u.a. die Länge des verwendeten Polymers, die Flexibilität des Rückgrats, die Größe der 
makromolekularen Anordnung in Wasser und der Zellaufnahmemechanismus durch Endozytose 
eine wesentliche Rolle, um ein maximales Ansteuern des GLUT5-Transporters und eine selektiven 
Aufnahme in GLUT5-überexprimierende Zellen zu erreichen. 
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a  b  s  t  r  a  c t
Curcuminoids  are highly  bioactive,  polyphenolic  compounds  derived  from  the  roots  of  Curcuma  longa.
Among  them,  curcumin  is the best known  and shows potential  against  various  diseases,  such  as  cancer,
neurodegenerative,  autoimmune  and infectious  diseases  combined  with  nontoxicity  up  to high  dosages
and fluorescent  properties.  Unfortunately,  it  has  some  disadvantages,  e.g., a  poor  solubility  in water or
a rapid  clearance,  which  prevent  this  natural  compound  from  reaching  its potential.  There are  many
strategies  to  overcome  these  drawbacks,  most notably  the  application  of  nanoparticulate,  micellar  or
liposomal  carriers.  Various  metals  also have advantageous  properties  that  can be used to mitigate  the
inherent  disadvantages  of  curcumin,  such  as higher  stability  under  physiological  conditions  and ease  of
detection  in vivo.  Metal  complexes  of  curcumin  and its  derivatives  broaden  the potential applications in
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adenocarcinoma epithelial cell line; A,  beta-amyloid; acac, acetylacetone pentan-2,4-dion; acdppz, 1-(9-acridinyl)dipyrido[3,2-a:2′ ,3′-c]phenazine; AchE, acetylcholine; AD,
Alzheimer disease; B16, mouse melanoma cell  line; BBB,  blood–brain barrier; bDHC, bis(dehydroxy)curcumin, (1E,6E)-1,7-Bis(3-methoxyphenyl)-1,6-heptadiene-3,5-dione;
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comparison  to the  parent  ligand  in modern  imaging  and  anticancer  strategies.  A  number  of  promising
derivatives  have  been  published  so far. This  review  focuses  on metal  complexes  of  curcumin and its
derivatives  for imaging and  anticancer  application.
© 2015 Elsevier  B.V.  All rights  reserved.
1. Introduction
Curcumin, also called diferuloylmethane, is an active, polyphe-
nolic compound derived from the root of  turmeric (Curcuma longa)
[1]. It was first isolated in 1815 and synthesized for the first time
in 1910 [2]. Many studies were published about  curcumin, its
analogs, and their  biological activity. Curcumin seems to be toxic
to  cancerous cells and cytoprotective to  healthy cells [1]. Further-
more, it interacts with a  wide  range of  molecular targets related
to different neurodegenerative, infectious, autoimmune, and other
diseases [3].  Additionally, it is  nontoxic up to high dosages [4].  How-
ever, phase I  and II clinical trials involving several types of cancer
revealed the  major limitations of  curcumin [1]. Its  poor bioavail-
ability caused by low serum levels, restricted tissue distribution,
rapid metabolism, and poor solubility prevent the effective clinical
application of curcumin [5]. Recently, many research groups have
sought to overcome these  disadvantages and improve the bioavail-
ability of curcumin using a  number of  different strategies; notable
among them are adjuvants such as  piperine [6] as  well as deliv-
ery systems based on nanoparticles [7],  liposomes [8], or micelles
[9]. Another strategy to increase the compound’s biological activ-
ity  is  the modification of the curcumin skeleton as  shown in  Fig. 1.
For instance, the introduction of various groups instead of  phe-
nolic hydroxyl-groups could avoid the abstraction of protons and
the subsequent degradation of  curcumin under basic conditions
[10].  The diketo-moiety is part of  the degradation process [11]. In
the last few decades a  considerable number of  compounds with
an  altered curcumin structure were synthesized in  order to evalu-
ate the resulting changes in biological activity. Many advantageous
structures were found and number of  quality articles have been
published covering the subject [4,12–15].
A variety of  metal ions can be complexed by the -diketo-moiety
of curcumin. The metal complexes so formed often possess a higher
stability than the easily degraded curcumin itself. The first com-
plexes of curcumin with medically valuable transition metals, such
as  Pd, Pt, Rh, and In, were published in 1997 [16]. In most cases the
resulting complexes exhibited favorable biological activity com-
pared with the parent ligands for a  number of  molecular targets.
Already published review articles focused Cu- and Zn-
complexes of  curcumin [17,18], this article instead discusses
complexes of curcumin and its derivatives with various metals
including not only  Cu- and Zn-complexes. Another excellent article
was published recently [19]. It  provides a  more general overview
about chemical properties of curcumin, the synthesis and char-
acterization of various corresponding metal complexes and their
non-medical and medical applications. The present work gives a
complementary but more detailed view on metal complexes of
curcumin and its derivatives strongly focusing on compounds for
molecular imaging and anticancer therapy. The first part deals
with complexes for imaging applications with an  emphasis on
Fig. 1. Schematic representation of  curcumin.
fluorescent probes and radionuclide complexes. The second part
has a  focus on complexes with potential anti-cancer activity via
various mechanisms of  action, such as  photodynamic therapy or
intercalative DNA binding.
2. Complexes for molecular imaging
Modern imaging is  based primarily on the measurement of  var-
ious signals with subsequent conversion to obtain interpretable
data. Common strategies include the detection of  positrons (PET,
positron emission tomography), gamma  rays (SPECT, single pho-
ton emission computed tomography), and other emitted radiation
of  different wavelengths (fluorescence, X-rays) as  well as  changes
in electron environments (MRI). This section will focus on cur-
cumin bearing complexes that can be detected using one of  the
aforementioned techniques.
The interaction of  curcumin with a high  number of  biological
targets [3] means that  complexes of curcumin and its derivatives
can be used to visualize various pathological structures linked to
different diseases. Besides the Parkinson’s disease, amyotrophic lat-
eral sclerosis (ALS), and Alzheimer’s disease (AD) are widespread
neurodegenerative afflictions of modern societies. In the case of
AD, its progression is  multifactorial. One cause is the imbalance
between pro-oxidant homoeostasis supported by radical oxygen
(ROS) and nitrogen species (RNS) and the anti-oxidant counter-
parts such as superoxide dismutase and glutathione. Furthermore,
the aggregation of  beta-amyloid (A) and the inhibition of acetyl-
choline (AchE) can be correlated to AD. There are two kinds of
A plaques associated with AD: dense core plaques are  fibrillar
and diffuse core ones are amorphous deposits.[20] Epidemiologi-
cal studies exhibited that there is  a  significantly smaller AD rate
in  India, which could be  linked to the elevated consumption of
turmeric relative to other regions [13].  The hydrophobic part of  the
contained curcumin allows them to cross the blood–brain barrier
(BBB), while the polar elements are responsible for protein binding.
In addition, both the deprotonation of  the phenolic groups and the
stabilization of the resulting charge in the -conjugated system
seem to be  important [21]. Metal complexes of curcumin and its
derivatives might share these properties of  the parent ligands and
are therefore interesting candidates for imaging of A plaques. In
addition, curcumin and its derivatives bind due to their miraculous
bioactivities to  many receptors, resulting in a  higher selectivity for
certain cancer cells, which means that they have significant poten-
tial for use  in  the imaging of cancer-related pathological structures
[1,12,22].
2.1. Radionuclides and MRI-tracer
PET-based imaging exploits the emission of positrons by
radionuclides, such as 18F  or 123I,  during their decay. A positron
travels a  short distance through the tissue before it is  annihilated
due to collision with an  electron. The subsequent emission of  two
-rays is analyzed by  the surrounding detectors [23]. Since the
development of PET in 1975, interest in potentially useful nuclides
has grown steadily. Currently, non-metallic positron emitters, such
as 18F  or 123I, are applied most frequently, but a  number of  metal-
based compounds are either in the early or later clinical stages, such
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Fig. 2. Schematic representation of the complexes 1 [26], 2a–c and 3a–c [27,28] aimed to  image A aggregates with different techniques.
as 64Cu-, 111In-,  and 90Y-labeled radiopharmaceuticals [24]. SPECT
devices make use directly -particle emitters. The use of collima-
tors and a gamma camera widens the efficiency of this technique
compared with common X-ray examinations [23].  Of preeminent
importance for SPECT imaging is 99mTc+,  a -emitter with nearly
ideal properties, which is used in 70–80% of all radiodiagnostic
examinations that utilize SPECT imaging [24].  Both SPECT and PET
are non-invasive techniques and offer high sensitivity using only
nanograms of molecular probes, but they are restricted by  their
poor spatial resolution. A much higher resolution is  achieved with
magnet resonance imaging (MRI). It can detect various endoge-
nous and exogenous nuclei like 1H  and 19F  which are sensitive
to their microenvironment. MRI  offers the possibility to  receive
metabolic and spectroscopic information, but is  limited because
higher amounts of  the molecular probe are required due to the
technique’s lower  sensitivity compared with SPECT or PET [25].
Multimodal SPECT-MRI and PET-MRI devices combine the advan-
tages of multiple systems and have sparked an  intense interest in
the development of  multifunctional probes.
The complexes discussed in this part reflect the potential to
image neurodegenerative and cancer related structures with the
help of  curcumin by  using various modern techniques such as PET,
SPECT and MRI. A Gd-curcumin complex 1 combines the advan-
tages of fluorescence microscopy with those of  MRI  for multimodal
detection [26]. One phenyl group of  the curcumin was  modified
with an amine linker  and the resulting structure was attached to the
known contrast agent  Gadopentetic acid (Gd3+-DTPA), as  shown in
Fig. 2.
This compound is the first curcumin derivative with an  amine
linker on  the phenyl ring, which might result in an  enhanced resis-
tance against hydrolysis, while also providing the option to perform
further modifications. Changes in compound’s optical properties
(fluorescence wavelength and intensity) when placed in  solution
with A aggregates demonstrate the binding properties of  the
novel contrast agent. The longitudinal relaxivity r1 is  one impor-
tant parameter for MRI  measurements. Contrast agents with higher
relaxivities can be administered at lower doses while still pro-
viding the same image quality and the higher the relaxivity of  a
contrast agent the lower are the doses required of  the agent [29].
The r1-value of the  amine-modified curcumin is  four times higher
than for Gd3+-DTPA, a  major advantage for MRI  detection [26]. The
complexation of  curcumin with 99mTc  and Re was also  described
and does not influence the binding behavior with A-aggregates
[27,28]. Further benefits are the emission of  -particles by 99mTc
and the resulting ability  to use  advanced imaging techniques like
SPECT. With respect to its properties, rhenium is an  interesting
metal for applications in  radiotherapy [24], but most progressive is
the use of  the [M(CO)3(H2O)3]
+ core  (2 M =  Re, 3  M  = 99mTc). The cor-
responding complexes can be varied by exchanging the relatively
labile water ligand for different monodentate ligands such as triph-
enylphosphine, imidazole, or isocyanocyclohexane (Fig. 2). These
“2+1”-complexes may  have significant advantages over other com-
plexes by changing properties like  solubility, receptor specificity,
and more. Other  suitable complexes considered for multimodal
applications were obtained by labeling curcumin (CUR), diacetyl-
curcumin (DAC) and bis(dehydroxy)curcumin (bDHC) successfully
with the positron emitter 68Ga  [30].  Complexes of the general
structure [68GaL2]
+ were prepared in high radiochemical yield and
purity, extensively characterized, and revealed to possess high
stability with regard to  transmetalation and transchelatation. In
particular [68Ga(CUR)2]
+ and [68Ga(DAC)2]
+ demonstrated a  high
affinity for A-aggregates, and thus they represent potentially suit-
able reagents for the early diagnosis of  AD with PET. Incubation of
A549 lung cancer cells with the mentioned Ga-complexes revealed
fluorescence intensity at least comparable to  the parent ligands.
Additionally, the localization of  the complexes within the cells is
different from conventional curcumin due to hydrophobicity dif-
ferences and hydrogen bridge bonds. They also show very high
stability when exposed to DTPA or Fe3+,  Cu2+ and Zn2+ solutions.
Therefore, they might be interesting candidates for multimodal
diagnosis of  lung cancer [30].
2.2. Fluorescent probes
In  the case of  curcumin and its derivatives, the emitted fluores-
cence is a  result of the delocalized -conjugated electronic system
and is  strongly influenced by solvents, tautomerism, and structural
modifications [13].
Complex 4 has two N,N′-dimethyl groups in the p-positions of
the aromatic rings of curcumin and a  boron difluoride moiety at the
enol–keto-group (Fig. 3)  [31].
These  modifications cause a strong red shift of the fluorescence,
opening up the compound’s application as a tracer in near-infrared
(NIR) microscopy, a  non-invasive, inexpensive technique with rela-
tively high  penetration depth [33].  In  solution with A-aggregates
the  quantum yield was  increased and the complex shows a blue
shift of the fluorescence from   =  805 nm to  =  715  nm,  which
is attributed to its incorporation into the hydrophobic environ-
ment of  the aggregates. With log Kow =  3,  the complex is relatively
hydrophobic and can pass the BBB. This was  demonstrated by  wild-
type mice experiments. The injected complex concentration was
measured at  different time points postmortem and exhibited a
fast clearance from the blood but a significantly slower clearance
from the brain. Ex vivo histology further supported this observation
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Fig. 3. Schematic representation of the complexes 4  [31] and 5 [32]  showed ben-
eficial fluorescent properties for NIR  microscopy or enhanced cell  uptake (anions
omitted).
[31]. Another study sought to systematically alter the curcumin lig-
ands in such BF2-complexes [34].  For instance, the introduction of
a meso-phenyl ring did not essentially change the photophysical
properties. The interesting feature of  this modification was  the pos-
sibility to introduce further groups at the ring to modulate solubility
and –-stacking interactions without changes of  the fluorescence
properties. Moreover, some BF2-complexes of  curcumin and its
derivatives have been recently synthesized [32].  The aromatic rings
were modified with a  variety of  electron donors, resulting in  the
fine-tuning of the optical properties. All complexes show fairly high
photostabilities and quantum yields. The conversion to an  interme-
diate triphenylphosphane introduced charges which might support
the absorption of  complex 5  in the cell plasma (Fig.  3). Fluorescence
measurements of this complex incorporated into gastric cancer
cells revealed a  strong green fluorescence without significant cell
toxicity. However, due to aggregation effects, all BF2-complexes
show a strong decrease of  fluorescence in  phosphate-buffered
saline (PBS) solution.
Some alterations of  the curcumin ligand have been demon-
strated to shift to the intended fluorescence wavelength. The
introduction of  two ethyl functionalities to the phenyl rings leads
to a  bipolar donor–acceptor–donor structure (D–A–D), that is
favorable for two-photon microscopy (2PM) [35].  Complexation
with copper (II) ions results in a  square-planar complex. Due to
intramolecular charge transfer (ICT), an  approximately 3-times
larger two photon absorption (TPA)-cross section () compared
with the free ligand is  observed. In vitro  assays with MCF-7 breast
cancer cells revealed that the complex is  nontoxic and relatively
stable under light exposure. In vivo studies in mice indicated an
increased fluorescence in  tumor tissues traced back by  the authors
to the overexpression of  epidermal growth factor receptor (EGFR).
Comparable results were obtained with the [M(DAC)2]  complexes
(M = Zn2+, Ni2+) [36]. In terms of diagnostic advantages, the complex
displayed moderate -values, optimal laser excitation wavelength
of   = 760 nm,  a low cellular toxicity even at longer incubation
times or  higher concentrations, and a cellular uptake in  the cyto-
sol or nucleus of  MCF-7 cells. Two lanthanide (Ln) complexes
[M(py)2(CUR)3]  (6,  7) with two additional pyridine ligands were
synthesized by the same group (Fig. 4)  [37].
The planar structure ensures an extension of  the -conjugated
system. Therefore, increased fluorescence compared with the com-
plexes with rare earth metals without the pyridine ligands, could
be observed. Additionally, the Eu-complex shows luminescence
in the NIR region, which is  enabled by  the pyridine ligands.
Remarkably, both Ln-complexes are nontoxic and possess high
-values and, therefore, seem to be  suitable for single or two-
photon fluorescence imaging. Further tests with propidium iodide
(PI) demonstrated the increased hydrophobicity compared with
the Zn- and Ni-complexes by enhanced localization on the cell
membrane. Introduction of butyl groups creates bipolar D–A–D
ligand like mentioned before and the resulting CuL2-complex 8
Fig. 4. Schematic representation of the curcumin complexes 6, 7 [37]  and 8  [38]
used for cancer cell imaging.
exhibited the ability to  distinguish between normal and cancer-
ous lung tissue in vivo, being nontoxic up to high  concentrations
at the same time [38].  One reason could be the better matching of
complex 8  and the monoclonal anti-EGFR antibody. These stud-
ies may  provide important insights for the future development
of novel imaging probes. The last  few examples clearly revealed
how the complexation of curcumin and its derivatives can result
in  improved -values. Such improvements are critical for applica-
tions in  2PM, which is  advantageous for its large penetration depth
and low tissue autofluorescence and self-absorption [36].
In conclusion, curcumin and its derivatives are suitable ligands
for metal complexes. Re, 99mTc, 68Ga, and Gd complexes were suc-
cessfully synthesized and tested toward application in  PET, SPECT
and MRI. Furthermore, the introduction of  the BF2-moiety, com-
plexation with metals like Cu2+ or Zn2+ as  well as the modification of
the ligand itself can change its fluorescence excitation wavelength
in  either direction, resulting in  the ability to utilize a wide range of
different fluorescence techniques, such as  NIR microscopy or 2PM.
Finally, the highly bioactive curcumin skeleton binds to  cancer-
related or neurodegeneration related pathological structures and
the coordinated metals allow metal complexes of  curcumin and its
derivatives to  generate useful images of  these structures.
3.  Potential anticancer agents
Cancer is the leading cause of  death in developed countries
and the second-largest cause of  death in  developing countries
after cardiovascular diseases [22]. More than 200 types of can-
cers are known in humans, depending on tissue and cell type
[22].  The most clinically established cancer treatment strategies are
surgery, radiotherapy, and chemotherapy. The chemotherapeutic
approach uses a combination of  drugs with various mechanisms
of action to  enhance the therapeutic efficiency. Roughly 80% of
all FDA-approved drugs arise from natural products, targeting a
huge number of molecular structures [39].  Among the large number
of  known phytochemicals, structures of  curcumin and its deriva-
tives offer high potential for the treatment of  cancer. Curcumin
itself inhibits tumor proliferation, growth, metastasis, invasion and
angiogenesis and causes damage even in  apoptosis resistant cells
[12].  This section discusses potentially anticancerous metal com-
plexes of curcumin and its derivatives with various mechanisms of
action.
3.1.  PDT-agents
Photodynamic therapy (PDT) is  a  minimally invasive technique
for the treatment of various diseases. It can be used to induce
cancer death via apoptosis or necrosis, harm the tumor’s critical
vascular system or cause inflammatory reactions. PDT  has many
benefits compared with chemotherapy, radiotherapy, or surgery.
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Fig. 5. Schematic representation of  porphyrin linked curcumin complexes 9–11 [43] and curcumin copper complex with ferrocenyl conjugated reduced Schiff-base of
l-tyrosin as ancillary ligand 12 [44].
Only  a few of them will be  discussed here, including reduced long-
term morbidity, no resistance development due to the absence
of 1O2-eliminating mechanisms, and no negative consequences
of repeated treatments. The three basic components of  any pho-
todynamic approach are light, oxygen, and the photosensitizer
[40].  The most widely used photosensitizer in current clinical
use is  Photofrin®, a tetrapyrrole-containing compound. However,
this compound has several disadvantages, e.g., long-lasting skin
photosensitivity and low absorbance at  =  630 nm [41].  Hence
there is great interest in alternatives which offer advantages over
Photofrin®, including absorption between  = 600 nm and 800 nm,
rapid  clearance from non-pathological tissue, and low toxicity in
the absence of an optical trigger is still high  [40]. Curcumin displays
strong antioxidant properties, which have been widely investigated
for the treatment of  and protection against neurodegenerative dis-
eases [13].  However, it was proved multiple times that curcumin
also have pro-oxidant properties, which means it is  capable of both
performing oxidation processes and protecting against them at the
same time. Consequently, the underlying mechanism of  radical
generation by curcumin has been investigated. Laser flash photoly-
sis ( = 355 nm)  of  curcumin reveals its ability to  generate 1O2 and
·OH  radicals, potentially causing biological damage in the presence
of oxygen and light [42].  Hence, curcumin and its derivatives are
not simply ligands for increasing the bioavailability or selectivity of
compounds used in  PDT. They offer the potential to perform photo-
dynamic therapy at different excitation wavelengths, a  worthwhile
approach for superficial diseases.
Bridging the  curcumin moiety via 1,6-dibromohexane and a
hydroxynaphthyl-group to  a porphyrin molecule yielded in  an
interesting modification of the curcumin skeleton [43].  The ligand,
as well as the resulting metal complexes 9–11, show strong binding
interactions with DNA and light-triggered cleavage activity (Fig.  5).
Those compounds combine the benefits of curcumin with the
thoroughly investigated ones of  porphyrin complexes, such as  gen-
erating 1O2 and  OH radicals, fine tuning of properties and others. A
novel class of Cu-complexes (Fig. 5) contains the curcumin ligand
on one site and biologically relevant l-amino acids such as, l-Tyr,
l-Trp and  l-Met bound to  a ferrocenyl (Fc) moiety on the other [44].
They reveal complete cleavage of  DNA after excitation at  =  454  nm
and are nontoxic in the absence of an optical trigger. This effect
was not observed under an  Ar-atmosphere, which emphasizes
the necessity of  oxygen. Different inhibition tests identified the
hydroxyl radical as  the cleaving species. The curcumin-conjugated
Cu-complexes showed a higher cytotoxicity after irradiation than
the free ligand and the acetylacetonate-conjugated (acac) com-
plexes. Curcumin is  not just a  fluorophore here, but rather the
key structure for causing apoptotic cell death by the photodynamic
approach. All complexes which connect curcumin by  a  Cu-center
with the Fc-appended reduced Schiff-bases of  amino acids demon-
strated a  cytosolic localization just like current porphyrin-based
PDT-agents. Other data was published that showed undesirable
properties of  the complexes compared with the parent compound
[45].  The authors synthesized a  set of curcumin-metal(II) hydroxo
complexes (M =  Cu2+, Zn2+,  Cd2+) by  using nitrate metal salts. The
complexation inhibits the cytotoxicity of  curcumin itself. Possi-
ble reasons could be the pre-exhaustion of  curcumin due to the
reaction with the nitrates or the geometry and symmetry of  the
resulting complexes. Similarly, the size of  the cations might influ-
ence the cytotoxicity, since the Cd-complex shows higher IC50
values than the Cu- and Zn-ones in all tested cancer cell lines.
Since the curcumin-conjugated vanadyl complex with VO2+-
core  showed complementary inhibition effects on mouse lym-
phoma cell proliferation like curcumin alone or vanadyl sulfate
[46],  it received significant attention from the scientific commu-
nity. Banerjee et al. investigated for the first time the phototoxicity
of curcumin complexes containing the VO2+-core in HeLa cells [47].
The authors synthesized a  complex 13 with comparable phototoxi-
city to  that  of  Photofrin®. The complexation of  curcumin increases
the solubility, introduces metal-based NIR absorption, and supports
the photocytotoxicity due to the dipyridophenazine (dppz) ligand
(Fig. 6).
Once taken up into HeLa cells, the complex mainly localizes in
the cytoplasm with slight nuclear uptake and triggers cell death
by  apoptosis after photoirradiation. A conversion of supercoiled
to nicked circular DNA of almost 90% at  =  785 nm indicates the
excellent DNA cleavage activity of  this compound. Moreover, a
set of novel bioorganometallic oxovanadium complexes 14a–c
were tested in  a photodynamic approach (Fig. 6)  [48,49].  They
contain several structures of curcumin and its derivatives com-
bined with a  terpyridine group to introduce different moieties.
The complexation of  curcumin and its derivatives can enhance the
relevant properties. The Fc-methyl-bis-(2-pyridylmethylamine),
bis-(2-pyridylmethyl)benzylamine and curcumin moieties did not
show remarkable photo-induced cleavage activity of  DNA. Addi-
tionally, the complexation overcomes the hydrolytic instability
of curcumin in  cell media. The resulting complexes bind to the
DNA by  surface aggregation and/or groove binding without sig-
nificant changes of  the specific viscosity of  the DNA. They show
toxicity following exposure to  visible light by the formation of
OH radicals via a redox pathway and low toxicity in the dark.
The complexes with acac instead of curcumin exhibit much higher
IC50 values, accentuating the major role of curcumin in phototox-
icity. The attachment of Fc enhanced the phototoxicity and the
cellular uptake with localization in  the cytoplasm and nucleus
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Fig.  6. Schematic representation of  a set of  selected oxovanadyl curcumin complexes 13  [47], 14a–c [48,49], 15a, 15b [50]  and 16 [51].
[48,49]. This could represent a  novel approach for the design
of curcumin-bearing complexes. Recently, more promising oxo-
vanadium curcumin complexes were prepared by altering the
tpy-ligand with a p-triphenylphosphonium methyl phenyl bro-
mide (TPPBr-Ph) [52].  The resulting complex is  highly toxic under
light exposure in HeLa and MCF-7 cells by  producing OH radicals.
However, due to the TPPBr-moiety, they  are also significantly toxic
in the absence of  light. The cationic TPPBr-group is  responsible
for  mitochondrial targeting inside the cells. A nearly hundred per-
cent uptake and such specific intracellular localization results in
a higher phototoxicity of this curcumin complex compared with
the acac-based one. Another oxovanadium complex with curcumin
completed by a (modified) naphthalimide moiety was highly active
[53].  An intercalative DNA binding mode of this complex is respon-
sible  for the cytotoxicity, resulting in low IC50 values comparable
to Photofrin®. Other potential PDT agents that  revealed excellent
properties were prepared by  the Banerjee group [50]. The oxovana-
dium complexes 15a and 15b bear (diglycosylated) curcumin as
well as a  1-(9-acridinyl)dipyrido[3,2-a:2′,3′-c]phenazine (acdppz)-
moiety (Fig. 6). The  glucose units increase the water solubility
of the curcumin and enhance the cellular uptake in cancer cells.
The planarity of  the acdppz-group augments the photocytotoxi-
city and facilitates fluorescence measurements due to the strong
green emission. Both complexes show phototoxicity in nanomolar
concentrations, which is more efficient than Photofrin®, combined
with low toxicity in the absence of light. NIR DNA cleavage by the
1O2 pathway, cellular damage by apoptosis, and intercalative DNA
binding combined with advantageous imaging properties might
lead to a new generation of PDT agents based on curcumin com-
plexes. The novel complex 16 offers high photocytotoxicity and is
less toxic in  healthy cells compared with cancerous cells with or
without an  optical trigger, which highlights the potential advan-
tages of curcumin complexes with the VO2+-core [51].
In another study, curcumin was  attached to  a  Co3+-chaperone-
system, which was used to deliver curcumin in  hypoxic tumor
regions by reduction to Co2+ [54].  Yet another study used bioessen-
tial cobalt to form novel heteroligand Co3+-complexes of  curcumin
with various phenanthroline bases as  ancillary ligands [55]. The
photocytotoxicity of these complexes increased with the planarity
of  the phenanthroline base. The complex [Co(dppz)2(CUR)](ClO4)2
revealed photocytotoxicity comparable to Photofrin® and strong
binding efficiency to human serum albumin (HSA). Thus, it has
significant potential for photochemotherapeutic applications and
opens up the possibility of utilizing bioessential cobalt for curcumin
complexation.
Recently, comparable Ln-complexes were synthesized as  well
[56].  The library of  La- and Gd-complexes contains curcumin and
its diglycosylated analogs with Ph-tpy or pyrenyl-tpy as  the second
ligand. The novel complexes with LnO6N3 cores reveal DNA plasmid
cleavage under visible light irradiation by the 1O2 and OH path-
ways. The metal complexes of  curcumin show beneficial properties
compared with curcumin alone and result in the first published lan-
thanide curcumin complex with photoactivated anticancer activity
comparable to Photofrin®.
3.2. DNA intercalating or binding agents
Besides the photodynamic approach, there are more possibili-
ties to  cause damage in cancer cells. A widely used and strongly
investigated one is  the direct interaction of  different compounds
with DNA. Under physiological conditions, many interaction modes
exist with various parts  of the DNA,  both covalently and non-
covalently. A possible interaction for cationic molecules is available
due to  the negatively charged phosphodiester groups along  the
double helix backbone. Interactions with the major groove of  the
DNA occur more readily for macromolecules such as proteins than
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Fig. 7. Schematic representation of  Cu-complexes with Knoevenagel condensates of  curcumin and bpy 17a or phen as second ligands 17b [59]  and DIP 18 [60] as ancillary
ligands.
for small compounds. The typical minor groove binder requires
the flexibility to follow the natural torsion of the double helix. A
positively charged, small molecule with planar aromatic ring sys-
tems is an exemplary intercalator. Two contiguous base pairs form
a binding slot for the intercalating molecule [57].  The biological
consequences of an  intercalative binding mode are versatile and
complicated. By occupying the DNA sites, intercalators cause com-
petitive inhibition of various enzymes, e.g., topoisomerase II, DNA
polymerase, and RNA polymerase in addition to their ability to
disturb the transcription and replication processes of DNA. Fur-
thermore, messenger RNA (mRNA) synthesis can be impaired by
frame-shift mutations. Intercalation causes DNA damage by single
strand breaks [58].
Modified curcumin-conjugated Cu-complexes 17a and 17b
were prepared to investigate the intercalative mode of  curcumin
complexes for the first time [59].  Knoevenagel condensates of  cur-
cumin were used as one ligand and 1,10-phenanthroline (phen) or
2,2′-bipyridyl (bpy) as  the second ligand (Fig.  7).
The intercalation strength strongly correlates with the ligands
phen and bpy. The phen complexes intercalated better than the bpy
counterparts. By attaching the common curcumin together with
a 4,7-diphenyl-1,10-phenanthroline-ligand (DIP) to the Cu center
(Fig. 7),  a novel complex 18  was obtained [60]. The DNA binding
strength is strongly enhanced due to the DIP ligand and the mode
of interaction was confirmed to  be the intercalation of  the complex
between two base pairs of the DNA. Furthermore, it could be proven
that the [CuL2] complexes (L  =  curcumin and its derivatives) show
anticancer activity. In vitro studies showed a  stronger inhibition of
tumor growth and in vivo tests with tumor bearing mouse increas-
ing the life span when treated with the Cu complexes [61,62]. It
is implied that the efficacy of  metallodrugs is dependent not only
on the structure of one ligand and the metal itself, but rather on all
subunits of the complex and their interactions. This central assump-
tion was confirmed by a  heteroligand, cyclopalladated curcumin
containing complex [63].  It exhibited significant improvements in
comparison to all  the bis- or trischelated homoligand complexes
with curcumin that came before it.  Similar results were obtained
for the heteroligand mononuclear Pd-complex 19 (Fig. 8)  [64].  It
inhibited cell growth and induced apoptosis when tested in vitro
with various human prostate cancer cell lines. Compared with cur-
cumin alone, complex 19 is significantly more effective. The authors
cite the dual functionality as  a key reason for the enhanced efficacy
as they attached two highly biologically active ligands on one com-
plex. The advantages of  the two  ligands were combined and the
poor bioavailability of  curcumin was  improved due to the formation
of highly stable complex 19. Other Pd-based curcumin complexes
20a and 20b  demonstrated antiproliferative activity in vitro by
inducing apoptosis in human colorectal cancer cells (Fig. 8)  [65].
A ruthenium-arene complex of curcumin was synthesized and
characterized by  Caruso et al. [66]. Those “half-sandwich” com-
plexes of Ru have good aqueous solubility, stability against ligand
exchange under physiological conditions, and high anticancer
activity in vitro and in vivo. The title compound 21  (Fig. 9) was tested
against five different cancer cell lines (HCT116, MCF-7, A2780, U-
87 and A549) and revealed the highest toxicity for the colo-rectal
tumor cell line (HCT116).
The molecular structure of 21  in  the crystal exhibited a  two-
dimensional network caused by  the chlorine atom and the resulting
hydrogen bonds. The DNA binding mode of  the complex was
investigated as  well. Computer simulations and electron spray
ionization mass spectrometry (ESI-MS) measurements revealed
a 20◦ twist between the phenyl groups as  well as  characteristic
Ru–N7-guanine binding. Previous studies indicated this stack-
ing as  intercalative and hydrophobic interactions [69].  Through
investigation of the demethoxy and bisdemethoxy curcumin ana-
log complexes, it was  furthermore validated that the phenyl and
methoxy groups of the curcumin do  not influence the mechanism
at all. This opens up entirely new possibilities for tailoring ligands to
fine-tune biological properties [66].  Even a  thiophene aromatic cur-
cumin derivative conjugated version of  complex 21 was  prepared;
it has moderate toxicity when tested against HeLa and human liver
cancer cell lines [70]. To further enhance the anticancer activity of
the complex 21, the labile chloride ligand was exchanged against
PTA to  obtain the charged compound 22 with excellent properties
Fig. 8. Schematic representation of heteroligand mononuclear Pd-complexes 19 [64],  20a and 20b  [65].
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Fig. 9. Schematic representation of  curcumin(oid)-conjugated Ru-complexes 21 [66], 22  [67]  (anions omitted), 23a and 23b  [68]  as DNA interactive agents.
Fig. 10. Schematic representation of curcumin-bearing Zn complexes with different ancillary ligands and counterions (24  [72], 25 and 26 [73]).
(Fig. 9)  [67].  Most of  these RAPTA-C like complexes show a  very high
toxicity in  A2780 cells, which is comparable to  cisplatin. The IC50
values for cisplatin-resistant ovarian cancer cells are ca. 100-fold
smaller than for cisplatin, offering real alternatives to platinum-
based anticancer agents. Furthermore, they are less toxic to HEK293
cells, possess superior solubility and are not strongly influenced by
modification of  the benzyl ring or the curcumin methoxy groups,
which could be used to attach relevant biomolecules for target-
ing. Unfortunately, the exact interaction mechanism is  not yet
known. The previously mentioned Knoevenagel condensates of
curcumin were used to  obtain two novel ruthenium complexes
23a and 23b (Fig. 9) [68]. The DNA interactions were identified as
intercalative and non-covalent binding modes. Regarding the dif-
ferent ligands, there was no recognizable trend, emphasizing the
complexity of  the interactions. The complexes and ligands were
tested against human red blood cells and revealed lower toxicity
than letrozole, one drug for the treatment of  cervical cancer. Fur-
thermore, out of  the four cell  lines tested they show the highest
toxicity against HeLa cells, making them to candidates for further
developments.
Since 2011, some Zn(II) complexes (Fig. 10) of  curcumin have
been described [71–74].
As in  other modified curcumin compounds, the complexation
of  curcumin overcomes its easy degradation and introduces a  flu-
orescent entity as  well. A  maximum emission at  =  540  nm and a
good quantum yield (˚  =  0,204) offers fluorescent techniques for
investigation [74]. Complex 24 was even more active than cur-
cumin in  LAN-5 neuroblastoma cells and showed the strongest
growth inhibition in all cell lines [72].  The interaction mode of
the fluorescent groups revealed their  perpendicular alignment to
the  helices as a  mixture of  intercalating and groove interaction.
Another common anticancer strategy is to  reactivate tumor spe-
cific p53 mutations. This can be performed by Zn (II), supporting
the overall toxicity of  the complex even more. In vivo tests exhib-
ited the ability of the complex to pass the blood-tumor barrier of
glioblastoma cells [71].  The same research group continued their
work to further improve the strategy. The authors investigated a
tetra-coordinated analog as well as different N,N-ligands, counteri-
ons and a dimeric complex. Two complexes (25 and 26) possessed
much higher cytotoxicity in  human neuroblastoma cells compared
with the other modified complexes or to the reference complex
itself (Fig. 10). The improved intercalation ability is  probably based
on the ionic character of  complex 25  and on the enhanced rigidity
and planarity of the aromatic region in the case of  complex 26. As
a  result, the treated cells underwent apoptosis involving the acti-
vation of  JNK, caspase-3, and changes in  mitochondrial membrane
potential [73].
3.3. Complexes with other modes of action
The following few examples of  metal complexes of  curcumin
and its derivatives show interaction modes besides intercalation or
radical-producing pathways and offer, therefore, new approaches
for the development of anticancer agents. Strongly modified com-
plexes of Cu and Zn with another ancillary ligand have been
synthesized and could lead to curcumin-containing drugs for
cancer therapy [75].  Complex 27 contains a 1,7-(di-9-anthracene-
1,6-heptadiene-3,5-dione) ligand (9Accm) and does not interact
with DNA by intercalation (Fig. 11). There is  rather a mixture of dif-
ferent mechanisms, including weak electrostatic interactions and
an  accumulation in vacuoles outside the nucleus. It  revealed very
high  activity against various cancer cell lines, even higher than cis-
platin. The assumed mechanism of action is  the exchange of the
chloride under physiological conditions, resulting in a  more soluble
species due to the resulting charge.
The modification of the curcumin skeleton at the central carbon
atom was also  successfully accomplished. A Fc moiety, for instance
(Fig.  11), has been used to push the potential of this compound class
toward alternative anticancer strategies [76].  The organometallic
moiety clearly enhanced the biological activity, e.g., higher cyto-
toxicity in B16 cells, stronger tubulin polymerization and rounding
up of  endothelial cells.  The biological efficacy depends on the linker
unit between curcumin and the Fc group and emphasizes the mul-
titargeting properties. Like other polyphenols [77], curcumin can
inhibit the proteasome function which heavily influences several
biological processes such as cell-cycle regulation and apoptosis.
The exchange of  the p-cymene group in  compound 21  against
benzene overcomes the mentioned biological restrictions while
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Fig. 11. Schematic representation of  9Accm-conjugated Cu-complex 27 [75] and Fc-modified curcumin skeleton 28 [76].
maintaining the proteasome inhibition of  curcumin [78].  The com-
plexation seems to  play for this compound another role. Instead
of direct metal proteasome interactions, the complex enhances the
stability of curcumin and keeps the activity at the same time. This
could be a new strategy to overcome the limitations of  chemother-
apy in  drug-resistant tumors.
4. Conclusions
Curcumin is one  promising natural compound with a  large vari-
ety of biological targets and interactions, linked to  a  number of
diseases. Unfortunately, its clinical application is  restricted by  its
the poor solubility in water, low absorption and bioavailability,
high metabolism rate, light sensitivity, and the rapid clearance.
To overcome these limitations, curcumin and its derivatives have
been modified, attached to phospholipids, micelles, nanoparticles,
liposomes and so forth. The complexation of  curcumin with dif-
ferent metals changes the activity in comparison with the free
ligands or  can mitigate some disadvantageous properties. Many
metals were used, resulting in potential candidates for applica-
tion in experimental biology or medicine. Gd3+, 99mTc+,  Re+ and
68Ga2+ are suitable candidates for modern imaging techniques,
such as fluorescence imaging, MRI, SPECT or PET. VO2+ in partic-
ular, but also Cu2+,  Ni2+,  and other metal complexes were tested
to explore their phototoxicity whereas Ru2+ and  Pd2+ complexes
act as intercalating agents. Further, some complexes revealed that
the complexation does not have to  take place at the -diketo-
moiety. The modification of the curcumin skeleton results in the
ability to fine-tune the compound’s properties. For instance, the
introduction of  electron-donating groups shifts the fluorescence
to higher wavelengths while glycosylated ligands enhance the
water solubility. Moreover, some heteroligand systems might be
more effective than homoligands. The combination of  the benefi-
cial properties of different ligand systems could lead to  new classes
of anticancer or imaging agents. However, the biological activity
and profile of  metal complexes of  curcumin and its derivatives
is highly complex and depends on a  variety of factors, e.g., the
selected metal, curcumin skeleton and its modifications, ancillary
ligand(s), the shape  of  the resulting complex, exchange capability
of the ligands, charge, and more. Therefore, in  the near future, a
continuous interest in the development of  novel curcumin-bearing
metal complexes for medical applications is expected. There is  still
a significant potential for growth in this area due to the relatively
small amount of reported curcumin-conjugated metal complexes.
Curcumin could, for example, be a  promising candidate to  maintain
the required cis-coordination of  platinum-based anticancer agents
together while enhancing their selectivity. Additionally, RAPTA-C-
like Ru-curcumin complexes could afford a  new level of biological
activity by modification of  the curcumin structure. Furthermore,
the  attachment of biomolecules could enhance the selectivity of
the complexes for imaging to distinguish between healthy and
pathological structures. In any  case, this area has only begun to
be explored and future developments will reveal the true potential
of  metal complexes of  curcumin and its derivatives.
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Cytotoxic Complexes
Synthesis and in vitro Toxicity of D-Glucose and D-Fructose
Conjugated Curcumin–Ruthenium Complexes
Michael Pröhl,[a,b] Tanja Bus,[a,b] Justyna A. Czaplewska,[a,b] Anja Traeger,[a,b]
Michael Deicke,[c] Henning Weiss,[c] Wolfgang Weigand,[b,c] Ulrich S. Schubert,[a,b] and
Michael Gottschaldt*[a,b]
Abstract: A series of carbohydrate-conjugated bis(demeth-
oxy)curcumin (BDC) ligands were synthesized by using the
Huisgen copper(I)-catalyzed cycloaddition between azido-func-
tionalized D-glucose and D-fructose as well as propargyl-modi-
fied BDC. The unprotected sugar ligands were treated with
Ru(bpy)2Cl2 to form curcumin-conjugated Ru complexes of gen-
eral formula Ru(bpy)2(L)Cl. The ligands as well as Ru complexes
were analyzed by NMR, IR, UV/Vis, and fluorescence spectro-
scopy, mass spectrometry as well as by elemental analysis (EA).
Introduction
In the last decades, medicinal inorganic chemistry has attracted
increased attention in disease therapy (e.g., cisplatin for cancer
treatment) as well as in disease diagnosis (e.g., 99mTc in
SPECT).[1] In addition to platinum-based drugs, other transition-
metal compounds also offer advantageous properties. Ru-based
complexes could overcome resistance problems often linked to
platinum-containing drugs or could diminish the extent of side
effects.[2] Further beneficial properties, such as easy access to
oxidation states +II and +III and the resulting possibility to ob-
tain low-reactive prodrugs, led to early clinical trials of ruth-
enium-based anticancer agents such as NAMI-A and promising
RuIII prodrugs such as RAPTA-T.[2] However, to improve the ther-
apeutic index, selectivity plays a major role. The current ap-
proach aims to target specific cell structures, which vary in com-
parison to healthy cells, e.g., transport proteins, antigens or re-
ceptors on the membrane surface, and which interact with the
potential drug. This is often realized by conjugation of the
metal complex to targeting moieties.[3]
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Incubation of L929, HepG2 and the breast cancer cell line MDA-
MB-231 revealed lower cytotoxicity of all carbohydrate-conju-
gated ligands compared with BDC. The Ru complexes exhibited
higher cytotoxicity than the parent ligands, in particular against
HepG2 cells, whereas the noncancerous L929 cell line remained
unaffected. Unexpectedly, the D-fructose-conjugated ligand
and its corresponding Ru complex did not show any significant
toxicity against MDA-MB-231 cells.
Carbohydrates, as a major energy source and substrates of
lipid and protein metabolism, are taken up into cells by highly
selective transport proteins.[4] Beside transporters for glucose
(the major carbohydrate) there are carriers such as GLUT5 for
fructose. GLUT5 is one of thirteen members of the known sac-
charide transporters (GLUTs), and its structure was determined
recently.[5] It is found in the membrane in the small intestine
and kidney cells, but is also reported to be overexpressed in
85 % of 33 tested breast cancer cell lines,[6] although another
group reported contradictory results.[7] The latter study con-
cludes that there is no overexpression of GLUT5 in breast cancer
tissue. However, it was shown that structural modifications of
D-fructose at the C1 and C6 position seems to be tolerated by
the GLUT5 transporter.[8] Based on that, dyes,[9] polymers,[10]
and nanoparticles[11] were functionalized with D-fructose to
successfully target breast cancer cells. Another approach to
study the possibility of GLUT5 targeting is the determination of
cell internalization of metal complexes modified with fructose
residues.[12] For instance, a fructose-conjugated IrIII complex re-
vealed a 3.6 times higher uptake into MCF-7 cells compared
with noncancerous HEK293T cells, whereas the corresponding
nonfunctionalized IrIII complex did not show any significant dif-
ferences in terms of cell-specific uptake.[12a] Another study ex-
hibited the enhanced accumulation of a fructose-conjugated
Re complex in breast cancer cells MDA-MB-231 and MCF-7 com-
pared with all other studied cancerous and noncancerous cell
lines. Uptake competition experiments with D-fructose indi-
cated the involvement of the GLUT5 transporter.[12b] Addition-
ally, the hydrophilicity of sugar moieties reduces the toxicity
and increases the solubility in water and therewith in the
plasma.[13] This offers the possibility to overcome disadvanta-
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geous properties of potentially biological active compounds
and to enhance the selectivity at the same time.
Besides a large number of other polyphenols, the diaryl-
hepanoid curcumin is a highly bioactive compound that is con-
tained in the roots of turmeric. It interacts with a large number
of molecular targets linked to major diseases of modern socie-
ties.[14] It is reported to possess beneficial properties such as
antimicrobial, antiinflammatory and chemopreventive effects
and low toxicity up to high dosages.[15] Unfortunately, medical
applications of curcumin and its derivatives are limited by some
major drawbacks such as rapid metabolism and poor solubility
in water. In the last decades many strategies have been tested
to overcome these disadvantages; for example, the use of piper-
ine as concomitant, nanoparticle-based systems or micellar for-
mulations.[16] Currently, metal complexes of curcumin and its
derivatives are a focus of the scientific community.[17] Cur-
cumin-conjugated metal complexes were found to have supe-
rior properties such as enhanced solubility in water,[18] higher
photocytotoxicity[19] or increased cytotoxicity by intercala-
tion.[20] In particular, a RAPTA-type complex of curcumin exhib-
ited outstanding properties such as an approximate 100 times
smaller IC50 value compared with that of cisplatin against cis-
platin-resistant ovarian cancer cells.[18] Furthermore, the attach-
ment of glucose to the curcumin skeleton in an oxovanadium
complex enhances both the solubility in water and the cellular
uptake in cancer cells.[21]
A powerful tool to append biomolecules to different struc-
tures is “click” chemistry.[22] It combines a few types of reactions
with several advantages including high yields, stereospecificity,
easily available starting materials, and gentle product isola-
tion.[23] In particular, the CuI-catalyzed Huisgen 1,3-dipolar
cycloaddition (CuAAC) between terminal alkynes and azides is
used for the synthesis of five-membered heterocyclic sys-
tems.[24]
Herein, we describe the synthesis, characterization, and eval-
uation of the cytotoxicity of two sugar-conjugated curcumin
ligands and their corresponding Ru(bpy)2 complexes.
Results and Discussion
Synthesis and Characterization
The synthesis of altered curcuminoids by using aldehydes in a
double aldol condensation with acetylacetone is well known
and offers the possibility to introduce functionalities to the cur-
cuminoid skeleton (Figure 1).[25] Compound 1 was obtained by
using a modification of a reported procedure: BF3·Et2O-pro-
moted one-pot synthesis with acetylacetonate and 4-(prop-
argyloxy)benzaldehyde in toluene. Subsequent recrystallization
resulted in the isolation of the desired product in high yield
and purity. Compound 1 was characterized by 1H, 13C and 19F
NMR spectroscopy and HRMS (ESI) as well as by elemental anal-
ysis to confirm the purity of the compound. The IR spectrum
reveals a strong band at ν˜ = 3290 cm–1 resulting from the
monosubstituted alkyne functionality (see the Supporting Infor-
mation, Figure S5). The azide-functionalized sugar moieties
were also synthesized according to reported procedures.[25]
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Bis(demethoxy)curcumin (BDC, 2) was synthesized in high
yields as previously reported.[26] Ligands 3a and 3b were pre-
pared according to the “Huisgen” 1,3-dipolar cycloaddition be-
tween compound 1 and 2 equiv. of the azido-sugars with
CuSO4 and sodium ascorbate as catalyst-forming pair. The yields
of both reactions were relatively low (42 % for 3a and 52 % for
3b). Thin-layer chromatography (TLC) revealed byproducts: the
copper complex of the ligands, the one-site-clicked product,
and the corresponding copper complex of it. The copper could
not be removed completely by extraction with ethylenedi-
aminetetraacetic acid (EDTA), probably because of the stability
of copper–curcumin complexes.[27] Flash column chromatogra-
phy led to the pure ligands. The 1H NMR spectra of the ligands
clearly revealed the disappearance of the ethynyl singlet of the
starting material at δ = 3.63 ppm and the appearance of a
signal for the triazole protons at δ = 8.11 ppm for 3a and δ =
8.20 ppm for 3b (see the Supporting Information, Figures S8
and S14). Furthermore, cleavage of the BF2 group was con-
firmed by the disappearance of the peak at δ = –138.14 ppm
in the 19F NMR spectra and the strong shift to lower fields of
all curcuminoid-related peaks in the 1H NMR spectra. ESI-MS
identified the ligands as [M + X]+ (X = H, Na, K). To form ligand
4a the acetyl groups of compound 3a were cleaved under basic
conditions by using sodium methoxide in anhydrous methanol
under argon. The reaction mixture was neutralized with ion ex-
change resin DOWEX (H+) and dialyzed in water for 1 week to
remove low-molar-mass impurities. The product was obtained
in good yield without any side products. The structure of the
ligand was established by HRMS (ESI) as [M + Na]+ (error:
1.4 ppm) and by elemental analysis. The disappearance of the
carbonyl band of the acetyl groups in the IR spectrum as well
as of the four singlets (δ = 1.89–2.02 ppm) in the 1H NMR spec-
tra and of the eight signals (δ = 168.97–170, 20.21–20.49 ppm)
in the 13C NMR spectra confirmed the success of the reaction
(see the Supporting Information, Figures S20–23). The signals
in the NMR spectra remained sharp and well separated. Due to
the glycosidic linkage, the glucose units are still present in the
pyranoide structure and, therefore, no stereoisomers are ob-
servable. The cleavage of the isopropylidene groups of com-
pound 3b was problematic. Neither standard acidic cleavage
procedures[28] nor acidic ion exchange resins could be success-
fully applied.[29] Given the high sensitivity of the curcuminoid
skeleton towards acids (as well as bases and light),[31] formic
acid was chosen to replace the isopropylidene groups under
relatively mild conditions.[30] The solution was stirred at room
temperature for 1 week, and the progress was monitored by
MS (ESI). The absence of all m/z peaks derived from the
ligands substituted with isopropylidene groups indicated the
full conversion. After removing the excess of formic acid in
vacuo, the resulting formic acid esters were cleaved under basic
conditions with aqueous 0.1 M NaOH. The crude product was
dialyzed to remove the formed sodium formate, then analyzed
by HRMS (ESI) as [M + Na]+ (error: 4.7 ppm) and by elemental
analysis to confirm the absence of any salts such as sodium
formate or NaCl. The 1H as well as the 13C NMR spectra con-
firmed the disappearance of the isopropylidene peaks (see the
Supporting Information, Figures S26–28). The NMR spectra
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clearly reveal the presence of different ligand species due to
the fructose isomers. The interaction between the hydroxy
groups of the sugar units and the curcuminoid enol moieties or
sugar hydroxy groups of neighboring molecules could stabilize
different forms of the sugar, resulting in wider peaks and more
complex NMR spectra. When measured in deuterated dimethyl
sulfoxide (DMSO), broad peaks between δ = 4.5 and 6.5 ppm
in the 1H NMR spectrum only appear to be coupling with the
sugar ring proton signals in 2D-COSY experiments. The signals
could be attributed to fructose hydroxy groups formed during
deprotection. Furthermore, there are at least three peaks for
each carbon atom of the fructose residues with different inten-
sities in the 13C NMR spectrum of compound 4b, confirming
the existence of stereoisomers. However, the ESI-MS revealed
only two major peaks ([M + Na]+ and [M – H + 2 Na]+), thus
establishing the identity of the ligand. Complexes 5a–c were
synthesized in methanol (5a) or a mixture of anhydrous meth-
anol and N,N-dimethylformamide (DMF) (5b and 5c) with so-
dium methoxide as a base (Figure 2). The mixtures were heated
under argon at 60 °C for 12 h. Excess Ru(bpy)2Cl2 was used to
complete the reaction of the ligands. For 5a and 5b, the reac-
tion mixture was concentrated, and the remaining excess of
precursor was filtered off after redissolving the crude product
in pure water. The remaining salts were removed from the
aqueous layer by dialysis against water. HRMS (ESI) showed the
pure complex 5a without signals of precursor or ligand as [M –
Cl]+ (error: 0.5 ppm) and [M – Cl + Na]2+. The 1H NMR spectrum
shows eight additional peaks in the aromatic region fitting to
the bipyridine (bpy) units of the product with a shift to lower
ppm values in comparison to the 1H NMR spectrum of 4a (see
the Supporting Information, Figures S32–34). The structure of
5b was challenging to validate because of the instability during
mass spectrometric measurements. HRMS (ESI) under soft con-
ditions with an orbitrap mass analyzer combined with LC-MS
experiments showed, next to product peak [M – Cl]+ (error:
1.8 ppm), different fragments; for example fragments without
fructose unit(s) or without triazole unit(s). MS/MS experiments
Figure 1. Schematic representation of the ligand synthesis. Reagents and conditions: (i) BF3·Et2O, p-(propargyloxy)benzaldehyde, tributyl borate, n-butylamine,
N2, 65 °C, toluene, 18 h; (ii) (1) BF3·Et2O, p-hydroxybenzaldehyde, tributyl borate, n-butylamine, N2, 65 °C, toluene, 6 h; (2) NaOH, 70 °C, CH3OH/H2O, 5 h;
(iii) azido-sugar, CuIISO4·5H2O, sodium ascorbate, Ar, 50 °C, THF/H2O, 12 h; (iv) 3a → 4a: (1) NaOMe, Ar, room temp., MeOH, 0.5 h; (2) DOWEX H
+; 3b → 4b:
(1) formic acid, room temp., 1 week; (2) 0.1 M NaOH, room temp., THF/H2O, 1 h.
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of the product ion identified the fragments as being generated
as a result of cleavage of the parent ion under the applied
conditions (see the Supporting Information, Figures S41–S42).
The 1H NMR spectrum shows an even higher complexity com-
pared to that of the ligand. Signals in the aromatic region ap-
pear that can be clearly distinguished from Ru(bpy)2Cl2 precur-
sor peaks. Furthermore, 2D-COSY and HSQC NMR measure-
ments prove the attachment of fructose. Figure 3 shows the 1H-
13C-HSQC experiments of 4b in comparison to 5b. The area
between δ = 3 and 4 ppm in the 1H NMR spectrum, and be-
tween δ = 50 and 100 ppm in the 13C NMR spectrum shows
the occurrence of proton and carbon peaks of various forms of
fructose units in the ligand as well as in the complex. The ob-
served pattern differs, which suggests the presence of different
ratios of fructose isomers. It is known that in aqueous solution
of D-fructose at pH 7, various forms exist and that the percent-
age of each form is strongly dependent on temperature, salts,
and other conditions.[31] It was also shown that certain isomers
can be stabilized; for example the presence of human serum
albumin (HSA) resulted in the stabilization of the open-chain D-
fructose by the NH2 functionalities of the Lys199 residue.
[32] In
contrast, in a D-fructose-decorated glycopolymer, the pyranose
form dominates, but also furanose forms were observable.[10]
The synthesis of 5c was performed as mentioned before, but
due to the high polarity and low solubility in water of com-
pound 5c it was neither suitable for normal-phase silica chro-
matography nor convenient for dialysis with water. Therefore,
the crude product was purified by size-exclusion chromatogra-
phy using Sephadex LH-20 and methanol as eluent to obtain
the pure complex. The 1H NMR spectrum revealed a shift of all
proton signals to lower fields, and additional peaks appeared
in the aromatic region fitting to the bpy units of the formed
complex (see the Supporting Information, Figure S45). HRMS
(ESI) confirmed the structure as [M – Cl]+ (error: 1.5 ppm).
The absorbance and emission spectra of all compounds were
measured in aerated methanol. Due to the polarity of methanol,
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the vibrational structure of the excitation and emission spectra
is not visible, and the absorption band is bathochromically
shifted compared to those recorded in more apolar solvents.[33]
Figure 2. Schematic representation of the complex synthesis. Reagents and conditions: (i), (ii) NaOMe, Ru(bpy)2Cl2, Ar, MeOH/DMF, 60 °C, 12 h.
Figure 3. 1H-13C-HSQC spectra of 4b and 5b (in [D6]DMSO) focusing on the area between δ = 3 and 4 ppm in the
1H NMR spectrum, and between δ = 50
and 100 ppm in the 13C NMR spectrum.
Eur. J. Inorg. Chem. 2016, 5197–5204 www.eurjic.org © 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim5200
The cleavage of the boron difluoride group results in an absorp-
tion band at λmax = 410 nm for compounds 3a and 3b, hypso-
chromically shifted compared with λmax = 477 nm of 1. Emis-
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sion spectra of compound 3a and 3b (λmax = 509 nm) and 1
(λmax = 541 nm) revealed the same behavior. The appearing
absorption bands for compounds 5a–c fit to π→π* transition
of the bpy ligands (λmax = 296 nm) and metal to ligand charge
transfer (MLCT) transition (λmax = 517 nm). The complexes re-
vealed fluorescence in methanol in the visible region at λmax =
585 nm when irradiated at λ = 296 nm. Furthermore, a smaller
emission maximum is observable at λ ≈ 450 nm, indicating two
separate chromophore systems. As also previously reported,[34]
fluorescence of the Ru complexes was quenched in water, and
therefore complexes 5a–c did not show any emission when
measured in aqueous solution.
Cytotoxicity Studies
Recent studies based on fluorescence using flow cytometry in-
dicated an increased uptake of D-fructose-conjugated lumines-
cent metal complexes into breast cancer cells.[12] Given that
complexes 5a–c show no fluorescence in water or cell media
due to quenching effects[34] the uptake behavior could not be
studied by spectroscopic methods. To evaluate the cytotoxicity
of the ligands and complexes, the inhibitory effect on the cellu-
lar metabolic activity of different cell types was investigated by
using a resazurin-based assay (alamarBlue, Thermo Fisher). The
noncancerous cell line L929, the liver cancer cell line HepG2 as
well as the breast cancer cell line MDA-MB-231 were treated
with ligands 2, 4a–b, and metal complexes 5a–c at varying con-
centrations for 24 h (see the Supporting Information, Figures
S51–S53). None of the tested compounds induced a significant
reduction in cell viability in noncancerous cell line L929. Carbo-
hydrate-conjugated metal complexes 5a and 5b revealed only
a slight inhibitory effect on the metabolic activity of MDA-MB-
231 cells, which might be attributed to the lipophilic properties
of the bipyridyl groups of the complexes, allowing for elevated
diffusion through the cell or nucleic membrane in comparison
to the more polar ligands 4a and 4b. Sugar-decorated ligands
4a and 4b had no influence on MDA-MB-231 cells. Fructose-
conjugated complex 5b revealed no specific cytotoxicity
against MDA-MB-231 cells. A concentration-dependent reduc-
tion of cell viability was observed for the sugar-free ligand 2
and complex 5c, which could be attributed to its increased
hydrophobicity due to missing hydrophilic sugar units. As a
consequence, a GLUT5-independent pathway seems to be
likely. In contrast to that, HepG2 cells exhibited sensitivity
against glucose- and fructose-conjugated metal complexes in-
dependent of tested concentration, as demonstrated by the de-
crease of cell viability below 50 % after 24 h. HepG2 remained
unaffected after treatment with carbohydrate-conjugated li-
gands as well as for the metal complex 5c. Previous studies
already revealed a selective uptake of glucose-substituted ruth-
enium complexes in HepG2 cells, which could contribute to the
enhanced cytotoxic effects seen in our investigations.[35] Fur-
thermore, increased cytotoxicity of curcumin as well as cur-
cumin-conjugated metal complexes against HepG2 cells is con-
sistent with previous reports.[36] Correlation between cytotoxic-
ity and specific uptake of D-fructose-conjugated compounds re-
quires further investigations.
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Conclusions
The conjugation of protected D-glucose and D-fructose to BDC
was achieved by using the click reaction between sugar azides
and a propargyl-modified curcumin derivative. Deprotection
procedures resulted in carbohydrate-conjugated ligands, which
were successfully treated with Ru(bpy)2Cl2 to form novel com-
plexes of the general formula Ru(bpy)2(L)Cl. All compounds
were extensively analyzed by 1H and 13C NMR, IR, UV/Vis, and
fluorescence spectroscopy, mass spectrometry as well as by ele-
mental analysis. Sugar-decorated ligands and complexes in-
duced a decrease in cell viability of HepG2 and only a slight
cytotoxicity for MDA-MB-231. However, BDC-based complex 5c
showed an increased cytotoxicity in breast cancer cell line,
whereas most HepG2 cells remained unaffected for all tested
concentrations, indicating a carbohydrate-independent path-
way. Increased cytotoxicity of fructose-conjugated compounds
in breast cancer cells was not observable in this study.
Experimental Section
Materials and General Experimental Details: All reagents and sol-
vents were commercial products purchased from Aldrich, Sigma,
Fluka, Across Organics, Strem, VWR or Alfa Aesar and were used
without further purification. Chromatographic separations were
performed with NP Silica RediSep Cartridges by Teledyne Isco. The
progress of reactions was monitored by thin-layer chromatography
(TLC) using glass plates precoated with silica gel 60 (Merck). Dialy-
ses were performed using Biotech CE membranes (MWCO 500-1000
Da) from Spectrum Labs. Cell cultivation was performed at 37 °C in
a humidified 5 % CO2 atmosphere. L929 (CCL-1, ATCC) and MDA-
MB231 (HTB-26, ATCC) cells were cultured in Dulbecco's MEM
(DMEM, Lonza) supplemented with 10 % fetal calf serum (FCS, Cap-
ricorn Scientific), 100 µg mL–1 streptomycin, and 100 IU mL–1 peni-
cillin (Biochrom, Merck). HepG2 cells (HB-8065, ATCC) were routinely
cultured in DMEM/F12 media (Biochrom, Merck Millipore). Consum-
ables for cell culture such as pipettes and cell culture plates (96
well) were obtained from Corning (USA) and Greiner Bio-one (Aus-
tria/Germany).
Instrumentation: 1H and 13C NMR spectra were measured with
Bruker spectrometers (600, 300 and 250 MHz). IR spectra were re-
corded with Nicolet AVATAR 370 DTGS and Bruker Tensor 37 spec-
trometers. UV/Vis absorption spectra were measured with Thermo
Unicam UV500 and analytikjena Specord250 spectrometers, and
fluorescence was recorded with a Jasco FP 6500 and an Infinite
M200 PRO microplate reader (298 K, methanol, 1 × 10–4 to
2 × 10–6 M solutions). High-resolution electron spray ionization mass
spectrometry [HRMS (ESI)] was measured with a Bruker MicroQTof
and a Thermo QExactive plus Orbitrap mass spectrometer coupled
to an ESI source. Elemental analyses were performed with a Leco
CHN-932. The alamarBlue cell viability assay (Thermo Fisher) was
performed with an Infinite M200 PRO microplate reader (Tecan) ac-
cording to the supplier's instructions.
Synthesis of the Curcuminoid Compounds: The synthesis of 1
was carried out according a modification of a reported procedure,
and 2 was synthesized as reported.[24]
Synthesis of the Azido-Sugars: 2-Azidoethyl 2,3,4,6-tetra-O-acetyl-
-D-glucopyranoside[25a] and 1-azido-1-deoxy-2,3:4,5-di-O-isoprop-
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ylidene--D-fructopyranoside were synthesized as previously re-
ported.[25b]
Compound 1: 2,4-Pentanedione (0.64 mL, 6.2 mmol) and BF3·Et2O
(1.16 mL, 9.4 mmol) were dissolved in anhydrous toluene (5 mL)
and stirred at 65 °C for 2 h. 4-(Propargyloxy)benzaldehyde (2 g,
12.5 mmol) in anhydrous toluene (40 mL) was added to the solu-
tion. After the addition of tributyl borate (3.9 mL, 15.6 mmol), the
resulting black mixture was stirred at 65 °C for 30 min. n-Butylamine
(0.43 mL, 4.34 mmol) was added dropwise until the color of the
solution changed to red, and stirring was continued at 65 °C over-
night. After cooling to room temperature, the precipitated solid was
collected by filtration and washed with small amounts of cold tolu-
ene and water. The crude product was dissolved in acetone, and
water was added slowly to precipitate 1 (2.575 g, 5.96 mmol) as a
red solid, isolated by filtration, washed with water and dried in
vacuo. Yield: 96 %. 1H NMR (300 MHz, [D6]DMSO): δ = 8.02 (d,
3J =
15.69 Hz, 2 H, 3-H), 7.88 (d, 3J = 8.59 Hz, 4 H, 6-H), 7.12 (m, 6 H, 4-
H, 7-H), 6.53 (s, 1 H, 1-H), 4.92 (s, 4 H, 9-H), 3.63 (s, 2 H, 11-H) ppm.
13C NMR (75 MHz, [D6]DMSO): δ = 179.33 (C-2), 160.37 (C-8), 146.27
(C-3), 131.61 (C-6), 127.53 (C-5), 119.17 (C-4), 115.61 (C-7), 101.73 (C-
1), 78.75 (C-10, C-11), 55.74 (C-9) ppm. 19F NMR (188 MHz,
[D6]DMSO): δ = –138.14 ppm. HRMS (ESI): calcd. for C25H19BF2NaO4
[M + Na]+ 455.1237; found 455.1219 (error: 4.8 ppm). C25H19BF2O4
(432.23): calcd. C 69.47, H 4.43; found C 69.44, H 4.56. IR (KBr): ν˜ =
667 (δ=CH), 3290 (ν=CH) cm
–1. UV/Vis: λ (ε × 10–3) = 477 (50.55), 458
(48.1), 254 (11.8 M–1 cm–1) nm. FL (CH3OH, λex = 477 nm): λ =
541 nm.
Compound 3a: 2-Azidoethyl 2,3,4,6-tetra-O-acetyl--D-gluco-
pyranoside (3.863 g, 9.26 mmol) and 1 (2 g, 4.63 mmol) were dis-
solved in degassed THF (150 mL), and sodium ascorbate (1.5 g,
7.57 mmol) and CuSO4 (0.24 g, 0.96 mmol) in degassed, pure water
(5 mL) were added, and the mixture was heated at 50 °C under Ar
for 12 h. When TLC (NP silica; EtOAc) indicated that no starting
material had remained, the solvent was evaporated, the crude prod-
uct was dissolved in CHCl3 and washed thrice with saturated, aque-
ous EDTA solution and thrice with pure water. The organic layer was
dried with Na2SO4, the solvent evaporated, and the product was
purified by flash column chromatography (NP silica, EtOAc) to ob-
tain the pure product (2.388 g, 1.96 mmol, 42 %). 1H NMR (600 MHz,
[D6]DMSO): δ = 8.11 (s, 2 H, 11-H), 7.71 (d,
3J = 8.82 Hz, 4 H, 6-H),
7.62 (d, 3J = 15.78 Hz, 2 H, 3-H), 7.12 (d, 3J = 8.88 Hz, 4 H, 7-H), 6.82
(d, 3J = 15.90 Hz, 2 H, 4-H), 6.10 (s, 1 H, 1-H), 5.25–5.18 (m, 6 H, 3′-
H, 9-H), 4.92 (t, 3J = 9.72 Hz, 2 H, 4′-H), 4.84 (d, 3J = 8.04 Hz, 2 H,
1′-H), 4.76–4.73 (m, 2 H,2′-H), 4.62–4.53 (m, 4 H, 1-Hspacer), 4.19 (dd,
2J = 12.30, 3J = 5.04 Hz, 2 H, 6′-H), 4.14–4.1 (m, 2 H, 2-Hspacer), 4.06
(dd, 2J = 12.24, 3J = 2.28 Hz, 2 H, 6′′-H), 3.99–3.92 (m, 4 H, 5′-H, 2-
Hspacer), 2.02–1.89 (4s, 12 H, acetyl H) ppm.
13C NMR (75 MHz,
[D6]DMSO): δ = 183.21 (C-2), 170.05–168.97 (acetyl C=O), 159.85
(C-8), 142.18 (C-10), 139.95 (C-3), 130.14 (C-6), 127.67 (C-5), 124.94
(C-11), 122.04 (C-4), 115.19 (C-7), 101.29 (C-1), 99.15 (C-1′), 71.91
(C-3′), 70.66 (C-5′), 70.57 (C-2′), 68.09 (C-4′), 67.41 (C-2spacer), 61.65
(C-6′), 61.26 (C-9), 49.34 (C-1spacer), 20.49–20.21 (acetyl CH3) ppm.
MS (ESI): calcd. for C57H66N6NaO24 [M + Na]
+ 1241.4; found 1241.3;
calcd. for C57H67N6O24 [M + H]
+ 1219.42; found 1219.41; calcd. for
C57H66KN6O24 [M + K]
+ 1257.38; found 1257.3. C57H66N6O24
(1219.17): calcd. C 56.15, H 5.46, N 6.89; found C 56.44, H 5.65, N
6.73. IR (KBr): ν˜ = 1755 (νCO), 2887 (νCH), 2958 (νCH2), 3145
(ν=CH) cm
–1. UV/Vis (CH3OH): λ (ε × 10
–3) = 410 (39.25), 243
(13.55 M–1 cm–1) nm. FL (CH3OH, λex = 410 nm): λ = 509 nm.
Compound 3b: 1-Azido-1-deoxy-2,3:4,5-di-O-isopropylidene--D-
fructopyranoside (1.74 g, 6.1 mmol) and 1 (1.318 g, 3.05 mmol)
were dissolved in degassed THF (100 mL), and sodium ascorbate
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(1 g, 5.05 mmol) and CuSO4 (0.15 g, 0.6 mmol) in degassed water
(5 mL) were added, and the mixture was heated at 50 °C under Ar
for 12 h. When TLC (NP silica; EtOAc/n-hexane, 2:1, v/v) indicated
that no starting material had remained, the solvent was evaporated,
and the crude product was dissolved in CHCl3 and washed thrice
with saturated, aqueous EDTA solution and thrice with pure water.
The organic layer was dried with Na2SO4, the solvent was evapo-
rated, and the product was purified by flash column chromatogra-
phy (NP silica; EtOAc/n-hexane, 2:1, v/v) to give the pure product
(1.503 g, 1.57 mmol, 52 %). 1H NMR (600 MHz, [D6]DMSO): δ = 8.20
(s, 2 H, 11-H), 7.69 (d, 3J = 8.82 Hz, 4 H, 6-H), 7.61 (d, 3J = 15.78 Hz,
2 H, 3-H), 7.12 (d, 3J = 8.82 Hz, 4 H, 7-H), 6.82 (d, 3J = 15.90 Hz, 2
H, 4-H), 6.09 (s, 1 H, 1-H), 5.22 (s, 4 H, 9-H), 4.66 (m, 6 H, 1′-H, 1′′-H,
4′-H), 4.43 (d, 3J = 2.26 Hz, 2 H, 3′-H), 4.27 (d, 3J = 8.7 Hz, 2 H, 5′-
H), 3.75 (dd, 4J = 1.59, 2J = 12.99 Hz, 2 H, 6′-H), 3.64 (d, 2J = 12.84 Hz,
2 H, 6′′-H), 1.41–0.81 (4 s, 12 H, isopropylidene H) ppm. 13C NMR
(75 MHz, [D6]DMSO): δ = 183.18 (C-2), 159.79 (C-8), 142.10 (C-3),
139.93 (C-10), 130.08 (C-6), 127.60 (C-5), 127.03 (C-11), 121.98 (C-4),
115.23 (C-7), 108.60 (isopropylidene C), 108.29 (isopropylidene C),
101.26 (C-1), 100.43 (C-2′), 70.33 (C-3′), 69.82 (C-5′), 69.32 (C-4′),
60.97 (C-9, C-6′), 54.84 (C-1′), 26.02–24.00 (isopropylidene CH3) ppm.
HRMS (ESI): calcd. for C49H58N6NaO14 [M + Na]
+ 977.3903; found
977.3875 (error: 2.8 ppm). C49H58N6O14·0.5H2O (964.04): C 61.05, H
6.17, N 8.72; found C 61.15, H 6.18, N 8.71. FTIR (GA): ν˜ = 613
(νC–isopropylidene), 1087 (νCOH), 1755 (νCO), 2941 (νCH), 2987
(νCH2) cm
–1. UV/Vis (CH3OH): λ (ε × 10
–3) = 410 (37), 243
(11.95 M–1 cm–1) nm. FL (CH3OH, λex = 410 nm): λ = 508 nm.
Compound 4a: Compound 3a (400 mg, 0.32 mmol) was dissolved
in CH3OH/CHCl3 (1:2, v/v; 10 mL) under Ar, and sodium methoxide
was added up to ca. pH 9. After 30 min, no protected ligand had
remained (monitored by TLC: NP silica; EtOAc), and DOWEX (H+)
was added to reach ca. pH 7. The resin was filtered off and the
solvent removed. The residue was dissolved in water, filtered and
dialyzed for 1 week against water to obtain the pure product
(180 mg, 0.20 mmol, 63 %). 1H NMR (600 MHz, [D6]DMSO): δ = 8.32
(s, 2 H, 3-H), 7.71 (d, 3J = 8.10 Hz, 4 H, 6-H), 7.62 (d, 3J = 15.78 Hz,
2 H, 3-H), 7.13 (d, 3J = 8.58 Hz, 4 H, 7-H), 6.82 (d, 3J = 15.12 Hz, 2
H, 4-H), 6.11 (s, 1 H, 1-H), 5.20 (s, 4 H, 9-H), 5.11 (d, 3J = 4.86 Hz, 2
H, 2′-OH), 4.98 (d, 3J = 4.80 Hz, 2 H, 3′-OH), 4.94 (d, 3J = 5.34 Hz, 2
H, 4′-OH), 4.61 (m, 4 H, 1-Hspacer), 4.54 (m, 2 H, HO-6′), 4.25 (d,
3J =
7.80 Hz, 2 H, 1′-H), 4.11 (m, 2 H, 2-Hspacer), 3.94 (m, 2 H, 2-Hspacer),
3.69 (m, 2 H, 6′-H), 3.44 (m, 2 H, 6′′-H), 3.17–3.12 (m, 4 H, 3′-H, 5′-
H), 3.06 (m, 2 H, 4′-H), 2.99 (m, 2 H, 2′-H) ppm. 13C NMR (75 MHz,
[D6]DMSO): δ = 183.23 (C-12′), 159.91 (C-6′′), 142.12 (C-4′′), 139.99
(C-11′′), 130.17 (C-8′′), 127.66 (C-9′′), 125.60 (C-3′′), 122.05 (C-10′′),
115.26 (C-7′′), 102.94 (C-1), 101.34 (C-13′′), 77.01 (C-5), 76.62 (C-3),
73.34 (C-2), 70.04 (C-4), 67.34 (C-1′′), 61.28 (C-5′′), 61.10 (C-6), 49.78
(C-2′′) ppm. HRMS (ESI): calcd. for C41H50N6NaO16 [M + Na]
+
905.3176; found 905.3163 (error: 1.4 ppm). C41H50N6O16·2.5H2O
(927.9): calcd. C 53.07, H 5.97, N 9.06; found C 53.25, H 5.58, N 8.84.
IR (KBr): ν˜ = 3352 (νOH) cm
–1. UV/Vis (CH3OH): λ (ε × 10
–3) = 408
(18.45), 243 (13.55 M–1 cm–1) nm. FL (CH3OH, λex = 408 nm): λ =
509 nm.
Compound 4b: Compound 3b (175 mg, 0.183 mmol) was dissolved
in formic acid/water (17:3, v/v; 10 mL) and stirred at room tempera-
ture for 1 week. When no isopropylidene groups had remained
(monitored by ESI-MS), formic acid was coevaporated with water
and the residue was dried. The crude product was dissolved in THF/
water mixture (1:1, v/v; 5 mL), and aqueous 0.1 M NaOH solution
was added to reach ca. pH 9. The solution was neutralized with
2.5 M HCl, freeze-dried, redissolved in water and dialyzed for 1 week
against water to obtain the pure product (84 mg, 0.106 mmol,
58 %). 1H NMR (600 MHz, [D6]DMSO): δ = 8.09 (s, 1 H, 11-H), 7.71
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(d, 3J = 8.46 Hz, 4 H, 6-H), 7.62 (d, 3J = 15.84 Hz, 2 H, 3-H), 7.13 (d,
3J = 8.52 Hz, 4 H, 7-H), 6.82 (d, 3J = 15.84 Hz, 2 H, 4-H), 6.10 (s, 1 H,
1-H), 5.22 (m, 4 H, 9-H), 4.59–4.37 (m, 4 H, 1′-H, 1′′-H), 3.88–3.41 (m,
10 H, 3-H, 4-H, 5-H, 6-H, 6′-H) ppm. 13C NMR (75 MHz, [D6]DMSO):
δ = 183.24 (C-2), 159.97 (C-8), 141.98 (C-10), 140.01 (C-9), 130.17
(C-6), 127.65 (C-5), 125.94 (C-11), 122.03 (C-4), 115.28 (C-7), 102.70
(C-2′), 101.32 (C-1), 100.24 (C-2′), 96.67 (C-2′), 82.60 (C-3′), 82.21 (C-
3′), 77.01 (C-5′), 76.10 (C-5′), 74.61 (C-5′), 69.55 (C-4′), 68.76 (C-4′),
68.53 (C-4′), 63.77 (C-6′), 62.49 (C-6′), 61.32 (C-6′), 61.25 (C-9), 54.75
(C-1′), 54.22 (C-1′), 54.04 (C-1′) ppm. HRMS (ESI): m/z calcd. for
C49H58N6O14Na [M + Na]
+: 817.2651; found 817.2613 (error:
4.7 ppm). C37H42N6O14·2.5H2O (839.81): calcd. C 52.92, H 5.64, N
10.01; found C 52.70, H 5.24, N 10.04. IR (KBr): ν˜ = 3352 (νOH) cm
–1.
UV/Vis (CH3OH): λ (ε × 10
–3) = 409 (8.75), 286 (4.10 M–1 cm–1) nm.
FL (CH3OH, λex = 408 nm): λ = 510 nm.
Compound 5a: Compound 4a (135 mg, 0.15 mmol) was dissolved
in anhydrous methanol under Ar, and sodium methoxide solution
(0.5 M in MeOH, 310 µL, 0.15 mmol) was added dropwise. The solu-
tion was stirred for 1 h, and [Ru(bpy)2Cl2] (81.7 mg, 0.17 mmol) in
methanol was slowly added. The mixture was heated to reflux un-
der Ar at 60 °C for 12 h. When TLC (NP silica; CH3CN/H2O/satd. aq.
KNO3, 40:4:1, v/v/v) indicated that no starting material had re-
mained, the solvent was evaporated. The crude product was dis-
solved in water, filtered and dialyzed for 1 week against water to
obtain the pure complex (191 mg, 0.14 mmol, 93 %). 1H NMR
(600 MHz, [D6]DMSO): δ = 8.80 (d,
3J = 8.28 Hz, 2 H, 3-Hbpy), 8.70
(d, 3J = 8.22 Hz, 2 H, 3′-Hbpy), 8.65 (d,
3J = 5.28 Hz, 2 H, 6-Hbpy), 8.30
(s, 2 H, 11-H), 8.18 (t, 3J = 7.80 Hz, 2 H, 4-Hbpy), 7.93 (t,
3J = 7.83 Hz,
2 H, 4′-Hbpy), 7.79 (m, 4 H, 6′-Hbpy, 5-Hbpy), 7.47 (d,
3J = 8.76 Hz, 4
H, 6-H), 7.31 (t, 3J = 6.69 Hz, 2 H, 5′-Hbpy), 7.01 (m, 6 H, 3-H, 7-H),
6.63 (d, 3J = 15.84 Hz, 2 H, 4-H), 5.93 (s, 1 H, 1-H), 5.13 (s, 4 H, 9-H),
4.58 (m, 4 H, 1-Hspacer), 4.24 (d,
3J = 7.86 Hz, 2 H, 1′-H), 4.09 (m, 2
H, 2-Hspacer), 3.92 (m, 2 H, 2-Hspacer), 3.68 (dd,
2J = 11.76, 3J = 1.80 Hz,
2 H, 6′-H), 3.45 (q, 3J = 5.92 Hz, 2 H, 6′′-H), 3.17–3.10 (m, 4 H, 3′-H,
5′-H), 3.06 (t, 3J = 9.18 Hz, 2 H, 4′-H), 2.98 (t, 3J = 9.18 Hz, 2 H,
2′-H) ppm. 13C NMR (75 MHz, [D6]DMSO): δ = 177.63 (C-2), 158.89
(C-2bpy), 158.76 (C-2′bpy), 157.39 (C-8), 152.84 (C-6′bpy), 149.41
(C-6bpy), 142.13 (C-10), 136.63 (C-4bpy), 135.33 (C-7), 135.00 (C-4′bpy),
129.08 (C-6), 128.31 (C-5), 126.79 (C-4), 126.49 (C-5bpy), 125.72
(C-5′bpy), 125.53 (C-11), 123.44 (C-3bpy, C-3′bpy), 115.10 (C-3), 102.92
(C-1′), 102.06 (C-1), 77.03 (C-5′), 76.61 (C-3′), 73.32 (C-2′), 70.02
(C-4′), 67.27 (C-2spacer), 61.13 (C-9), 61.05 (C-6′), 49.72 (C-1spacer)
ppm. HRMS (ESI): calcd. for C61H65N10O16Ru [M – Cl]
+ 1295.3618;
found 1295.3629 (error: 0.5 ppm). IR (KBr): ν˜ = 1425 (νCH), 768
y(δoop) cm
–1. UV/Vis (CH3OH): λ (ε × 10
–3) = 517 (9.85), 410 (31.4),
391 (34.7), 296 (46.7), 245 (27.1 M–1 cm–1) nm. FL (CH3OH, λex =
296 nm): λ = 586 nm.
Compound 5b: Compound 4b (26 mg, 32.7 µmol) was dissolved in
anhydrous DMF (5 mL) under Ar, and sodium methoxide solution
(0.5 M in MeOH, 75 µL, 37.5 µmol) was added dropwise. The solution
was stirred for 1 h, and [Ru(bpy)2Cl2] (18 mg, 37.2 µmol) in an-
hydrous DMF (4 mL) was slowly added. The mixture was heated to
reflux under Ar at 60 °C for 12 h. When TLC (NP silica; CH3CN/H2O/
satd. aq. KNO3, 40:4:1, v/v/v) indicated that no starting material had
remained, the solvent was evaporated. The crude product was dis-
solved in water, filtered and dialyzed for 1 week against water to
obtain the pure complex (28 mg, 22.5 µmol, 69 %). 1H NMR
(600 MHz, [D6]DMSO): δ = 8.89 (d,
3J = 5.79 Hz, 2 H, 3-Hbpy), 8.78
(d, 3J = 8.12 Hz, 2 H, 3′-Hbpy), 8.63 (d,
3J = 8.04 Hz, 2 H, 6-Hbpy), 8.15
(t, 3J = 7.81 Hz, 2 H, 4-Hbpy), 8.06–7.97 (m, 2 H, 11-H), 7.85 (t,
3J =
6.60 Hz, 2 H, 4′-Hbpy), 7.79 (t,
3J = 7.81 Hz, 4 H, 6′-Hbpy, 5-Hbpy),
7.63–7.58 (m, 6 H, 6-H, 3-H), 7.39 (m, 2 H, 5′-Hbpy), 7.21 (m, 4 H, 7-
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H), 6.76 (d, 3J = 8.63 Hz, 2 H, 4-H), 6.28–6.22 (m, 1 H, 1-H), 5.13–4.82
(m, 4 H, 9-H), 4.59–4.56 (m, 4 H, 1′-H, 1′′-H), 3.72 (d, 3J = 2.76 Hz, 2
H, 4′-H), 3.54–3.51 (m, 4 H, 6′-H, 6′′-H), 3.30–3.17 (m, 4 H, 3′-H, 5′-
H) ppm. 13C NMR (75 MHz, [D6]DMSO): δ = 176.03 (C-2), 159.95 (C-
8), 158.14 (C-2bpy), 157.75 (C-2′bpy), 153.10 (C-6′bpy), 149.51 (C-6bpy),
139.11 (C-10), 137.62 (C-4′bpy), 135.76 (C-4bpy), 134.11 (C-7), 130.62,
129.18 (C-6), 128.35 (C-5), 126.98 (C-4), 126.17 (C-11), 123.84 (C-
3bpy), 123.58 (C-3′bpy), 115.27 (C-3), 80.12 (C-2′), 74.36 (C-5′), 70.43
(C-4′), 69.69 (C-3′), 64.95 (C-6′, C-6′′), 64.22 (C-1′), 61.71 (C-1′′, C-
9) ppm. HRMS (ESI Orbitrap): calcd. for C57H57N10O16Ru [M – Cl]
+
1207.3110; found 1207.3112 (error: 1.7 ppm). FTIR (GA): ν˜ = 3360
(νOH), 3307 (νOH), 2920 (νCH), 2850 (νCH2), 1632 (νC=C) cm
–1. UV/Vis
(CH3OH): λ (ε × 10
–3) = 499 (3.96), 349 (4.89), 294 (29.78), 245
(12.89 M–1 cm–1) nm. FL (CH3OH, λex = 296 nm): λ = 536 nm.
Compound 5c: Compound 1 (45 mg, 0.15 mmol) was dissolved in
anhydrous methanol (30 mL) under Ar, and sodium methoxide solu-
tion (0.5 M in MeOH, 0.17 mmol, 350 µL) was added. The solution
was stirred for 1 h, and [Ru(bpy)2Cl2] (71 mg, 0.15 mmol) in an-
hydrous DMF (30 mL) was added dropwise. The mixture was heated
under Ar at 60 °C for 12 h. When TLC (NP silica; CH3CN/H2O/satd.
aq. KNO3, 40:4:1, v/v/v) indicated that no starting material had re-
mained, the solvent was evaporated. The crude product was dis-
solved in methanol, filtered and purified by size-exclusion chroma-
tography (Sephadex LH-20) to obtain the pure complex (41 mg,
0.05 mmol, 37 %). 1H NMR (600 MHz, [D6]DMSO): δ = 8.79 (d,
3J =
8.22 Hz, 2 H, 3-Hbpy), 8.69 (d,
3J = 8.22 Hz, 2 H, 3′-Hbpy), 8.64 (d,
3J =
5.04 Hz, 2 H, 6-Hbpy), 8.17 (m, 2 H, 4-Hbpy), 7.92 (m, 2 H, 4′-Hbpy),
7.78 (m, 4 H, 6′-Hbpy, 5-Hbpy), 7.32 (m, 6 H, 6-H, 5′-Hbpy), 6.93 (d,
3J =
15.72 Hz, 2 H, 3-H), 6.72 (d, 3J = 8.40 Hz, 2 H, 7-H), 6.52 (d, 3J =
15.78 Hz, 2 H, 4-H), 5.86 (s, 1 H, 1-H) ppm. 13C NMR (150 MHz,
[D6]DMSO): δ = 177.68 (C-2), 158.97 (C-2bpy), 158.80 (C-2′bpy), 157.40
(C-8), 152.81 (C-6′bpy), 149.40 (C-6bpy), 136.55 (C-4bpy), 135.92 (C-3),
134.92 (C-4′bpy), 129.21 (C-6), 126.45 (C-5), 126.25 (C-5bpy), 125.70
(C-5′bpy), 125.47 (C-4), 123.43 (C-3bpy, C-3′bpy), 115.84 (C-7), 101.75
(C-1) ppm. HRMS (ESI): calcd. for C39H31N4O4Ru [M – Cl]
+ 721.1405;
found 721.1383 (error: 1.5 ppm). UV/Vis (CH3OH): λ (ε × 10
–3) =
516.5 (14.55), 412.5 (48.1), 395 (49.9), 296 (58.35), 245 (34.8 M–1 cm–1)
nm. FL (CH3OH, λex = 296 nm): λ = 585 nm.
Determination of Cytotoxicity: Cytotoxicity studies were per-
formed with the mouse fibroblast cell line L929, as well as with
HepG2 and MDA-MB-231 cells. In detail, cells were seeded at 104
cells per well in a 96-well plate and incubated for 24 h. Afterwards,
the test substances (2, 4a, 4b, 5a–c) at indicated concentrations
(25, 50, 100 µM) were added to the cells, and the plates were incu-
bated for a further 24 h. Subsequently, the medium was replaced
with a mixture of fresh culture medium and alamarBlue solution
(Thermo Fisher), prepared according to the manufacturer's instruc-
tions. After a further incubation of 4 h at 37 °C, the fluorescence
was measured at λem = 570 nm/λem = 610 nm, with untreated cells
on the same well plate serving as negative controls. The negative
control was standardized as 0 % of metabolism inhibition and re-
ferred to as 100 % viability. Data are expressed as mean ± SD of
three independent determinations.
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Figure S1. 19F-NMR spectrum of 1 in DMSO-d6. 
10 8 6 4 2 0
-2000
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
δ [ppm]
int
en
sity
 
Figure S2. 1H-NMR spectrum of 1 in DMSO-d6. 
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Figure S3. 13C-NMR spectrum of 1 in DMSO-d6. 
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Figure S4. ESI-TOF-MS of 1 in acetonitrile. 
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Figure S5. IR spectrum of 1.  
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Figure S6. UV-Vis spectrum of 1 (2 x 10-5 M, aerated CH3OH). 
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Figure S7. Emission spectrum of 1 (λex = 477 nm, 2 x 10-6 M, aerated CH3OH).  
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 Figure S8. 1H-NMR spectrum of 3a in DMSO-d6.  
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Figure S9. 13C-NMR spectrum of 3a in DMSO-d6. 
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Figure S10. ESI-TOF-MS of 3a in acetonitrile.  
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Figure S11. IR spectrum of 3a. 
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Figure S12. UV-Vis spectrum of 3a (2 x 10-5 M, aerated CH3OH).  
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Figure S13. Emission spectrum of 3a (λex = 410 nm, 2 x 10-6 M, aerated CH3OH). 
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Figure S14. 1H-NMR spectrum of 3b in DMSO-d6. 
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Figure S15. 13C-NMR spectrum of 3b in DMSO-d6.  
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Figure S16. ESI-TOF-MS of 3b in acetonitrile. 
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Figure S17. IR spectrum of 3b.  
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Figure S18. UV-Vis spectrum of 3b (2 x 10-5 M, aerated CH3OH). 
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Figure S19. Emission spectrum of 3b (λex = 410 nm, 2 x 10-6 M, aerated CH3OH). 
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 Figure S20. 1H-NMR spectrum of 4a in DMSO-d6.  
200 180 160 140 120 100 80 60 40 20 0
-5000000
0
5000000
10000000
15000000
20000000
25000000
30000000
35000000
40000000
δ [ppm]
int
en
sity
 
Figure S21. 13C-NMR spectrum of 4a in DMSO-d6. 
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Figure S22. ESI-TOF-MS of 4a in acetonitrile.   
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Figure S23. IR spectrum of 4a. 
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Figure S24. UV-Vis spectrum of 4a (2 x 10-5 M, aerated CH3OH).  
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Figure S25. Emission spectrum of 4a (λex = 408 nm, 2 x 10-6 M, aerated CH3OH). 
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Figure S26. 1H-NMR spectrum of 4b in DMSO-d6. 
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Figure S27. 13C-NMR spectrum of 4b in DMSO-d6.   
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Figure S28. ESI-TOF-MS of 4b in acetonitrile. 
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Figure S29. IR spectrum of 4b.   
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Figure S30. UV-Vis spectrum of 4b (2 x 10-5 M, aerated CH3OH). 
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Figure S31. Emission spectrum of 4b (λex = 408 nm, 2 x 10-6 M, aerated CH3OH). 
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Figure S32. 1H-NMR spectrum of 5a in DMSO-d6.
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Figure S33. 13C-NMR spectrum of 5a in DMSO-d6. 
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Figure S34. ESI-TOF-MS of 5a in acetonitrile.   
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Figure S35. IR spectrum of 5a. 
200 300 400 500 600
0
10
20
30
40
50
λ = 517 nm
λ = 410 nm
λ = 391 nm
λ = 245 nm
λmax = 296 nm
λ [nm]
ε *
 10
-3  (
M-1
 * c
m-1
)
 
Figure S36. UV-Vis spectrum of 5a (2 x 10-5 M, aerated CH3OH).  
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Figure S37. Emission spectrum of 5a (λex = 296 nm, 2 x 10-6 M, aerated CH3OH). 
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Figure S38. 1H-NMR spectrum of 5b in DMSO-d6. 
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Figure S39. 13C-NMR spectrum of 5b in DMSO-d6.
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Figure S40. ESI-Orbitrap-MS of 5b with various fragments F1-F6. 
 
Figure S41. Schematic representation of fragments F1-F6 resulting from the parent ion of 5b. 
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Figure S42. IR spectrum of 5b. 
250 300 350 400 450 500 550 600
-5
0
5
10
15
20
25
30
35
40
λ = 499 nmλ = 349 nm
ε *
 10
-3  (
M-1
 * c
m-1
)
λ [nm]
λ = 245 nm
λmax = 294 nm
 
Figure S43. UV-Vis spectrum of 5b (1 x 10-4 M, aerated CH3OH). 
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Figure S44. Emission spectrum of 5b (λex = 296 nm, 10-6 M, aerated CH3OH). 
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Figure S45. 1H-NMR spectrum of 5c in DMSO-d6. 
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Figure S46. 13C-NMR spectrum of 5c in DMSO-d6. 
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Figure S47. ESI-TOF-MS of 5c in acetonitrile. 
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Figure S48. IR spectrum of 5c. 
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Figure S49. UV-Vis spectrum of 5c (2 x 10-5 M, aerated CH3OH). 
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Figure S50. Emission spectrum of 5c (λex = 296 nm, 10-6 M, aerated CH3OH). 
 
Determination of cytotoxicity 
To determine the cytotoxic potential of the corresponding complexes on different cell types, the 
inhibitory effect on the cellular metabolic activity was investigated via a resazurin based assay 
(alamarBlue, Thermo Fisher). For this purpose, the non-cancer cell line L929, the liver cancer 
cell line HepG2 as well as the breast cancer cell line MDA-MB-231 were used. 
Control: L929 
 
Figure S51. Relative viability of L929 cells (mouse fibroblasts) after 24 h incubation with the complexes at indicated 
concentrations. Values represent the mean ± S.D. (n=3). 
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Figure S52. Relative viability of HepG2 cells after 24 h incubation with the complexes at indicated concentrations. 
Values represent the mean ± S.D. (n=3). 
Breast cancer: MDA-MB-231 
 
Figure S53. Relative viability of MDA-MB-231 after 24 h incubation with the complexes at indicated concentrations. 
Values represent the mean ± S.D. (n=3). 
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Table S1. Absorption spectra, absorption coefficients and emission spectra of all compounds 
Abrev Absorption wavelength λ / nm 
Absorption coefficient 
ε x 10-3 / M-1 cm-1 
Emission wavelength λ / nm  
(irradiation wavelength λex / nm) 
1 477; 458; 254 50.55; 48.10; 11.80 541 (477) 
3a 410; 243 39.25; 13.55 509 (410) 
3b 410; 243 37.00; 11.95 508 (410) 
4a 408; 243 18.45; 13.55 509 (408) 
4b 409; 286 8.75; 4.10 510 (408) 
5a 517; 410; 391; 296; 245 9.85; 31.40; 34.70; 46.70; 27.10 586 (296) 
5b 499; 349; 294; 245 3.96; 4.89; 29.78; 12.89 536 (296) 
5c 516.5; 412.5 395; 296; 245 14.55; 48.10; 49.90; 58.35; 34.80 585 (296) 
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grades and types.[2] The number of specific targets is high, 
in which 60%–80% of all cases are hormone receptors of 
the human epidermal growth factor receptor (HER) family 
that can be targeted by endocrine therapy.[3] By lacking 
progesterone and estrogene receptor overexpression as 
well as amplification of HER2 genes at the same time, a 
tumor type with a shorter median time from relapse to 
death was identified in 1987 and is nowadays treated 
with Trastuzumab, a monoclonal antibody.[4] Triple-
negative tumors are described by the lack of hormone 
receptor expression as well as HER2 receptors, an aggres-
sive type with insufficient therapy options and poor prog-
nosis, which represents roughly 15% of all breast cancer 
tumors.[3] Besides the treatment with the monoclonal 
antibody Bevacizumab, that blocks angiogenesis by inhib-
iting vascular endothelial growth factor A, there are more 
than 50 clinical trials ongoing, which address various tar-
gets such as the epidermal growth factor,[5] Src tyrosine 
kinase,[6] and heat shock protein 90 to develop strategies 
against this aggressive kind of breast cancer.[7]
Another target, which is controversially discussed in 
the present literature, is the GLUT5 transporter, a highly 
affine D-fructose transporter.[8] While Gowrishankar 
The high affinity of GLUT5 transporter for D-fructose in breast cancer cells has been discussed 
intensely. In this contribution, high molar mass linear poly(ethylene imine) (LPEI) is function-
alized with D-fructose moieties to combine the selectivity for the GLUT5 transporter with the 
delivery potential of PEI for genetic material. The four-step synthesis of a thiol-group bearing 
D-fructose enables the decoration of a cationic polymer backbone with D-fructose via thiol-ene 
photoaddition. The functionalization of LPEI is confirmed by 2D NMR techniques, elemental 
analysis, and size exclusion chromatography. Importantly, a D-fructose decoration of 16% ren-
ders the polymers water-soluble and eliminates the cytotox-
icity of PEI in noncancer L929 cells, accompanied by a reduced 
unspecific cellular uptake of the genetic material. In contrast, 
the cytotoxicity as well as the cell specific uptake is increased 
for triple negative MDA-MB-231 breast cancer cells. Therefore, 
the introduction of D-fructose shows superior potential for 
cell targeting, which can be assumed to be GLUT5 dependent.
D-Fructose-Decorated Poly(ethylene imine) for 
Human Breast Cancer Cell Targeting
Christoph Englert, Michael Pröhl, Justyna A. Czaplewska, Carolin Fritzsche, 
Elisabeth Preußger, Ulrich S. Schubert, Anja Traeger, Michael Gottschaldt*
C. Englert, M. Pröhl, Dr. J. A. Czaplewska, C. Fritzsche,  
E. Preußger, Prof. U. S. Schubert, Dr. A. Traeger,  
Dr. M. Gottschaldt
Laboratory of Organic and Macromolecular Chemistry (IOMC)
Friedrich Schiller University Jena
Humboldtstrasse 10, 07743 Jena, Germany
E-mail: michael.gottschaldt@uni-jena.de
C. Englert, M. Pröhl, Dr. J. A. Czaplewska, C. Fritzsche,  
E. Preußger, Prof. U. S. Schubert, Dr. A. Traeger,  
Dr. M. Gottschaldt
Jena Center for Soft Matter (JCSM)
Friedrich Schiller University Jena
Philosophenweg 7, 07743 Jena, Germany
1. Introduction
With around 1.65 million new cases of cancer and around 
590 thousand deaths resulted from cancer in 2015 in the 
United States, human breast cancer represents the second 
leading death cause after heart diseases. Among them, 
230 thousand new cases derive from breast cancer from 
which around 41 thousand ended deadly.[1] It is described 
as a highly heterogeneous type of cancer with manifold 
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et al. declined the overexpression of GLUT5 in all breast 
cancer tissues,[9] Nualart and co-workers claimed GLUT5 
as overexpressed in 85% of 33 tested breast cancer cell 
lines,[10] also confirmed for estrogen-receptor posi-
tive MCF-7 and triple-negative MDA-MB-231 breast 
cancer cell lines.[11] Nevertheless, that implies a possible 
enhanced selectivity of anticancer agents by the attach-
ment of D-fructose and its derivatives. Previous studies 
revealed that modifications at C1- and C6-position of the 
sugar are tolerated by the GLUT5 transporter.[12] For this 
reason, D-fructose was successfully attached to dyes,[13] 
metal complexes,[14] polymers,[15] and nanoparticles[16] 
and tested with various breast cancer cell lines, revealing 
an increased uptake for the D-fructose conjugated com-
pounds and structures.
Nowadays, one opportunity of cancer treatment is the 
manipulation of the pathways in tumors on the level 
of the cellular genetic information, e.g., by the intro-
duction of genetic material. This promising anticancer 
approach has gained increasing interest over the last 
decade and various potential carriers have been inves-
tigated.[15] Since viral vectors possess considerable cyto-
toxicities and immunological concerns, nonviral vectors 
like cationic cell penetrating peptides,[17] antibodies[18] 
and lipid-based carriers[19] have been intensively investi-
gated. Cationic polymers, e.g., poly(ethylene imine) (PEI), 
represent another class of suitable candidates to com-
plex genetic material by electrostatic interactions.[20] Due 
to its superior buffering ability leading to endosomal 
escape (“proton sponge effect”), PEI is known as the gold 
standard of polymeric carriers for gene delivery.[21] How-
ever, its full potential is restricted through its high cyto-
toxicity and non-biodegradability.[22] One useful strategy 
to overcome these limitations is the modification of the 
PEI backbone[23] and/or the introduction of side chains. 
The latter approach has been extensively studied, e.g., by 
functionalization of PEI with various carbohydrates[24] or 
stealth polymers, like poly(ethylene glycol).[25]
Herein, we focused on the installation of D-fructose 
moieties at side chains of high molar mass linear PEI to 
combine the selectivity for the GLUT5 transporter and 
the delivery potential of genetic material. To remain a 
defined quantity of cationic ethylene imine units, a post-
polymerization functionalization using N-succinimidyl-
4-pentenate was chosen. This enables the synthesis of 
glycopolymer structures[26] by the reaction with thiol 
sugars utilizing the metal-free thiol-ene photoaddition. 
The designed copolymer and respective precursors were 
investigated concerning their bio- and hemocompat-
ibility, their affinity for binding and release of genetic 
material (exemplified for plasmid DNA) and their specific 
cellular uptake (MDA-MB231 breast cancer vs. noncancer 
L929 and primary human umbilical vein endothelial cells, 
HUVEC).
2. Experimental Section
2.1. Materials
2-Ethyl-2-oxazoline (EtOx) and methyl tosylate were obtained 
from Acros Organics, distilled (over barium oxide (BaO) in the case 
of EtOx), and stored under argon atmosphere. Pyridine, meth-
anol, dichloromethane, 4-N,N-dimethylamino-pyridine (DMAP), 
2,2-dimethoxy-2-phenylacetophenone (DMPA) and rhodamine B 
isothiocyanate were obtained from Sigma-Aldrich (Steinhausen, 
Germany) and are of analytical grade and are used without fur-
ther purification. Acetonitrile was purified on a MBraun solvent 
purification system (MB SPS-800). N-Succinimidyl-4-pentenate 
was prepared according to literature procedures.[27] Ethidium 
bromide solution (1%, 10 mg mL−1) was purchased from Carl 
Roth (Karlsruhe, Germany). AlamarBlue, YOYO-1 iodide, Hoechst 
33342 trihydrochloride, heparin and Cy5 dye were obtained from 
Thermo Fisher (Germany). Plasmid pEGFP-N1 (4.7 kb, Clontech, 
USA encoding green fluorescent protein (EGFP) was isolated with 
the Giga Plasmid Kit provided by Qiagen (Hilden, Germany). If 
not stated otherwise, cell culture materials, cell culture media 
and solutions were obtained from Biochrom (Berlin, Germany).
2.2. General Methods and Instrumentation
The polymerizations as well as the hydrolysis of poly(2-ethyl-
2-oxazoline) were performed under microwave irradiation in an 
Initiator Sixty single-mode microwave synthesizer from Biotage, 
equipped with a noninvasive IR sensor (accuracy 2%). Chroma-
tographic separations were performed using normal phase (NP) 
silica RediSep Cartridges by Teledyne Isco. The reaction progress 
was monitored by thin-layer chromatography (TLC) using glass 
plates precoated with silica gel 60 (Merck).
Proton (1H) nuclear magnetic resonance (NMR) spectra were 
recorded at room temperature using spectrometers from Bruker 
(300, 600 MHz). 13C NMR was recorded at 100 MHz. Chemical 
shifts (δ) are expressed in parts per million relative to tetra-
methylsilane (TMS).
Size exclusion chromatographic (SEC) investigations were per-
formed on an Agilent Technologies 1200 Series gel permeation 
chromatography system equipped with a G1329A auto sampler, 
a G131A isocratic pump, a G1362A refractive index detector, and 
both a PSS Gram 30 and a PSS Gram 1000 column placed in series. 
As eluent a 0.21% LiCl solution in N,N-dimethylacetamide (DMAc) 
was used at 1 mL min−1 flow rate and a column oven tempera-
ture of 40 °C. Molar masses were calculated using poly(styrene) 
standards. High-resolution electron spray ionization mass spec-
trometry (HR-ESI-MS) was measured with a Bruker MicroQTof 
and elemental analysis were measured with a Leco CHN-932.
2.2.1. Synthesis of 1-(2-(Benzyloxy)ethyl)-
2,3:4,5-di-O-isopropylidene-β-D-fructopyranoside (2)
6.5 g (25 mmol) of 2,3:4,5-di-O-isopropylidene-β-D-fructopy ranoside 
1 was dissolved in 150 mL of dry THF, 4 g NaH (166.7 mmol) 
were added and the mixture stirred for 20 min under nitrogen. Sub-
sequently, benzyl 2-bromoethyl ether (10 g, 43.6 mmol) was added 
dropwise and reaction was conducted for 7 d (controlled during 
this time with TLC). After no starting material had remained (TLC, 
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SiO2, EtOAc/cyclohexane, v/v, 1:2), 50 mL of methanol were slowly 
added and the reaction mixture was evaporated. The crude product 
was dissolved in 200 mL of ethyl acetate and washed twice with 
each 200 mL of saturated NaHCO3 solution and once with 200 mL 
of water. The organic phase was dried with Na2SO4 and the solvent 
was removed. The product 2 was purified by column chromatog-
raphy (SiO2, EtOAc/cyclohexane, v/v, 1:2) and collected as light 
yellow oil. Yield: 8.69 g (70%).
1H-NMR (300 MHz, CDCl3, δ): 7.39–7.24 (m, 5H, Bn), 4.62–
4.58 (dd, J = 7.92 Hz, 2.61 Hz, 1H, H-4), 4.56 (s, 2H, Bn-CH2), 4.44 
(d, J = 2.6 Hz, 1H, H-3), 3.92 (dd, J = 7.9 Hz, 1.1 Hz, 1H, H-5), 3.81 
(dd, J = 13 Hz, J = 1.85 Hz, 1H, H-6), 3.77–3.68 (m, 3H, H-1, H-1′, 
H-6′), 3.67–3.58 (m, 4H, CH2), 1.54, 1.47, 1.43, 1.35 (4s, 12H, CH3); 
13C-NMR (CDCl3, 75 MHz, δ): 138.26 (Bn-Cq), 128.33, 127.66, 127.56 
(Bn), 108.90 (isopropylidene-Cq), 108.54 (isopropylidene-Cq), 
102.72 (C2), 73.23 (Bn-CH2), 72.47 (CH2), 71.38 (C1), 71.03 (C5), 
70.22 (C4), 69.99 (C3), 69.37 (CH2), 61.01 (C6), 26.56, 25.87, 25.29, 
24.03 (CH3). MS (ESI) m/z: [M+Na]
+ calcd for C21H30O7Na, 417.19; 
found, 417.18; [M+K]+ calcd for C21H30O7K, 433.16; found, 433.16. 
Anal. calcd. for C21H30O7: C 63.94, H 7.67; found: C 63.90, H 7.69.
2.2.2. Synthesis of 1-(2-(Hydroxyl)ethyl)-2,3:4,5-di-O-
isopropylidene-β-D-fructopyranoside (3)
8.38 g (21.2 mmol) of 2 were dissolved in 300 mL of methanol and 
0.23 g of palladium on charcoal (3 wt%) were added to the reac-
tion mixture. The reaction flask was evacuated and refilled with 
hydrogen several times. After stirring for 48 h, the catalyst was 
filtered off and the solvent was evaporated to obtain the product 
as colorless oil. Yield: 6.03 g (95%).
1H-NMR (300 MHz, CDCl3, δ): 4.62–4.56 (dd, J = 8.0 Hz, 2.5 Hz, 
1H, H-4), 4.35 (d, J = 2.5 Hz, 1H, H-3), 4.26–4.21 (dd, J = 8.0 Hz, 
1.1 Hz, 1H, H-5), 3.90 (dd, J = 13.0 Hz, J = 1.8 Hz, 1H, H-6), 
3.80–3.56 (m, 5H, H-6, H-1, H-1′, CH2), 2.18 (s, 1H, OH), 1.53, 1.49, 
1.41, 1.34 (4s, 12H, CH3); 
13C-NMR (CDCl3, 75 MHz, δ): 108.98 
(Cq), 108.44 (Cq), 102.59 (C2), 73.26 (CH2), 72.20 (C1), 70.76 (C5), 
70.69 (C3), 70.14 (C4), 61.49 (CH2), 60.97 (C6), 26.44, 25.70, 25.18, 
23.89 (CH3). MS (ESI) m/z: [M+Na]
+ calcd for C14H24O7Na, 327.14; 
found, 327.14; [M+K]+ calcd for C14H24O7K, 343.12; found, 343.12; 
[2M+Na]+ calcd for C28H48O14Na, 631.29; found, 631.29. Anal. 
calcd. for C14H24O7: C 55.25, H 7.95; found: C 55.24, H 8.14.
2.2.3. Synthesis of 1-(2-(Methanesulfonyl)ethyl)-2,3:4,5-di-
O-isopropylidene-β-D-fructopyranoside (4)
5 g (16.4 mmol) of 3 were dissolved in 30 mL of CH2Cl2 and 
6.825 mL (49.24 mmol) of Et3N and 20 mg 4-DMAP (0.16 mmol) 
were added. The reaction mixture was cooled to 0 °C and 3 mL 
(38.8 mmol) of mesyl chloride were added dropwise to the solu-
tion.[28] The reaction mixture was left to slowly warm to room 
temperature and stirred for 2 h. After no starting material had 
remained (TLC, SiO2, EtOAc/cyclohexane, v/v, 2:1), 50 mL CH2Cl2 
were added and the mixture was washed thrice with each 
200 mL of water and twice with each 200 mL of saturated, aqueous 
NaHCO3 solution. The organic layer was dried over Na2SO4 and the 
solvent was removed. The crude product was dissolved in 10 mL of 
ethyl acetate, filtered over silica gel and collected as yellowish oil.
Yield: 5.78 g (92%). 1H-NMR (CDCl3, 300 MHz, δ): 4.63–4.58 
(dd, J = 7.9 Hz, 2.6 Hz, 1H, H-4), 4.40–4.33 (m, 3H, H-3, CH2), 
4.26–4.21 (dd, J = 7.9 Hz, 0.9 Hz, 1H, H-5), 3.94–3.64 (m, 6H, H-1, 
H-1′, H-6, H-6′, CH2), 3.05 (s, 3H, SCH3), 1.54, 1.47, 1.42, 1.34 
(4s, 12H, CH3); 
13C-NMR (CDCl3, 75 MHz, δ): 108.95 (Cq), 108.68 
(Cq), 102.38 (C2), 72.84 (CH2), 70.91 (C5), 70.11 (C4, C3), 69.70 (C1), 
68.61 (CH2), 61.06 (C6), 37.34 (SCH3), 29.33 (CH2), 26.52, 25.88, 
25.33, 24.00 (CH3). MS (ESI) m/z: [M+Na]
+ calcd for C15H26O9SNa, 
405.12; found, 405.12. Anal. calcd. for C15H26O9S: C 47.11, H 6.85, 
S 8.38; found: C 47.22, H 6.96, S 8.25.
2.2.4. Synthesis of 1-O-(2-Mercapto-ethyl)-2,3:4,5-di-O-
isopropylidene-β-D-fructopyranoside (5)
1.311 g (3.43 mmol) of 4 was dissolved in 15 mL 2-butanone, 
0.78 g (10.25 mmol) thiourea was added, and the mixture was 
heated to 95 °C under reflux for 7 h.[29] After no starting mate-
rial had remained (TLC, SiO2, EtOAc/cyclohexane, v/v, 2:1), the 
solvent was evaporated, 15 mL CH2Cl2, 15 mL H2O and 0.874 g 
K2S2O5 (3.93 mmol) were added and the mixture was heated to 
reflux for 12 h. The organic layer was washed thrice with each 
200 mL of water, dried with anhydrous Na2SO4, filtered, and 
evaporated to effort after column chromatography (SiO2, EtOAc/
cyclohexane, v/v, 1:1) the pure product.
Yield: 0.842 g (76.7%). 1H-NMR (600 MHz, CDCl3, δ): 4.61 
(dd, J = 7.92 Hz, 2.58 Hz, 1H, H-4), 4.39 (d, J = 2.58 Hz, 1H, H-3), 4.23 
(dd, J = 7.92 Hz, 1.32 Hz, 1H, H-5), 3.90 (dd, J = 12.99 Hz, 3J = 1.83 Hz, 
1H, H-6) 3.74–3.70 (m, 2H, H-6′, H-1), 3.65–3.56 (m, 3H, H-1′, 
CH2), 2.71–2.68 (m, 2H, CH2), 1.59 (t, J = 8.25 Hz, 1H, SH), 1.53–1.34 
(4s, 12H, CH3); 
13C-NMR (150 MHz, CDCl3, δ): 109.07 (Cq), 108.71 
(Cq), 102.64 (C2), 73.62 (CH2),72.36 (C1), 71.11 (C5), 70.30 (C4), 
70.23 (C3), 61.16 (C6), 26.69, 26.02, 25.52, 24.27 (CH3), 24.14 (CH2). 
HRMS (ESI) m/z: [M+Na]+ calcd for C14H24O6SNa, 343.1186; found, 
343.1200. Anal. calcd. for C14H24O6S: C 52.48, H 7.55, S 10.01; 
found: C 52.77, H 7.64, S 10.39.
2.2.5. Synthesis of Linear Poly(ethylene imine) (P1)
Poly(2-ethyl-2-oxazoline) (PEtOx) used as starting material in this 
study was synthesized according to literature procedures.[30] The 
monomer 2-ethyl-2-oxazoline (3.965 g) and the initiator methyl 
tosylate (12.42 mg, 0.067 mmol) were dissolved in dry acetoni-
trile (6.0 mL) under inert conditions in a glovebox. After stirring 
for a few minutes the microwave vial was heated in a microwave 
synthesizer for 128 min at 140 °C. The polymerization mixture 
was diluted with 5 mL dichloromethane and precipitated in 
250 mL ice-cold diethyl ether. Subsequently, the precipitate was 
filtered off and lyophilized (yield: 3.720 g, 94%).
Accordingly, PEtOx (degree of polymerization (DP) = 575, 
2.7 g) was treated with an excess of 6 M aqueous hydrochloric 
acid (250 mL) at 100 °C for 16 h under reflux.[31] The excess of 
hydrochloric acid and the resulting propionic acid were removed 
under reduced pressure. The residue was dissolved in water fol-
lowed by the addition of 3 M NaOH to reach pH = 8. Precipitation 
occurred and the precipitated, hydrolyzed linear poly(ethylene 
imine) was filtered off. The residue was redissolved in 10 mL 
of N,N-dimethylformamide and precipitated two times into 
300 mL ice-cold diethyl ether. The obtained product was dried 
in vacuo at 85 °C. The degree of hydrolysis of the resulting linear 
poly(ethylene imine) P1 was determined by 1H NMR spectroscopy 
(yield: 1.0 g, 85%).
Macromol. Biosci. 2017,  DOI: 10.1002/mabi.201600502
C. Englert et al.
Macromolecular
Bioscience
www.mbs-journal.de
© 2017  WILEY-VCH Verlag GmbH &  Co.  KGaA, Weinheim www.advancedsciencenews.com
1600502 (4 of 16)
PEtOx: DP = 575. 1H NMR (300 MHz, D2O, δ): 3.70–3.20 
(NRCH2CH2), 2.41–2.08 (CH2CH3), 1.09–0.79 (CH2CH3). SEC 
(DMAc, LiCl): Mn = 69 000 g mol
−1, Ð = 1.3.
P1: EtOx:EI [%] = 2:98. 1H NMR (300 MHz, MeOD, δ): 3.58–3.41 
(NRCH2CH2), 2.91–2.61 (NHCH2CH2), 2.56–2.36 (CH2CH3), 
1.18–1.06 (CH2CH3).
2.2.6. Synthesis of P(EI-stat-ButEnOx) (P2)
P1 (500 mg) and the catalyst 4-N,N-dimethylamino-pyridine 
(DMAP, 50 mg, 0.41 mmol) were dissolved in pyridine (5 mL) 
at 80 °C. A defined quantity of N-succinimidyl-4-pentenate 
(465 mg) was dissolved in pyridine (5 mL) and heated up to 
80 °C. The two solutions were combined and 2 mL pyridine 
added to obtain a 3 wt% mixture of P1 and stirred for 16 h at 
80 °C. Afterward, the mixture was filtered and precipitated into 
300 mL ice-cold diethyl ether (Et2O). The precipitated copoly mer 
was filtered off and washed with 30 mL of diethyl ether. 
The purified product P2 was dried under reduced pressure 
(yield: 860 mg, 89%).
EI:ButEnOx [%] = 73:27. 1H NMR (600 MHz, DMSO-d6, δ): 5.89–
5.74 (HCCH2), 5.06–4.91 (HCCH2), 3.58–3.20 (NRCHCH2), 
2.80–2.45 (NHCH2CH2), 2.44–2.34 (CH2CH2C2H3), 2.27–
2.16 (CH2CH2C2H3). SEC (DMAc, LiCl, polystyrene): Mn = 
8000 g mol−1, Ð = 1.3. Anal. calcd. for C1927H3811N575O155: C 61.69, 
H 10.24, N 21.47; found: C 60.90, H 10.43, N 22.91.
2.2.7. Synthesis of P(EI-stat-ButEnOx-stat-isoFruButOx) 
via Thiol-Ene Photoaddition (isoP3)
P2 (558 mg) was dissolved in 5 mL methanol. In a second vial, the 
photoinitiator DMPA (6.5 mg, 0.025 mmol) and a 1.2-fold excess 
per double bond of 5 (840 mg) were dissolved in methanol (5 mL). 
The combined solution (5 wt% of P2) was deoxygenated with 
argon for 20 min and stirred in a UV chamber (λ = 365 nm) for 
18 h. Subsequently, the copolymer was precipitated two times in 
300 mL ice-cold diethyl ether. After filtration, the copolymer was 
dried under reduced pressure at 40 °C (yield: 980 mg, 70%).
EI:ButEnOx:isoFruButOx [%] = 73:11:16. 1H NMR (600 MHz, 
DMSO-d6, δ): 5.90–5.74 (HCCH2), 5.07–4.88 (HCCH2), 4.57 
(H-4), 4.27 (H-3), 4.22 (H-5), 3.73 (H-6), 3.66 (CH2), 3.55 (H-6, 
CH2), 3.48 (H-1), 3.43 (H-1), 3.40–3.12 (NRCH2CH2), 2.78–2.46 
(NHCH2CH2), 2.42–2.16 (CH2CH2C2H3), 1.53 (CH2CH2C
H2CH2), 1.47–1.26 (isopropylidene). SEC (DMAc, LiCl): Mn = 11 
600 g mol−1, Ð = 1.9. Anal. calcd. for C3123H5835N575O707S92: C 57.09, 
H 8.95, N 12.26, S 4.49; found: C 57.39, H 9.23, N 13.35, S 4.18.
2.2.8. Synthesis of P(EI-stat-ButEnOx-stat-FruButOx) via 
Deprotection (P3)
The cleavage of the isopropylidene groups was performed under 
acidic conditions.[32] The copolymer isoP3 (685 mg) was dis-
solved in a THF/H2O mixture (22.5/22.5 mL) and acidified with 
2 M hydrochloric acid (6.75 mL). The solution was heated to 
40 °C for 12 h. Subsequently, the mixture was neutralized with 
1.2 g NaHCO3 and THF as well as formed acetone were evapo-
rated under reduced pressure. Purification of the deprotected 
D-fructose conjugate was performed by dialysis against water 
using a Spectra/Por 3 dialysis membrane (3500 g mol−1 cutoff). 
Finally, the product was lyophilized and obtained as a yellowish 
powder (yield: 324 mg, 53%). EI:ButEnOx:FruButOx [%] = 73:11:16. 
SEC (DMAc, LiCl): Mn = 9800 g mol
−1, Ð = 1.2. Anal. calcd. for C2571
H5099N575O707S92: C 52.94, H 8.81, N 13.81, S 5.06; found: C 53.60, 
H 9.13, N 14.91, S 4.66.
2.3. Polymer Labeling with Cy5 (P1-Cy5)
P1 (40 mg) and triethylamine (360 µL) were dissolved in meth-
anol (10 mL). After addition of the cyanine-5-NHS-ester (1 mg) 
the reaction was stirred at room temperature overnight. The 
labeled polymer was precipitated in 250 mL ice-cold diethyl 
ether, filtered, and redissolved in methanol (15 mL). Further puri-
fication was performed by dialysis against a mixture of water/
methanol using a Spectra/Por 3 dialysis membrane (3500 g mol−1 
cutoff). Finally, the product was dried under reduced pressure 
(yield: 15 mg, 37%; labeling efficiency: 2.0% of dye).
2.4. Copolymer Labeling with Rhodamine  
(P2-Rho, P3-Rho)
The copolymer (P2: 35 mg, P3: 40 mg) and triethylamine (200 µL) 
were dissolved in DMF (4 mL). After addition of Rhodamine B 
isothiocyanate (0.7 mg) the reaction was stirred at room tem-
perature for 18 h. Purification was performed by dialysis against 
water using a Spectra/Por 3 dialysis membrane (3500 g mol−1 
and subsequently 6–8000 g mol−1 cutoff). Finally, the product 
was lyophilized and obtained as a reddish powder. The calcu-
lated labeling efficiency (via UV–vis spectroscopy) for conjuga-
tion was 1.4% of dye for the P2-Rho (yield: 23 mg, 66%) and 30.4% 
of dye for the labeled P3 (yield: 26 mg, 65%). To achieve compa-
rable fluorescence intensities, the labeled P3 was mixed with the 
unlabeled P3 (1:19) to obtain P3-Rho (new label efficiency: 1.5% 
of dye).
2.5. Polyplex Preparation
Polyplexes of plasmid desoxyribonucleic acid (pDNA) and 
selected polymers were prepared by mixing stock solutions of 
15 µg mL−1 pDNA and the respective polymers (1 mg mL−1) in dif-
ferent amounts to obtain various N/P ratios (nitrogen of polymer 
to phosphate of pDNA) in HBG (HEPES buffered glucose)  buffer 
(20 × 10−3 M 4-(2-hydroxethyl) piperazine-1-ethanesulfonic acid 
and 5% (w/v) glucose, pH 7.2). The solutions were vortexed for 
10 s at maximal speed and incubated at room temperature for 
20 min to ensure a complex formation.
2.6. Determination of Cytotoxicity
Cytotoxicity studies were performed with the mouse fibroblast 
cell line L929 (CCL-1, ATCC), as recommended by ISO10993-5. Fur-
thermore, the breast cancer cell line MDA-MB-231 and the HUVEC 
cells were used. The cells were routinely cultured in Dulbecco’s 
modified eagle’s medium (Lonza, Basel) supplemented with 10% 
fetal calf serum (FCS), 100 U mL−1 penicillin, and 100 µg mL−1 
streptomycin at 37 °C in a humidified 5% (v/v) CO2 atmosphere. 
HUVEC cells were cultured in M199 Medium (Lonza, Basel) sup-
plemented with 17.5% FCS, 680 × 10−6 M L-glutamin, 25 µg mL−1  
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heparin, 7.5 g mL−1 endothelial mitogenic, Vitamin C (5 µg mL−1), 
human serum and 100 U mL−1 penicillin, and 100 µg mL−1 strep-
tomycin at 37 °C in a humidified 5% (v/v) CO2 atmosphere. In 
detail, cells were seeded at 1 × 104 cells per well in a 96-well 
plate and incubated for 24 h, whereas no cells were seeded in 
the outer wells. Subsequently, P1, P2, and P3 were added to the 
cells in fresh media at indicated concentrations and the plates 
were incubated for 24 h. Control cells were incubated only with 
fresh culture medium. Subsequently, media was replaced by a 
mixture of fresh culture medium and AlamarBlue solution, pre-
pared according to the manufacturer’s instructions. After a fur-
ther incubation of 4 h at 37 °C, the fluorescence was measured 
at Ex 570/Em 610 nm, with untreated cells on the same well plate 
serving as negative controls. The negative control was set as 0% 
of metabolism inhibition and referred as 100% viability. Cell via-
bility below 70% was considered indicative of cytotoxicity. Data 
are expressed as mean ± standard deviation (SD) of three inde-
pendent determinations of six data points each.
2.7. Hemocompatibility and Erythrocyte Aggregation
The interaction of polymers with cellular membranes was inves-
tigated by analyzing the release of hemoglobin from erythro-
cytes. Blood from sheep, collected in heparinized tubes, was 
provided by the Institute of Laboratory Animal Science and 
Animal Welfare, Friedrich Schiller University Jena. The blood 
was centrifuged at 4500 × g for 5 min, and the pellet was washed 
three times with cold 1.5 × 10−3 M phosphate buffered saline 
(PBS, pH 7.4). After dilution of erythrocytes with PBS in a ratio 
of 1:7, aliquots of erythrocyte suspension were mixed 1:1 with 
the indicated polymer solution up to 100 µg mL−1 and incu-
bated in a water bath at 37 °C for 60 min. After centrifugation 
at 2400 × g for 5 min, the hemoglobin release into the superna-
tant was determined spectrophotometrically at a wavelength 
of 544 nm using a microplate reader (TECAN Infinite M200 Pro, 
Crailsheim, Germany). Complete hemolysis (100%) was achieved 
using 1% Triton X-100 serving as positive control. Pure PBS was 
used as negative control (0% hemolysis). The hemolytic activity 
of the polycations was calculated using Equation (1)
= ×
−
−
A A
A A
%Hemolysis 100
( )
( )
Sample Negative control
Positive control Negative control  
(1)
A value less than 2% hemolysis rate was classified as non-
hemolytic, 2%–5% as slightly hemolytic and >5% as hemolytic. 
Experiments were run in triplicates and were performed with 
three different batches of donor blood.
To study the influence of aggregation, erythrocytes were iso-
lated as described above. The erythrocyte suspensions were 
mixed 1:1 with the polymer solutions (100 µL total volume) in 
a clear flat bottomed 96-well plate. The cells were incubated at 
37 °C for 2 h, and the absorbance was measured at 645 nm in 
a microplate reader. Cells, which were treated with PBS, served 
as negative control and 25 kDa branched PEI (BPEI) (50 µg mL−1, 
Sigma-Aldrich) was used as positive control. Absorbance values 
of the test solutions lower than the negative control were 
regarded as aggregation. Experiments were run in triplicates and 
were performed with three different batches of donor blood.
2.8. Ethidium Bromide Quenching Assay (EBA)
The formation of polyplexes with pDNA was examined by 
quenching of the ethidium bromide fluorescence. Briefly, 
15 µg mL−1 pDNA in a total volume of 100 µL HBG buffer were 
incubated with ethidium bromide (0.4 µg mL−1) for 10 min at 
room temperature. Subsequently, polyplexes with different 
amounts of polymer (various N/P ratios) were prepared in black 
96-well plates (Nunc Thermo Fisher). The samples were incu-
bated at room temperature for 15 min before fluorescence meas-
urements. The fluorescence of the samples was measured at an 
excitation wavelength of 525 nm and an emission wavelength 
of 605 nm using a Tecan Genios Pro fluorescence plate reader 
(Tecan, Crailsheim, Germany). A sample containing only pDNA 
and ethidium bromide was used to calibrate the device to 100% 
fluorescence against a background of 0.4 µg mL−1 of ethidium 
bromide in HBG solution. The percentage of dye displaced upon 
polyplex formation was calculated using Equation (2)
[ ] = ×F
F
RFU % 100
sample
pDNA  
(2)
Here, RFU is the relative fluorescence and Fsample and FpDNA are 
the fluorescence intensities of a given sample and the ethidium 
bromide intercalated into pDNA alone.
2.9. Heparin Dissociation Assay
To investigate the release of pDNA from polyplexes, the heparin 
dissociation assay was performed. Polyplexes with an N/P ratio 
of 30 were prepared as described above in a total volume of 
100 µL HBG buffer containing ethidium bromide (0.4 µg mL−1). 
After incubation in the dark at room temperature for 15 min, 
the polyplexes were transferred into a black 96-well plate, and 
heparin solutions of indicated concentrations were added. The 
solutions were mixed and incubated for further 30 min at 37 °C 
in the dark. The fluorescence of ethidium bromide was measured 
at Ex 525 nm/Em 605 nm with a Tecan microplate reader. The 
percentage of intercalated ethidium bromide was calculated as 
described above.
2.10. Dynamic and Electrophoretic Light Scattering (ELS)
Dynamic light scattering was performed on a Zetasizer Nano ZS 
(Malvern Insturments, Herrenberg) with an He-Ne laser oper-
ating at a wavelength of λ = 633 nm. All measurements (30 runs, 
triplicate) were carried out at 25 °C after an equilibration time 
of 120 s. The counts were detected at an angle of 173°. The 
mean particle size was approximated as the effective (z-average) 
diameter and the width of the distribution as the polydisper-
sity index of the particles (PDI) obtained by the cumulants 
method assuming a spherical shape. ELS was used to measure 
the zeta potential (ζ). The measurement was performed on a 
Zetasizer Nano ZS (Malvern Instruments, Herrenberg, Germany) 
by applying laser Doppler velocimetry. For each measurement, 
20 runs were carried out using the slow-field reversal and the 
fast-field reversal mode at 150 V. Each experiment was per-
formed in triplicate at 25 °C. The zeta potential was calculated 
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from the electrophoretic mobility (µ) according to the Henry’s 
equation. Henry coefficient f(ka) was calculated according 
to Oshima.
2.11. Uptake Studies
For uptake studies, cells were cultured as described above. Sub-
sequently, cells were seeded at a density of 105 (HUVEC, 3 × 105) 
cells per mL in 24-well plates and cultured for 24 h. One hour 
prior to the addition of the polyplexes, the medium was changed 
to OptiMEM (Life Technologies, Darmstadt, Germany). The poly-
plexes were prepared as described above and at least 50 µL poly-
plex solution of N/P 50 were added to the cells cultured with 
500 µL media. The plates were incubated for 1 h at 37 °C under 
5% CO2 atmosphere.
For flow cytometry studies the pDNA (pEGFP-N1) was labeled 
with YOYO-1 iodide prior to the polyplex preparation. For labe-
ling of 1 µg pDNA, 0.026 µL of 1 M YOYO-1 solution was mixed 
with pDNA and incubated for 20 min at 4 °C protected from 
light. Afterward, HBG buffer and polymers were added at 
the indicated N/P ratio and the polyplexes were formed as 
described previously. The cells were washed and harvested 
after 1 h and 10% trypan blue was added to quench the outer 
fluorescence of the cells. To determine the relative uptake of 
the polyplexes, 10 000 cells were measured by flow cytometry 
using a Cytomics FC 500 (Beckman Coulter) and the amount 
of viable cells showing YOYO-1 signal (FL1) were gated. Dead 
cells were identified via counterstaining with propidium 
iodide. The experiments were performed at least three times 
independently.
Live cell imaging was performed for uptake studies. In detail, 
cells (105 cells mL−1) were seeded on glass-bottomed dishes 
(Greiner, Germany) and cultivated for 24 h in a humidified 
atmosphere. One hour prior to the polymer addition, the cells 
were rinsed with PBS and the medium was changed to OptiMEM. 
The polyplexes were formed with P1-Cy5, or P2-Rho, and P3-Rho, 
added to the cells, and incubated for one additional hour. Sub-
sequently, the medium was replaced by fresh culture medium 
or PBS supplemented with Hoechst 33342 for nucleus staining. 
Imaging was performed with LSM880, Elyra PS.1 system (Zeiss, 
Oberkochen, Germany) applying a 63× 1.4 NA plan apochromat 
oil objective.
2.12. Transfection Studies
For transfection studies HUVEC cells were seeded at a density 
of 2 × 105 cells mL−1 in 24-well plates 1 d before transfection. 
One hour prior to transfection, cells were rinsed with PBS and 
supplemented with 1 mL of OptiMEM (Life Technologies). Poly-
plexes (50 µL) were added to the cells and the plates were incu-
bated for 4 h in the incubator. Afterward, the supernatant was 
replaced by 1 mL of fresh growth medium and the cells were 
further incubated for 20 h. For analysis, adherent cells were 
harvested by trypsinization. The relative expression of EGFP 
fluorescence of 104 cells was quantified via flow cytometry 
using a Cytomics FC 500 (Beckman Coulter). For determination 
of the transfection efficiency viable cells expressing EGFP were 
gated.
3. Results and Discussion
To conjugate a D-fructose derivative to a cationic polymer 
backbone, the thiol-ene photoaddition was utilized as the 
method of choice since it can be performed under mild 
conditions (low temperature, no toxic metal catalysts) 
in high yields.[33] Previous studies revealed that overex-
pressed D-fructose receptors of various breast cancer cell 
lines tolerate only defined positions of the introduced func-
tional groups.[12] Several modifications at the C1 position 
of fructopyranose have been reported to be tolerated by 
GLUT5.[13,14,34] Since 1-deoxy-1-mercapto-fructopyranose 
did not react with the respective copolymers by thiol-ene 
photoaddition, an ethyl spacer had to be installed at the C1 
position between the D-fructose moiety and the thiol group.
3.1. Synthesis of Thio-Functionalized D-Fructose
The D-fructose derivative bearing a thiol-group was 
obtained in a four-step synthesis from commercially avail-
able 2,3:4,5-di-O-isopropylidene-β-D-fructopyranoside (1). 
First, a benzyl ether group was introduced by the conversion 
of 1 with benzyl-2-bromoethyl ether (Scheme 1) resulting 
in 1-(2-(benzyloxy)ethyl)-2,3:4,5-di-O-isopropylidene-β- 
D-fructopyranoside (2). In a second step, the benzyl group 
of 2 was cleaved under standard conditions with H2/palla-
dium on activated charcoal to obtain 3 in high yield (95%). 
The OH-group was transformed into a leaving group by 
mesylation with mesyl chloride under argon atmosphere 
analog to a literature procedure.[28] In a substitution reac-
tion, the thiol functionality was introduced stepwise 
by transformation to the isothioronium salt and, subse-
quently, hydrolysis to yield the product 1-O-(2-mercapto-
ethyl)-2,3:4,5-di-O-isopropylidene-β-D-fructopyranoside (5).
Characterization of the synthesis pathway by 1H 
NMR spectroscopy for the compounds 1–5 is illustrated 
in Figure 1. The successful introduction of the “benzyl 
ethyl” substituent (1–2) can be followed by the proton 
signals in the aromatic region (7.24–7.39 ppm), the ben-
zylic CH2 signal (4.56 ppm), and the disappearance of the 
OH-quadruplet (2.09 ppm). After cleavage of the benzyl 
group (3), the disappearance of the aromatic and the ben-
zylic CH2 signals is observed. The successful substitution 
with mesyl chloride is characterized by the appearance 
of a sharp singlet at 3.02 ppm (4). The disappearance of 
the mesyl singlet and the appearance of a quadruplet 
(1.58 ppm) confirm the successful introduction of the 
thiol group (5). For the subsequent polymer modification, 
the protected thio-fructose 5 was used.
3.2. Synthesis of a D-Fructose Bearing Cationic Copolymer
The homopolymer poly(2-ethyl-2-oxazoline) (PEtOx) 
was synthesized according to a literature procedure by 
Macromol. Biosci. 2017,  DOI: 10.1002/mabi.201600502
D-Fructose-Decorated Poly(ethylene imine) for Human Breast Cancer Cell Targeting
Macromolecular
Bioscience
www.mbs-journal.de
© 2017  WILEY-VCH Verlag GmbH &  Co.  KGaA, Weinheimwww.advancedsciencenews.com
(7 of 16) 1600502
microwave supported cationic ring-opening polymeriza-
tion.[30] Before purification, the NMR signals of tosylate 
protons of the initiator MeOTos were used to calculate 
the degree of polymerization (575). This high molar mass 
homopolymer was used as starting material for the subse-
quent synthesis of linear poly(ethylene imine) (P1). For this 
purpose, PEtOx was hydrolyzed in half concentrated hydro-
chloric acid (see Scheme 2).[35]
The formed ethylene imine units were functionalized 
with N-succinimidyl-4-pentenate to introduce double 
bonds to the polymer.[36] The resulting copolymer P(EI-
stat-ButEnOx) (P2) revealed an ethylene imine content 
Macromol. Biosci. 2017,  DOI: 10.1002/mabi.201600502
Scheme 1. Schematic representation of the four-step synthesis of 1-O-(2-mercapto-ethyl)-2,3:4,5-di-O-isopropylidene-β-D-fructopyranoside: 
a) benzyl-2-bromoethyl ether, NaH, THF, rt; b) H2/Pd, CH3OH, rt; c) mesyl chloride, Et3N, 4-DMAP, CH2Cl2, 0 °C; d) (1) thiourea, butanone, 95 °C, 
(2) K2S2O5, CH2Cl2/H2O, 50 °C.
Figure 1. 1H NMR of D-fructose derivatives – (300 and 600 MHz CDCl3/CD2Cl2).
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of 73% (referring to the repeating units) to enable an 
effective binding of genetic material (Table 1). The 
introduction of the functionalized D-fructose was per-
formed by thiol-ene photoaddition which represents 
a mild and metal-free reaction type. For this purpose, 
the corresponding precursor P2 was converted with the 
protected thio-fructose 5 under UV irradiation at room 
temperature to yield the copolymer P(EI-stat-ButEnOx-
stat-isoFruButOx) (isoP3). Surprisingly, a full conver-
sion of the double bonds was not possible even after 
stepwise photoaddition using an excess of protected 
thio-fructose. Steric hindrance by the bulky side chains 
(including the isopropylidene protecting groups) could 
be one possible explanation. However, a high function-
alization with carbohydrates rather hinders a stable 
polyplex formation.[24a] Subsequent deprotection of the 
isopropylidene groups resulted in P(EI-stat-ButEnOx-stat-
FruButOx) (P3) revealing 16% of repeating units func-
tionalized with D-fructose. Interestingly, this content of 
D-fructose modification rendered the final polymer P3 
water soluble.
Characterization by 1H NMR confirms the presence of 
2-butenyl-2-oxazoline (ButEnOx) and ethylene imine (EI) 
units in P2 (Figure 2), proven by the appearance of proton 
signals of the double bond at 5.9 ppm (HCCH2, A) and 
5.0 ppm (HCCH2, B). To calculate the composition of 
the obtained copolymer, the integral of the signals of 
the double bond (5.9 ppm) was compared to the integral 
of the ethylene imine backbone (2.9–2.5 ppm). Since the 
ethylene imine units are not used for further modifica-
tion, their content remains constant, representing 73% 
of repeating units of the copolymer. The successful func-
tionalization of P2 with 5 is shown by the appearance 
of D-fructose related signals between 4.6 and 3.4 ppm 
after photoaddition (isoP3, Figure 2). Furthermore, four 
singlets of the isopropylidene groups appear between 
1.5 and 1.1 ppm. After treatment with hydrochloric 
acid, neutralization, and dialysis against water (cutoff: 
3500 g mol−1) the signals of the protecting groups disap-
peared, indicating the successful deprotection of isoP3 
and, consequently, the formation of P(EI-stat-ButEnOx-
stat-FruButOx) (P3). The isopropylidene cleavage results 
in the formation of a hemiketal structure and, there-
fore, in an equilibrium of pyranoses, furanoses, and an 
open-chained form, which can be distinguished via 2D 
NMR spectroscopy according to literature.[34] Since the 
ring proton signals of D-fructose are covered in the 1H 
NMR spectra by the signals of the polymer backbone 
(Figure 2, P3), heteronuclear single quantum coherence 
(HSQC) NMR spectroscopy was used to prove their pres-
ence beneath the signals of the copoly mer backbone as 
well as the successful formation of deprotected D-fructose 
moieties at the polymer (Figure 3).
The successful photoaddition, resulting in a single 
(poly meric) species (P3) and, hence, the absence of degra-
dation, was further confirmed utilizing diffusion-ordered 
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Scheme 2. Schematic representation of the synthesis of P(EI-stat-ButEnOx-stat-FruButOx): a) 6 M HCl, 100 °C under reflux; b) pyridine, 4-N,N-
dimethylamino-pyridine, N-succinimidyl-4-pentenate, 80 °C; c) D-fructose derivative (), methanol, 2,2-dimethoxy-2-phenylacetophenone, 
room temperature, UV = 365 nm; d) THF/H2O, 2 M HCl, 40 °C.
Table 1. Composition and molar masses for PEtOx and P1–P3.
Abbreviation Name NMRa) SECb) Sugar contentc)
Mn (theo) [g mol
−1] Mn [g mol
−1] Ð [mol%]
PEtOx PEtOx575 57 000 69 000 1.3 –
P1 LPEI575 24 800 – – –
P2 P(EI73%-stat-ButEnOx27%) 37 500 8000 1.3 –
isoP3 P(EI73%-stat-ButEnOx11%-stat-iso-
FruButOx16%)
67 000 11 600 1.9 11
P3 P(EI73%-stat-ButEnOx11%-stat- 
FruButOx16%)
59 600 9800 1.2 12
a)Determined by 1H NMR (calculated from tosylate signals of MeOTos before purification; b)SEC: DMAc, 0.21% LiCl, polystyrene calibra-
tion; c)Determined by elemental analysis.
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Figure 2. Comparison of 1H NMR spectra of the precursor copolymer P, the protected D-fructose copolymer P and the final product P 
(600 MHz, DMSO-d6).
Figure 3. HSQC NMR of the copolymer P (DMSO-d6, 600 MHz).
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NMR spectroscopy (DOSY NMR) (Figure 4). The diffusion 
coefficient of P3 is larger than for the precursor copolymer 
P2, indicating a decrease of the hydrodynamic radius of 
the polymer in solution.
A comparison of the composition and molar masses 
of the prepared copolymers obtained by size exclusion 
chromatography (SEC) is depicted in Table 1. The cati-
onic polymers P1–P3 show undesired interactions with 
the column and a change in the elution behavior. Fur-
thermore, an SEC calibration for cationic polymers is not 
available, which complicates the determination of mean-
ingful accurate molar masses with this technique. For this 
reason, a meaningful determination of molar masses of 
the copolymers by size exclusion measurements was not 
possible. However, for the modified poly(ethylene imine)s 
a trend is clearly visible. After the photoaddition of the 
protected thio-fructose the signal of isoP3 is observed 
at lower elution volumes indicating an increased hydro-
dynamic volume. Deprotection results in a slight shift 
to higher elution volumes, and, therefore, to lower 
molar masses.
To enable a more detailed insight into the uptake in 
noncancer (L929) and triple negative breast cancer cells 
(MDA-MB-231) via microscopy, the precursor P2 and the 
final copolymer P3 were labeled using one equivalent of 
Rhodamine B isothiocyanate per polymer chain. For com-
parison with the nontargeted standard polymer, Cy5-
labeled P1 was used.
3.3. Bio- and Hemocompatibility
Recently, cationic polymers such as PEI have been used 
extensively as nonviral vectors to deliver genetic material 
into mammalian cells. The cytotoxicity of the polymers 
represents a major drawback for potential applications. 
Former studies revealed increased biocompatibility of 
linear PEI (LPEI) compared to branched PEI.[37] Further-
more, cytotoxicity strongly depends on the molar mass 
and the cationic charge density.[22a] This study aimed to 
investigate the impact of functionalization with D-fruc-
tose (P3) in noncancerous fibroblast cell line L929, rou-
tinely used for toxicity screenings, in HUVEC cell line and 
in breast cancer cell line MDA-MB-231 compared to linear 
PEI (P1) and the precursor polymer P2.
P1 exhibits a concentration-dependent cytotoxicity in 
the cell lines observed using the AlamarBlue assay (Figure 
5). Increased concentrations result in reduced cell via-
bility, as reported before for LPEI of the respective mole-
cular mass.[38] Treatment with 5 µg mL−1 decreases the 
cell viability to 15.8% in L929 cells, 2.8% in HUVEC and 1% 
in MDA-MB-231 cells, respectively. P2 causes a dramati-
cally reduced viability of breast cancer cells MDA-MB-
231 (IC50 < 10 µg mL−1). In contrast, P2 shows an increased 
biocompatibility in HUVEC cells (IC50 = 205 µg mL−1) 
and over the entire concentration range in L929 cells 
(IC50 > 500 µg mL−1). The D-fructose-conjugated poly mer 
P3 displays even improved biological properties. No sig-
nificant reduction of the viability in mouse fibroblast 
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Figure 4. DOSY NMR of the precursor P (green) and the final copolymer P (orange) (DMSO-d6, 600 MHz, 25 °C).
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L929 cells and in the primary human endo thelial HUVEC 
cells was observed after 24 h treatment with P3 for all 
tested concentrations (IC50 > 500 µg mL−1). The cytotox-
icity of P3 (IC50 = 35 µg mL−1) toward breast cancer cells 
is concentration dependent, comparable to P2. As a con-
sequence, D-fructose-conjugated polymer P3 combines 
strongly enhanced biocompatibility for the noncancer cell 
line L929 as well as primary human cells HUVEC on the 
one hand and selective toxicity for breast cancer cell line 
MDA-MB-231.
Red blood cells (RBC) aggregates are naturally formed 
by plasma proteins, which is a reversible process.[39] In 
the presence of various polymers irreversible erythro-
cyte aggregation can occur due to membrane interactions 
forming bridges between the polymers and the eryth-
rocytes, which increases the blood viscosity and can be 
dangerous for vital organs.[40] The erythrocyte aggrega-
tion caused by polymers P1, P2, and P3 was studied using 
BPEI as positive control (Figure 6A). None of the investi-
gated polymers revealed a membrane perturbing activity 
up to 100 µg mL−1 and therefore no formation of eryth-
rocyte aggregation was observable. The disruption of the 
RBC membrane and the detection of hemoglobin, another 
known side effect of cationic polymers, were measured for 
all investigated polymers (Figure 6B). As a general trend, 
it was found that cell release of hemoglobin of P3 was 
lower when compared to P1 or P2 for all measured concen-
trations (100 µg mL−1, 2.4%). P1 and P2 caused only slight 
hemolysis (2%–5%) up to 100 µg mL−1. However, P3 reveals 
a very high hemocompatibility regarding irreversible RBC 
aggregation and hemolytic potential. Therefore, it offers 
outstanding properties for advanced uptake studies.
3.4. Characterization of Polyplexes
To investigate the binding of the D-fructose-bearing copoly-
mers with genetic material, pDNA was utilized for model 
studies. The efficient delivery of nucleic acids into cells 
comes along with several requirements. Among others, 
this comprises the condensation of genetic material in a 
compact mode as well as the dissociation from the vector 
after it has been transferred into the cellular cytoplasm or 
nucleus.[38]
To investigate the condensation of pDNA with P1, P2, 
and P3, the EBA was used. For this purpose, the oligonu-
cleotides were preincubated with ethidium bromide (EB) 
resulting in a fluorescent DNA-EB complex. Subsequently, 
increasing amounts of polymers were added to form poly-
plexes at different nitrogen (polymer) to phosphate (DNA) 
ratios (N/P). It should be noted that the N/P calculations 
are based on all nitrogens (N) of the polymer, also the 
ones showing no activity for complex formation (amides 
in the backbone of, e.g., ButEnOx). The electrostatic and 
hydrophobic interactions between the polymers and the 
nucleic acid lead to the displacement of EB and, hence, 
to a reduction of the fluorescence intensity that corre-
lates with the affinity for complexation.[41] The modi-
fied polymers (P2 and P3) as well as linear poly(ethylene 
imine) (P1) revealed decreasing fluorescence intensity 
of ethidium bromide showing an interaction with the 
DNA (Figure 7A). For P1, a stable polyplex formation is 
observed for N/P ratios between 10 and 40 (≈25% RFU). 
The polymers P2 and P3 revealed a decreased fluores-
cence intensity plateau between N/P 15 and 40 (57% RFU 
at N/P 40). The smaller content of ethylene imine 
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Figure 5. Cell-type-dependent cytotoxicity assay of P–P using AlamarBlue. Nontreated cells served as 100% relative viability. Cells were 
treated 24 h with the indicated concentrations of the polymers.
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units (73%) combined with steric challenging side chains 
(ButEnOx) that hinders a tight attachment to the DNA 
might be reasons for the higher fluorescence level. How-
ever, polymers P2 and P3 were able to form polyplexes by 
complexation with pDNA, as this RFU was also reported 
for other transfection polymers.[42]
The heparin dissociation assay was used to analyze 
the formed polyplexes concerning DNA release. Heparin 
is a sulfated glycosaminoglycan with multiple negative 
charges in the polymer chain, which competes with the 
nucleic acid of the polyplex. Increasing amounts of hep-
arin displace the pDNA of the polyplexes. Ethidium bro-
mide is added (in the same concentration as for the EBA) 
and intercalates into the free pDNA again. As the result, 
an increase of fluorescence intensity can be observed 
(Figure 7B). For P2 and P3, the pDNA was released rapidly 
to nearly 100% (10 U mL−1 heparin) whereas P1 required 
increased amounts of anionic competitor (40 U mL−1 hep-
arin) for a full dissociation, indicating a less pronounced 
releasing profile. This correlates well with the data deter-
mined by the EBA (Figure 7A).
The size of the polyplexes is of crucial importance since 
they are usually internalized into cells via endocytic path-
ways. In literature, critical sizes of polymeric nanocar-
riers up to a maximum of 200 nm are recommended for 
efficient delivery.[43] As depicted in Table 2, all polyplexes 
Macromol. Biosci. 2017,  DOI: 10.1002/mabi.201600502
Figure 6. A) Erythrocyte aggregation assay of polymers at indicated concentrations. BPEI served as positive control and PBS as negative con-
trol. B) Hemolysis assay of erythrocytes after incubation with polymers at indicated concentrations. Triton X-100 served as positive control 
(100% hemolysis) and PBS as negative control (1.99%). A value less than 2% hemolysis rate is classified as nonhemolytic, 2%–5% as slightly 
hemolytic and >5% as hemolytic. Values represent the mean ± SD (n = 3).
Figure 7. Polyplex formation and stability with plasmid DNA using the polymers P, P, and P. A) Affinity of complexation of respective 
polymers at indicated N/P ratios (ethidium bromide quenching assay). B) Dissociation assay of polyplexes formed at N/P 20 using heparin 
(0–60 U mL−1). Values represent the mean ± SD (n = 3); * represents a significant (p < 0.01) difference between P and P; # indicates no 
significant difference (p < 0.05) to 100% relative fluorescence.
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are in the nanometer scale with a positive zeta potential; 
the polyplexes formed of P1, P2, and P3 revealed favorable 
sizes smaller than 200 nm. The slightly increased sizes 
of the polyplexes formed with the modified polymers P2 
and P3 can be explained by the introduction of polymeric 
side chains with bulky groups not interacting with the 
genetic material. These results show the complexation 
of large pDNA molecules (300–400 nm pure pDNA) into 
compact polyplex structures, a central prerequesite for 
gene delivery.
3.5. Cell-Type-Dependent Uptake Efficiency
Beside complexation and protection of the genetic mate-
rial, one major challenge is the cellular uptake of the 
polyplexes. For nontargeted cationic polyplexes, inter-
nalization into cells by endocytosis, followed by the endo-
somal release of the pDNA into the cytosol, is reported.[44] 
The functionalization of cationic polymers with targeting 
units such as D-fructose can change the interaction with 
cells depending on the interaction with cell type spe-
cific receptors. This interaction as well as usually fast and 
specific internalization of polyplexes can be visualized 
and quantified by microscopy as well as flow cytometry, 
respectively. For this purpose, pDNA was preincubated 
with YOYO-1, a DNA specific dye with high fluorescence 
intensity once intercalated with no displacement during 
polyplex formation. The cellular uptake into noncancerous 
L929 as well as HUVEC and breast cancer MDA-MB-231 
cells after 1 h (a time point at which no cytotoxicity had 
been observed) at different concentrations measured by 
flow cytometry is depicted in Figure 8. P1 showed a strong 
uptake in all tested cell types indicating no cell specificity. 
At N/P 10, P2 and P3 revealed no uptake in all three cell 
lines. P2 polyplexes at N/P 20 can be detected in MDA-
MB-231 and HUVEC cells, higher N/P values induce pDNA 
uptake in all tested cells. P3 polyplexes were only detect-
able in MDA-MB-231 cells at N/P value 20. At N/P 50 the 
amount of pDNA is even increased compared to P1 in 
MDA-MB-231 cells. In contrast to this, the uptake of genetic 
material into the control cells is reduced. These results 
indicate a positive influence of D-fructose units toward cell 
specific uptake of polyplexes into breast cancer cells. Non-
cancerous L929 and HUVEC cells efficiently take up poly-
plexes formed with P1 and P2, but less efficient with P3. 
In contrast, D-fructose targeted P3 enables the uptake of 
pDNA polyplexes at N/P ratio of 50 into MDA-MB-231 cells 
in a concentration-dependent manner.
Table 2. Size and zeta potential of pDNA polyplexes of P1–P3 at N/P 20 in HBG buffer measured by dynamic and electrophoretic light 
scattering.
Polymeric system z-Average  
[d nm−1]
PDI Number-weighted size  
[d nm−1]
Zeta potential  
[mV]
P1 217 ± 8 0.47 71 ± 13 24.0 ± 0.4
P2 264 ± 11 0.35 109 ± 33 24.3 ± 1.1
P3 165 ± 1 0.26 83 ± 29 17.6 ± 0.4
Figure 8. Uptake study. Polyplexes formed with YOYO-1 labeled pDNA were incubated with L929, HUVEC, and MDA-MB-231 cells in OptiMEM 
for 1 h with the polyplexes of the copolymers P–P at indicated N/P ratios. The amount of cells (%), which have taken up pDNA polyplexes rel-
ative, as well as the mean fluorescence intensity (MFI) of all viable cells compared to pDNA control without polymers were depicted. Values 
represent the mean ± SD (n ≥ 3); * represents statistical significant difference in MFI to P N/P 50 of L929 and HUVEC, ANOVA, p-value < 0.01.
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To support these findings and to rule out that poly-
plexes sticking to the cell membrane influence the data 
from flow cytometry, the uptake of polyplexes with 
labeled polymers was visualized by live cell confocal laser 
scanning microscopy (CLSM) (Figure 9). To further investi-
gate cell morphologies, also transmitted light and nuclei 
staining (Hoechst 33342, blue) was plotted. It can be 
clearly observed that all cells have taken up polyplexes/
polymers, which supports the results of the flow cytom-
etry. Furthermore, some aggregates can be detected in 
case of P2 in all cell lines, but to a higher extent in MDA-
MB-231. P3 is also taken up by all investigated cell lines, 
but the intensity is considerably higher in MDA-MB-231 
cells, further supporting the results obtained by flow 
cytometry.
3.6. Transfection Efficiency
To investigate, whether an increased cell-specific uptake 
of genetic material results in enhanced transfection effi-
ciency, the delivery and expression of a protein coded on 
a plasmid DNA was tested (Figure 10). Interestingly, 20%–
30% of cells were expressing EGFP if P1 polyplexes were 
used, but over 40% were reached in the case of P2 poly-
plexes (as it can be found in literature)[45] and only 1% for 
P3 polyplexes. Even an increase in the N/P value did not 
result in an increased transfection efficiency of P3. The 
same trend P2 > P1 > P3 could be observed, if the amount 
of EGFP is considered (mean fluorescence intensity, MFI). 
This indicates that P3 has to be further optimized not just 
only to deliver genetic material but also to transfect the 
targeted cells.
Transfection efficiency is the result of some more 
events than just successful uptake. Besides the uptake, 
the endosomal release of the polyplexes usually mediated 
by the proton sponge effect represents another important 
parameter. In our case, the latter step might be hindered 
by the amount of coupled fructose residues. Even if the 
transfection investigations for P3 failed, the described 
modification of cationic polymers can be used to further 
develop the concept of D-fructose conjugated cationic 
polymers. Potential approaches for future research to 
increase the transfection efficiencies are the synthesis 
of different polymer compositions varying the ethylene 
imine/sugar ratio and, additionally, the introduction 
of amino functionalities to the side chains (analog to 
Ref.[38]).
4. Conclusions
A novel thiol-functionalized D-fructose derivative 5 was 
synthesized starting from commercially available pro-
tected D-fructose 1 in a four-step synthesis. Thiol-ene 
photoaddition of 5 to double bond containing copolymer 
P(EI-stat-ButEnOx) P2 resulted in the isopropylidene 
bearing D-fructose conjugated polymer iso-P3. Deprotec-
tion under acidic conditions led to water soluble polymer 
Figure 9. Live cell uptake studies. Polyplexes formed at N/P 50 with labeled polymers (red) P1-Cy5, P2-Rho, and P3-Rho were added to L929, 
HUVEC, and MDA-MB-231 cells. The cells were analyzed after 1 h via confocal laser scanning microscopy (CLSM) using the same laser settings 
for each cell line. The cell nucleus was stained with Hoechst 33342 (blue). Scale bar: 20 µm.
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P3. To evaluate GLUT5 targeting of D-fructose conjugated 
polymer P3 in comparison to sugar-free polymers P1 and 
P2 cytotoxicity, uptake and transfection studies were 
performed. Cytotoxicity assays of P3 revealed almost no 
toxicity against fibroblast cells (L929) as well as human pri-
mary HUVEC cells in the tested concentration range (up to 
500 µg mL−1), but a very pronounced cytotoxicity for breast 
cancer cells (MDA-MB-231). Furthermore, no irrevers-
ible RBC aggregation and a low hemolytic potential was 
observed for P3. Condensation experiments with pDNA 
exhibited stable polyplexes of P3 at an N/P ratio > 15. 
When treated with anionic competitor heparin (10 U mL−1), 
polyplexes of P3 offered a rapid release of pDNA to nearly 
100%. Additionally, the polymers were labeled with dyes 
to obtain P1-Cy5, P2-Rho, and P3-Rho. After the forma-
tion of labeled polyplexes, the cell-type-dependent uptake 
via flow cytometry and live cell CLSM was investigated. 
At N/P 50, MFI for P3 was low in L929 or HUVEC and high 
for MDA-MB-231 cell line, whereas P1 and P2 revealed a 
reverse trend. Results of live cell imaging are in accordance 
with the results from flow cytometry, indicating cell-type-
dependent interaction of D-fructose conjugated polymer 
P3. These findings might be attributed to D-fructose con-
jugation and therefore to GLUT5 mediated transport into 
cells.
The determination of the transfection efficiencies 
revealed unexpected low EGFP expressions, in particular 
for P3. The modification of LPEI only represents one 
example to install D-fructose on a cationic polymer. To 
achieve appropriate transfection efficiencies it is neces-
sary to investigate the influence of different polymer 
compositions comprising varying ethylene imine and 
D-fructose contents. Further approaches comprise the 
introduction of different cationic functionalities in the 
side chains of various polymer classes.
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a b s t r a c t
A pyridyl triazole (pyta) modiﬁed sucrose ligand was prepared in a seven step synthesis using D-glucose
as the protection group for D-fructose and starting from commercially available sucrose. After
complexation with Ru(bpy)2Cl2 precursor, the sucrose-conjugated Ru complex of the general formula
[Ru(bpy)2(L)]Cl2 was formed. Acidic cleavage of the D-glucose unit led to the ﬁrst D-fructose conjugated
metal complex via D-fructose C6 in literature. Additionally, pyta-modiﬁed D-fructose via C1 and the
corresponding Ru complex were synthesized. All compounds were analyzed by Rf values, speciﬁc rota-
tion, NMR, IR, UV/Vis and ﬂuorescence spectroscopy, mass spectrometry and elemental analysis.
© 2017 Elsevier Ltd. All rights reserved.
1. Introduction
The attachment of carbohydrates represents a strategy to
enhance the hydrophilicity and selectivity of the corresponding
metal complexes due to their interaction with various biological
structures [1]. Among a diversity of sugars, which are extensively
used for biomedical applications, D-fructose gained interest for the
targeting of the GLUT5 receptor. In general, carbohydrates are
entering into the cells by highly selective transport proteins
(GLUTs) [2]. Among the thirteen known saccharide transporters,
GLUT5 is speciﬁc for D-fructose and its structure was conﬁrmed
recently [3]. The incidence of GLUT5 is controversially discussed in
literature. Next to the existence in the kidney, colon and adrenal
cells, it is supposed to be overexpressed in more than 85% of 33
tested breast cancer cell lines [4], whereas another group claimed
there is no GLUT5 overexpression in any breast cancer tissue [5].
Additionally, the GLUT5 receptor might be overexpressed in acute
myeloid leukemia cells [6]. Since it is known that structural mod-
iﬁcations of the C1 as well as of the C6 position of the D-fructose are
tolerated by the GLUT5 transporter [7,8], there is intensive research
in chemical modiﬁcation of D-fructose, the attachment of these
derivatives to various structures and in their biological properties.
Therefore, nanoparticular formulations [9,10] as well as dyes [11],
micelles [12,13] and polymers [14e16] have been successfully
functionalized with D-fructose to address breast cancer cell lines.
Also, low molar mass metal complexes conjugated with various D-
fructose residues were used to investigate their interactions with
the GLUT5 transporter. For instance, Re complexes were function-
alizedwith D-fructose and their phosphorescencewas used to show
the selective accumulation in breast cancer cell lines MCF-7 and
MDA-MB-231 mediated by GLUT5 [17]. A D-fructose conjugated
Ir(III) complex exhibited a 3.7 times higher uptake in MCF-7 than in
non-cancerous cells. In contrast to that, the D-fructose-free complex
did not display any selectivity [18]. Also, the natural compound
bisdemethoxycurcuminwas successfully labeled with D-fructose by
using Cu(I)-catalyzed “click” reaction between azides and alkynes
and then complexed to Ru. Incubation of L929, HepG2 and MDA-
MB-231 revealed a high biocompatibility of these compounds due
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to the curcumin moiety, but unfortunately, detailed uptake studies
were not performed [19].
The importance of the substitution position was shown very
recently for a set of D-glucose conjugated platinum complexes. The
C2-substituted D-glucose Pt complex showed an enhanced accu-
mulation in various cancer cell lines, whereas the C3-substituted
analogue was the least active complex [20]. Since the C1 and the
C3 position of D-fructopyranose are easy to address due to
commercially available starting materials with protection groups,
all presented studies focused on compounds, which were cova-
lently bound to these positions of the D-fructose moiety, whereas
modiﬁcations of the C6 position of D-fructose are rarely discussed.
Sucrose was used as a starting point, since it contains a unit of D-
glucose, which is a(1e2) covalently bound to D-fructofuranose
(Fig. 1).
The glycosidically linked D-glucose avoids ring opening re-
actions of the D-fructofuranose and, therefore, enables the selective
modiﬁcation of the C6’-position of the sucrose molecule. Sucrose is
cultivated in sugar beets to produce crystalline sugar [21]. Addi-
tionally, it is used for macroporous alumina ceramics [22], dye
sensitized solar cells [23] and hollow carbon nanospheres [24]. Due
to the renewable and biocompatible properties of sucrose, it was
also investigated regarding its use for the synthesis of polymers
[25e27], nanoparticles [28] and low molar mass bioactive com-
pounds [29].
The Cu(I)- catalyzed “click” reaction between azides and alkynes
provides a very effective tool for the synthesis of ﬁve-membered
heterocyclic systems, with good tolerance of other functional
groups, simple reaction conditions and a high selectivity [30]. The
formation of 1,4-substituted triazoles enables various features like
hydrogen bonding and the attendance in dipol-dipol interactions,
render them to isosteres of amides, a key structure in biological
molecules [31]. Synthetic protocols of carbohydrate chemists can
easily introduce azide or alkyne functionalities into sugar residues
[32]. The formation of carbohydrate-conjugated triazoles can result
in beneﬁcial properties such as anticancerous and antiviral effects
as well as in ﬂuorescent glycoprobes for diagnostics [33,34].
Additionally, click reactions with other N-alkynes such as 2-ethynyl
pyridine result in potentially bidentate chelators and, therefore, the
possibility to form various metal complexes [35,36].
Here we present the synthesis of pyridyl triazole (pyta) conju-
gated sugars using Cu(I) catalyzed click reactions between azides
and alkynes. In particular, the pyta group was introduced to D-
fructose via C1 in a four step synthesis and to the C60 position of
sucrose (which represents the C6 position of the D-fructofuranose)
in a seven step synthesis. The ligands were reacted with Ru(b-
py)2Cl2 to form complexes of the general formula [Ru(bpy)2(L)]Cl2
and in the case of sucrose-conjugated Ru complex, the D-glucose
unit was cleaved to form the ﬁrst D-fructose-conjugated complex at
C6. The cytotoxicity and uptake of the complexes was evaluated as
well.
2. Results and discussion
2.1. Synthesis and characterization
The aim was the synthesis of novel D-fructose derivatives
substituted at C6. For modiﬁcation of this position of D-fructose,
sucrose was chosen as the starting molecule. At ﬁrst, D-fructose-
moiety in sucrose had to be modiﬁed selectively at the C60 position
(Fig. 2). Starting from acetylated and C6’-tert-butyl-diphenl-silyl
(TBDPS)-protected sucrose 1 [37,38], the silylether was cleaved by a
ﬂuoride source. For this, TBAF was used to form a hydroxyl group at
C60 to avoid HF or HF-pyridine as cleaving agent [38]. Due to the
migration and ﬂuorolysis of the acetyl groups by using only TBAF,
acetic acid was added to eliminate these side reactions [39].Fig. 1. Schematic representation of a sucrose molecule.
Fig. 2. Schematic representation of the synthesis of the ligands. a) TBAF, CH3COOH, DMF/H2O, rt, 24 h; b) p-toluenesulfonyl chloride, Et3N, CH2Cl2, 0
C, 2 h; c) NaN3, 120
C, 10 min
(mw); d) 2-ethynyl-pyridine, Cu(II)SO4  5H2O, sodium ascorbate, tert-BuOH/H2O, 60
C, 25 min (mw); e) 1. NaOMe, CH3OH, rt, 24 h, 2. DOWEX H
þ to pH ¼ 7; f) 2-ethynyl-pyridine,
Cu(II)SO4  5H2O, sodium ascorbate, THF/H2O, 60
C, 2 d; g) 2 M HCl, EtOH/H2O, 1. 40
C 12 h, 2. rt, 24 h.
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Following this procedure, the desired product 2 was obtained in
moderate yield (66%). Success of the reaction is shown by the
disappearance of the tert-butyl (d ¼ 1.07 ppm) and the aromatic
signals (d ¼ 7.30e7.78 ppm) in the 1H NMR spectrum as well as by
the appearance of [MþNa]þ peak in the mass spectrum and the
crystal structure (SI, Figs. S1 and S3). Reaction of mesylated sucrose
derivative [38] with NaN3 in DMF at 80
C did not result in the
desired product. Due to long reaction time, poor yield and partial
cleavage of protection groups, when applying 80 C in DMF, the
route for the synthesis of N3-functionalized sucrose was changed.
Tosyl chloride was chosen to form tosylated sucrose derivative 3 in
quantitative yield. Appearance of signals in the 1H NMR at
d ¼ 2.46 ppm (CH3) and d ¼ 7.36e7.8 ppm (phenyl moiety) as well
as the [MþNa]þ signal in HR-MS (error: 3.4 ppm) proved the suc-
cessful introduction of the tosyl group (SI, Figs. S6 and S8). Reaction
with an excess of sodium azide led to N3-functionalized sucrose
derivative 4 in quantitative yield. Disappearance of four tosyl-
related peaks in the 13C NMR (d ¼ 128e146 ppm and
d ¼ 21.66 ppm) proved success of the reaction (SI, Fig. S12). Cu(I)-
catalyzed “click” reaction between sucrose-azide and 2-ethynyl-
pyridine resulted in the sucrose derivative 5 with pyridyl triazole
(pyta) functionality. Like for previously reported procedures [38],
microwave irradiation of a mixture of tert-butanol and water as
solvent and Cu(II)SO4  5H2O and sodium ascorbate as catalyst
forming pair offers a fast and easy approach for the synthesis. Tri-
azole proton signal detected in 1H NMR spectrum at d ¼ 8.26 ppm
as well as [MþNa]þ signal in HR-MS (error: 0.3 ppm) conﬁrms the
structure of 5 (SI, Figs. S15 and S17). Standard deprotection pro-
cedure with NaOMe in methanol resulted in water soluble pyta-
functionalized sucrose 6 in quantitative yield. Cleavage of the
acetyl groups was proven by the disappearing of the signals in 1H
NMR (d ¼ 2.01e2.18 ppm) and 13C NMR spectra (d ¼ 20.48e20.67
ppm). Furthermore, the structure of the ligand was conﬁrmed by
the [MþNa]þ peak in HR-MS with an error of 4.0 ppm (SI,
Figs. S20eS22). To cleave off the D-glucose, compound 6was stirred
with 2M HCl at 40 C in water for 12 h. Unfortunately, in this way
only products of decomposition were observed. The alternative
synthesis strategy was the cleavage of the D-glucose after conju-
gation to the Ru complex (Fig. 3).
The synthesis of pyta-functionalized D-fructose via C1 was uti-
lized in a two-step synthesis started from 1-azido-1-deoxy-2,3:4,5-
di-O-isopropylidene-b-D-fructopyranose [40]. Cu(I)-catalyzed
“click” reaction between azido-fructose 7 and 2-ethynyl-pyridine
resulted in the pyta-conjugated D-fructose derivative 8 in high yield
(92%). Success of the reaction is proven by the appearance of signals
in the aromatic region in the 1H NMR spectrum, which correspond
to the triazole and pyridine protons (SI, Fig. S25). Additionally, the
[MþH]þ signal in the HR-MS spectrum (error: 0.3 ppm) conﬁrms
the structure of the desired compound (SI, Fig. S27). Acidic cleavage
of the isopropylidene groups of sugar 8 was performed by stirring
with 2 M HCl in the presence of water. The crude product was
extracted with dry acetonitrile to remove most of the NaCl, which
was formed by neutralization with aqueous NaHCO3 solution.
Disappearance of signals related to isopropylidene groups in 1H
NMR (d ¼ 0.87e1.50 ppm) as well as in 13C NMR spectra
(d ¼ 109.31e109.52 ppm and 24.05e26.35 ppm) and the [MþH]þ
signal in HR-MS (error: 2.5 ppm) conﬁrm the formation of the
desired compound 9 (SI, Figs. S30eS32).
Ligands 6, 9 and 10 were reacted with Ru(bpy)2Cl2 to form
complexes of the general formula [Ru(bpy)2(L)]Cl2 (Fig. 3), which
are soluble in water, methanol and polar solvents.
Complexation reaction of 6 with Ru(bpy)2Cl2 was carried out in
CH3OH at 60
C and resulted in complex 11 in moderate yield.
Triethylamine was added to avoid partial cleavage of D-glucose
from the sucrose ligand. Due to the charged character of the formed
complex, a size exclusion column (Sephadex LH-20 in H2O) was
used to purify compound 11. Aromatic signals, which belong to the
bpy-ligands of the complex, appear in 1H (d ¼ 7e9 ppm) and 13C
NMR spectra (d ¼ 120e160 ppm). Additionally, another signal with
the same intensity is appearing for each signal in 1H aswell as in 13C
NMR spectra, indicating the existence of l- and D-isomers (Fig. 4).
Furthermore, the structure of complex 11was proven by HR-MS
as [M-2Cl]2þwith an error of 2.9 ppm (SI, Figs. S36eS38). Stirring at
pH ¼ 2 in water for 16 h at 40 C resulted in the D-fructose conju-
gated Ru complex 12 via C6 in high yield. The structure of the
desired complex was conﬁrmed by the disappearance of the D-
glucose-related signals by 1HNMR (d¼ 5.23 ppm and d¼ 4.99 ppm)
as well as by HR-MS as [M-2Cl]2þ with an error of 1.9 ppm (SI,
Figs. S42 and S44). Due to the cleavage of the D-glucose unit, the C2
position of the D-fructose moiety is changed from full to semi acetal
structure. This results in the existence of stereoisomers of the D-
fructose, in particular the a- and b-D-fructofuranose and the open-
chained form, which is clearly visible in the appearance of addi-
tional signals in the 13C NMR spectrum between 60 and 85 ppm,
when measured in deuterated water (SI, Fig. S43). Those results are
in accordance to literature, where various D-fructose conjugated
compounds revealed this behavior in NMR [14,19].
The reaction of 9with Ru(bpy)2Cl2 in a similar manner to that of
Fig. 3. Schematic representation of the complex syntheses. a) Ru(bpy)2Cl2, Et3N, CH3OH, 60
C, 12 h; b) 2 M HCl, H2O, 40
C, 16 h; c) Ru(bpy)2Cl2, DMF, 125
C, 2 h (mw); d)
Ru(bpy)2Cl2, CH3OH, 60
C, 12 h.
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sucrose complex 11was not satisfying due to long reaction time (>1
week) and formation of side products. Hence, complexation reac-
tion of 9was carried out in DMF at 125 C for 2 h under microwave
irradiation. After puriﬁcation via size exclusion column (Sephadex
LH-20, water), complex 13was obtained inmoderate yield and high
purity. Next to the product signal in HR-MS ([M-2Cl]2þ, error:
0.2 ppm), additional signals in 1H NMR as well as in 13C NMR
spectra in the aromatic region in comparison to spectra of ligand 9
prove the successful formation of the desired complex (SI, Figs. S48,
S50 and S51). The appearance of signals between d ¼ 9.3 ppm and
9.7 ppm for the triazole proton of the pyta ligand (H-5ta) in
1H NMR
spectrum showed the presence of different forms of the D-fructose
in solution and the existence of l- and D-isomers (SI, Fig. S49). For
compound 13, when dissolved in deuterated DMSO, an approxi-
mate amount of 37.5% b-D-fructopyranose, 27% b-D-fructofuranose,
27% a-D-fructofuranose and 8.5% of the open-chain D-fructose was
detected by 1H measurements. The equilibrium between the
different forms is strongly dependent from pH, temperature, sol-
vent, presence of salts and others [41e43].
Since the rhenium (I) tricarbonyl complex of ligand 10 exhibited
remarkable cytotoxicity in HepG2 cells [36], the corresponding Ru
complex of 10 was synthesized. Complex 14 was prepared and
puriﬁed in a similar manner to that of sucrose complex 11. Success
of the reaction is shown by the appearance of signals in 1H NMR as
well as in 13C NMR spectrum, which belong to bipyridine groups of
the complex (SI, Figs. S55 and S56).
The absorbance and emission spectra of all compounds were
measured in aerated methanol and are summarized in the sup-
porting information (Table S1). The absorption bands of com-
pounds 5, 6, 8 and 9 at lmax ¼ 280 nmwere associated with p/p*
transitions of the ligands. For the Ru complexes 11 to 14 an addi-
tional absorption maximum at around lmax ¼ 440 nm was
observed, which ﬁts to the metal to ligand charge transfer (MLCT)
transition. The complexes revealed ﬂuorescence in the visible re-
gion at around lmax ¼ 600 nm and when excited at around
lex ¼ 440 nm.
Additionally, dynamic light scattering (DLS) experiments were
conducted and revealed the formation of particles with average
sizes of 500 ± 37 nm (PDI ¼ 0.146) for complex 14 dissolved in
water, whereas for all other complexes no well-deﬁned correlation
function was observable, indicating no particle formation.
2.2. Cytotoxicity and cell-type dependent uptake studies
To investigate the compounds regarding their cytotoxicity, non-
cancerous cell line L929 and breast cancer cell lines MCF-7 and
MDA-MB-231 were treated with ligands 6, 9 and 10 and metal
complexes 11 to 14 at varying concentrations for 24 h in serum-
containing media. As expected, none of the tested compounds
revealed signiﬁcant cytotoxicity for the tested cell lines using these
conditions (SI, Figs. S61eS63).
Since studies showed an enhanced uptake of D-fructose conju-
gated metal complexes into breast cancer cells [17,18], complexes
11 to 14 were also tested for their uptake behavior using ﬂow
cytometry and live-cell CLSM (SI, Figs. S64 and S65). As also pre-
viously reported [19,44], the ﬂuorescence of these kind of com-
plexes was quenched in aqueous media and therefore, no
meaningful results regarding their uptake could be obtained by
these measurements (SI, Fig. S60). To quantify the uptake of the
complexes into cells ICP-MS experiments were performed (SI,
Fig. S66). ICP-MS revealed an increased, unspeciﬁc uptake of sugar-
free complex 14 in comparison to the other complexes into all
tested cell lines. This might be attributed to the formation of par-
ticles in water and the resulting enhanced uptake into cells. The
Fig. 4. Details of A) 1H NMR spectrum of compound 11 in D2O; B)
1H NMR spectrum of compound 12 in D2O; C)
13C NMR spectrum of compound 11 in D2O; D)
13C NMR spectrum of
compound 12 in D2O.
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uptake of D-fructose conjugated complexes 12 and 13 into breast
cancer cell lines MDA-MB-231 and MCF-7 was not signiﬁcantly
increased in comparison to sucrose bearing complex 11. In contrast
to other studies [17,18], the results here show that for this type of D-
fructose substituted metal complexes an enhanced GLUT5 medi-
ated uptake is not observable.
3. Conclusion
In this work we presented the modiﬁcation of sucrose in a seven
step synthesis to modify the C6 position of the D-fructose unit
exclusively with a pyridyl triazole (pyta) group. The D-glucose unit
acts as protection group of the D-fructofuranose. Using this
approach, C6-modiﬁed D-fructose derivatives are accessible in high
yields, since up to now D-fructose derivatives were modiﬁed
exclusively at the C1 or C3 position. Additionally, pyridyl triazole
modiﬁed D-fructose via C1 was prepared in four-step synthesis,
starting from commercially available isopropylidene-protected D-
fructose. For both pyridyl triazole D-fructose derivatives as well as
for pyta sucrose, Ru complexes of the general formula [Ru(bpy)2(L)]
Cl2 were prepared. All compounds were analyzed by Rf values,
speciﬁc rotation, 1H NMR and 13C NMR, IR, UV/Vis and ﬂuorescence
spectroscopy, mass spectrometry as well as by elemental analysis.
No cytotoxic effects could be detected for concentrations up to
100 mmol  L1 against L929, MDA-MB-231 or MCF-7 cells.
4. Experimental part
4.1. Materials and general experimental details
All reagents and solvents were commercial products purchased
from Sigma-Aldrich, Fluka, Across Organics, Strem, VWR or Alfa
Aesar and were used without further puriﬁcation. Chromato-
graphic separations were performed with NP silica RediSep Car-
tridges from Teledyne Isco. The progress of the reactions was
monitored by thin-layer chromatography (TLC) using glass plates
precoated with silica gel 60 (Merck). Microwave-assisted syntheses
were performed in a Initiator Sixty single-mode microwave syn-
thesizer from Biotage equipped with a noninvasive IR sensor. FT-IR
measurements were conducted utilizing a Brewster angle setup.
Samples were prepared on clean double side polished silicon wa-
fers (p-type silicon wafers (100), resistivity 10e20 U cm obtained
from Siegert Wafer). Samples were dropcasted onto the wafer and
the solvent was allowed to dry. Spectra were obtained at a reso-
lution of 4 cm1 and 32 spectra were measured for each sample for
averaging purposes. Spectra were baseline corrected by the Bruker
analysis software OPUS 5.5. The alamarBlue solution for cytotox-
icity studies was purchased from Thermo Fisher. Cell cultivation
was performed at 37 C in a humidiﬁed 5% CO2 atmosphere. L929
(CCL-1, ATCC), MDA-MB231 (HTB-26, ATCC) and MCF-7(ATCC) cells
were cultured in Dulbecco's MEM (DMEM, Biochrom) supple-
mented with 10% fetal calf serum (FCS, Capricorn Scientiﬁc),
100 mg mL1 streptomycin and 100 IU mL1 penicillin (Biochrom,
Merck). HUVEC cells were kindly provided by the Institute of
Biochemistry, Friedrich Schiller University, group of Prof. Mosig.
Consumables for cell culture, like pipettes and cell culture plates
(96-well) were obtained from Corning (USA) and Greiner Bio-one
(Austria/Germany). Crystallographic data were corrected for Lor-
entz and polarization effects; absorptionwas taken into account on
a semi-empirical basis using multiple-scans [45,46] The structures
were solved by direct methods (SHELXS) and reﬁned by full-matrix
least squares techniques against Fo2 (SHELXL-97) [47]. All hydrogen
atoms (with exception of the methylene group of C23 from com-
pound 3) were located by difference Fourier synthesis and reﬁned
isotropically. The hydrogen atoms of the methylene group were
included at calculated positions with ﬁxed thermal parameters. All
non-hydrogen atoms were reﬁned anisotropically [47]. Crystallo-
graphic data as well as structure solution and reﬁnement details are
summarized in Table S2. MERCURY was used for structure repre-
sentations [48]. Dynamic light scattering experiments were carried
out at 25 C (l ¼ 633 nm) after an equilibration time of 120 s. The
counts were detected at an angle of 173. Each measurement was
performed in triplicate. The mean particle size was approximated
as the effective (Z-average) diameter and the width of the distri-
bution as the polydispersity index of the particles (PDI) obtained by
the cumulants method assuming a spherical shape of the particles.
4.2. Instrumentation
1H NMR and 13C NMR spectra were measured with Bruker
spectrometers (600, 500, 300 and 250 MHz). IR spectra were
recorded with a Bruker Tensor 37 FT-IR spectrometer. UV/Vis ab-
sorption spectra were measured with an AnalytikJenaAG Spe-
cord250 spectrometer and ﬂuorescence was recorded with a Jasco
FP 6500 (298 K, methanol, 105 M solutions). High Resolution
electron spray ionization mass spectrometry (HR-ESI-MS) was
measured with a Bruker MicroQTof. Elemental analysis was per-
formed with a Leco CHN-932. The alamarBlue cell viability assay
(Thermo Fisher) was performed with an Inﬁnite M200 PRO
microplate reader (Tecan) according to supplier's instructions.
Speciﬁc rotation was measured in a Jasco P-2000 polarimeter.
Crystallographic data was collected on a Nonius KappaCCD
diffractometer using graphite-monochromated Mo-Ka radiation.
For the uptake studies of HUVEC, MCF-7 and MDA-MB-231 cells a
ﬂow cytometer (Cytomics FC 500; Beckman Coulter, Krefeld, Ger-
many) and a confocal laser scanning microscope ELYRA PS1
LSM880 (Carl Zeiss, Jena, Germany) were used (see below). ICP-MS
measurements were performed using a XSeriesII (Thermo Fisher).
Dynamic light scattering was performed on a Zetasizer Nano ZS
(Malvern Instruments, Herrenberg, Germany).
4.3. Synthesis of the ligands
4.3.1. 60-O-tert-butyldiphenylsilyl-10,2,3,30,4,40,6-hepta-O-acetyl-
sucrose (1)
Silylated sucrose derivative was synthesized according to liter-
ature procedures [37,38].
4.3.2. 10,2,3,30,4,40,6-Hepta-O-acetyl-sucrose (2)
19 g (21.72 mmol) of 1 were dissolved in 380 mL DMF and a
solution of 5.679 g (21.72 mmol) TBAF and 1.242 mL (21.72 mmol)
CH3COOH in 27 mL H2O was added dropwise. The reaction mixture
was stirred for 24 h at room temperature. After TLC (SiO2, EtOAc:n-
hexane, v/v 2:1) indicated that no silylated sucrose was left, the
solvent was evaporated. The crude product was re-dissolved in
300 mL EtOAc, washed thrice with brine and the organic layer was
dried with Na2SO4. Puriﬁcation by column chromatography (SiO2,
EtOAc:n-hexane, v/v 2:1) resulted in 9.165 g (14.40 mmol) of a
colorless oil. Yield: 66%. Crystals were obtained by slow diffusion of
n-hexane in a solution of the ligand in CHCl3. Rf 0.75 (SiO2, EtOAc);
[a]20D ¼ þ139.8 (c 0.1, CHCl3); IR: ~n ¼ 2961 (nCH), 1749 (nCO) cm
1;
1H NMR (300 MHz, CDCl3): d 5.66 (s, 1H, H-1), 5.48e5.37 (m, 3H, H-
4, H-3, H-30), 5.10 (t, 1H, J3 9.51 Hz, H-5), 4.87 (d, 1H, J3 10.41 Hz, H-
2), 4.26e4.03 (m, 6H, H-6, H-10, H-40, H-50), 3.84 (dd, 2H, J212.81 Hz,
H-60), 2.16e1.99 (m, 21H, H-Ac). 13C NMR (75 MHz, CDCl3):
d 170.68e169.47 (CO), 103.3 (C-20), 90.07 (C-1), 81.64 (C-10), 76.11
(C-3), 73.66 (C-30), 70.25 (C-2), 69.37 (C-4), 68.74 (C-6), 67.96 (C-5),
63.89 (C-50), 61.41 (C-40), 61.14 (C-60), 20.73e20.55 (CH3). Calcd. for
C26H36O18 (636.56 g mol
1): C, 49.06; H, 5.70. Found: C, 49.23; H,
5.71. ESI-MS found [2MþK]þ (7.5%) 1311.32, [2MþNa]þ (33.6%)
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1295.35, [MþK]þ (71.9%) 675.15, [MþNa]þ (100%) 659.18.
4.3.3. 10,2,3,30,4,40,6-Hepta-O-acetyl-60-O-tosyl-sucrose (3)
7.35 g (10.99 mmol) of 2 were dissolved in 60 mL dry CH2Cl2,
8 mL (57.71 mmol) of Et3N were added and a solution of 2.39 g
(12.54 mmol) p-toluenesulfonyl chloride in 20 mL dry CH2Cl2 was
added dropwise at 0 C under Ar. After 2 h stirring at room tem-
perature, TLC (SiO2, EtOAc:n-hexane, v/v 2:1) indicated that no
starting material remained. The solution was washed thrice with
saturated, aqueous NaHCO3 solution, dried with Na2SO4 and puri-
ﬁed by column chromatography (SiO2, EtOAc:n-hexane, v/v 2:1) to
obtain 8.8 g (11.13 mmol) of a colorless oil. Yield: 96%. Crystals were
obtained by slow diffusion of n-hexane into a solution of the ligand
in CHCl3. Rf 0.23 (SiO2, EtOAc:n-hexane, v/v, 1:1); [a]
20
D¼þ168.2 (c
0.1, CHCl3); IR: ~n ¼ 1751 (nCO), 820 (d CH) cm
1; 1H NMR (600 MHz,
CDCl3): d 7.80 (d, 2H, J3 8.22 Hz, H-2
00), 7.36 (d, 2H, J3 8.28 Hz, H-3
00),
5.42 (d,1H, J3 6.12 Hz, H-1), 5.39e5.36 (m, 2H, H-3
0, H-3), 5.22 (t,1H,
J3 5.82 Hz, H-4
0), 4.98 (t, 1H, J3 9.90 Hz, H-4), 4.79 (dd, 1H, J3
10.44 Hz, 3.60 Hz, H-2), 4.32e4.19 (m, 4H, H-5, H-6, H-10), 4.11e4.03
(m, 4H, H-50, H-10, H-60), 2.46 (s, 3H, H-500), 2.13e2.00 (m, 21H, H-
Ac). 13C NMR (100 MHz, CDCl3): d 170.69e169.58 (CO), 145.18 (C-
100), 132.66 (C-400), 129.94 (C-300), 128.08 (C-200), 103.86 (C-20), 89.85
(C-1), 78.81 (C-10), 75.23 (C-3), 74.78 (C-30), 70.03 (C-2), 69.47 (C-4),
69.33 (C-6), 68.47 (C-5), 68.26 (C-50), 62.53 (C-40), 62.23 (C-60),
21.66 (C-500), 20.67e20.45 (CH3). Calcd. for C33H42O20S
(790.74 g  mol1): C, 50.12; H, 5.35; S, 4.06. Found: C, 50.29; H,
5.38; S, 4.16. HR-ESI-MS m/z calcd. for C33H42O20SNa [MþNa]
þ:
813.1882; found: 813.1855 (error: 3.4 ppm).
4.3.4. 10,2,3,30,4,40,6-Hepta-O-acetyl-6’-azido-6’-deoxy-sucrose (4)
5.673 g (7.17 mmol) of 3 were dissolved in 10 mL DMF, 2.8 g
(43.07 mmol) of NaN3 were added and the suspension was stirred
for 10 min in the microwave at 120 C. After cooling to room
temperature the solvent was removed and the crude product re-
dissolved in 200 mL EtOAc. The organic layer was washed thrice
with saturated, aqueous NaHCO3 solution, dried with Na2SO4 and
puriﬁed by column chromatography (SiO2, EtOAc:n-hexane, v/v
3:2) to obtain 4.704 g (7.11 mmol) of a colorless oil. Yield: 99%. Rf
0.32 (SiO2, EtOAc:n-hexane, v/v, 1:1); [a]
20
D ¼ þ108 (c 0.1, CHCl3);
IR: ~n ¼ 2104 (nazide), 1753 (nCO) cm
1; 1H NMR (300 MHz, CDCl3):
d 5.63 (d, 1H, J3 3.60 Hz, H-1), 5.50e5.43 (m, 2H, H-3
0, H-3), 5.31 (t,
1H, J3 6.17 Hz, H-4
0), 5.09 (t, 1H, J3 9.80 Hz, H-4), 4.91 (dd, 1H, J3
10.41 Hz, 3.63 Hz, H-2), 4.31e4.10 (m, 6H, H-5, H-6, H-50, H-10),
3.74e3.47 (m, 2H, H-60), 2.16e2.01 (m, 21H, H-Ac). 13C NMR
(75 MHz, CDCl3): d 170.67e169.56 (CO), 103.89 (C-2
0), 90.35 (C-1),
80.15 (C-50), 75.73 (C-30, C-40), 70.20 (C-2), 69.42 (C-3), 68.56 (C-5),
68.24 (C-4), 62.73 (C-10), 61.99 (C-6), 52.88 (C-60), 20.70e20.48
(CH3). Calcd. for C33H42O20S (661.57 gmol
1): C, 47.20; H, 5.33; N,
6.35. Found: C, 47.49; H, 5.37; N, 5.96. ESI-MS found [MþK]þ
(26.9%) 700.16, [MþNa]þ (100%) 684.18.
4.3.5. 10,2,3,30,4,40,6-Hepta-O-acetyl-6’-deoxy-6’-(4-(2-pyridyl)-
1,2,3-triazole-1-yl) sucrose (5)
4.704 g (7.11 mmol) of 4 and 1.077 mL (10.7 mmol) 2-ethynyl-
pyridine were dissolved in 5 mL degassed tert-butanol under Ar.
585 mg (2.95 mmol) of sodium ascorbate and 383 mg (1.53 mmol)
of Cu(II)SO4  5H2O in each 2.5 mL degassed H2O were added and
the mixture was heated at 60 C for 25 min under microwave
irradiation. After TLC (SiO2, EtOAc:n-hexane, v/v 1:1) indicated that
no starting material remained, the solvent was evaporated and the
crude product was re-dissolved in 250 mL of EtOAc and washed
thrice with each 100 mL of aqueous ammonia solution (25%) and
once with 200 mL brine. The organic layer was dried with Na2SO4
and puriﬁed by column chromatography (SiO2, EtOAc) to obtain
4.493 g (5.88 mmol) of a colorless oil. Yield: 83%. Rf 0.57 (SiO2,
EtOAc); [a]20D ¼ þ119.8 (c 0.1, CHCl3); UVeVis: l (CH3OH, ε  10
3/
M1 cm1): 280 (14.97) nm; IR: ~n ¼ 1751 (nCO) cm
1. 1H NMR
(300 MHz, CDCl3): d 8.58 (d, 1H, J3 4.29 Hz, H-6py), 8.26 (s, 1H, H-
5ta), 8.17 (d, 1H, J3 7.92 Hz, H-3py), 7.80 (t, 1H, J3 7.74 Hz, H-4py), 7.25
(m, 1H, H-5py), 5.65 (d, 1H, J3 3.54 Hz, H-1), 5.56e5.41 (m, 3H, H-3
0,
H-3, H-4), 5.08 (t, 1H, J3 9.86 Hz, H-4
0), 4.97e4.75 (m, 3H, H-2, H-6),
4.54e4.49 (m, 1H, H-5), 4.35e4.29 (m, 1H, H-50), 4.25e3.93 (m, 4H,
H-10, H-60), 2.18e2.01 (m, 21H, H-Ac). 13C NMR (75 MHz, CDCl3):
d 170.51e169.53 (CO), 150.00 (C-6py), 149.31 (C-2py), 148.37 (C-4ta),
137.00 (C-5py), 123.33 (C-5ta), 122.94 (C-3py), 120.34 (C-4py), 103.79
(C-20), 90.26 (C-1), 79.53 (C-50), 75.51 (C-3), 74.93 (C-30), 69.94 (C-
2), 69.35 (C-40), 69.04 (C-5), 68.32 (C-4), 62.63 (C-10), 62.31 (C-6),
53.04 (C-60), 20.67e20.48 (CH3). Calcd. for C33H40N4O17
(764.69 g  mol1): C, 51.83; H, 5.27; N, 7.33. Found: C, 51.96; H,
5.43; N, 7.16. HR-ESI-MS m/z calcd. for C33H40N4O17Na [MþNa]
þ:
787.2281; found: 787.2278 (error: 0.3 ppm).
4.3.6. 60-Deoxy-6’-(4-(2-pyridyl)-1,2,3-triazole-1-yl) sucrose (6)
4.493 g (5.88 mmol) of 5 were dissolved in 100 mL dry CH3OH
and 76.4mL of a 0.5 MNaOMe solution (38.2mmol) in CH3OHwere
slowly added under argon. Themixturewas stirred for 24 h at room
temperature and Amberlite IR-120 (Hþ) resin was added until the
pH value changed to 7. The resin was ﬁltered, washed with CH3OH
and the solvent was evaporated. The crude product was re-
dissolved in water and washed thrice with CHCl3. Then, the
aqueous layer was freeze-dried to obtain 2.72 g (5.78 mmol) of a
colorless oil. Yield: 98%. Rf 0.22 (SiO2, CH3CN:H2O:KNO3(aq), v/v,
40:4:1); [a]20D¼þ69.6 (c 0.1, CH3OH); UVeVis: l (CH3OH, ε 10
3/
M1 cm1): 281 (13.19) nm. IR: ~n ¼ 3333 (nOH) cm
1. 1H NMR
(300 MHz, CDCl3): d 8.45e8.08 (m, 2H, H-5ta, H-6py), 7.85e7.57 (m,
2H, H-3py, H-4py), 7.22 (s, 1H, H-5py), 5.32 (d, 1H, J3 3.60 Hz, H-1),
4.8e4.6 (m, 2H, H-3, H-4), 4.19e4.00 (m, 3H, H-40, H-6), 3.86e3.40
(m, 7H, H-5, H-10, H-30, H-50, H-60), 3.31 (t, 1H, J3 9.45 Hz, H-2).
13C
NMR (75 MHz, CDCl3): d 148.91 (C-2py), 144.68 (C-6py), 138.39 (C-
3py, C-4py, C-5py), 124.46 (C-4ta, C-5ta), 104.05 (C-2
0), 92.22 (C-1),
79.02 (C-50), 76.19 (C-3), 75.60 (C-30), 72.77 (C-2), 72.53 (C-40),
70.99 (C-5), 69.48 (C-4), 61.14 (C-10), 60.61 (C-6), 52.98 (C-60). Calcd.
for C19H26N4O10  2.5 H2O (515.48 g mol
1): C, 44.27; H, 6.06; N,
10.87. Found: C, 44.44; H, 5.77; N, 10.84. HR-ESI-MS m/z calcd. for
C19H26N4O10Na [MþNa]
þ: 493.1501; found: 493.1481 (error:
4.0 ppm).
4.3.7. 1-Azido-1-deoxy-2,3:4,5-di-O-isopropylidene-b-D-
fructopyranose (7)
The azide was synthesized as previously reported [40].
4.3.8. 1-(4-(2-Pyridyl)-1,2,3-triazole-1-yl)-1-deoxy-2,3:4,5-di-O-
isopropylidene-b-D-fructopyranose (8)
6.777 g (23.8 mmol) of 7 and 2.88 mL of 2-ethynyl pyridine
(28.5 mmol) were dissolved in 100 mL degassed THF. 471 mg
(2.4 mmol) of sodium ascorbate and 297 mg (1.2 mmol) of Cu(II)
SO4  5H2O in each 5 mL degassed H2O were added and the
mixture was heated to 60 C for two days. After TLC (SiO2, EtOAc:n-
hexane, v/v 1:2) indicated that no starting material remained, the
solvent was evaporated and the crude product was re-dissolved in
300 mL EtOAc and washed thrice with each 100 mL of aqueous
ammonia solution (25%) and once with 200 mL of brine. The
organic layer was dried with Na2SO4, ﬁltered and the solvent was
evaporated. The crude product was re-crystallized from a mixture
of EtOAc and n-hexane (EtOAc:n-hexane, v/v 1:4) to obtain 8.521 g
(5.88 mmol) of a colorless oil. Yield: 92%. Rf 0.22 (SiO2, EtOAc:n-
hexane, v/v, 1:1); [a]20D ¼ þ42 (c 0.1, CHCl3); UVeVis: l (CH3OH,
ε  103/M1 cm1): 279 (8.90); 238 (14.79) nm. IR: ~n ¼ 3159
(n¼CH); 1605 (nC¼C); 1421 (d¼CH); 1045 (d¼CH); 1011 (d¼CH); 980
(d¼CH) cm
1. 1H NMR (300 MHz, CDCl3): d 8.60 (d, 1H, J3 4.80 Hz, H-
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6py), 8.30 (s, 1H, H-5ta), 8.19 (d, 1H, J3 7.96 Hz, H-3py), 7.80 (td, 1H, J3
1.68 Hz,1H, H-4py), 7.24 (m,1H, H-5py), 4.81 (d,1H, J214,31 Hz, H-1),
4.68e4.60 (m, 2H, H-4, H-1), 4.52 (d, 1H, J3 2.73 Hz, H-3), 4.27 (m,
1H, H-5), 3.95e3.78 (m, 2H, H-6), 1.50e0.87 (4s, 12H, CH3).
13C NMR
(75 MHz, CDCl3): d 150.32 (C-6py), 149.40 (C-2py), 148.16 (C-4ta),
136.81 (C-4py), 124.80 (C-5ta), 122.77 (C-5py), 120.29 (C-3py), 109.52
(Cq), 109.31 (Cq), 100.81 (C-2), 70.78 (C-3), 70.58 (C-5), 70.11 (C-4),
61.89 (C-6), 55.34 (C-1), 26.35e24.05 (CH3). Calcd. for C33H40N4O17
(388.42 g  mol1): C, 58.75; H, 6.23; N, 14.42. Found: C, 58.80; H,
6.27; N, 14.46. HR-ESI-MS m/z calcd. for C19H25N4O5 [MþH]
þ:
389.1819; found: 389.1818 (error: 0.3 ppm).
4.3.9. 1-(4-(2-Pyridyl)-1,2,3-triazole-1-yl)-1-deoxy-b-D-
fructopyranose (9)
515 mg of 8 (1.33 mmol) were dissolved in 10 mL of ethanol and
5 mL of an aqueous 2 M HCl solution were added slowly. After
10 mL of water were added, the solution was heated to 40 C for
12 h and stirred at rt for additional 24 h. After TLC (SiO2, EtOAc)
indicated that no starting material remained, the solution was
neutralized with NaHCO3 and lyophilized. The crude residue was
thrice suspended in 100 mL of dry acetonitrile and ﬁltered. The
organic layers were combined and the solvent was evaporated to
obtain 360 mg (1.17 mmol) of a colorless oil. Yield: 88%. Rf 0.42
(SiO2, CH3CN:H2O:KNO3(aq), v/v, 40:4:1); [a]
20
D ¼ 24 (c 0.1,
CH3OH); UVeVis: l (CH3OH, ε  10
3/M1 cm1): 280 (36.38); 240
(57.27) nm. IR: ~n ¼ 3537 (nOH), 3493 (nOH), 3360 (nOH), 3176 (nOH)
cm1. 1H NMR (250 MHz, DMSO-d6): d 8.60 (d, 1H, J3 2.04 Hz, H-
6py), 8.51e8.37 (m, 1H, H-5ta), 8.05 (d, 1H, J3 8.04 Hz, H-3py), 7.92 (t,
1H, J3 7.69 Hz, H-4py), 7.35 (t, 1H, J3 5.80 Hz, H-5py), 6.22e4.75 (m,
4H, 2-OH, 3-OH, 4-OH, 5-OH), 4.68e4.41 (m, 2H, H-1), 3.91e3.35
(m, 5H, H-3, H-4, H-5, H-6). 13C NMR (75 MHz, DMSO-d6): d 150.67
(C-2py), 150.60 (C-2py), 150.48 (C-2py), 150.04 (C-6py), 150.01 (C-6py),
147.38 (C-4ta), 147.26 (C-4ta), 147.17 (C-4ta), 137.64 (C-4py), 137.61 (C-
4py), 124.77 (C-5ta), 124.67 (C-5ta), 124.62 (C-5ta), 123.36 (C-5py),
123.27 (C-5py), 123.23 (C-5py), 119.81 (C-3py), 119.77 (C-3py), 103.19
(C-2), 100.67 (C-2), 97.17 (C-2), 96.60 (C-2), 83.09 (C-3), 82.75 (C-3),
82.53 (C-3), 77.50 (C-5), 76.58 (C-5), 75.16 (C-5), 69.98 (C-4), 69.20
(C-4), 68.78 (C-4), 64.24 (C-6), 63.10 (C-6), 61.69 (C-6), 55.22 (C-1),
54.78 (C-1), 54.61 (C-1). Calcd. for C13H16N4O5 (308.29 g  mol
1):
C, 50.65; H, 5.23; N, 18.17; found: C, 50.37; H, 5.15; N, 18.15. HR-ESI-
MS m/z calcd. for C13H17N4O5 [MþH]
þ: 309.1193; found: 309.1186
(error: 2.5 ppm).
4.3.10. 2-(1-(4-(tert-Butyl)benzyl)-1H-1,2,3-triazole-4-yl)pyridine
(10)
The ligand was synthesized like previously reported [49].
Crystals were obtained by slow diffusion of n-hexane into a solution
of the ligand in CHCl3.
4.4. Synthesis of the complexes
4.4.1. 60-Deoxy-6’-(4-(2-pyridyl)-1,2,3-triazole-1-yl) sucrose
bis(2,2’-bipyridine) ruthenium(II) dichloride (11)
To a solution of 200 mg (0.43 mmol) of 6 in 25 mL CH3OH,
206 mg (0.43 mmol) of Ru(bpy)2Cl2 in 25 mL CH3OH and 60 mL
(0.43 mmol) Et3N were added. The mixture was stirred for 12 h at
60 C. After cooling to room temperature the mixture was
concentrated and was puriﬁed by a sephadex LH-20 column in H2O
to obtain 198 mg (0.25 mmol) of a red oil. Yield: 58%. Rf 0.1 (SiO2,
CH3CN:H2O:KNO3(aq), v/v, 40:4:1); [a]
20
D ¼ þ60.2 (c 0.1, CH3OH);
UVeVis: l (CH3OH, ε  10
3/M1 cm1): 444 (11.97), 287 (54.07)
nm. Fluorescence (CH3OH, lex ¼ 444 nm): lem ¼ 599 nm. IR:
~n ¼ 3343 (nOH), 1643 (nC¼N) cm
1. 1H NMR (300 MHz, D2O): d 8.81
(m, 2H, H-5ta), 8.43 (m, 8H, H-3bpy, H-3'bpy), 8.08 (m, 2H, H-6py),
7.96e7.71 (m, 18H, H-3py, H-4bpy, H-4'bpy, H-6bpy, H-6'bpy), 7.62 (m,
2H, H-4py), 7.36e7.10 (m, 10H, H-5py, H-5bpy, H-5'bpy), 5.23 (m, 1H,
H-1), 4.99 (m, 1H, H-1), 4.11e3.14 (m, 26H, H-2, H-3, H-4, H-5, H-6,
H-10, H-30, H-40, H-50, H-60). 13C NMR (125 MHz, D2O):
d 157.61e156.95 (C-2bpy, C-2'bpy), 152.04e151.43 (C-6py, C-6'py),
150.59 (C-2py), 148.20 (C-6py), 148.17 (C-6py), 137.94 (C-4ta),
137.65e137.32 (C-4py, C-4bpy, C-4'bpy), 127.16e125.65 (C-3py, C-3bpy,
C-3'bpy), 123.94 (C-5ta),123.66e122.63 (C-5py, C-5bpy, C-5'bpy),
103.98 (C-20), 103.83 (C-20), 92.18 (C-1), 91.86 (C-1), 78.59 (C-50),
78.47 (C-50), 76.04 (C-3), 75.92 (C-3), 75.69 (C-30), 75.63 (C-30),
72.83 (C-2), 72.62 (C-2), 72.51 (C-40), 72.44 (C-40), 70.99 (C-5), 70.93
(C-5), 69.60 (C-4), 69.57 (C-4), 60.93 (C-10), 60.87 (C-10), 60.71 (C-6),
60.59 (C-6), 54.37 (C-60), 54.26 (C-60). HR-ESI-MS m/z calcd. for
C39H42N8O10Ru [M-2Cl]
2þ: 442.1028; Found: 442.1021 (error: 2.9).
4.4.2. 6’-(4-(2-Pyridyl)-1,2,3-triazole-1-yl)-6’-deoxy-D-
fructofuranose bis(2,2’-bipyridine) ruthenium(II) dichloride (12)
118 mg (0.12 mmol) of 11 were dissolved in 40 mL H2O and
20mL 2MHClwere added and the resultingmixturewas stirred for
16 h at 40 C. After TLC (SiO2, CH3CN:H2O:KNO3(aq), v/v, 40:4:1)
indicated that no starting material remained, the solution was
neutralized with aqueous 2 M NaOH solution. The solution was
concentrated and puriﬁed by a Sephadex LH-20 column in H2O to
obtain 50 mg (0.06 mmol) of a red oil. Yield: 51%. Rf 0.14 (SiO2,
CH3CN:H2O:KNO3(aq), v/v, 40:4:1); [a]
20
D ¼ þ39.2 (c 0.1, CH3OH);
UVeVis: l (CH3OH, ε  10
3/M1 cm1): 443 (12.26), 286 (56.24),
239 (31.20) nm. Fluorescence (CH3OH, lex ¼ 444 nm):
lem ¼ 600 nm. IR: ~n ¼ 3379 (nOH), 1607 (nC¼N), 779 (dbpy) cm
1. 1H
NMR (500 MHz, D2O): d 8.89 (m, 2H, H-5ta), 8.46e8.34 (m, 8H, H-
3bpy, H-3'bpy), 8.1 (m, 2H, H-6py), 8.01e7.69 (m, 18H, H-3py, H-4bpy,
H-4'bpy, H-6bpy, H-6'bpy), 7.61 (t,
3J ¼ 4.63 Hz, 2H, H-4py), 7.39e7.15
(m, 10H, H-5py, H-5bpy, H-5'bpy), 4.67e2.60 (m, 14H, H-1
0, H-30, H-40,
H-50, H-60). 13C NMR (125 MHz, D2O): d 157.47e156.93 (C-2bpy, C-
2'bpy), 151.89e151.43 (C-6bpy, C-6'bpy), 150.62e150.56 (C-2py), 147.92
(C-6py), 147.88 (C-6py), 137.94 (C-4ta), 137.72e137.31 (C-4py, C-4bpy,
C-4'bpy), 127.31e126.47 (C-3py, C-3bpy, C-3'bpy), 125.65 (C-5ta),
123.96e122.66 (C-5py, C-5bpy, C-5'bpy), 105.12 (C-2
0), 104.61 (C-20),
102.15 (C-20), 101.97 (C-20), 81.26 (C-50), 81.11 (C-50), 79.24 (C-30),
78.42 (C-30), 77.86 (C-50), 77.68 (C-50), 77.16 (C-40), 76.60 (C-40),
75.13 (C-30), 75.06 (C-30), 74.64 (C-40), 74.62 (C-40), 62.86 (C-10),
62.45 (C-10), 62.27 (C-10), 62.20 (C-10), 53.50 (C-60), 52.71 (C-60),
52.33 (C-60), 46.66 (C-60). HR-ESI-MS m/z calcd. for C33H32N8O5Ru
[M-2Cl]2þ: 361.0764; found: 361.0775 (error: 1.9 ppm).
4.4.3. 1-(4-(2-Pyridyl)-1,2,3-triazole-1-yl)-1-deoxy-b-D-
fructopyranose bis(2,2’-bipyridine) ruthenium(II) dichloride (13)
85 mg of 9 (0.28 mmol) and 134 mg of Ru(bpy)2Cl2 (0.28 mmol)
were dissolved in 15 mL DMF and were stirred at 125 C for 2 h in
the microwave. After cooling to room temperature, the solvent was
evaporated in vacuo. The crude product was redissolved in 3 mL of
H2O, ﬁltered and was puriﬁed by a Sephadex LH-20 column in H2O
to obtain 106 mg (0.13 mmol) of a red oil. Yield: 48%. Rf 0.14 (SiO2,
CH3CN:H2O:KNO3(aq), v/v, 40:4:1); [a]
20
D ¼ 21 (c 0.1, CH3OH);
UVeVis: l (CH3OH, ε  10
3/M1 cm1): 440 (9.14); 285 (53.24);
240 (24.92) nm. Fluorescence (CH3OH, lex ¼ 439 nm):
lem ¼ 604 nm. IR: ~n ¼ 3402 (nOH), 1603 (nC¼N), 779 (dbpy) cm
1. 1H
NMR (400 MHz, DMSO-d6): d 9.67e9.37 (m, 2H, H-5ta), 8.94e8.48
(m, 10H, H-6py, H-3bpy, H-3'bpy), 8.23e8.07 (m, 10H, H-3py, H-6bpy,
H-6'bpy), 7.91e7.39 (m, 20H, H-4py, H-5py, H-4bpy, H-4'bpy, H-5bpy, H-
5'bpy), 6.55e6.18 (m, 2H, 3-OH), 5.98e5.67 (m, 2H, 5-OH),
5.46e5.34 (m, 4H, 5-OH, 4-OH), 5.11e4.99 (m, 2H, 4-OH), 4.96e4.68
(m, 2H, 2-OH), 4.69e4.33 (m, 4H, H-1), 4.02e3.21 (m,10H, H-3, H-4,
H-5, H-6). 13C NMR (75 MHz, CDCl3): d 157.74e157.08 (C-2bpy, C-
2'bpy), 152.23e151.58 (C-6bpy, C-6'bpy), 151.29 (C-2py), 151.11 (C-2py),
147.19 (C-6py), 147.07 (C-6py), 138.80 (C-4ta), 138.32e138.09 (C-4py,
C-4bpy, C-4'bpy), 128.26e126.61 (C-3py, C-3bpy, C-3'bpy), 126.52 (C-
M. Pr€ohl et al. / Carbohydrate Research 446-447 (2017) 19e27 25
5ta), 125.02 (C-5ta), 124.89e123.22 (C-5py, C-5bpy, C-5'bpy), 102.72 (C-
2), 102.54 (C-2), 100.34 (C-2), 100.11 (C-2), 96.84 (C-2), 96.40 (C-2),
83.58 (C-3), 82.99 (C-3), 82.59 (C-3), 82.36 (C-3), 82.17 (C-3), 79.09
(C-5), 78.49 (C-5), 76.63 (C-5), 75.35 (C-5), 70.16 (C-4), 70.00 (C-4),
69.46 (C-4), 69.30 (C-4), 69.10 (C-4), 64.43 (C-6), 62.99 (C-6), 61.42
(C-6), 61.19 (C-6), 57.99 (C-1), 57.38 (C-1), 57.17 (C-1), 56.86 (C-1).
HR-ESI-MS m/z calcd. for C33H32N8O5Ru [M-2Cl]
2þ: 361.0764;
Found: 361.0769 (error: 0.2 ppm).
4.4.4. 2-(1-(4-(tert-Butyl)benzyl)-1H-1,2,3-triazole-4-yl)pyridine
bis(2,2’-bipyridine) ruthenium(II) dichloride (14)
195 mg (0.40 mmol) of Ru(bpy)2Cl2 precursor complex were
dissolved in 10 mL CH3OH and 118 mg (0.40 mmol) of ligand 10 in
20 mL CH3OH were slowly added. The mixture was stirred for
12 h at 60 C. After cooling to room temperature the mixture was
concentrated and puriﬁed by a Sephadex LH-20 column in CH3OH
to obtain 262 mg (0.34 mmol) of a red oil. Yield: 85%. Rf 0.42 (SiO2,
CH3CN:H2O:KNO3(aq), v/v, 40:4:1); [a]
20
D ¼ 7.2 (c 0.1, CH3OH);
UVeVis: l (CH3OH, ε  10
3/M1 cm1): 443 (12.11); 287 (54.57)
nm. Fluorescence (CH3OH, lex ¼ 444 nm): lem ¼ 600 nm. IR:
~n ¼ 1608 (nC¼N), 777 (dbpy) cm
1. 1H NMR (500 MHz, DMF-d7):
d 10.05 (s, 1H, H-5ta), 9.16 (m, 2H,H-3bpy), 9.08 (m, 2H, H-3'bpy), 8.72
(d, 1H, J3 7.90 Hz, H-6py), 8.31 (m, 3H, H-4bpy, H-4'bpy), 8.24 (t, 1H, J3
3.43 Hz, H-4'bpy), 8.19 (m, 3H, H-6bpy, H-6'bpy), 8.10 (d,1H, J3 5.45 Hz,
H-3py), 8.04 (t, 1H, J3 4.88 Hz, H-5py), 7.88 (d, 1H, J3 5.49 Hz, H-6bpy),
7.68 (m, 3H, H-5bpy, H-4py), 7.60 (m, 1H, H-5'bpy), 7.53 (m, 1H, H-
5'bpy), 7.40 (m, 2H, H-3Bn), 7.21 (m, 2H, H-2Bn), 5.89 (q, 2H, J3
24.01 Hz, CH2), 1.29 (s, 9H, CH3) ppm.
13C NMR (125 MHz, DMF-d7):
d 157.98 (C-2bpy), 157.62 (C-2bpy), 157.53 (C-4Bn), 157.28 (C-1Bn),
152.37 (C-5py), 152.29 (C-6bpy), 152.00 (C-3py), 151.79 (C-6bpy),
151.51 (C-2py), 151.16 (C-2'bpy), 148.07 (C-5ta), 138.46 (C-6'bpy),
138.07 (C-5py), 137.87 (C-4'bpy), 131.89 (C-4ta), 127.91 (C-4py), 127.84
(C-2Bn), 127.44, 127.16 (C-5'bpy), 126.28 (C-5'bpy), 125.81 (C-3Bn),
124.94 (C-5bpy), 124.89 (C-3bpy), 124.44 (C-3'bpy), 124.15 (C-3'bpy),
123.26 (C-6py), 54.85 (CH2), 48.78 (Cq), 30.80 (CH3).
4.5. Biological studies
4.5.1. Determination of cytotoxicity
Cytotoxicity studies were performed with L929, MCF-7 and
MDA-MB-231 cells. Cells were seeded at 104 cells per well in a 96-
well plate and incubated for 24 h. Afterwards, the test substances (6
and 9 to 14) at indicated concentrations (25, 50, 100 mmol L1) were
added to the cells and the plates were incubated for further 24 h.
Subsequently, the medium was replaced by a mixture of fresh
culture medium and alamarBlue solution (Thermo Fisher), pre-
pared according to the manufacturer's instructions. After a further
incubation of 4 h at 37 C, the ﬂuorescence was measured at
lex ¼ 570 nm/lex ¼ 610 nm, with untreated cells on the same well
plate serving as negative controls. The negative control was stan-
dardized as 0% of metabolism inhibition and referred as 100%
viability. Data are expressed as mean ± SD of three independent
determinations.
4.5.2. Uptake studies
HUVEC, MCF-7 and MDA-MB-231 cells were cultured as
described above. Subsequently, cells were seeded at a density of
105 cells per mL in 24-well plates and cultured for 24 h. One hour
prior to the addition of the complexes, themediumwas replaced by
fresh culture medium. The plates were incubated for 1 h at 37 C
under 5% CO2 atmosphere. Metal complexes were added to the cells
at indicated concentrations for 1 h. Afterwards the cells were
washed, harvested and 10% trypan blue was added to quench the
outer ﬂuorescence of the cells. To determine the relative uptake of
the metal complexes, 10,000 cells were measured by ﬂow
cytometry using a Cytomics FC 500 (Beckman Coulter). The ex-
periments were performed at least three times independently. Live
cell imaging was additionally performed for uptake studies. In
detail, cells (105 cells mL1) were seeded on glass-bottomed dishes
(Greiner, Germany) and cultivated for 24 h in a humidiﬁed atmo-
sphere. One hour prior to the metal complex addition, the cells
were rinsed with phosphate buffered saline (PBS) and the medium
was changed to fresh culture medium. The metal complexes were
added to the cells and incubated for one additional hour. Imaging
was performed with LSM880, ELYRA PS.1 system (Zeiss, Oberko-
chen, Germany) applying a 63  1.4 NA plan apochromat oil
objective. The excitation wavelength was lex ¼ 488 nm and the
ﬂuorescence was detected from l ¼ 553e650 nm. Since the com-
plexes showed no measurable ﬂuorescence in aqueous media, ICP-
MS studies were performed. Cells were grown to 50% conﬂuency in
a 6-well plate. Unless speciﬁed, the cells were incubated with the
Ru complexes 11 to 14 (50 mM) in D-fructose-free medium at 37 C
under a 5% CO2 atmosphere for 1 h. The mediumwas then removed
and cells were washed gently with PBS. The cells were trypsinized
and harvested. The harvested cells were digested with 65% HNO3 at
60 C in an ultrasonic bath for 1 h and afterwards incubated at room
temperature over night to ensure complete digestion. The samples
were then diluted with ultrapure water (Millipore Merck) to a ﬁnal
concentration of 2% HNO3 and measured by ICP-MS.
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Figure S1. 1H NMR spectrum of 2 in CDCl3. 
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Figure S2. 13C NMR spectrum of 2 in CDCl3. 
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Figure S3. ESI-TOF-MS spectrum of 2 in acetonitrile. 
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Figure S4. IR spectrum of 2. 
 
 
Figure S5. Molecular structure of 2. Crystals were obtained by diffusion of n-hexane into a solution of 2 in CHCl3. 
Thermal ellipsoids are drawn at 50% propability and hydrogen atoms are omitted for clarity. Blue-colored carbon C26 
represents the C6’ position of the sucrose derivative. 
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Figure S6. 1H NMR spectrum of 3 in CDCl3. 
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Figure S7. 13C NMR spectrum of 3 in CDCl3. 
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Figure S8. ESI-TOF-MS spectrum of 3 in acetonitrile. 
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Figure S9. IR spectrum of 3. 
 
 
Figure S10. Molecular structure of 3. Crystals were obtained by diffusion of n-hexane into a solution of 3 in CHCl3. 
Thermal ellipsoids are drawn at 50% propability and hydrogen atoms are omitted for clarity. Blue-colored carbon C26 
represents the C6’ position of the sucrose derivative.  
8 
 
O
AcO
AcO
O
OAc
OAc
OAc
OAcO
OAc
N3
4
1
2
3
4 5
6
1'
2' 3'
4'
5'
6'
 
 
10 8 6 4 2 0
δ [ppm]
 
Figure S11. 1H NMR spectrum of 4 in CDCl3. 
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Figure S12. 13C NMR spectrum of 4 in CDCl3. 
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Figure S13. ESI-TOF-MS spectrum of 4 in acetonitrile. 
10 
 
4000 3500 3000 2500 2000 1500 1000 500
0,0
0,2
0,4
0,6
0,8
1,0
2104
1753
Tr
a
n
sm
is
si
on
λ-1 [cm-1]
 
Figure S14. IR spectrum of 4. 
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Figure S15. 1H NMR spectrum of 5 in CDCl3. 
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Figure S16. 13C NMR spectrum of 5 in CDCl3. 
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Figure S17. ESI-TOF-MS spectrum of 5 in acetonitrile. 
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Figure S18. IR spectrum of 5. 
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Figure S19. UV-Vis spectrum of 5 (10-5 M, aerated CH3OH). 
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Figure S20. 1H NMR spectrum of 6 in D2O. 
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Figure S21. 13C NMR spectrum of 6 in D2O. 
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Figure S22. ESI-TOF-MS spectrum of 6 in acetonitrile. 
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Figure S23. IR spectrum of 6. 
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Figure S24. UV-Vis spectrum of 6 (10-5 M, aerated CH3OH). 
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Figure S25. 1H NMR spectrum of 8 in CDCl3. 
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Figure S26. 13C NMR spectrum of 8 in CDCl3. 
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Figure S27. ESI-TOF-MS spectrum of 8 in acetonitrile. 
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Figure S28. IR spectrum of 8. 
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Figure S29. UV-Vis spectrum of 8 (10-5 M, aerated CH3OH). 
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Figure S30. 1H NMR spectrum of 9 in DMSO-d6. 
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Figure S31. 13C NMR spectrum of 9 in DMSO-d6. 
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Figure S32. ESI-TOF-MS spectrum of 9 in acetonitrile. 
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Figure S33. IR spectrum of 9. 
 
300 400 500 600 700
0
10
20
30
40
50
60 λmax = 240 nm
ε *
 
10
-
3  
[M
-
1  
*
 
cm
-
1 ]
λ [nm]
λ
max
 = 280 nm
 
Figure S34. UV-Vis spectrum of 9 (10-5 M, aerated CH3OH). 
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Figure S35. Molecular structure of 10. Crystals were obtained by diffusion of n-hexane into a solution of 3 in CHCl3. 
Thermal ellipsoids are drawn at 50% propability and hydrogen atoms are omitted for clarity. 
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Figure S36. 1H NMR spectrum of 11 in D2O. 
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Figure S37. 13C NMR spectrum of 11 in D2O. 
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Figure S38. ESI-TOF-MS spectrum of 11 in acetonitrile. 
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Figure S39. IR spectrum of 11. 
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Figure S40. UV-Vis spectrum of 11 (10-5 M, aerated CH3OH). 
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Figure S41. Emission spectrum of 11 (10-5 M, aerated CH3OH, λex = 444 nm). 
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Figure S42. 1H NMR spectrum of 12 in D2O. 
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Figure S43. 13C NMR spectrum of 12 in D2O. 
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Figure S44. ESI-TOF-MS spectrum of 12 in acetonitrile. 
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Figure S45. IR spectrum of 12. 
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Figure S46. UV-Vis spectrum of 12 (10-5 M, aerated CH3OH). 
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Figure S47. Emission spectrum of 12 (10-5 M, aerated CH3OH, λex = 444 nm). 
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Figure S48. 1H NMR spectrum of 13 in DMSO-d6. 
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Figure S49. Assignment of different forms of D-fructose to signals in 1H NMR spectrum of 13. 
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Figure S50. 13C NMR spectrum of 13 in DMSO-d6. 
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Figure S51. ESI-TOF-MS spectrum of 13 in acetonitrile. 
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Figure S52. IR spectrum of 13. 
35 
 
300 400 500 600 700
0
10
20
30
40
50
60
λ
max
 = 440 nm
ε *
 
10
-
3  
[M
-
1  
*
 
cm
-
1 ]
λ [nm]
λ
max
 = 285 nm
λ
max
 = 240 nm
 
Figure S53. UV-Vis spectrum of 13 (10-5 M, aerated CH3OH). 
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Figure S54. Emission spectrum of 13 (10-5 M, aerated CH3OH, λex = 439 nm). 
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Figure S55. 1H NMR spectrum of 14 in DMF-d7. 
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Figure S56. 13C NMR spectrum of 14 in DMF-d7. 
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Figure S57. IR spectrum of 14. 
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Figure S58. UV-Vis spectrum of 14 (10-5 M, aerated CH3OH). 
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Figure S59. Emission spectrum of 14 (10-5 M, aerated CH3OH, λex = 444 nm). 
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Table S1. Summarized absorption emission data of all measured compounds. 
Compound 
Absorption wavelength 
λ / nm 
Extinction coefficient 
ε × 10-3 / M-1 cm-1 
Emission wavelength λ / nm  
(excitation wavelength λex / nm) 
5 280 14.97 - 
6 281 13.19 - 
8 279; 238 8.90; 14.79 - 
9 280; 240 36.38; 57.27 - 
11 444; 287 11.97; 54.07 599 (444) 
12 443; 286; 239 12.26; 56.24; 31.20 600 (444) 
13 440, 285, 240 9.14; 53.24; 24.92 604 (439) 
14 443; 287 12.11; 54.57 600 (444) 
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Table S2. Crystal data and refinement details for the X-ray structure determinations of the compounds 2, 3 and 10. 
Compound 2 3 10 
formula C26H36O18 C33H42O20S C18H20N4 
fw (g∙mol-1) 636.55 790.73 292.38 
T/°C -140(2) -140(2) -140(2) 
crystal system monoclinic orthorhombic triclinic 
space group P 21 P 21 21 21 P ī 
a/ Å 13.2532(3) 12.9943(1) 5.9855(2) 
b/ Å 8.3392(2) 13.7547(1) 11.2424(4) 
c/ Å 13.8749(4) 21.6137(2) 12.3320(4) 
α/° 90 90 101.426(2) 
β/° 92.726(1) 90 100.763(2) 
γ/° 90 90 97.072(2) 
V/Å3 1531.73(7) 3863.07(5) 787.96(5) 
Z 2 4 2 
ρ (g∙cm-3) 1.380 1.360 1.232 
µ (cm-1)  1.18  1.64  .76 
measured data 11782 23896 7827 
data with I > 2σ(I) 5796 8394 2962 
unique data (Rint) 6747/0.0322 8856/0.0236 3567/0.0259 
wR2 (all data, on F2)a) 0.0957 0.0782 0.1249 
R1 (I > 2σ(I)) a) 0.0508 0.0326 0.0524 
S b) 1.135 1.070 1.036 
Res. dens./e∙Å-3 0.263/-0.187 0.342/-0.253 0.241/-0.212 
Flack-parameter -0.4(9) -0.01(5) - 
absorpt method multi-scan multi-scan multi-scan 
absorpt corr Tmin/max 0.6830/0.7456 0.7141/0.7456 0.6949/0.7456 
CCDC No. 1527070 1527071 1527071 
a)
 Definition of the R indices: R1 = (ΣFo-Fc)/ΣFo; wR2 = {Σ[w(Fo2-Fc2)2]/Σ[w(Fo2)2]}1/2 with w-1 = ฀2(Fo2) + 
(aP)2+bP; P = [2Fc2 + Max(FO2]/3; b) s = {Σ[w(Fo2-Fc2)2]/(No-Np)}1/2. 
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Figure S60. Emission spectrum of 12 in CH3OH and H2O after excitation at λex = 444 nm (10-5 M). Fluorescence in 
water is quenched. 
 
Determination of cytotoxicity 
To determine the cytotoxic potential of the corresponding complexes on different cell types, the inhibitory effect on the 
cellular metabolic activity was investigated via a resazurin based assay (alamarBlue, Thermo Fisher). For this 
purpose, the non-cancerous cell line L929 and the breast cell lines MDA-MB-231 and MCF-7 were used. 
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Figure S61. Relative viability of L929 cells after 24 h incubation with the complexes at indicated concentrations in 
serum-containing media. Values represent the mean ± S.D. (n=3). 
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Figure S62. Relative viability of MDA-MB-231 cells after 24 h incubation with the complexes at indicated 
concentrations in serum-containing media. Values represent the mean ± S.D. (n=3). 
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Figure S63. Relative viability of MCF-7 cells after 24 h incubation with the complexes at indicated concentrations in 
serum-containing media. Values represent the mean ± S.D. (n=3). 
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Figure S64. Complexes 11 to 14 were incubated with HUVEC, MCF-7 and MDA-MB-231 cells in serum-containing 
media. The mean fluorescence intensity (MFI) of all viable cells is visualized. Values represent the mean ± S.D. (n ≥ 
3). Complexes 11 to 13 show no significant increased MFI values. Complex 14 revealed increased MFI which might 
be due to particle formulation. This was also verified by DLS measurements.  
Dynamic light scattering was performed on a Zetasizer Nano ZS (Malvern Instruments, Herrenberg, Germany). After 
an equilibration time of 180 s, 3×30 s runs were carried out at 25 °C (λ = 633 nm). The counts were detected at an 
angle of 173°. Each measurement was performed in triplicate. The mean particle size was approximated as the 
effective (Z-average) diameter and the width of the distribution as the polydispersity index of the particles (PDI) 
obtained by the cumulants method assuming a spherical shape of the particles. 
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Figure S65. Complexes 11 to 14 were incubated with HUVEC, MCF-7 and MDA-MB-231 cells in serum containing 
media and analyzed after 24 h. 
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Figure S66. Uptake of complexes 11 to 14 (Ru in fg per cell). L929, MDA-MB-231 and MCF-7 cells were incubated at 
50 μM for 1 h. The uptake was determined by ICP-M. For controls not incubated with complexes, no Ru content was 
determined (Ru < 0.03 fg / cell). 
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ABSTRACT: Despite an increasing effort to design well-defined
glycopolymers, the convenient synthesis of polymers with
higher DPs (>100) and without tedious protection and depro-
tection steps remains a challenge. Combining the reversible
addition fragmentation transfer (RAFT) polymerization and the
efficient substitution of primary bromo groups by thiols, we
were able to synthesize a set of well-defined glycopolymers
with DPs of up to 115. With the polymerization of the highly
reactive monomer (2-bromoethyl)-acrylate polymers with low
dispersities were obtained that could efficiently be functional-
ized with various sugar thiol(ate)s. In particular, derivatives of
D-glucose, D-galactose, and D-mannose gave excellent degrees
of functionalization close to quantitative conversion using only
a slight excess of the thiol. This atom efficient synthesis can
even be applied for copolymers with acid or base labile com-
ponents due to the use of unprotected sugar moieties and,
hence, the lack of further deprotection steps. Binding studies
with the lectin concanavalin A and the subsequent competition
studies with a-D-methyl-mannopyranose (aMeMan) proved the
effective binding of these derivatives and revealed a DP- and
carbohydrate-dependent clustering and dissolution. VC 2017
Wiley Periodicals, Inc. J. Polym. Sci., Part A: Polym. Chem.
2017, 00, 000–000
KEYWORDS: carbohydrates; glycosylation; lectins; nucleophilic
substitution; polymers; postmodification; RAFT
INTRODUCTION Synthetic, carbohydrate-functionalized poly-
mers gained increased interest in biological sciences due to
the crucial role of natural glycoconjugates in cell-cell recog-
nition processes. The main interactions of living organisms
are saccharide-protein, protein-protein, and protein-antibody
interactions and include binding possibilities in a multivalent
manner caused by hydrophobic and electrostatic interactions
as well as by hydrogen bonding.1 The saccharide-protein
interactions were found to play important roles in cell adhe-
sion and cell differentiation, but also in inflammations, viral
replications, and parasitic infections.2
Biological events are often related to the interaction between
carbohydrates and lectins. Lectins are binding proteins with high
stereo-specificity for carbohydrates. A single saccharide reveals
only a low affinity for its natural ligand, whereas multivalent
interactions between a single or more lectins with one or more
of the corresponding carbohydrate units are highly prevalent in
nature.3 The so-called “cluster-effect”4 strongly influences the
design of well-defined glycopolymer architectures.
Early glycopolymer synthesis was conducted by Kobayashi
et al. in 1985, who prepared lactose and D-maltose conju-
gated styrene polymers, offering strong interactions with
hepatocytes and D-galactose selective lectins.5 Since then,
various polymers with defined architectures can be obtained
due to the use of modern polymerization techniques and
available sugar derivatives. In general, there are two ways to
obtain carbohydrate-conjugated polymers: Polymerization of
carbohydrate-conjugated monomers (glycomonomers) or
postpolymerization conjugation of a suitable, reactive poly-
mer. Many attempts were performed to polymerize glycomo-
nomers in a controlled manner by anionic6 and cationic,7
controlled radical,8 ring-opening,9 and other polymerization
techniques.10 However, the synthesis of glycomonomers usu-
ally requires various steps and the functional groups of
unprotected glycomonomers reveal incompatibility with
most controlled polymerization techniques.11 Additionally,
high molar mass polymers with a narrow distribution are
still challenging to obtain by polymerizing glycomonomers.
To postmodify polymers with carbohydrates, a reactive
Additional Supporting Information may be found in the online version of this article.
VC 2017 Wiley Periodicals, Inc.
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polymer backbone is required. For this purpose, many
functional groups are reported, including 4-nitrophenyl car-
bonate,12 para-fluoro-phenyl,13 alkinyl-,14 alkenyl,15 and
others.11
A relatively unexplored reaction for the postmodification of
polymers represents the nucleophilic substitution of various
alkyl halides with suitable nucleophiles. Mainly used in
metal-catalyzed polymerizations, the use of halide-containing
polymers obtained by reversible deactivation radical poly-
merization (RDRP) techniques is limited. This is primarily
attributed to the sensitivity of alkyl halides towards abstrac-
tion by radicals, which is intentionally used in iodine trans-
fer polymerization.16 However, only a few examples using
RDRP for alkyl halide monomers are reported and even less
are applied for the synthesis of glycopolymers. Stenzel and
coworkers reported the synthesis of star shaped glycopoly-
mers derived from poly(vinyl benzylchloride) (PVBC) via
reversible addition-fragmentation polymerization (RAFT).17
The polymers were reacted with equimolar amounts of 1-
deoxy-1-thio-b-D-glucopyranose sodium salt in DMSO for
110 h without any catalyst. Also poly(epichlorhydrin)
obtained via cationic ring-opening polymerization (CROP)
was postmodified with 1-deoxy-1-thio-b-D-glucopyranose to
obtain bristle-like polymers with moderate dispersity
(Ð5 1.68).18 Recently, the Perrier group demonstrated the
versatility of poly(bromoethyl acrylate) (PBEA), which was
polymerized via RAFT.19 Various nucleophiles were used to
yield efficient substitution of the bromides, which resulted in
polymers with a wide range of functionalities including
already a D-glucose derivative. However, a rather large excess
of the nucleophile 1-deoxy-1-thio-b-D-glucopyranose sodium
salt was used to form the D-glucosylated acrylate. To the best
of our knowledge, there is no systematic study, which shows
the synthesis of glyco-homopolymers by controlled radical
polymerization techniques with low dispersities and DPs
exceeding 100 units comparing different sugar residues.
Based on these results, we attempted to further exploit the
reaction based on PBEA to synthesize a whole library of
various glycopolymers and to test their suitability for selec-
tive binding to well-known lectins (Fig. 1). For this pur-
pose, polymers with lengths ranging from 45 to 115
repeating units were prepared by RAFT polymerization and
subsequently modified with various sugar residues (D-glu-
cose, D-galactose, D-mannose). All these polymers were
finally tested for their affinity to the binding-protein conca-
navalin A (Con A).
EXPERIMENTAL
Materials and Methods
All reagents and solvents were commercial products pur-
chased from Sigma-Aldrich (triethylamine, dioxan, AIBN, Con
A), Roth (DMSO, Zellutrans dialysis tube), or Carbosynth (a-
D-thiomannose sodium salt) and were used without further
purification. (4-Cyanopentanoic acid)ylethyl trithiocarbonate
(CPAETC) was synthesized as previously reported.19,20 HBS
buffer (0.10 M HEPES, 0.9 M NaCl, 1 mM CaCl2, 1 mM MgCl2,
and 1 mM MnCl2) was prepared with Milli-Q water as the
solvent.
Equipment
1H NMR spectra were measured with a Bruker spectrometer
(300 MHz). Elemental analysis was performed with a Leco
CHN-932. Size-exclusion chromatography (SEC) of polymers
P1 to P3 was performed on a Agilent system (series 1200)
equipped with a G1310A pump, a G1362A refractive index
detector and a PSS GRAM column with DMAc (1 0.21 wt %
LiCl) as eluent. The column oven was set to 40 8C and a
polystyrene (PS) standard was used for calibration. SEC of
polymers P4 to P12 was performed on a Jasco system
equipped with a PU-980 pump, a RI-2031 Plus refractive
index detector and a PSS SUPREMA column with H2O (1
0.1 M NaNO3 and 0.05% NaN3) as eluent. The column oven
was set to 30 8C and a pullulan standard was used for cali-
bration. UV/Vis absorbance spectra were measured with an
Analytik Jena AG Specord250 spectrometer. Quartz cuvettes
were purchased from Hellma Analytics.
Syntheses of the Thio-Sugars
1-Deoxy-1-thio-b-D-glucopyranose and 1-deoxy-1-thio-b-D-gal-
actopyranose were synthesized according to literature
procedures.21
Synthesis of 2-Bromoethyl Acrylate (BEA)
The BEA monomer was synthesized according to a modified
literature procedure.19 Thirty-eight milliliter of acryloyl chlo-
ride (0.54 mol) were dissolved in 250 mL dry CH2Cl2 under
an Ar atmosphere and 82 mL of Et3N (0.59 mol) were
added. The mixture was cooled to 0 8C and 53 mL of 2-
bromoethanol (0.66 mol) dissolved in 40 mL CH2Cl2 were
added dropwise. The reaction mixture was allowed to stir
for 18 h at room temperature. Subsequently, the solution
was filtered and the organic layer was washed thrice with
saturated, aqueous NaHCO3 solution. Additionally, the
organic layer was stirred with 250 mL of 0.1 M NaOH(aq)
FIGURE 1 Schematic representation of the polymers P1 to P12 obtained via RAFT with subsequent postglyosylation.
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solution for 24 h separated and dried with Na2SO4. The solu-
tion was filtered and the organic solvent was evaporated in
vacuo to obtain the crude product as a colorless oil. Ten mil-
ligram of 2,6-di-tert-butyl-4-methylphenol were added and
the product was subjected a fractionated destillation under
vacuum to yield 34.97 g (0.2 mol) of the desired product in
highest purity and 37% yield. bp 55 8C (4.5 mmHg). dH (300
MHz; CDCl3) 6.49 (m, 1H, CH2@CH), 6.19 (m, 1H, CH2@CH),
5.90 (m, 1H, CH2@CH), 4.48 (t, 2H,
3J 6.2, CH2CH2Br), and
4.48 (t, 2H, 3J 6.2, CH2CH2Br).
General Procedure for the Syntheses of PBEA
Homopolymers
CPAETC, BEA, and AIBN were dissolved in dioxane and the
reaction mixture was deoxygenated with Ar for 10 min and
stirred at 65 8C for 4 h. After completion, the solution was
cooled to room temperature, opened to air, and precipitated
in diethyl ether to give PBEA homopolymers P1 to P3.
P1
1H NMR (300 MHz; CDCl3, d ppm) 4.99–4.88 (1 H, m), 4.42
(2n H, br s), 3.57 (2n H, br s), 3.40 (2 H, t, 3J 7.4), 2.49 (2n
H, br s), 2.05 (2n H, br s), 1.94–1.50 (2n1 1 H, m), 1.48–
1.41 (3 H, m), 0.95 (3 H, t, 3J 7.3). SEC (DMAc1 0.21 wt %
LiCl, PS standard): Mn5 8,800 g mol
21, Mw5 9,600 g mol
21,
Ð5 1.10.
P2
1H NMR (300 MHz; CDCl3, d ppm) 4.98–4.88 (1 H, m), 4.43
(2n H, br s), 3.57 (2n H, br s), 3.39 (2 H, t, 3J 7.2), 2.47 (2n
H, br s), 2.15–1.97 (2n H, br s), 1.90–1.39 (2n H, m), 0.96
(3 H, t, 3J 7.4). SEC (DMAc1 0.21 wt % LiCl, PS standard):
Mn5 11,200 g mol
21, Mw5 13,500 g mol
21, Ð5 1.21.
P3
1H NMR (300 MHz; CDCl3, d ppm) 4.98–4.88 (1 H, m), 4.42
(2n H, br s), 3.57 (2n H, br s), 3.38 (2 H, t, 3J 6.4), 2.47 (2n
H, br s), 2.14–1.96 (2n H, m), 1.92–1.39 (2n H, m), 0.95
(3 H, t, 3J 7.3). SEC (DMAc1 0.21 wt % LiCl, PS standard):
Mn5 18,000 g mol
21, Mw5 20,000 g mol
21, Ð5 1.11.
General Procedure for the Postpolymerization
Modification with Glc and Gal
One hundred milligram of the precursor polymer was dis-
solved in 1 mL DMSO and a solution of the desired carbohy-
drate (DP1.1 equiv.) in 1 mL DMSO was added. The solution
was deoxygenated with Ar for 30 min and 1 equiv. (based
on the carbohydrate) dry triethylamine was added dropwise.
The reaction mixture was stirred at room temperature for
one day and dialyzed against water for one week (CE,
MWCO: 3.5 kDa). The dialyzed solution was freeze-dried to
obtain the desired polymer.
P4
1H NMR (300 MHz; D2O, d ppm) 4.49 (n H, d,
3J 9.8, HGlc-1),
4.24 (2n H, br s), 3.85–3.69 (n H, m), 3.69–3.55 (n H, m),
3.47–3.17 (4n H, m), 3.07–2.74 (2n H, m), 2.33 (2n H, br s),
2.03–1.00 (2n1 1 H, m). SEC (H2O, 0.1 M NaNO3, 0.05%
NaN3, pullulan standard): Mn5 10,000 g mol
21, Mw5 11,800
g mol21, Ð5 1.19. Anal. calcd for C503H824O317S48: C, 44.81;
H, 6.16; S, 11.41; Br, 0. Found: C, 43.87; H, 6.17; S, 10.81; Br,
0.89.
P5
1H NMR (300 MHz; D2O, d ppm) 4.44 (n H, d,
3J 9.3, HGal-1),
4.25 (2n H, br s), 3.89 (n H, s), 3.82–3.41 (5n H, m), 3.16–
2.72 (2n H, m), 2.36 (2n H, br s), 2.04–1.00 (2n1 1 H, m).
SEC (H2O, 0.1 M NaNO3, 0.05% NaN3, pullulan standard):
Mn5 9,900 g mol
21, Mw5 12,000 g mol
21, Ð5 1.22. Anal.
calcd for C503H824O317S48: C, 44.81; H, 6.16; S, 11.41; Br, 0.
Found: C, 41.88; H, 6.13; S, 11.99; Br, 1.99.
P7
1H NMR (300 MHz; D2O, d ppm) 4.49 (n H, d,
3J 9.7, HGlc-1),
4.24 (2n H, br s), 3.85–3.70 (n H, m), 3.70–3.56 (n H, m),
3.55–3.18 (4n H, m), 3.11–2.70 (2n H, m), 2.37 (2n H, br s),
2.11–1.00 (2n1 1 H, m). SEC (H2O, 0.1 M NaNO3, 0.05%
NaN3, pullulan standard): Mn5 17,400 g mol
21, Mw5 21,800
g mol21, Ð5 1.25. Anal. calcd for C866H1418O548S81: C, 44.84;
H, 6.16; S, 11.20; Br, 0. Found: C, 44.15; H, 6.18; S, 9.48; Br,
2.14.
P8
1H NMR (300 MHz; D2O, d ppm) 4.44 (n H, d,
3J 8.9, HGal-1),
4.24 (2n H, br s), 3.90 (n H, s), 3.83–3.41 (5n H, m), 3.17–
2.71 (2n H, m), 2.38 (2n H, br s), 2.04–0.99 (2n1 1 H, m).
SEC (H2O, 0.1 M NaNO3, 0.05% NaN3, pullulan standard):
Mn5 16,400 g mol
21, Mw5 21,000 g mol
21, Ð5 1.28. Anal.
calcd for C866H1418O548S81: C, 44.84; H, 6.16; S, 11.20; Br, 0.
Found: C, 43.28; H, 6.18; S, 9.31; Br, 3.09.
P10
1H NMR (300 MHz; D2O, d ppm) 4.49 (n H, d,
3J 9.7, HGlc-1),
4.24 (2n H, br s), 3.86–3.69 (n H, m), 3.69–3.55 (n H, m),
3.55–3.17 (4n H, m), 3.08–2.71 (2n H, m), 2.36 (2n H, br s),
2.06–1.00 (2n1 1 H, m). SEC (H2O, 0.1 M NaNO3, 0.05%
NaN3, pullulan standard): Mn5 23,300 g mol
21, Mw5 29,300
g mol21, Ð5 1.26. Anal. calcd for C1273H2084O807S118: C,
44.86; H, 6.16; S, 11.10; Br, 0. Found: C, 43.53; H, 6.20; S,
10.20; Br, 1.54.
P11
1H NMR (300 MHz; D2O, d ppm) 4.44 (n H, d,
3J 9.1, HGal-1),
4.24 (2n H, br s), 3.89 (n H, s), 3.83–3.41 (5n H, m), 3.22–
2.72 (2n H, m), 2.37 (2n H, br s), 2.09–1.00 (2n1 1 H, m).
SEC (H2O, 0.1 M NaNO3, 0.05% NaN3, pullulan standard):
Mn5 23,300 g mol
21, Mw5 29,900 g mol
21, Ð5 1.28. Anal.
calcd for C1273H2084O807S118: C, 44.86; H, 6.16; S, 11.10; Br,
0. Found: C, 41.73; H, 6.05; S, 10.58; Br, 2.52.
General Procedure for the Postpolymerization
Modification with Man
One hundred milligram of the precursor polymer was dis-
solved in 1 mL DMSO and a solution of Man-SNa (DP1.1
equiv.) in 0.5 mL H2O was added. The solution was deoxygen-
ated with Ar for 30 min, stirred at room temperature for one
day and dialyzed against water for one week (CE, MWCO: 3.5
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kDa). The dialyzed solution was freeze-dried to obtain the
desired polymer.
P6
1H NMR (300 MHz; D2O, d ppm) 5.30 (n H, s, HMan-1), 4.49–
4.07 (3n H, m), 3.97 (n H, s), 3.93–3.49 (4n H, m), 2.88 (2n
H, s), 2.38 (2n H, br s), 2.11–0.93 (2n1 1 H, m). SEC (H2O,
0.1 M NaNO3, 0.05% NaN3, pullulan standard): Mn5 3,300
g mol21, Mw5 4,800 g mol
21, Ð5 1.44. Anal. calcd for
C503H824O317S48: C, 44.81; H, 6.16; S, 11.41; Br, 0. Found: C,
43.76; H, 6.27; S, 10.36; Br, 0.
P9
1H NMR (300 MHz; D2O, d ppm) 5.30 (n H, s, HMan-1), 4.50–
4.06 (3n H, m), 3.97 (n H, s), 3.92–3.47 (4n H, m), 2.88 (2n
H, s), 2.38 (2n H, br s), 2.12–0.93 (2n1 1 H, m). SEC (H2O,
0.1 M NaNO3, 0.05% NaN3, pullulan standard): Mn5 9,400
g mol21, Mw5 12,600 g mol
21, Ð5 1.34. Anal. calcd for
C866H1418O548S81: C, 44.84; H, 6.16; S, 11.20; Br, 0. Found: C,
43.80; H, 6.14; S, 10.45; Br, 0.
P12
1H NMR (300 MHz; D2O, d ppm) 5.30 (n H, s, HMan-1), 4.47–
4.06 (3n H, m), 3.98 (n H, s), 3.93–3.46 (4n H, m), 2.88 (2n
H, s), 2.38 (2n H, br s), 2.15–0.97 (2n1 1 H, m). SEC (H2O,
0.1 M NaNO3, 0.05% NaN3, pullulan standard): Mn5 15,900
g mol21, Mw5 21,200 g mol
21, Ð5 1.33. Anal. calcd for
C1273H2084O807S118: C, 44.86; H, 6.16; S, 11.10; Br, 0. Found:
C, 43.83; H, 6.16; S, 10.42; Br, 0.36.
Turbidimetry Assay
The aggregation studies with Con A were conducted as pre-
viously reported.22 Con A was fully dissolved in HBS buffer
( 1 mg mL21) and diluted to a 1 lM stock solution. 1 mL
of the Con A stock solution was added to a quarz glass
cuvette, which was placed in the UV–Vis spectrometer. One
milliliter of a 50 lM (50 lM per sugar unit) stock solution
of the polymer in HBS buffer was appended with a pipette
to the ground of the glass cuvette and the absorbance of the
mixture was immediately recorded at k5 420 nm for 30 min
every 0.5 s. The interaction rate was calculated by using the
slope of the linear fit of the steepest portion. Every experi-
ment was conducted thrice.
Reversal Aggregation Assay
The competition experiments with a-D-methyl-mannopyra-
nose were carried out according to literature procedure.22
The solutions of the turbidimetry assay were allowed to rest
for 2 h at room temperature. Following the addition of
0.2 mL of a 54 mM stock solution of methyl-a-D-mannopyra-
noside in HBS buffer, the absorbance at k5 420 nm was
immediately recorded for 60 min every 0.5 s.
RESULTS AND DISCUSSION
RAFT Polymerization of BEA
Similar to the previously published procedure, the BEA
monomer was polymerized using CPAETC as chain transfer
agent (CTA) and AIBN as radical initiator for the RAFT pro-
cess. Optimizing the synthesis and purification procedure for
the monomer (see experimental section for details) we were
able to increase the final DP of the polymers without the
loss of control. As a consequence, various DPs could be
addressed by changing the ratio [monomer]/[CTA] (Table 1).
For all polymers, low dispersity (Ð  1.2) and narrow
mono-modal distributions were obtained, emphasizing the
capabilities to polymerize halide-containing monomers by
RDRP. In addition, we analyzed the end group fidelity using
NMR analysis. The intensities of the signals at d5 0.95 ppm
for the terminal CH3 group and of the signal at d5 3.38 ppm
for the CH2 group next to the trithiocarbonate match well
with the expectations proving the excellent retention of the
RAFT end group. Recent studies showed the synthesis of a
similar polymer named poly(2-bromoethyl methacrylate) by
postmodification of poly(2-hydroxyethyl methacrylate) with
a mixture of various chemicals.23 Our study represents a
more effective approach due to the lack of postbromination
procedures and the introduction of the bromide directly to
the monomer circumventing the requirement for additional
tedious modification steps.
Postglycosylation
With the defined precursor polymers at hand, the various car-
bohydrates were examined for the next step. For this purpose,
the thiolated carbohydrates (1-deoxy-1-thio-b-D-glucopyra-
nose,21 1-deoxy-1-thio-b-D-galactopyranose,21 and commer-
cially available 1-deoxy-1-thio-b-D-mannopyranose sodium
salt) were reacted with precursor polymers P1 to P3 in a SN2
reaction (Table 2). These carbohydrates were chosen for
TABLE 1 Summary of BEA Polymerization
Abbrev. [M]0/CTA [CTA]/I0 Conv.
a (%) Mn,th
b (g/mol) Mn,NMR
c (g/mol) Mn,SEC
d (g/mol) Ð
P1 60 10 69 7,600 8,300 8,800 1.10
P2 150 10 58 15,700 14,200 11,200 1.21
P3 300 5 42 22,700 20,800 18,000 1.11
a Determined from 1H NMR of the polymerization mixture before
precipitation.
b Calculated from monomer conversion.
c Determined from 1H NMR end-group analysis [calculated from signal
intensity of the proton of the tertiary C-atom next to trithiocarbonate
(d5 4.93 ppm) in comparison to the proton signal of the C1 atom of the
acryl ester (d5 4.43 ppm) before postmodification]. These ratios were
used to calculate the DP.
d SEC: DMAc10.21 wt % LiCl, PS calibration.
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different reasons. D-galactose (Gal) conjugated polymers were
shown to bind to hepatocytes via a receptor-mediated mecha-
nism and, therefore, representing useful targeting moieties for
the development of polymers used in various biomedical
fields, such as tissue engineering and drug-loaded nanopar-
ticles.24 D-Mannose (Man) is in the focus of the scientific com-
munity due to its strong interactions with the lectin Con A
and with macrophages, which overexpress mannose-receptors
on their surface.25 D-Glucose (Glc) interacts with transport
proteins like with the GLUT1 transporter, which is shown to
be overexpressed in various types of cancers, such as renal
cell carcinoma26 or non-small cell lung carcinoma.27
D-Galactose and D-glucose were attached using only 1.1
equivalents of the deprotected b-1-thiol derivatives. The SN2
reactions with polymers P1 to P3 were conducted in DMSO
and the thiol functionalities of the carbohydrates were
deprotonated with one equivalent of triethyl amine. The
reactions were stopped after 24 h and purified by dialysis
against H2O (MWCO: 3.5 kDa) to remove low-molar mass
impurities and side-products such as DMSO and formed
triethyl ammoniumbromide. In the case of D-mannose attach-
ment, 1.1 equivalents of the commercially available sodium
salt of the a-1-thiol derivative of D-mannose were used.
Therefore, no base is required and the formation of sodium
bromide as a side-product represents the driving force for
the substitution reaction. The mannosylated polymers were
purified in a similar manner to the gluco- and galactosylated
ones. The success of the reaction can be shown by various
NMR techniques as depicted for polymer P12 in Figure 2,
representative for all other polymers. All spectra of polymers
P1 to P12 are available in the Supporting Information (Fig.
S1–S47).
The substitution of the bromides in P3 against the sugar-
thiolate results in the formation of a thio-ether. This is
clearly visible in the shift of the ethyl acrylate signals from
d5 4. 42 ppm in P3 to d5 4.22 ppm in P12, respectively,
from d5 3.57 ppm in P3 to d5 2.89 ppm in P12 in the 1H
NMR spectra. Additionally, the signal of the C1 proton
appears nicely isolated at d5 5.30 ppm, whereas the other
D-mannose proton signals are visible between d5 3.5 and
4.5 ppm. As also previously shown,28 the attachment of car-
bohydrates result in water-soluble polymers P4 to P12,
whereas precursor polymers P1 to P3 revealed nonsolubility
in water. Additionally, by binding D-mannose S-glycosidically
to the polymer backbone, a thioether is formed, which pos-
sesses a lower rate of hydrolysis of the thioglycosidic bond
by enzymatic cleavage relative to O-glycosydically coupled
sugar residues.29
TABLE 2 Overview of the Glycopolymers P4 to P12 Prepared
and Tested in This Study
Abbrev. DP
Attached
Sugar (R1) Mn,th
a Mn,SEC
b Ð
P4 45 Glc 13,500 10,000 1.19
P5 45 Gal 13,500 9,900 1.22
P6 45 Man 13,500 3,300 1.44
P7 78 Glc 23,200 17,400 1.25
P8 78 Gal 23,200 16,400 1.28
P9 78 Man 23,200 9,400 1.34
P10 115 Glc 34,100 23,300 1.26
P11 115 Gal 34,100 23,300 1.28
P12 115 Man 34,100 15,900 1.33
a Calculated by assuming polymers with the respective DP and full sub-
stitution of the bromide groups.
b SEC: H2O, 0.1 M NaNO3, 0.05% NaN3, Pullulan calibration.
FIGURE 2 Left: Comparison of 1H NMR of compounds P3 (measured in CDCl3) and P12 (measured in D2O) between d50 and 6
ppm. Intermittent axis between d54.6 and 5 ppm was used due to solvent residue signal in the spectrum of P12. Right: 1H
diffusion-ordered NMR (DOSY) at T525 8C of P12. [Color figure can be viewed at wileyonlinelibrary.com]
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1H diffusion-ordered NMR (DOSY) investigations of P12
revealed the appearance of all signals (except the signal for
the solvent residue) at high diffusions constants typical for
polymers (D5 510211 m2 s21), indicating the successful
attachment of D-mannose units without the appearance of
any side-products.
In contrast to the previous polymers P1 to P3 the end group
fidelity of the RAFT group could not be determined after
postpolymerization functionalization due to the overlap of
the important signals in the NMR with the signals of the
sugar moiety. Reinitiation experiments, however, indicated a
degradation of the trithiocarbonate as no block formation is
observed.
To further evaluate the quality of the substitution reaction,
the elemental composition of polymers P4 to P12 was ana-
lyzed. The determined halogen content represents the
remaining bromoethyl ester content and can be used to cal-
culate the degree of functionalization (DF) with the following
equation (Table 3).
DF5 12
Br content ðsugar polymerÞ
Br content ðPBEAÞ
3100
The DF ranges from 93 to 100% and some general tenden-
cies are noticeable. D-Mannose functionalized polymers P6,
P9, and P12 showed remaining Br content between 0 and
the lower detection limit (0.36%), whereas the other poly-
mers revealed Br content between 0.89 and 3.09%. There-
fore, the use of the sodium salt of the corresponding thiol-
sugars, instead of the thiol-sugars and a suitable base, seems
to be beneficial for the substitution reaction. This might be
attributed to the decreased solubility of the formed sodium
bromide in the solvent mixture of D-mannosylated polymers
in comparison to the solubility of the formed triethyl ammo-
niumbromide of the other polymers in DMSO. Additionally,
the DF with D-galactose is generally decreased in comparison
to D-glucose, which might be caused by the existence of
small amounts of 1-deoxy-1-thio-a-D-galactopyranose, which
could be sterically hindered during the substitution reaction.
Due to the well resolved signals from the C1 protons of the
D-mannose units in 1H NMR, they can be used to validate the
DF by comparing their intensity to that of the backbone sig-
nal at d5 2.9 ppm. The obtained data is in good agreement
with the results obtained from the elemental analysis of the
polymers.
The polymers P4 to P12 were also investigated via SEC to
obtain information about the increase of the molar mass of
the polymers and their dispersities (Fig. 3).
The traces still show a mono-modal distribution and the dis-
persity remains narrow below 1.5, indicating no formation of
macromolecular side-products during the SN2 reaction and
the absence of previously observed chain-chain coupling due
to the removal of the CTA and the subsequent disulfide for-
mation or other side reactions.19 The latter can certainly be
attributed to the reduced excess of thio-sugar molecules
used for the substitution. The symmetric broadening of the
SEC traces and the slight increase of the dispersities relative
to the precursor polymers P1 to P3 is most probably related
to the difference in the SEC system applied for the analysis
of the polymers and potential interactions of the attached
sugar moieties with the column material. An indication for
this phenomenon is further the later elution of D-mannosy-
lated polymers P6, P9, and P12 in comparison to the corre-
sponding D-glucosylated or D-galactosylated polymers,
respectively, although the absolute molar masses should be
very similar. An additional effect for this shift in the elution
TABLE 3 Elemental Compositions of Polymers P4 to P12; the Calculated DFs are Based on Theoretical Br Content of Polymers P1
to P3
Abbrev. DP Saccharide Elemental Compositiona (%) DF (%)
C H S Br
P1 45 – 33.74 4.00 1.16 43.35 –
P4 45 Glc 43.87 6.17 10.81 0.89 97.9
P5 45 Gal 41.88 6.13 11.99 1.99 95.4
P6 45 Man 43.76 6.27 10.36 0 100
P2 78 – 33.66 3.97 0.68 43.89 –
P7 78 Glc 44.15 6.18 9.48 2.14 95.1
P8 78 Gal 43.28 6.18 9.31 3.09 93
P9 78 Man 43.80 6.14 10.45 0 100
P3 115 – 33.63 3.96 0.46 44.12 –
P10 115 Glc 43.53 6.20 10.20 1.54 96.5
P11 115 Gal 41.73 6.05 10.58 2.52 94.3
P12 115 Man 43.83 6.16 10.42 0.36 99.2
a Elemental composition of starting material polymers P1 to P3 was calculated assuming one polymer species with the depicted DP.
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volume might be the interaction between the axial C2
hydroxyl groups of the D-mannose units and the carboxylic
ester functionalities on the polymer backbone, which
decrease the resulting hydrodynamic radius, whereas D-glu-
cose and D-galactose possess equatorial hydroxyl groups at
their C2 atoms. Another reason could be the stronger inter-
action of D-mannose with the column material in comparison
to the other sugars. D-Glucose conjugated polymers roughly
eluted after the same volume than the D-galactolysated poly-
mers with the same DP.
Lectin Binding
One critical requirement for the application of glycopoly-
mers, for example, in targeted drug delivery, is their ability
to selectively bind to lectins for the respective type of sugar.
To examine the binding efficacy of the glycopolymers, turbi-
dimetry assays were performed for the polymers P4 to P12
using the lectin Con A. Con A consists of aggregates of
25,000 g mol21 size. While existing at pH range 5–5.6 as a
dimer, Con A is predominantly aggregating into tetramers
above pH5 7.30 Each monomer unit is known to selectively
bind to one unit of a-gluco- or a-mannopyranose, but no
binding should be observed in the case of the galactopyra-
nose.31 The rate of clustering was monitored in real-time by
measuring the absorbance at k5 420 nm over time after
mixing the lectin and polymer solutions. The change in tur-
bidity is related to the rate of receptor-receptor associations
caused by the sugar-units of the polymers.32 The slope of
the steepest portion of the initial curve was used to repre-
sent the clustering rate, expressed in arbitrary units per sec-
ond (a.u. s21).22 The initial values of the curves are
correlated to the formation of isolated Con A polymer clus-
ters, whereas interactions between the clusters occur at later
points. The formation of cross-linked clusters of higher order
increases over the time and, therefore, the analysis is limited
to the initial portion of the curve.33 The experimental results
are summarized in Figure 4. All spectra of the triplicate
measurements including the linear fits are available in the
Supporting Information (Fig. S9, S14, S18, S23, S28, S32,
S37, S42, and S46).
Polymers P5, P8, and P11 bearing D-galactose residues did
not show any aggregation with Con A over a time period of
30 min, which is in accordance to previously reported D-gal-
actolysated polymers.14 D-Glucosylated and D-mannosylated
polymers exhibited the formation of Con A clusters with
varying clustering rates. As a general trend, the polymers
grafted with D-mannose residues revealed higher rates of
Con A clustering than their D-glucosylated polymers with the
same DP. This might be attributed to the higher binding
affinity of the Con A tetramers to a-D-mannose in comparison
to D-glucose residues. Another reason could be the decreased
hydrodynamic radius of D-mannosylated polymers relative to
the D-glucosylated ones, which could offer beneficial shape
or length of the polymers in solution in terms of Con A bind-
ing. The absorbance of D-mannose bearing polymers reached
FIGURE 4 Results of turbidimetry measurements. Left: Absorbance (k5 420 nm) curves after adding 1 mL solution of polymers P4
to P12 (50 lM per sugar unit) to 1 lM solutions of Con A in HBS buffer. Right: Calculated rates of clustering between Con A tet-
ramers and D-glucosyl- or D-mannosylated polymers obtained by a linear fit of the steepest portions of the curves, k values repre-
sent the average of three replicates. [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 3 SEC traces of polymers P4 to P12 (H2O, 0.1 M
NaNO3, 0.05% NaN3, Pullulan standard). [Color figure can be
viewed at wileyonlinelibrary.com]
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very fast a plateau and stayed almost constant at this level
for the remaining measurement, which is attributed to a
rapid precipitation of most of the Con A tetramers (Fig. 4).
In contrast, D-glucosylated polymers exhibited a continuous,
but slower increase of the absorbance, indicating secondary
interactions such as cross-linked clusters or partially soluble
conjugates. In particular, the shortest D-glucose bearing poly-
mer P4 exhibited different clustering rates compared to all
other polymers. One reason is the general decreased affinity
of D-glucose to Con A relative to D-mannose. Another one is
certainly the overall length of the polymer. Considering a
fully stretched chain the length of P4 can be estimated to be
80 Å taking into account the binding angles. The distance
between two binding sites of the Con A tetramer is around
72 Å and,34 therefore, the length of the polymer, which is
just above the distance between the binding sites, paired
with the low affinity of Con A towards D-glucose did not
result in fast agglutination of the Con A clusters. In the light
of this, the existence of a critical polymer length for high
clustering rates of Con A aggregates is assumed, which is
also in accordance to literature reports.35
Another trend is obtained by comparing the rate of cluster-
ing caused by the polymers with the same sugar residues,
but with different DPs. With higher DPs (for D-glucose as
well as for D-mannose bearing polymers) the precipitation of
Con A clusters is promoted more rapidly. Therefore, we
assume a dependency of the speed of clustering with the
epitope density, which was also reported for other glycopoly-
mers.33,35 Additionally, the rate of clustering for polymers
with D-mannose residues seems to approximate a constant
level in dependency of the DP. A lower increase of the clus-
tering rates for D-mannosylated polymers with higher DPs
relative to P12 in comparison to the increase between P9 to
P12 is expected. To exactly determine the required DP, more
turbidimetry investigations with D-mannosylated polymers of
higher DPs are necessary. The described polymerization and
postglycosylation could be used to synthesize these polymers
in future studies.
Reversal Aggregation
In addition to the previous binding assays, the strengths and
efficiencies of the interaction between glycopolymer and lec-
tin can be evaluated by competition experiments. For this
purpose, the aggregates formed during turbidimetry assays
were allowed to rest for around 2 h to finish the formation
of higher-order aggregates and were subsequently treated
with an excessive amount of a-D-methyl-mannopyranose
(aMeMan), a competitor for the binding sites of Con A. The
absorbance at k5 420 nm over the time was monitored and
the results are summarized in Figure 5 for D-manno- and D-
glucosylated polymers. The D-galactose bearing polymers
were omitted due to the inefficient binding to the lectin Con
A and all spectra are available in the Supporting Information
(Fig. S10, S19, S24, S33, S38, and S47).
The results of the reversal aggregation assay revealed
carbohydrate-specific and length-dependent tendencies. The
rates of the dissolution of the D-glucosylated polymers are
strongly enhanced relative to those of the D-mannosylated
polymers when treated with the monovalent competitor
aMeMan in large excess. The turbidity was rapidly reduced
to a constant level, indicating a rather weak interaction
between Con A and the D-glucose bearing polymers. Addi-
tionally, the dissolution of the D-glucose Con A clusters hap-
pened faster with increasing DP of the polymers. The
dissolution of the cluster of D-mannosylated polymers was
slow but continuous to a constant level, indicating higher
binding affinity of the Con A tetramers to D-mannosylated
polymers. Other tendencies are observable when comparing
the difference of the highest and the lowest absorbance
(k5 420 nm) after addition of Con A to the difference
FIGURE 5 Results of reversal aggregation measurements. Left: Absorbance (k5 420 nm) curves after adding 0.2 mL solution of
aMeMan (54 mM) to the polymer solutions (50 lM per sugar unit) in HBS buffer. Right: Calculated rates of the reverse interaction
between Con A aggregates and the competitor aMeMan obtained by a linear fit of the steepest portions of the curves. [Color figure
can be viewed at wileyonlinelibrary.com]
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obtained after addition of aMeMan. First of all, the Con A
aggregates of D-mannosylated polymers (P6, P9, P12) were
not completely dissolved after adding the competitor and a
clear trend is that with higher DP, the amount of undissolved
Con A clusters remaining in solution increases (Fig. 6, Sup-
porting Information Table S1).
Comparing the different sugar moieties (except for the D-gal-
actolysated polymers) all aggregates with D-glucosylated pol-
ymers revealed decreased stability relative to the respective
clusters of the D-mannosylated polymers with the same DP.
This is in accordance with the results we obtained for the
reversal aggregation assay showing higher dissolution rates
for increasing DPs of the polymers (P4<P7<P10). It is fur-
ther noteworthy to mention that we observe an increased total
stability of the D-glucosylated polymers P7 (69%) and P10
(62%) although Con A clusters of D-glucose are commonly fully
dissolved after adding aMeMan.22 For the D-mannosylated poly-
mers an even higher stability is observed despite the addition
of almost 1000 equivalents of the competitor aMeMan, which
has the same binding motif. This could indicate beneficial prop-
erties of the presented polymers in terms of their length, the
flexibility of the polymeric backbone and way of attachment of
the pendant sugar moieties, which may yield in an improved
binding strength to the lectin.
CONCLUSION
In summary, this work demonstrates the high potential of
the combination of RAFT polymerization and the bromo-thio
substitution to create different, well-defined sugar-conju-
gated polymers. The basis for the reactive scaffold is the (2-
bromo-ethyl)-acrylate monomer that enables excellent con-
trol in the RAFT polymerization and high DPs of up to 115
repeating units. The bromides were readily substituted in a
post-glycosylation procedure by addition of almost equal
amounts of sugar-thiol(ate)s, in particular D-glucose, D-galac-
tose, and D-mannose, in an SN2 reaction. The substitution
was performed directly with unprotected carbohydrates,
emphasizing the versatility of this method towards potential
copolymers or linker structures, which are labile under the
basic or acidic conditions usually applied for the deprotec-
tion of sugar units. Furthermore, the reactions are highly
atom efficient and create only nontoxic side-products
(triethyl ammoniumbromide, sodium bromide). The analytics
of the novel polymers revealed mono-modal distributions
with narrow dispersities and excellent DF of up to 100%,
which was confirmed by elemental analysis. Binding studies
of Con A with the synthesized polymers as multivalent
ligands prove the selective binding ability of the sugar moie-
ties as expected for the small molecules. D-Mannosylated
polymers revealed higher clustering rates than the D-glucosy-
lated polymers, whereas D-galactose bearing polymers
showed no formation of cluster with Con A at all. With the
linear, high molar mass polymers at hand, we could also
demonstrate that the precipitation of Con A clusters is pro-
moted more rapidly with increasing DP of the polymers.
Reverse results were obtained by treating the Con A clusters
with monovalent competitor a-D-methyl-mannopyranose
(aMeMan). The turbidity of the D-glycosylated polymer clus-
ters was rapidly reduced to a constant level, whereas the D-
mannosylated ones decreased slower but continuous. This
indicates a weak interaction between the Con A binding site
and the multivalent D-glucose bearing polymers. Additionally,
the remaining undissolved clusters of D-glucosylated and D-
mannosylated polymers indicate an excellent binding affinity
of these new types of polymers, which surpasses most other
reported polymers with respective sugar groups attached.
This work demonstrated the use of RAFT for the polymeriza-
tion of bromide-containing monomer BEA with high control
and DPs higher than 100 as well as the subsequent post-
glycosylation with almost quantitative DFs by versatile SN2
reaction with thiol(ate) derivatives of various sugars. The D-
mannose bearing polymers via thioether functionality revealed
the formation of very stable clusters with the lectin Con A.
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Figure S1. 1H NMR spectrum of 2-bromoethyl acrylate in CDCl3. 
 
Figure S2. 1H NMR spectrum of P1 in CDCl3. 
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Figure S3. 1H NMR spectrum of P2 in CDCl3. 
 
Figure S4. 1H NMR spectrum of P3 in CDCl3. 
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Figure S5. SEC trace of P1 to P3 (DMAc + 0.21 wt.% LiCl, PS calibration). 
 
Figure S6. 1H NMR spectrum of P4 in D2O. 
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Figure S7. 1H DOSY NMR spectrum of P4 in D2O. 
 
Figure S8. SEC trace of P4 (H2O, 0.1 M NaNO3, 0.05 % NaN3, pullulan standard). 
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Figure S9. Absorbance (λ = 420 nm) curves after adding 1 mL of 1 μM solution of Con A 
in HBS buffer to the solution of the polymer P4 (50 μM per sugar unit, in HBS). The 
linear fit of the steepest portions of the curves were used to calculate the clustering rate 
k = 3,3411·10-5 a.u.·s-1. 
 
Figure S10. Absorbance (λ = 420 nm) curves after adding 0.2 mL solution of αMeMan 
(54 mM) to the Con A aggregates suspension in HBS buffer. Calculated rate of the 
reverse interaction between Con A aggregates and the competitor αMeMan was 
obtained by a linear fit of the steepest portions of the curve, k = 1.06·10-3 a.u.·s-1. 
7 
 
 
Figure S11. 1H NMR spectrum of P5 in D2O. 
 
Figure S12. 1H DOSY NMR spectrum of P5 in D2O. 
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Figure S13. SEC trace of P5 (H2O, 0.1 M NaNO3, 0.05 % NaN3, pullulan standard). 
 
Figure S14. Absorbance (λ = 420 nm) curves after adding 1 mL of 1 μM solution of 
Con A in HBS buffer to the solution of the polymer P5 (50 μM per sugar unit, in HBS).  
9 
 
 
Figure S15. 1H NMR spectrum of P6 in D2O. 
 
Figure S16. 1H DOSY NMR spectrum of P6 in D2O. 
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Figure S17. SEC trace of P6 (H2O, 0.1 M NaNO3, 0.05 % NaN3, pullulan standard). 
 
Figure S18. Absorbance (λ = 420 nm) curves after adding 1 mL of 1 μM solution of 
Con A in HBS buffer to the solution of the polymer P6 (50 μM per sugar unit, in HBS). 
The linear fit of the steepest portions of the curves were used to calculate the clustering 
rate k = 1.16·10-3 a.u.·s-1. 
11 
 
 
Figure S19. Absorbance (λ = 420 nm) curves after adding 0.2 mL solution of αMeMan 
(54 mM) to the Con A aggregates suspension in HBS buffer. Calculated rate of the 
reverse interaction between Con A aggregates and the competitor αMeMan was 
obtained by a linear fit of the steepest portions of the curve, k = 1.02·10-4 a.u.·s-1. 
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Figure S20. 1H NMR spectrum of P7 in D2O. 
 
Figure S21. 1H DOSY NMR spectrum of P7 in D2O. 
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Figure S22. SEC trace of P7 (H2O, 0.1 M NaNO3, 0.05 % NaN3, pullulan standard). 
 
Figure S23. Absorbance (λ = 420 nm) curves after adding 1 mL of 1 μM solution of 
Con A in HBS buffer to the solution of the polymer P7 (50 μM per sugar unit, in HBS). 
The linear fit of the steepest portions of the curves were used to calculate the clustering 
rate k = 6.481·10-4 a.u.·s-1. 
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Figure S24. Absorbance (λ = 420 nm) curves after adding 0.2 mL solution of αMeMan 
(54 mM) to the Con A aggregates suspension in HBS buffer. Calculated rate of the 
reverse interaction between Con A aggregates and the competitor αMeMan was 
obtained by a linear fit of the steepest portions of the curve, k = 1.94·10-3 a.u.·s-1. 
 
15 
 
 
Figure S25. 1H NMR spectrum of P8 in D2O. 
 
Figure S26. 1H DOSY NMR spectrum of P8 in D2O. 
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Figure S27. SEC trace of P8 (H2O, 0.1 M NaNO3, 0.05 % NaN3, pullulan standard). 
 
Figure S28. Absorbance (λ = 420 nm) curves after adding 1 mL of 1 μM solution of 
Con A in HBS buffer to the solution of the polymer P8 (50 μM per sugar unit, in HBS). 
17 
 
 
Figure S29. 1H NMR spectrum of P9 in D2O. 
 
Figure S30. 1H DOSY NMR spectrum of P9 in D2O. 
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Figure S31. SEC trace of P9 (H2O, 0.1 M NaNO3, 0.05 % NaN3, pullulan standard). 
 
Figure S32. Absorbance (λ = 420 nm) curves after adding 1 mL of 1 μM solution of 
Con A in HBS buffer to the solution of the polymer P9 (50 μM per sugar unit, in HBS). 
The linear fit of the steepest portions of the curves were used to calculate the clustering 
rate k = 1.98·10-3 a.u.·s-1. 
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Figure S33. Absorbance (λ = 420 nm) curves after adding 0.2 mL solution of αMeMan 
(54 mM) to the Con A aggregates suspension in HBS buffer. Calculated rate of the 
reverse interaction between Con A aggregates and the competitor αMeMan was 
obtained by a linear fit of the steepest portions of the curve, k = 9.91·10-5 a.u.·s-1. 
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Figure S34. 1H NMR spectrum of P10 in D2O. 
 
Figure S35. 1H DOSY NMR spectrum of P10 in D2O. 
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Figure S36. SEC trace of P10 (H2O, 0.1 M NaNO3, 0.05 % NaN3, pullulan standard). 
 
Figure S37. Absorbance (λ = 420 nm) curves after adding 1 mL of 1 μM solution of 
Con A in HBS buffer to the solution of the polymer P10 (50 μM per sugar unit, in HBS). 
The linear fit of the steepest portions of the curves were used to calculate the clustering 
rate k = 1.06·10-3 a.u.·s-1. 
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Figure S38. Absorbance (λ = 420 nm) curves after adding 0.2 mL solution of αMeMan 
(54 mM) to the Con A aggregates suspension in HBS buffer. Calculated rate of the 
reverse interaction between Con A aggregates and the competitor αMeMan was 
obtained by a linear fit of the steepest portions of the curve, k = 4.6·10-3 a.u.·s-1. 
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Figure S39. 1H NMR spectrum of P11 in D2O. 
 
Figure S40. 1H DOSY NMR spectrum of P11 in D2O. 
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Figure S41. SEC trace of P11 (H2O, 0.1 M NaNO3, 0.05 % NaN3, pullulan standard). 
 
Figure S42. Absorbance (λ = 420 nm) curves after adding 1 mL of 1 μM solution of 
Con A in HBS buffer to the solution of the polymer P11 (50 μM per sugar unit, in HBS). 
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Figure S43. 1H NMR spectrum of P12 in D2O. 
 
Figure S44. 1H DOSY NMR spectrum of P12 in D2O. 
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Figure S45. SEC trace of P12 (H2O, 0.1 M NaNO3, 0.05 % NaN3, pullulan standard). 
 
Figure S46. Absorbance (λ = 420 nm) curves after adding 1 mL of 1 μM solution of 
Con A in HBS buffer to the solution of the polymer P10 (50 μM per sugar unit, in HBS). 
The linear fit of the steepest portions of the curves were used to calculate the clustering 
rate k = 2.11·10-3 a.u.·s-1. 
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Figure S47. Absorbance (λ = 420 nm) curves after adding 0.2 mL solution of αMeMan 
(54 mM) to the Con A aggregates suspension in HBS buffer. Calculated rate of the 
reverse interaction between Con A aggregates and the competitor αMeMan was 
obtained by a linear fit of the steepest portions of the curve, k = 1.13·10-4 a.u.·s-1. 
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Table S1. Comparison of the total increase respectively decrease of the absorbance 
after adding Con A respectively αMeMan to the polymer solution. 
Abbrev. Modulus of the total 
increase of the 
absorbance at 
λ = 420 nm after 
adding Con A 
Modulus of the total 
decrease of the 
absorbance at 
λ = 420 nm after 
adding αMeMan 
Percentage of 
dissoluted Con A 
clusters 
P4 0.0219 0.0212 97 
P6 0.0600 0.0400 67 
P7 0.1062 0.0729 69 
P9 0.0733 0.0234 32 
P10 0.1171 0.0729 62 
P12 0.0706 0.0171 24 
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Abstract
Eight difluoroboron complexes of curcumin derivatives carrying alkyne groups containing substituents have been synthesized
following an optimised reaction pathway. The complexes were received in yields up to 98% and high purities. Their properties as
fluorescent dyes have been investigated. Furthermore, a strategy for the hydrolysis of the BF2 group has been established using
aqueous methanol and sodium hydroxide or triethylamine.
Introduction
In recent years curcumin, a pigment naturally occurring in
curcuma longa, and its analogues, the curcuminoids, have at-
tracted much attention regarding their biological activities [1].
These include antioxidant [2] and radical scavenging [3], anti-
tumor [4] and anti-inflammatory [5] activities, as well as HIV
inhibition [6]. Despite showing activity against several diseases
and having only negligible side effects, low water solubility and
fast degradation limit their potential medical application to this
day [7].
The formation of the curcumin structure motif takes place by a
base catalysed aldol condensation between the corresponding
aldehyde and 2,4-pentanedione. To avoid a Knoevenagel con-
densation at the C-3 atom (Scheme 1a), the β-diketone moiety
needs to be fixed into the enol form. In principle, this can be
achieved by two different methods. The first one described by
Pabon et al. utilises boric oxide in ethyl acetate as an intermedi-
ate agent (Scheme 1a) [8]. Boric acid esters like tri-n-butyl
borate are normally used to scavenge water being produced
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Scheme 1: Synthesis of the curcumin structure motif using (a) boric oxide or (b) boron trifluoride.
during the reaction, while piperidine [9] and n-butylamine
[10,11] are typical bases used as catalysts for this type of reac-
tion (Scheme 1). Although working well with vanillin and simi-
lar derivatives, the yields strongly decrease when employing
other aldehydes [12]. This procedure also requires a rather ex-
tensive work-up including several extraction steps and chroma-
tography [8]. A second, more recent approach first published by
Rao et al. relies on boron trifluoride as the complexing agent
[13]. The reaction was altered by Zhang et al. to be carried out
in toluene (Scheme 1b) [14]. This reaction produces the BF2
complex of the corresponding curcuminoid in yields up to 98%
and high purity as an insoluble solid, which requires only a
minimum of work-up.
The BF2 complexes by themselves have attracted attention
regarding their properties as fluorescent dyes with fluorescence
quantum yields of up to 60% and Stokes shifts of up to
5000 cm−1 [9]. Additionally, the incorporation of the BF2 group
forces the β-diketone unit into the enol form, which leads to in-
creased rigidity and enhanced photostability of the molecule
[9].
Although a range of papers reports the synthesis of BF2 com-
plexes of β-diketones such as curcuminoids [13,14] or diben-
zoylmethanes [15,16], to our knowledge the reported proce-
dures for the hydrolysis of these complexes are very limited and
not always reproducible.
As part of our ongoing research to increase the selectivity of
antitumor active metal complexes [17-22], our focus was on the
synthesis of curcuminoids that could serve as building blocks to
attach sugars like D-fructose or D-glucose [23]. Due to the easy
accessibility to azido sugars [24,25] we decided to synthesise a
range of curcuminoids bearing propargyl and pent-1-yn-5-yl
ether groups as partners for click reactions [26]. We already
observed that for the BF2 complex of bispropargyl function-
alised bisdemethoxycurcumin, the BF2 group was hydrolysed
under regular click reaction conditions [23].
In this paper we report on the synthesis and spectroscopic char-
acterization of the above mentioned compound as well as seven
other novel curcuminoid BF2 complexes containing terminal
triple bonds in their side chains. We also optimized the reaction
conditions for the cleavage of the BF2 group to release the
curcuminoids as an alternative synthetic route to substituted
curcumins.
Results and Discussion
Synthesis
BF2 complexes
First, we prepared the aldehydes 1ah as the starting materials
by Williamson ether synthesis of the corresponding hydroxy-
benzaldehydes with either propargyl bromide in dry DMF or
5-chloropent-1-yne in dry acetonitrile. As bases we used potas-
sium carbonate for the propargyl ethers and caesium carbonate
for the ethers with the longer side chains. Aqueous work-up
achieved the aldehydes in excellent yields of up to 98%. NMR
spectroscopic results were found to be in good accordance with
the data published elsewhere [27-30].
We received the BF2 complexes 2ah by aldol reactions be-
tween the in situ generated BF2 complex of 2,4-pentanedione
and the corresponding aromatic aldehydes 1ah. Following a
procedure reported originally by Zhang [14], we were able to
isolate 2ah in yields ranging from 56 to 96% (Table 1).
The amount of base required have to be increased from 0.1 to
ca. 0.6 equiv due to the formation of HF, which forms n-butyl-
ammonium fluoride as a main impurity. Therefore, all com-
plexes were purified by recrystallization from a mixture of ace-
tone and water. Because most of the compounds were partially
hydrolysed when heated to 80 °C in aqueous acetone solution,
Beilstein J. Org. Chem. 2017, 13, 22642272.
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Table 1: BF3·Et2O-promoted synthesis of curcuminoidBF2 complexes 2ah.
Entry R1 R2 R3 Yield (%) a
2a H O-propargyl OMe 90
2b H O-propargyl H 96
2c Br O-propargyl OMe 94
2d Br O-propargyl H 65
2e H O-propargyl O-propargyl 74
2f H OMe O-propargyl 88
2g H OMe O-pent-4-yn-1-yl 56
2h H O-pent-4-yn-1-yl H 87
aYield after recrystallization.
we carried out the purification at room temperature. The final
compounds were characterized by 1H, 11B{1H}, 13C{1H} and
19F{1H} NMR spectroscopy, EI mass spectrometry, elemental
analyses as well as UVvis absorption and fluorescence spec-
troscopy.
The proton NMR spectra of all compounds exhibit the charac-
teristic AB spin systems (J = approx. 16 Hz) occurring from the
trans-olefinic protons in combination with a singlet at around
6.5 ppm. Signals in 19F{1H} NMR appeared as sharp singlets at
around −140 ppm, while 11B{1H} NMR signals appear as up to
3 ppm broad singlets at about +0.9 ppm. No coupling between
19F and 11B nuclei was observed because of the high quadru-
pole moment of the 11B nucleus. Due to the high relative mass
difference between both naturally occurring boron isotopes,
signals for the 10B19F and 11B19F complexes with Δδ ≈ 0.1 ppm
could be found in the 19F{1H} NMR spectrum. Several addi-
tional signals were observed after a few hours, as the com-
pounds started to hydrolyse due to residual water in DMSO-d6.
Resonances at −148.6 ppm in 19F{1H} and −1.3 ppm in
11B{1H} spectra (sharp singlet) could be assigned to BF4− as
the most common hydrolysis byproduct by comparison with
HBF4 in DMSO-d6.
X-ray crystallography
Compounds 2f, 2g and 2h were also characterized by X-ray
diffraction methods. Crystals suitable for analysis were grown
by slow diffusion of n-hexane into CH2Cl2 solutions. All BF2
complexes show the expected tetrahedral coordination sphere
around the boron atom and the all-trans geometry of the olefinic
double bonds (Figure 1). Bond lengths and angles around the
boron atom are in good accordance to values published for simi-
lar complexes [9]. One aromatic ring of 2f is twisted by approx.
8° out of the plane formed by the ligand backbone and the
second aromatic ring (Figure 1a). The twisting is stabilized by
an intermolecular interaction between one propargyl CH2
proton and a methoxy oxygen atom (see Supporting Informa-
tion File 1 for intermolecular distances as well as selected bond
length and angles). This interaction also induces the respective
propargyl group to be turned by approximately 70° out of the
plane formed by the backbone. Due to sterical intermolecular
interactions in 2g, one pent-5-yne-1-yl chain is in gauche/anti
conformation, while the other is in the more favoured anti/anti
conformation (Figure 1b) with the torsion angles only slightly
differing from the ideal 60° or 180°, respectively. The aromatic
rings are almost coplanar with the backbone. In both cases, one
of the longer side chains lays mostly within the molecule plane,
while the other is turned out. The structure of complex 2h
shows C2 symmetry with both side chains in gauche/anti con-
formation. The deviation from the ideal angles is higher than
that for 2g. The plane formed by each phenyl ring is turned by
approximately 5° out of the plane of the backbone.
BF2 cleavage
To hydrolyse the BF2 complexes and release the free ligands we
investigated several mixtures of organic solvents and water in
4:1 ratios as well as dry THF as a control reaction at 65 °C
(Table 2). Complex 2b was chosen as the model compound
(Scheme 2) as 3b has been previously reported in the literature
[31].
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Figure 1: ORTEP drawings in side view (left) and top view (right) of complexes 2f (a), 2g (b) and 2h (c). Hydrogen atoms are omitted from top view
for clarity.
Scheme 2: BF2 group hydrolysis of complex 2b.
From the solvents screened, methanol and THF containing
water show the best results (Table 2). Comparison with data re-
ported in the literature [31] as well as the absence of a 19F{1H}
NMR signal proved the success of the reaction. As expected, in
the control reaction in dry THF no cleavage reaction was ob-
served.
Interestingly, upon upscaling from 0.4 mmol to 4 mmol 2b the
yield of 3b decreased to approx. 40%. Alterations of reaction
time and temperature resulted in no significant changes.
Rao and co-worker report, that for the BF2 complex or unsubsti-
tuted curcumin a tautomeric form exists in solution, which acts
as a weak acid [13]. Only the BF2 group of the deprotonated
Table 2: Optimization of reaction conditions for BF2 group cleavage.
Solvent Additive Time (h) Yield (%)
THFa none 18 75b
MeOHa none 18 80b
EtOHa none 18 65b
DMFa none 6 30b
dry THF none 18 0
THFa NaOHc 6 80d
MeOH a NaOHc 3.5 98d
aContaining 20% H2O; bYield after purification by column chromatogra-
phy; c5 wt % in water; dYield after recrystallization from acetone/water.
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Scheme 3: Suggested mechanism of BF2 complex hydrolysis.
acid is able to become hydrolysed. In our case, although no free
OH groups are present, we have also observed a similar pH
value dependence as reported by Rao [13]. For this reason, we
suggest that the possibility to form a quinoid structure is respon-
sible for the increased stability of the BF2 complex in acidic
solution (Scheme 3). At higher temperatures, there is an equilib-
rium between the quinoid form of the BF2 complex with a
formal negative charge on the boron atom (II, borate) and a
structure with one cleaved boron oxygen bond having the
formal negative charge localized on the oxygen atom (III, best
described as a difluoroboric acid ester). The ester is prone to a
nucleophilic attack of a hydroxide ion, while the borate is not.
After the nucleophilic attack a hydroxy difluoroborate (IV) is
formed, which undergoes fast hydrolysis to boric acid, hydro-
gen fluoride and the corresponding curcuminoid in the anionic
form (V). The latter finally becomes protonated by one equiva-
lent of HF (VI). If no additional base is present, the hydroxide
concentration decreases with ongoing hydrolysis so far, that the
reaction effectively stops.
To confirm our suggestion we carried out the hydrolysis reac-
tions of 4 mmol 2b in 80% aq methanol or THF again with the
addition of 10 mol % of NaOH. The final yields could be in-
creased to 98 and 80%, respectively. Additionally, we could
observe a much shorter reaction time. This proves the necessity
for a base to be present to complete the reaction.
We were able to apply this procedure to BF2 complexes 2ac
and 2e to receive the curcuminoids 3 in good to excellent yields.
2d and 2fh were found to possess a relatively low solubility in
methanol and especially 2d to be more sensitive to nucleophilic
bases when heated in solution. To increase the solubility, most
of the water added was replaced by DMSO (Table 3). This im-
proved the solubility and did not induce any additional impuri-
ties. We also changed the base from NaOH to triethylamine for
these compounds to avoid partial decomposition. The disadvan-
tage of triethylamine was a longer reaction time of seven to
eighteen hours, probably due to the lower hydroxide concentra-
tion.
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Table 3: Hydrolysis reactions.
Entry R1 R2 R3 Solvent
(MeOH/DMSO/H2O)
Base Yield (%)a
3a H O-propargyl OMe 8:0:2 NaOHb 87
3b H O-propargyl H 8:0:2 NaOH 92
3c Br O-propargyl OMe 8:0:2 NaOH 92
3d Br O-propargyl H 8:1.5:0.5 TEA n/a
3e H O-propargyl O-propargyl 8:0:2 NaOH 84
3f H OMe O-propargyl 8:1.5:0.5 TEA 90
3g H OMe O-pent-4-yn-1-yl 8:1.5:0.5 TEA 80
3h H O-pent-4-yn-1-yl H 8:1.5:0.5 TEA 95
aYield after recrystallization; b5 wt % solution in water.
Figure 2: Absorbance (left) and emission (right) spectra of compounds 2a (orange), 2b (black), 2c (blue), 2d (red), 2e (purple), 2f (green), 2g (yellow)
and 2h (grey) in CH2Cl2.
Regarding the 1H NMR spectra, we found that all crude prod-
ucts contain small amounts of decomposition products resulting
from base induced cleavage of the backbone. Recrystallization
from acetone or ethanol and water mixtures gave the pure prod-
ucts 3ac and 3eh as yellow or orange solids in good to excel-
lent yields. They were characterized by 1H and 13C{1H} NMR
spectroscopy, mass spectrometry, UV-visible spectroscopy and
elemental analysis. For 3d we found two sets of NMR signals in
both 1H and 13C{1H} NMR spectra with relative intensities of
1:0.25, which could be assigned to be no starting material.
These did not change upon alteration of NMR solvent or tem-
perature. Also, no [M]+ signals or any expected fragments for
3d were found in EI or ESIMS spectra.
Optical spectroscopy
To investigate their properties as fluorescent dyes we measured
the UVvis absorption and fluorescence spectra of the BF2
complexes 2ah. Measurements were carried out in dichloro-
methane at room temperature and under ambient atmosphere.
The results are shown in Figure 2.
All BF2 complexes show strong absorption bands with absorp-
tion maxima between 475 and 503 nm resulting from ππ*
transitions [9]. Extinction coefficients range from roughly
9500 to over 50000 M−1 cm−1 (Table 4). All absorption curves
show secondary maxima or shoulders at slightly shorter wave-
lengths.
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Table 4: Absorption and emission spectral properties of BF2 complexes 2ah in CH2Cl2. See Supporting Information File 1 for details on the mea-
surement setup.
Compound λmaxabs (nm) ε · 10-3 (M−1 cm−1) λmaxem (nm) Φa τb (ns) Stokes-shift (cm−1)
2a 497 41.0 548 0.51 1.68 1873
2b 480 10.1 528 0.29 1.21 1894
2c 476 48.5 522 0.27 1.01 1851
2d 475 19.8 524 0.25 1.01 1969
2e 487 30.0 547 0.38 1.56 2252
2f 497 52.8 550 0.49 1.55 1939
2g 503 18.2 590 0.34 1.57 2932
2h 489 9.5 542 0.18 1.50 2000
aFluorescence quantum yield was determined against rhodamine 6G (Φ = 0.95) in ethanol. bFluorescence lifetime upon 400 nm excitation.
As solvatochromism is a known property for curcumin and its
derivatives [32,33], we investigated the solvatochromism of 2b
as an example compound in five different solvents (Figure 3).
Solvents were chosen by their ET(30) values of polarity as de-
termined by Reichardt [34]. With rising solvent polarity, the
vibrational structure of the absorption band is being lost. In tol-
uene, THF and dichloromethane the compound shows only
weak solvatochromism. Interestingly, a positive solvato-
chromism relative to the more nonpolar solvents is appearing in
DMSO, while the absorption band is slightly being shifted
hypsochromically in methanol.
Figure 3: Absorbance spectra of 2b in methanol (orange), tetrahydro-
furan (red), toluene (black), dichloromethane (green) and dimethyl sulf-
oxide (blue).
In solution, upon excitation at 365 nm, green, yellow or orange
fluorescence can be observed (Figure 4).
All fluorescence spectra are characterized by two maxima, one
in the range of 520550 nm and one in the range of
580590 nm. However, there are distinct differences in the in-
tensity ratios of these two maxima between the compounds. For
2bd, the lower energy maximum appears as a shoulder, for 2a
and 2eh, it appears as a local maximum, and for 2g it repre-
Figure 4: Compounds 2ah in dichloromethane solution in daylight
(top) and under 365 nm irradiation (bottom).
sents the global maximum of emission. This trend can be ratio-
nalized by taking the electronic structure of the compounds into
account. With increasing electron density of the aromatic
system, the emission intensity in the low-energy regime of the
spectrum increases. It is also noteworthy, that regarding 2a and
2f, which are regioisomers, the second fluorescence band is
more intense for 2f than for 2a. For the complexes containing a
brominated phenyl ring, the presence of an additional electron-
donating methoxy group has almost no impact on the fluores-
cence properties.
Conclusion
We have synthesized a series of novel curcuminoidBF2 com-
plexes by an improved synthetic route. All complexes were
received in high yields and purities and characterized by 1H,
11B, 13C and 19F NMR spectroscopy, mass spectrometry and
elemental analysis. We found the complexes to possess high
absorption in the range of 475 to 500 nm and strong fluores-
cence between 520 and 590 nm, resulting in Stokes shifts of up
to 3000 cm−1. Finally, an effective strategy to hydrolyse the
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BF2 group and release the curcuminoids could be established
using aqueous methanol and mild basic conditions. In some
cases, when the solubility of the substrates was low, DMSO was
used as an additional solvent. These compounds can act as
building blocks for the attachment of biomolecules via click
chemistry.
Supporting Information
Supporting Information File 1
Experimental data, X-ray crystallographic details, selected
bond lengths and angles, copies of NMR spectra.
[http://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-13-223-S1.pdf]
Supporting Information File 2
CIF files for complexes 2f, 2g and 2h. These data
(CCDC-1526555 for 2f, CCDC-1526556 for 2g, and
CCDC-1526557 for 2h) can be obtained free of charge
from The Cambridge Crystallographic Data Centre via
http://www.ccdc.cam.ac.uk/data_request/cif.
[http://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-13-223-S2.cif]
References
1. Esatbeyoglu, T.; Huebbe, P.; Ernst, I. M. A.; Chin, D.; Wagner, A. E.;
Rimbach, G. Angew. Chem., Int. Ed. 2012, 51, 53085332.
doi:10.1002/anie.201107724
2. Tønnesen, H. H.; Greenhill, J. V. Int. J. Pharm. 1992, 87, 7987.
doi:10.1016/0378-5173(92)90230-Y
3. Anto, R.; Kuttan, G.; Babu, K. V. D.; Rajasekharan, K. N.; Kuttan, R.
Int. J. Pharm. 1996, 131, 17. doi:10.1016/0378-5173(95)04254-7
4. Kuttan, R.; Bhanumathy, P.; Nirmala, K.; George, M. C. Cancer Lett.
1985, 29, 197202. doi:10.1016/0304-3835(85)90159-4
5. Ghosh, S.; Hayden, M. S. Nat. Rev. Immunol. 2008, 8, 837848.
doi:10.1038/nri2423
6. Artico, M.; Di Santo, R.; Costi, R.; Novellino, E.; Greco, G.; Massa, S.;
Tramontano, E.; Marongiu, M. E.; De Montis, A.; La Colla, P.
J. Med. Chem. 1998, 41, 39483960. doi:10.1021/jm9707232
7. Ammon, H. P. T.; Wahl, M. A. Planta Med. 1991, 57, 17.
doi:10.1055/s-2006-960004
8. Pabon, H. J. J. Recl. Trav. Chim. Pays-Bas 1964, 83, 379386.
doi:10.1002/recl.19640830407
9. Bai, G.; Yu, C.; Cheng, C.; Hao, E.; Wei, Y.; Mu, X.; Jiao, L.
Org. Biomol. Chem. 2014, 12, 16181626. doi:10.1039/c3ob42201a
10. Pedersen, U.; Rasmussen, P. B.; Lawesson, S.-O. Liebigs Ann. Chem.
1985, 15571569. doi:10.1002/jlac.198519850805
11. Nurfina, A. N.; Reksohadiprodjo, M. S.; Timmerman, H.; Jenie, U. A.;
Sugiyanto, D.; van der Goot, H. Eur. J. Med. Chem. 1997, 32,
321328. doi:10.1016/S0223-5234(97)89084-8
12. Khan, M. A.; El-Khatib, R.; Rainsford, K. D.; Whitehouse, M. W.
Bioorg. Chem. 2012, 40, 3038. doi:10.1016/j.bioorg.2011.11.004
13. Rao, E. V.; Sudheer, P. Indian J. Pharm. Sci. 2011, 73, 262270.
14. Liu, K.; Chen, J.; Chojnacki, J.; Zhang, S. Tetrahedron Lett. 2013, 54,
20702073. doi:10.1016/j.tetlet.2013.02.015
15. Ono, K.; Yoshikawa, K.; Tsuji, Y.; Yamaguchi, H.; Uozumi, R.;
Tomura, M.; Taga, K.; Saito, K. Tetrahedron 2007, 63, 93549358.
doi:10.1016/j.tet.2007.07.004
16. Hu, J.; He, Z.; Wang, Z.; Li, X.; You, J.; Gao, G. Tetrahedron Lett.
2013, 54, 41674170. doi:10.1016/j.tetlet.2013.05.099
17. Mügge, C.; Marzo, T.; Massai, L.; Hildebrandt, J.; Ferraro, G.;
Rivera-Fuentes, P.; Metzler-Nolte, N.; Merlino, A.; Messori, L.;
Weigand, W. Inorg. Chem. 2015, 54, 85608570.
doi:10.1021/acs.inorgchem.5b01238
18. Mügge, C.; Liu, R.; Görls, H.; Gabbiani, C.; Michelucci, E.; Rüdiger, N.;
Clement, J. H.; Messori, L.; Weigand, W. Dalton Trans. 2014, 43,
30723086. doi:10.1039/c3dt52284a
19. Mügge, C.; Micheucci, E.; Boscaro, F.; Gabbiani, C.; Messori, L.;
Weigand, W. Metallomics 2011, 3, 987990. doi:10.1039/c1mt00069a
20. Mügge, C.; Rothenburger, C.; Beyer, A.; Görls, H.; Gabbiani, C.;
Casini, A.; Michelucci, E.; Landini, I.; Nobili, S.; Mini, E.; Messori, L.;
Weigand, W. Dalton Trans. 2011, 40, 20062016.
doi:10.1039/c0dt00845a
21. Hildebrandt, J.; Häfner, N.; Görls, H.; Kritsch, D.; Ferraro, G.; Dürst, M.;
Runnebaum, I. B.; Merlino, A.; Weigand, W. Dalton Trans. 2016, 45,
1887618891. doi:10.1039/c6dt01388k
22. Hildebrandt, J.; Görls, H.; Häfner, N.; Ferraro, G.; Dürst, M.;
Runnebaum, I. B.; Weigand, W.; Merlino, A. Dalton Trans. 2016, 45,
1228312287. doi:10.1039/c6dt02380k
23. Pröhl, M.; Bus, T.; Czaplewska, J. A.; Traeger, A.; Deicke, M.;
Weiss, H.; Weigand, W.; Schubert, U. S.; Gottschaldt, M.
Eur. J. Inorg. Chem. 2016, 51975204. doi:10.1002/ejic.201600801
24. Kieburg, C.; Sadalapure, K.; Lindhorst, T. K. Eur. J. Org. Chem. 2000,
20352040.
doi:10.1002/1099-0690(200006)2000:11<2035::AID-EJOC2035>3.0.C
O;2-V
25. Maryanoff, B. E.; McComsey, D. F.; Costanzo, M. J.; Hochman, C.;
Smith-Swintosky, V.; Shank, R. P. J. Med. Chem. 2005, 48,
19411947. doi:10.1021/jm040124c
26. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B.
Angew. Chem., Int. Ed. 2002, 41, 25962599.
doi:10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO
;2-4
27. Pal, M.; Parasuraman, K.; Yeleswarapu, K. R. Org. Lett. 2003, 5,
349352. doi:10.1021/ol027382t
28. Kant, R.; Kumar, D.; Agarwal, D.; Gupta, R. D.; Tilak, R.;
Awasthi, S. K.; Agarwal, A. Eur. J. Med. Chem. 2016, 113, 3449.
doi:10.1016/j.ejmech.2016.02.041
29. Zammit, S. C.; Cox, A. J.; Gow, R. M.; Zhang, Y.; Gilbert, R. E.;
Krum, H.; Kelly, D. J.; Williams, S. J. Bioorg. Med. Chem. Lett. 2009,
19, 70037006. doi:10.1016/j.bmcl.2009.09.120
30. Goto, H.; Nimori, S.; Akagi, K. Synth. Met. 2005, 155, 576587.
doi:10.1016/j.synthmet.2005.09.044
31. Gomes, D. de C. F.; Alegrio, L. V.; Edilson Freire de Lim, M.;
Leon, L. L.; Araújo, C. A. C. Arzneim. Forsch. 2002, 52, 120124.
doi:10.1055/s-0031-1299867
32. Khopde, S. M.; Priyadarsini, K. I.; Palit, D. K.; Mukherjee, T.
Photochem. Photobiol. 2000, 72, 625631.
doi:10.1562/0031-8655(2000)0720625EOSOTE2.0.CO2
33. Barik, A.; Priyadarsini, K. I. Spectrochim. Acta, Part A 2013, 105,
267272. doi:10.1016/j.saa.2012.12.036
34. Reichardt, C. Chem. Rev. 1994, 94, 23192358.
doi:10.1021/cr00032a005
Beilstein J. Org. Chem. 2017, 13, 22642272.
2272
License and Terms
This is an Open Access article under the terms of the
Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which
permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
The license is subject to the Beilstein Journal of Organic
Chemistry terms and conditions:
(http://www.beilstein-journals.org/bjoc)
The definitive version of this article is the electronic one
which can be found at:
doi:10.3762/bjoc.13.223
S1 
 
Supporting Information  
for 
Curcuminoid–BF2 complexes: Synthesis, 
fluorescence and optimization of BF2 group cleavage  
 
Henning Weiss1, Jeannine Reichel1, Helmar Görls1, Kilian Rolf Anton Schneider2, Mathias 
Micheel3, Michael Pröhl4, Michael Gottschaldt4, Benjamin Dietzek2,3 and Wolfgang Weigand1, 
4
* 
 
Address: 1Institute for Inorganic and Analytical Chemistry, Friedrich-Schiller-Universität Jena, 
Humboldtstrasse 8, 07743 Jena, Germany, 2Institute for Physical Chemistry, Friedrich-
Schiller-Universität Jena, Helmholtzweg 4, 07743 Jena, Germany, 3Leibniz Insitute of 
Photonic Technology (IPHT), Albert-Einstein-Straße 9, 07745 Jena, Germany and 4Jena 
Center of Soft Matter, Friedrich-Schiller-Universität Jena, Philosophenweg 7, 07743 Jena, 
Germany 
 
Email: Wolfgang Weigand - wolfgang.weigand@uni-jena.de 
*Corresponding author 
 
Experimental data, X-ray crystallographic details, selected bond lengths and angles, 
copies of NMR spectra 
 
 
 
S2 
 
Table of contents 
1. General remarks S3 
2. Synthesis of aldehydes 1 and characterization data S4 
3. Synthesis of BF2 complexes 2 and characterization data S6 
4. Synthesis of curcuminoids 3 and characterization data S11 
5. X-ray crystallographic data for 2f, 2g and 2h S16 
6. References S18 
7. Intermolecular interactions in 2f S19 
8. Copies of NMR spectra for 2 and 3 S20 
 
 
 
 
 
 
 
 
 
 
 
S3 
 
1: General remarks: 
All, except hydrolysis reactions, were carried out under nitrogen atmosphere using 
standard Schlenk techniques. DMF and acetonitrile were dried over calcium hydride, 
toluene over sodium and benzophenone, while THF was stored over KOH. All 
solvents were distilled prior to use. Starting materials were commercially sourced and 
used without further purification. 3-Bromo-4-hydroxy-5-methoxybenzaldehyde and 3-
bromo-4-hydroxybenzaldehyde were received following a literature procedure [1]. 
NMR spectra were recorded on Bruker Avance 200, 400 or 600 spectrometers in 
regular borosilicate glass tubes. Chemical shifts are reported in ppm relative to 
external TMS for 1H and 13C{1H}, FCCl3 for 19F{1H} and BF3·OEt2 for 11B{1H} NMR, 
respectively. Coupling constants are reported in Hz. EI and ESI–TOF–MS were 
recorded on SSQ 710 and MAT95XL (Finnigen MAT) devices in positive mode. UV–
vis spectra were measured on a Specord D 600 spectrometer by Analytik Jena. 
Fluorescence spectra were recorded on a Jasco FP-6300 fluorescence 
spectrometer. Relative fluorescence quantum yields were measured by comparing 
the areas under the fluorescence emission spectrum of dilute (0.02 < A < 0.06) 
solutions of 2a–h in dichloromethane. Rhodamine 6G in ethanol ( = 0.95) was used 
as the standard. Final values were determined by using equations reported in the 
literature [2]. Spectrally resolved emission decay curves were determined employing 
a Hamamatsu HPDTA streak camera. Samples were excited by pulses centred at 
400 nm created by frequency doubling the output of a Ti:sapphire laser (Tsunami, 
Newport Spectra-Physics GmbH). The repetition rate of the fundamental is reduced 
to 400 kHz by a pulse selector (model 3980, Newport Spectra-Physics GmbH). 
Emission was collected for solutions from a 1 cm cuvette in a 90° angle and 
spectrally dispersed on the detector using a CHROMEX spectrograph. 
S4 
 
Measurements were performed with a polarizer set to magic angle, i.e., set to 54.7° 
with respect to the excitation polarization, in the detection path. Spectrally and time-
resolved emission data was spectrally integrated and analysed using DecayFit 
software [1]. All decay curves could adequately fitted by a monoexponential decay 
model. 
2. Synthesis of aldehydes 1 and characterization data: 
Aldehydes 1 were synthesized following two general procedures. Analytical results 
are in good accordance to data published elsewhere [3–7]. 
General procedure (1a–f): The respective hydroxybenzaldehyde (6 mmol) was 
dissolved in DMF and K2CO3 (3.3 g, 24 mmol) and propargyl bromide (0.63 mL, 6.6 
mmol; 80 wt % in toluene) were added. The resulting suspension was stirred at room 
temperature overnight and poured into ice water. The precipitated solid was collected 
by filtration, washed with water and dried in air to receive the respective ethers as off-
white solids. 
General procedure (1g–h): The respective hydroxybenzaldehyde (6 mmol) was 
dissolved in acetonitrile (30 mL) and Cs2CO3 (2.9 g, 9 mmol), KI (1 g, 6 mmol) and  
5-chloropent-1-yne (0.7 mL, 6.6 mmol) were added. The mixture was stirred under 
reflux overnight and cooled to room temperature. Ethyl acetate and water (15 mL 
each) were added and the organic phase was extracted with water (3 × 15 mL) and 
brine, dried (Na2SO4) and evaporated under reduced pressure to yield the respective 
ethers as pale yellow solids. 
3-Methoxy-4-propargyloxybenzaldehyde (1a) from 3-methoxy-4-hydroxy 
benzaldehyde: Yield 95%. 1H-NMR (400 MHz, CDCl3): δ 9.85 (s, 1H); 7.45 (dd, 1H, J 
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= 8.2, 1.8 Hz); 7.41 (d, 1H J = 1.8 Hz); 7.13 (d, 1H, J = 8.2 Hz); 4.84 (d, 2H, J = 2.4 
Hz); 3.92 (s, 3H); 2.56 (t, 1H, J = 2.4 Hz). 
4-Propargyloxybenzaldehyde (1b) from 4-hydroxybenzaledhyde: Yield 99%. 1H-
NMR (400 MHz, CDCl3): δ 9.88 (s, 1H); 7.84 (d, 2H, J = 8.8 Hz); 7.07 (d, 2H, J = 8.7 
Hz); 4.76 (d, 2H, J = 2.3 Hz); 2.57 (t, 1H, J = 2.4 Hz). 13C{1H}-NMR (101 MHz, 
CDCl3): δ 190.9; 162.5; 132.0; 130.7; 115.3; 77.6; 76.5; 56.0. 
3-Bromo-4-propargyloxy-5-methoxybenzaldehyde (1c) from 3-bromo-4-hydroxy-
5-methoxybenzaldehyde: Yield 94%. 1H-NMR (600 MHz, CDCl3): δ 9.84 (s, 1H); 7.65 
(d, 1H J = 1.8 Hz); 7.38 (d, 1H, J = 1.7 Hz); 4.87 (d, 2H J = 2.4 Hz); 3.93 (s, 3H); 2.49 
(t, 1H, J = 2.4 Hz). 13C{1H}-NMR (151 MHz, CDCl3): δ 190.0; 154.3; 149.3; 133.6; 
128.8; 118.8; 110.1; 78.2; 76.3; 60.3; 56.4. 
3-Bromo-4-propargyloxybenzaldehyde (1d) from 3-bromo-4-
hydroxybenzaldehyde: Yield 92%. 1H-NMR (400 MHz, CDCl3) δ 9.85 (s, 1H); 8.09 (d, 
1H, J = 2.0 Hz, 1H); 7.82 (dd, 1H, J = 8.5, 2.0 Hz); 7.17 (d, 1H, J = 8.5 Hz); 4.87 (d, 
2H, J = 2.4 Hz); 2.60 (t, 1H, J = 2.4 Hz). 13C{1H}-NMR (101 MHz, CDCl3): δ 189.7; 
158.7; 134.9; 131.4; 130.9; 113.3; 113.2; 77.3; 77.0; 57.0. 
3,4-Bis-(propargyloxy)benzaldehyde (1e) from 3,4-dihydroxybenzaldehyde and 2.4 
eq. of propargyl bromide: Yield 83%. The product was purified by column 
chromatography (silica gel, ethyl acetate / hexanes 1:2). 1H-NMR (400 MHz, CDCl3): 
δ 9.88 (s, 1H); 7.58 (d, 1H, J = 1.8 Hz); 7.53 (dd, 1H, J = 8.2, 1.8 Hz); 7.18 (d, 1H, J 
= 8.3 Hz); 4.86 (d, 2H, J = 2.4 Hz); 4.83 (d, 2H, J = 2.4 Hz); 2.57 (t, 1H, J = 2.4 Hz); 
2.55 (t, 1H, J = 2.4 Hz). 
3-Propargyloxy-4-methyoxybenzaldehyde (1f) from isovanillin: Yield 95%. 1H-
NMR (600 MHz, CDCl3): δ 9.78 (s, 1H); 7.46 (d, 1H J = 1.6 Hz); 7.44 (dd, 1H, J = 8.2, 
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1.7 Hz); 6.94 (d, 1H, J = 8.2 Hz); 4.75 (d, 2H, J = 2.4 Hz, 2H); 3.88 (s, 3H); 2.52 (t, 
1H, J = 2.4 Hz). 13C{1H}-NMR (151 MHz, CDCl3): δ 190.6; 154.9; 147.2; 129.8; 127.2; 
112.0; 110.9; 77.8; 76.5; 56.6; 56.1. 
3-(Ppent-4-yn-1-yloxy)-4-methoxybenzaldehyde (1g) from isovanillin: Yield 94%. 
1H-NMR (400 MHz, CDCl3): δ 9.84 (s, 1H); 7.45 (dd, 1H, J = 8.2, 1.8 Hz); 7.42 (d, 1H, 
J = 1.8 Hz); 6.97 (d, 1H, J = 8.1 Hz); 4.18 (t, 2H, J = 6.3 Hz); 3.94 (s, 3H); 2.43 (td, 
2H, J = 6.9, 2.7 Hz); 2.12 – 2.03 (m, 2H); 1.98 (t, 1H, J = 2.6 Hz). 
4-(Pent-4-yn-1-yloxy)-benzaldehyde (1h) from 4-hydroxybenzaledhyde: Yield 93%. 
1H-NMR (400 MHz, DMSO-d6): δ 9.86 (s, 1H); 7.85 (d, 1H, J = 8.7 Hz); 7.11 (d, 1H, J 
= 8.7 Hz); 4.14 (t, 2H, J = 6.2 Hz); 2.80 (t, 1H J = 2.8 Hz); 2.34 (td, 2H, J = 7.1, 2.8 
Hz); 1.97 – 1.88 (m, 2H). 13C{1H}-NMR (101 MHz, DMSO-d6): δ 191.3; 163.5; 131.9; 
129.7; 114.9; 83.5; 71.7; 66.6; 27.5; 14.5. 
 
3. Synthesis of BF2 complexes 2 and characterization data: 
General procedure (modified from lit. [8]): 
2,4-Pentanedione (0.3 mL, 3 mmol) and BF3·OEt2 (0.55 mL, 4.4 mmol) were 
dissolved in toluene (5 mL) and stirred at 65 °C for 2 h. Then, the respective 
aldehyde (6 mmol) dissolved in the minimum amount of toluene was transferred into 
the solution, followed by tri-n-butyl borate (1.85 mL, 7.4 mmol). Stirring was 
continued for 30 min and n-butylamine (approx. 0.6 equiv) was added dropwise until 
a color change was observed and a solid began to precipitate. The resulting 
suspension was kept stirring at 65 °C overnight. After cooling to room temperature 
the crude product was separated by filtration and washed with small amounts of cold 
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toluene and water. The isolated solid was dissolved in acetone at room temperature 
and water was added slowly. The resulting suspension was filtered and the isolated 
solid washed with water and dried in air to receive the pure product. 
2a · H2O:  
 
Yield 90%, purple solid. m. p.: 221.5 – 222.5 °C. 1H-NMR (400 MHz, DMSO-d6): δ 
7.97 (d,2H, J = 15.6 Hz), 7.56 (d, 2H, J = 1.5 Hz), 7.52 (d, 2H, J = 8.4 Hz, 2,1 Hz), 
7.13 (d, 2H, J = 8.5 Hz), 7.07 (d, 2H, J = 15.7 Hz), 6.55 (s, 1H), 4.88 (d, 4H, J = 2.2 
Hz), 3.86 (s, 6H), 3.60 (t,  2H, J = 2.2 Hz). 13C{1H}-NMR (101 MHz, DMSO-d6): δ 
179.11, 152.88, 146.71, 146.65, 126.85, 125.82, 119.02, 113.53, 112.26, 101.26, 
78.93, 78.56, 56.09, 55.85. 11B{1H}-NMR (128 MHz, DMSO-d6): δ 0.9 (s). 19F{1H}-
NMR (188 MHz, DMSO-d6): δ -138.4 (s). EI-MS: m/z (%) = 492 (15); 387 (25); 215 
(100). UV/Vismax [nm] ( [M-1cm-1]): 497 (41013). Anal. calcd. for C27H23BF2O6·H2O: 
C (63.55); H (4.94). Found: C (63.27); H (4.72). 
2b: 
 
Yield 96%, red solid. m. p.: 253 – 254 °C.  1H-NMR (600 MHz, DMSO-d6): δ 7.98 (d, 
2H, J = 15.4 Hz, H-5); 7.85 (d, 4H, J = 8.5 Hz); 7.10 (d, 4H, J = 8.3 Hz); 7.07 (d, 2H, 
J
 
= 15.4 Hz); 6.53 (s, 1H); 4.91 (s, 4H); 3.62 (s, 2H). 13C{1H}-NMR (150 MHz, DMSO-
d6): δ 55.8; 78.8; 101.8; 115.6; 119.2; 127.5; 131.6; 146.3; 160.4; 179.4. 19F{1H}-
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NMR (188 MHz, DMSO-d6): δ -138.1. 11B{1H}-NMR (128 MHz, DMSO-d6): δ -1.26. 
EI-MS: m/z (%) = 432 (60); 413 (20); 393 (5); 327 (35); 185 (100). UV/Vismax [nm] ( 
[M-1cm-1]): 480 (10128). Anal. calcd. for C25H19BF2O4: C (69.47); H (4.43). Found: C 
(69.44); H (4.56). 
2c · H2O:  
 
Yield 94%, orange solid. m. p.: 279.5 – 280 °C. 1H-NMR (600 MHz, DMSO-d6): δ 
7.99 (d, 2H, J = 15.7 Hz); 7.79 (d, 2H, J = 2.0 Hz); 7.61  (d, 2H, J = 2.2 Hz); 7.32 (d, 
2H, J = 15.8 Hz); 6.53 (s, 1H); 4.83 (d, 4H, J = 2.6 Hz); 3.91 (s, 6H); 3.57 (t, 2H, J = 
2.5 Hz). 13C{1H}-NMR (150 MHz, DMSO-d6): δ  179.9; 153.5; 146.0; 145.2; 131.9; 
125.8; 122.2; 117.9; 113.4; 78.9; 78.7; 59.8; 56.5. 19F{1H}-NMR (188 MHz, DMSO-
d6): δ -137.6 (s). 11B{1H}-NMR (193 MHz, DMSO-d6): δ 0.90 (s). EI-MS: m/z (%) = 
650 (1); 611 (5); 545 (2); 293 (2); 96 (100). UV/Vismax [nm] ( [M-1cm-1]): 476 
(48514). Anal. calcd. for C27H21BBr2F2O6·H2O: C (48.54); H (3.47). Found: C (48.49); 
H (3.29). 
2d: 
 
Yield 92%, orange solid. m. p.: 251 °C (dec.). 1H-NMR (600 MHz, DMSO-d6): δ 8.22 
(s, 2H); 7.96 (d, 2H, J = 15.7 Hz); 7.90 (d, 2H, = 8.3 Hz); 7.29 (d, 2H, J = 8.5 Hz); 
7.22 (d, 2H, J
 
= 15.7 Hz); 6.50 (s, 1H); 5.03 (s, 4H); 3.68 (s, 2H). 13C{1H}-NMR (150 
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MHz, DMSO-d6): δ 179.6; 156.2; 145.0; 133.8; 131.2; 129.0; 120.6; 114.3; 112.0; 
102.4; 79.3; 78.2; 56.9. 19F{1H}-NMR (188 MHz, DMSO-d6): δ = -137.8 (s). 11B{1H}-
NMR (128 MHz, DMSO-d6): δ = 0.88 (s). EI-MS: m/z (%) = 590 (2); 485 (2); 39 (100). 
UV/Vismax [nm] ( [M-1cm-1]): 475 (19847). Anal. calcd. for C25H17BBr2F2O4: C 
(50.89); H (2.90). Found: C (50.58); H (2.83). 
2e: 
 
Yield 74%, purple solid. m. p.: 251.5 – 252.5 °C. 1H-NMR (400 MHz, DMSO-d6): δ = 
7.98 (d, 2H, J = 15.6 Hz); 7.59 (d, 2H, J = 1.8 Hz); 7.52 (dd, 2H, J = 8.6 Hz, J = 1.8 
Hz); 7.18 (d, 2H, J = 8.6 Hz); 7.10 (d, 2H, J = 15.7 Hz); 6.58 (s, 1H); 4.93 (d, 4H, J = 
2.3 Hz); 4.90 (d, 4H, J = 2.3 Hz); 3.64 (t, 2H, J = 2.3 Hz); 3.61 (t, 2H, J = 2.3 Hz). 
13C{1H}-NMR (100 MHz, DMSO-d6): δ = 179.3; 150.5; 147.0; 146.6; 127.6; 125.2; 
119.5; 113.9; 102.4; 78.92; 78.87; 78.7; 56.1. 19F{1H}-NMR (188 MHz, DMSO-d6): δ = 
-138.27. 11B{1H}-NMR (193 MHz, DMSO-d6): δ = -0.88. EI-MS: m/z (%) = 540 (12); 
344 (48); 305 (84); 91 (55); 28 (100). UV/Vismax [nm] ( [M-1cm-1]): 487 (29973). 
Anal. calcd. for C31H23BF2O6: C (68.91); H (4.29). Found: C (68.74); H (4.37). 
2f · 0.4 H2O: 
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Yield 88%, red solid. m. p.: 208.5 – 209.5 °C. 1H-NMR (400 MHz, DMSO-d6): δ = 
7.96 (d, 2H, J = 15.6 Hz); 7.55 (s, 2H); 7.50 (d, 2H, J = 8.3 Hz); 7.11 (d, 2H, J = 8.4 
Hz); 7.05 (d, 2H, J = 15.7 Hz); 6.54 (s, 1H); 4.88 (d, 4H, J = 2.6 Hz); 3.85  (s, 6H). 
13C{1H}-NMR (101 MHz, DMSO-d6): δ 179.2, 152.9, 146.8, 146.7, 129.0, 128.3, 
126.9, 125.9, 125.4, 119.1, 113.6, 112.3, 79.0, 78.6, 56.2, 55.9, 38.7. 19F{1H}-NMR 
(188 MHz, DMSO-d6): δ = -138.3. 11B{1H}-NMR (193 MHz, DMSO-d6): δ = 0.90. EI-
MS: m/z (%) = 492 (60); 426 (42); 387 (44); 215 (100). UV/Vismax [nm] ( [M-1cm-1]): 
497 (52812). Anal. calcd. for C27H23BF2O6·0.4H2O: C (64.93); H (4.80). Found: C 
(64.96); H (4.70). 
2g · 0.25 H2O: 
 
Yield 56%, dark red solid. m. p.: 205 – 206 °C. 1H-NMR (400 MHz, DMSO-d6): δ = 
7.95 (d, 2H, J = 15.7 Hz); 7.49 (d, 2H, J = 2.0 Hz); 7.45 (dd, 2H, J = 8.5, 2.0 Hz); 7.08 
(d, 2H, J = 15.7 Hz); 7.07 (d, 2H, J = 15.7 Hz); 6.49 (s, 1H); 4.11 (t, 4H, J = 6.0 Hz); 
3.84 (s, 6H); 2.85 (t, 2H, J = 2.4 Hz); 2.34 (td, 2H, J = 7.1, 2.8 Hz); 1.90 – 1.94 (m, 
4H). 13C{1H}-NMR (100 MHz, DMSO-d6): δ = 179.1; 152.7; 148.3; 146.7; 127.1; 
125.2; 118.9; 112.5; 112.0; 101.3; 83.7; 71.6; 66.8; 55.8; 27.7; 14.5. 19F{1H}-NMR 
(188 MHz, DMSO-d6): δ = -138.3. 11B{1H}-NMR (193 MHz, DMSO-d6): δ = 0.90. EI-
MS: m/z (%) = 548 (18); 529 (23); 482 (98); 243 (60); 177 (100). UV/Vismax [nm] ( 
[M-1cm-1]): 503 (18194). Anal. calcd. for C31H31BF2O6·0.25H2O: C (67.34); H (5.74). 
Found: C (67.28); H (5.43). 
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2h · 0.5 H2O:  
 
Yield 87%, orange solid. m. p.: 225 – 226 °C. 1H-NMR (600 MHz, DMSO-d6): δ 7.97 
(d, 2H, J = 15.6 Hz); 7.83 (d, 4H, J = 8.6 Hz); 7.06 (d, 4H, J = 8.4 Hz); 7.06 (d, 2H, J 
= 16.0 Hz); 6.51 (s, 1H); 4.13 (t, 4H, J = 6.2 Hz); 2.82 (t, 2H J = 3.1 Hz); 2.34 (td, 4H, 
J = 7.0, 2.9 Hz); 1.91 (p, 4H, J = 6.8 Hz). 13C{1H}-NMR (150 MHz, DMSO-d6): δ 
179.2; 161.8; 146.4; 131.8; 126.9; 118.8; 115.3; 101.6; 83.5; 71.7; 66.4; 27.6; 14.4. 
19F{1H}-NMR (188 MHz, DMSO-d6): δ = -138.2. 11B{1H}-NMR (193 MHz, DMSO-d6): δ 
= 0.88. EI-MS: m/z (%) = 488 (63); 469 (16); 422 (36); 344 (88); 213 (100); 147 (58). 
UV/Vismax [nm] ( [M-1cm-1]): 489 (9481). Anal. calcd. for C29H27BF2O4·0.5 H2O: C 
(70.04); H (5.67). Found: C (70.20); H (5.75). 
 
4. Synthesis of curcuminoids 3 and characterization data: 
General procedure (3a–c and 3e): The respective curcuminoid–BF2 complex 2 (1.5 
mmol) was dissolved in methanol (40 mL) and water (10 mL). NaOH (3 mmol, 5% 
w/w aqueous solution) was added upon which the color turned to reddish green. The 
solution was stirred at 70 °C for 3 to 4 h and monitored by TLC (ethyl acetate/n-
hexane 2:3). After the reaction was completed, the solution was cooled to room 
temperature and acidified with 2 M HCl. Methanol was removed under reduced 
pressure and the precipitated solid was collected by filtration, washed neutral with 
water, recrystallized from acetone/water or ethanol/water and dried in air. 
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General procedure (3d and 3f–h): The respective curcuminoid–BF2 complex 2 
(0.25 mmol) was dissolved in DMSO (10 mL) and methanol (200 mL) and water (5 
mL) were added subsequently. To the resulting suspension was added triethylamine 
(0.5 mmol) upon which the color turned to orange-green. The solution was stirred at 
50 °C for 7 to 18 h and monitored by TLC (ethyl acetate/n-hexane 1:1). After the 
reaction was completed, the solution was cooled to room temperature and acidified 
with 2 M HCl. Methanol was removed under reduced pressure and the resulting oil 
was poured into ice water. The precipitated solid was isolated by filtration, washed 
five times with water (20 mL), recrystallized from acetone/water and dried in air. 
3a · 0.5 H2O [8]:  
 
Yield 87%, orange solid. m. p.: 170 – 171 °C. 1H-NMR (400 MHz, DMSO-d6): δ 7.60 
(d, 2H, J = 15.9 Hz); 7.39 (d, 2H, J = 1.9 Hz); 7.28 (dd, 2H, J = 8.3, 1.9 Hz); 7.09 (d, 
2H, J = 8.3 Hz); 6.87 (d, 2H, J = 15.9 Hz); 6.13 (s, 1H); 4.86 (d, 4H, J = 2.6 Hz); 3.85 
(s, 6H); 3.61 (t, 2H, J = 2.6 Hz). 13C{1H}-NMR (100 MHz, DMSO-d6): δ 183.0; 149.4; 
148.5; 140.0; 128.5; 122.5; 114.0; 111.2; 100.8; 78.8; 78.2; 56.1; 55.6. EI-MS: m/z 
(%) = 444 (30); 426 (25); 405 (8); 387 (38); 215 (100). UV/Vismax [nm] ( [M-1cm-1]): 
414 (17254). Anal. calcd. for C27H24O6·0.5H2O: C (71.51); H (5.56). Found: C 
(71.18); H (5.75). 
3b · 0.25 H2O:  
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Yield 92%, brownish yellow solid. m. p.: 176 – 178 °C. 1H-NMR (400 MHz, DMSO-
d6): δ 7.70 (d, 4H, J = 8.7 Hz); 7.59 (d, 2H, J = 15.9 Hz); 7.05 (d, 4H, J = 8.7 Hz); 
6.81 (d, 2H, J = 8.7 Hz); 6.11 (s, 1H); 4.87 (d, 4H, J = 2.2 Hz); 3.60 (t, 2H, J = 2.2 
Hz). 13C{1H}-NMR (100 MHz, DMSO-d6): 183.2; 159.0; 139.9; 130.1; 128.0; 122.3; 
115.4; 101.4; 79.0; 78.6; 55.6. EI-MS: m/z (%) = 384 (29); 366 (10); 345 (10); 185 
(90); 180 (100). UV/Vismax [nm] ( [M-1cm-1]): 410 (41437). Anal. calcd. for 
C25H20O4·0.25 H2O: C (77.20); H (5.31). Found: C (77.57); H (5.18). 
3c · 0.5 H2O:  
 
Yield 92%, yellow-orange solid. m. p.: 207.5 – 209.5 °C. 1H-NMR (400 MHz, DMSO-
d6): δ 7.61 (d, 2H, J = 2.0 Hz); 7.58 (d, 4H, J = 15.9 Hz); 7.47 (d, 2H, J = 2.0 Hz); 
7.02 (d, 4H, J = 15.8 Hz); 6.14 (s, 1H); 4.78 (d, 4H, J = 2.6 Hz); 3.90 (s, 6H); 3.54 (t, 
2H, J = 2.4 Hz). 13C{1H}-NMR (100 MHz, DMSO-d6): δ 183.1; 153.6; 144.6; 138.8; 
132.7; 125.2; 124.6; 117.8; 112.0; 102.1; 78.9; 78.8; 59.7; 56.4. EI-MS: m/z (%) = 
602 (18); 584 (10); 563 (17); 545 (35); 517 (13). UV/Vismax [nm] ( [M-1cm-1]): 405 
(36739). Anal. calcd. for C27H22Br2O6·0.5H2O: C (53.05); H (3.79). Found: C (52.89); 
H (3.72). 
3e · 0.5 H2O:  
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Yield 84%, yellow solid. m. p.: 153 – 154 °C. 1H-NMR (400 MHz, DMSO-d6): δ 7.58 
(d, 2H, J = 15.8 Hz); 7.45 (d, 2H, J = 1.8 Hz); 7.33 (dd, 2H, J = 8.5 Hz, 1.7 Hz); 7.12 
(d, 2H, J = 8.5 Hz); 6.84 (d, 2H, J = 15.9 Hz); 6.14 (s, 1H); 4.89 (d, 4H, J = 2.4 Hz); 
4.88 (d, 4H, J = 2.3 Hz; 3.60 - 3.62 (m, 4H). 13C{1H}-NMR (100 MHz, DMSO-d6): δ 
183.2; 148.9; 147.0; 140.1; 128.2; 123.3; 122.7; 113.9; 113.0; 101.1; 79.0; 78.9; 
78.7; 78.6; 56.1; 56.0. EI-MS: m/z (%) = 492 (20); 474 (8); 453 (17); 239 (100). 
UV/Vismax [nm] ( [M-1cm-1]): 405 (50732). Anal. calcd. for C31H24O6·0.5H2O: C 
(74.24); H (5.02). Found: C (74.11); H (4.93). 
3f · 0.6 H2O:  
 
Yield 90%, yellow-orange solid. m. p.: 176 – 177 °C. 1H-NMR (400 MHz, DMSO-d6): δ 
7.58 (d, 2H, J = 15.9 Hz); 7.42 (d, 2H, J = 1.8 Hz); 7.32 (dd, J = 8.4 Hz, 1.7 Hz); 7.05 
(d, 2H, J = 8.5 Hz); 6.80 (d, 2H, J = 15.9 Hz); 6.12 (s, 1H); 4.87 (d, 4H, J = 2.3 Hz); 
3.82 (s, 6H); 3.57 (t, 2H, J = 2.3 Hz). 13C{1H}-NMR: (400 MHz, DMSO-d6): δ = 183.2; 
151.4; 146.7; 140.3; 127.4; 123.9; 122.3; 112.7; 112.2; 101.0; 79.2; 78.5; 56.1; 55.7. 
EI-MS: m/z (%) 444 (19); 426 (17); 405 (10); 215 (60); 188 (100); 173 (75).  
UV/Vismax [nm] ( [M-1cm-1]): 418 (25029). Anal. calcd. for C27H24O6·0.6H2O: C 
(71.23); H (5.58). Found: C (71.03); H (5.26). 
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3g · 0.5 H2O:  
 
Yield 80%, yellow-orange solid. m. p.: 132 – 133 °C. 1H-NMR (400 MHz, DMSO-d6): 
δ = 7.56 (d, 2H, J = 15.6 Hz); 7.35 (d, 2H, J = 2.1 Hz); 7.26 (dd, 2H, J = 8.4, 2.1 Hz); 
7.01 (d, 2H, J = 8.4 Hz); 6.81 (d, 2H, J = 15.8 Hz); 6.10 (s, 1H); 4.09 (t, 4H, J = 6.2 
Hz); 3.81 (s, 6H); 2.82 (t, 2H, J = 2.7 Hz); 2.34 (td, 2H, J = 7.1, 2.7 Hz); 1.89 – 1.93 
(m, 4H). 13C{1H}-NMR (100 MHz, DMSO-d6): δ = 183.2; 151.2; 148.2; 140.3; 127.6; 
123.1; 122.1; 111.9; 111.8; 83.7; 71.6; 66.8; 55.7; 27.8; 14.5. EI-MS: m/z (%) = 500 
(49); 482 (100); 467; 404 (37); 256 (47); 232 (70); 203 (31); 178 (55). UV/Vismax 
[nm] ( [M-1cm-1]): 405 (11036). Anal. calcd. for C31H32O6·0.5H2O: C (73.07); H (6.53). 
Found: C (73.15); H (6.47). 
3h:  
 
Yield 95%, orange solid. m. p.: 153.5 – 154.5 °C. 1H-NMR (400 MHz, DMSO-d6): δ = 
16.32 (br s, 1H); 7.67 (d, 4H, J = 8.8 Hz); 7.59 (d, 2H, J = 15.9 Hz); 7.00 (d, 4H, J = 
8.8 Hz); 6.78 (d, 2H, J = 15.9 Hz); 6.08 (s, 1H); 4.09 (t, 4H, J = 6.2 Hz); 2.82 (t, 2H, J 
= 2.6 Hz); 2.34 (td, 4H, J = 7.1, 2.6 Hz); 2.34 (td, 2H, J = 7.1, 2.7 Hz); 1.90 (qui, 4H, J 
= 6.7 Hz). 13C{1H}-NMR (100 MHz, DMSO-d6): δ = 183.2; 160.3; 140.0; 130.2; 127.4; 
121.9; 114.9; 101.2; 83.6; 71.7; 66.2; 27.6; 14.4. EI-MS: m/z (%) = . UV/Vismax [nm] 
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( [M-1cm-1]): 414 (29870). Anal. calcd. for C29H28O4: C (79.07); H (6.41). Found: C 
(78.86); H (3.36). 
 5. X-ray crystallographic data for 2f, 2g and 2h 
 
The intensity data for the compounds were collected on a Nonius KappaCCD 
diffractometer using graphite-monochromated Mo-K radiation. Data were corrected 
for Lorentz and polarization effects; absorption was taken into account on a semi-
empirical basis using multiple-scans [9-11]. The structures were solved by direct 
methods (SHELXS [12]) and refined by full-matrix least squares techniques against 
Fo2 (SHELXL-97 [13]). All hydrogen atoms were located by difference Fourier 
synthesis and refined isotropically. All non-hydrogen atoms were refined 
anisotropically [12]. Crystallographic data as well as structure solution and refinement 
details are summarized in Table S1. MERCURY [13] was used for structure 
representations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
S17 
 
 
 
Table S1: Crystal data and refinement details for the X-ray structure determinations 
of the compounds 2f–2h. 
Compound 2f 2g 2h 
formula C27H23BF2O6 C31H31BF2O6 C29H27BF2O4 
fw (g∙mol-1) 492.26 548.37 488.32 
T/°C -140(2) -140(2) -140(2) 
crystal system triclinic triclinic monoclinic 
space group P ī P ī C 2/c 
a/ Å 8.5535(3) 11.1586(3) 10.7368(3) 
b/ Å 10.2782(3) 11.2846(3) 16.3081(5) 
c/ Å 14.3695(5) 11.7934(3) 14.5077(5) 
α/° 101.013(2) 88.864(2) 90 
ȕ/° 102.402(2) 83.361(2) 102.498(2) 
Ȗ/° 101.684(2) 69.043(2) 90 
V/Å3 1171.36(7) 1377.12(6) 2480.06(13) 
Z 2 2 4 
ρ (g∙cm-3) 1.396 1.322 1.308 
µ (cm-1) 
 1.07  .99  .95 
measured data 7699 17970 8445 
data with I > 2σ(I) 3677 5030 2349 
unique data (Rint) 5140/0.0384 6282/0.0289 2741/0.0321 
wR2 (all data, on 
F2)a) 0.1551 0.1180 0.1189 
R1 (I > 2σ(I)) a) 0.0778 0.0494 0.0456 
S b) 1.168 1.050 1.067 
Res. dens./e∙Å-3 0.310/-0.310 0.326/-0.208 0.432/-0.223 
absorpt method multi-scan multi-scan multi-scan 
absorpt corr 
Tmin/max 0.6526/0.7456 0.6925/0.7456 0.6783/0.7456 
CCDC No. 1526555 1526556  1526557 
a)
 Definition of the R indices: R1 = (Fo-Fc)/Fo; 
wR2 = {[w(Fo2-Fc2)2]/[w(Fo2)2]}1/2 with w-1 = 2(Fo2) + (aP)2+bP; P = [2Fc2 + 
Max(FO2]/3; 
b)
 s = {[w(Fo2-Fc2)2]/(No-Np)}1/2. 
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7. Intermolecular interactions in 2f: 
 
 
Figure S1: ORTEP drawing showing intermolecular interactions between two molecules of 
2f. Calculated distances are given in Å. 
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8. NMR spectra for compounds 2 and 3 
 
Figure S2: 1H NMR spectrum (400 MHz, DMSO-d6) of 2a. 
 
Figure S3: 13C{1H} NMR spectrum (100 MHz, DMSO-d6) of 2a. 
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Figure S4: 19F{1H} NMR spectrum (188 MHz, DMSO-d6) of 2a. 
 
Figure S5: 11B{1H} NMR spectrum (128 MHz, DMSO-d6) of 2a. 
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Figure S6: 1H NMR spectrum (400 MHz, DMSO-d6) of 2b. 
 
Figure S7: 13C{1H} NMR spectrum (100 MHz, DMSO-d6) of 2b. 
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Figure S8: 19F{1H} NMR spectrum (188 MHz, DMSO-d6) of 2b. 
 
Figure S9: 11B{1H} NMR spectrum (128 MHz, DMSO-d6) of 2b. 
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Figure S10: 1H NMR spectrum (600 MHz, DMSO-d6) of 2c. 
 
Figure S11: 13C{1H} NMR spectrum (150 MHz, DMSO-d6) of 2c. 
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Figure S12: 19F{1H} NMR spectrum (188 MHz, DMSO-d6) of 2c. 
 
Figure S13: 11B{1H} NMR spectrum (128 MHz, DMSO-d6) of 2c. 
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Figure S14: 1H NMR spectrum (600 MHz, DMSO-d6) of 2d. 
 
Figure S15: 13C{1H} NMR spectrum (150 MHz, DMSO-d6) of 2d. 
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Figure S16: 19F{1H} NMR spectrum (188 MHz, DMSO-d6) of 2d. 
 
Figure S17: 11B{1H} NMR spectrum (128 MHz, DMSO-d6) of 2d. 
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Figure S18: 1H NMR spectrum (400 MHz, DMSO-d6) of 2e. 
 
Figure S19: 13C{1H} NMR spectrum (100 MHz, DMSO-d6) of 2e. 
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Figure S20: 19F{1H} NMR spectrum (188 MHz, DMSO-d6) of 2e. 
 
Figure S21: 11B{1H} NMR spectrum (128 MHz, DMSO-d6) of 2e. 
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Figure S22: 1H NMR spectrum (400 MHz, DMSO-d6) of 2f. 
 
Figure S23: 13C{1H} NMR spectrum (101 MHz, DMSO-d6) of 2f. 
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Figure S24: 19F{1H} NMR spectrum (188 MHz, DMSO-d6) of 2f. 
 
Figure S25: 11B{1H} NMR spectrum (128 MHz, DMSO-d6) of 2f. 
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Figure S26: 1H NMR spectrum 400 MHz, DMSO-d6) of 2g. 
 
Figure S27: 13C{1H} NMR spectrum (100 MHz, DMSO-d6) of 2g. 
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Figure S28: 19F{1H} NMR spectrum (188 MHz, DMSO-d6) of 2g. 
 
Figure S29: 11B{1H} NMR spectrum (128 MHz, DMSO-d6) of 2g. 
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Figure S30: 1H NMR spectrum (600 MHz, DMSO-d6) of 2h. 
 
Figure S31: 13C{1H} NMR spectrum (150 MHz, DMSO-d6) of 2h. 
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Figure S32: 19F{1H} NMR spectrum (188 MHz, DMSO-d6) of 2h. 
 
Figure S33: 11B{1H} NMR spectrum (128 MHz, DMSO-d6) of 2h. 
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Figure S34: 1H NMR spectrum (400 MHz, DMSO-d6) of 3a. 
 
Figure S35: 13C{1H} NMR spectrum (100 MHz, DMSO-d6) of 3a. 
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Figure S36: 1H NMR spectrum (400 MHz, DMSO-d6) of 3b. 
 
Figure S37: 13C{1H} NMR spectrum (100 MHz, DMSO-d6) of 3b. 
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Figure S38: 1H NMR spectrum (400 MHz, DMSO-d6) of 3c. 
 
Figure S39: 13C{1H} NMR spectrum (100 MHz, DMSO-d6) of 3c. 
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Figure S40: 1H NMR spectrum (400 MHz, DMSO-d6) of 3d. 
 
Figure S41: 13C{1H} NMR spectrum (100 MHz, DMSO-d6) of 3d. 
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Figure S42: 1H NMR spectrum (400 MHz, DMSO-d6) of 3e. 
 
Figure S43: 13C{1H} NMR spectrum (100 MHz, DMSO-d6) of 3e. 
S41 
 
 
Figure S44: 1H NMR spectrum (400 MHz, DMSO-d6) of 3f. 
 
Figure S45: 13C{1H} NMR spectrum (100 MHz, DMSO-d6) of 3f. 
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Figure S46: 1H NMR spectrum (400 MHz, DMSO-d6) of 3g. 
 
Figure S47: 13C{1H} NMR spectrum (100 MHz, DMSO-d6) of 3g. 
S43 
 
 
Figure S48: 1H NMR spectrum (400 MHz, DMSO-d6) of 3h. 
 
Figure S49: 13C{1H} NMR spectrum (100 MHz, DMSO-d6) of 3h. 
